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CHAPTER I 
I N T R O D U C T I O N 
The present study was induced by the old pharmacological problem why the 
antihistamines do not inhibit the histamine-induced gastric acid secretion. The 
fact that they lack this action is remarkable. As will be discussed in chapter II, 
histamine has a number of different actions in the body. One of these actions 
is a powerful stimulation of gastric acid secretion. The antihistamines are a 
numerous family of drugs, the first member of which was synthetized by Bovet 
and Straub in 1937 (133). They inhibit all actions of histamine with exception 
of its gastric secretory effect. 
The problem in question has a pure molecular-pharmacological side, but it 
is also closely connected with some aspects of the physiology of gastric se-
cretion. As for the molecular-pharmacological aspect, the antihistamines are 
classified as competitive antagonists of histamine. As will be discussed in greater 
detail in chapter III, this means that their inhibitory action is based on a com-
petition with histamine for the specific receptors of the last-mentioned drug. 
According to the classical view this would imply that the antihistamines and 
histamine have affinity to the same receptors. But if this holds true, it is re-
markable indeed that the antihistamines are inactive with respect to the 
histamine-induced gastric secretion. 
Theoretically there are two possible explanations for the exceptional character 
of the secretory effect of histamine. First, it could be that the gastric histamine-
receptors are situated in a biophase in which the antihistamines do not pene-
trate, or, at least, penetrate so much less than histamine that even if maximally 
high doses of an antihistamine are administered, the drug cannot effectively 
compete with histamine for the secretory receptors. Secondly, it could be that 
the gastric secretory receptors of histamine are essentially different from the 
histamine receptors situated elsewhere in the body and that the antihistamines 
do not have affinity to them. It might be that the histamine receptors proper 
would be different, but it is not necessary to make this supposition ; it would 
amount to the same thing if the additional receptor areas of the gastric secretory 
receptors would considerably differ from those of the other histamine receptors. 
(The additional receptor areas may be essential for the affinity of a competitive 
antagonist (49) ; cf. p. 107-111.) 
The second theoretical explanation is analogous to the theory put forward 
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by Ahlquist in 1948 with respect to the effects of adrenaline (15). It had been 
known for a long time that a group of effects of adrenaline could be inhibited 
competitively by antiadrenergic substances like dihydroergotamine, piperoxan, 
etc., whereas another group of effects was not influenced by these compounds. 
According to the explanation proposed by Ahlquist adrenaline has affinity to 
two types of receptors, the α-adrenergic and the ß-adrenergic receptors, whereas 
the competitive antagonists of adrenaline mentioned above have affinity to the 
α-adrenergic receptors only. Ten years later the first ß-adrenergic-blocking 
drug, dichlorisoprenaline, was introduced by Powell and Slater (779). Perhaps 
the antihistamines known today are 'a-histaminergic-blocking substances', 
whereas the 'ß-histaminergic-blocking substances', which would be able to 
block the secretory effect of histamine on the stomach, are still to be discover-
ed (144). 
So much is certain, that possible competitive antagonists of histamine with 
respect to gastric acid secretion should be able to reach the secretory histamine-
receptors and should have affinity to them. The chance that a drug would meet 
both conditions seemed best, if its structure would rather closely resemble that 
of histamine itself (cf. p. 170). The way to 'build' a competitive antagonist of a 
certain agonist by substituting smaller or larger groups to the molecules of the 
agonist in question has found many earlier applications in pharmacology (42, 
44, 48, 49, 576, 829, 830). Particularly it has been stressed that if in a series of 
homologous compounds a gradual change in chemical structure causes a loss 
of activity, it may be worth while to test the 'inactive' compounds as possible 
antagonists of the 'active' ones (54). It seemed indicated, therefore, to test a 
number of substances with a histamine moiety in their molecular structure with 
respect to gastric acid secretion, and to include in this study a homologous 
series of histamine derivatives with substituents of increasing dimensions. 
For practical reasons, however, this could not be realized. In connection 
with limitations in chemical synthetic facilities we had to tackle the problem 
via a parallel route: we could test a homologous series of N-substituted deriv-
atives of 2-(ß-aminoethyl)-pyridine and a number of other compounds which 
contained a 2-(ß-aminoethyl)-pyridine moiety. The compound 2-(ß-amino-
ethyl)-pyridine is a histaminomimetic drug (600, 998). Grossman et a\.(399) 
tested the substance on dogs with vagally denervated pouches of the entire 
stomach and listed it as having 'no effect' with respect to gastric acid secretion ; 
this, however, seems to mean only that the drug has a lower affinity to the 
secretory receptors than histamine, since in our study 2-(ß-aminoethyl)-pyridine 
proves to be a gastric secretagogue with considerable intrinsic activity. In a 
later stage also some substances with a histamine moiety could be added to the 
test compounds. 
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In the first instance it was planned to study the test substances on the gastric 
secretion of conscious dogs with gastric fistulae. For reasons to be discussed in 
chapter VII, the experimental set-up was changed during the study; the later 
experiments were performed on anaesthetized cats with perfused stomachs. 
The possibility to study the compounds on isolated gastric mucosa secreting 
in vitro had been considered but this approach was not adopted ; the main 
reason was that this technique works smoothly only if the gastric mucosa of 
certain amphibians (generally Rana catesbeiana) is used, whereas it seems to 
encounter considerable difficulties with respect to warm-blooded animals. 
As will be discussed in the chapters III and IV, it is very useful to test new 
substances on simple isolated systems before they are studied in whole ex-
perimental animals. The determination of the intrinsic-activity values and 
affinity values of the compounds with respect to the histaminergic system 
in the guinea-pig ileum and the cholinergic system in the rat intestine gave 
occasion to study a few aspects of the relation between drug structure and 
activity in these systems. A number of the compounds included in the study 
were not chosen with a view to their possible inhibitory action on the histamine-
induced gastric acid secretion, but especially since they might contribute in this 
respect. 
The structure of this thesis further may be elucidated by the following notes 
about the different chapters: 
Chapter II is a short introduction to the physiology and pharmacology of 
histamine. 
In chapter III the basic concepts of molecular pharmacology are introduced 
and some aspects of the hypotheses concerning drug-receptor interactions and 
stimulus-effect relations are discussed. In this chapter the various subjects are 
discussed first on the basis of reasonings, whereas the mathematical calculations 
which accompany the theory but which may be not indispensable for an insight 
in the matter are confined to the second part of the chapter. 
The greater part of the presented material originates with Ariens and van 
Rossum. However, a new approach to the mathematical formulation of in-
trinsic activity in general is given, while also the presented considerations about 
metaffinoid and metactoid interaction, together with the formulae describing 
these two types of noncompetitive interaction and the accompanying arith-
matics have not been published before. 
In chapter IV the technique of making cumulative concentration-effect curves 
on isolated organs and the determination of numerical expressions of affinity 
and intrinsic activity are discussed. Much emphasis is laid on a correct statistical 
handling of the affinity values; the results of the analyses presented in the second 
part of this chapter may hold a warning against a thoughtless application of 
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Statistical techniques. A difference between two sample means should not be 
called significant at a certain probability level on the basis of calculated standard 
errors of the mean, without a preceding analysis of the basic material. 
Chapter V gives the results of the experiments on isolated organs. In this 
chapter the reader will find, i.a., some observations on the possible role of 
additional receptor areas for the affinity of competitive antagonists, on the 
presence or absence of correlations between рАг- and pD2'-values in different 
receptor-effector systems, and on the consequences of a number of molecular 
modifications with respect to the affinity values. In connection with the last 
subject the applicability of the so-called rule of Pfeiffer was studied. 
Chapter VI is a review of the physiology of gastric acid secretion. Especially 
the more controversial issues are discussed in greater detail. 
In chapter VII the applied technique of measuring gastric secretion in con­
scious dogs with a permanent gastric fistula and the results of the experiments 
on these dogs are discussed. The gastric secretory responses to histamine gave 
occasion to make some observations with respect to the upper limit of gastric 
acidity, whereas the different theories about the concentration with which the 
gastric acid is produced are compared with the experimental results. A number 
of drugs were tested as possible competitive antagonists of histamine with 
respect to gastric secretion; further the actions of some other gastric secret-
agogues and that of serotonin were studied. 
Chapter VIII and IX, to conclude, describe the development of a new ap­
paratus for continuous registration of the rate of gastric acid production in the 
cat's stomach and the results obtained with this apparatus in the further study 
of the action of some secretagogues and the possible influence of some anti­
histamines on gastric acid secretion. In comparison with older methods the 
technique in question has advantages which may justify the expectation that it 
will find further applications. 
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CHAPTER II 
H I S T A M I N E 
INTRODUCTION 
Histamine is 4(5)-(ß-aminoethyl)-imidazole (fig. i). It was synthetized for the 
first time by Windaus and Vogt in 1907 (1040). At that time the amine was not 
yet known to occur in living organisms. When, in 1910, Barger and Dale, 
Ackermann and Kutscher independently demonstrated the occurrence of 
histamine in biological material (6, 70, ¡85) and especially when, in the same 
year, the classical study of Dale and Laidlaw concerning its pharmacological 
actions was published (223), the interest of the medical world was raised. Since 
that time the drug has continued to be a subject of study, so much so that re-
cently a textbook with nearly one thousand pages could be devoted to histamine 
alone (429). It goes without saying, therefore, that the introduction presented 
in what follows can only give a very sketchy picture of the subject. 
I > • • N l | > · • N 
histamine 
FIO. 1. 
OCCURRENCE 
Histamine was first shown to be present in Secale cornutum (70, 71) and in 
a culture of saprophytes (6). The amine was demonstrated since in a great 
variety of organisms. 
In man it was proved to be present in the intestinal mucosa (73), stomach 
(817), liver (1), lung (ill), muscle (927), skin (946), hypophysis (1, 11) and 
many other tissues. Likewise it occurs in nearly all tissues of the other mammals 
tested (305, 402). The amine is known to occur commonly in fish (676), it was 
found in the chicken (89, 90) and high concentrations are present in a number 
of invertebrate species, not seldom as a constituent of venoms used in defence 
and attack (8,107,182, 264, 497, 592, 666, 676, 677, 678). 
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Histamine is synthetized by various kinds of bacteria and by some fungi ; it 
is also found in yeast extract (121). The intestinal flora of man is able to form 
important amounts of histamine from histidine present in the food (108, 565, 
671) or even from urea (606). Bacterial transformation of histidine into his-
tamine further may have a toxicological aspect: it seems to be the cause of 
group poisonings which occasionally occur after consumption of unhygienically 
processed tuna or - less often - after consumption of other kinds of fish or 
shellfish ( ¡35, 841). 
Also in higher plants the occurrence of the amine is far from rare (293, 535, 
351, 625,626, 842, 844, 1023). Germinating spinach seeds, for instance, have a 
high histamine-forming capacity (406) and may contain nearly 0.5 mg of 
histamine per gram of fresh material (1023). The formation and presence of 
histamine in the cottonplant (625, 626) possibly plays a role in the genesis of 
byssinosis. Summarizing it may be stated that histamine is of wide-spread 
occurrence throughout the living nature. 
PHARMACOLOGICAL ACTIONS 
Histamine exercises its influence in the body mainly on the smooth muscles, 
the blood vessels and the digestive glands. 
1. Most smooth muscles of nearly all kinds of fishes, birds and mammals can 
be made to contract by histamine. Large differences in sensitivity between 
various kinds of animals exist: rat and mouse are relatively resistant, guinea-pig 
and cat are very sensitive. Usually the sensitivity of the smooth muscles is re-
flected in the general acute toxicity of histamine. In man a subcutaneous in-
jection of 2-8 mg of histamine causes a severe intoxication, characterized by 
expiratory dyspnoea and cardiovascular collapse. 
In most species the bronchioles and the uterus are the most sensitive organs. 
The guinea-pig, for instance, may die from asphyxiation as a result of breathing 
air in which a histamine solution is nebulized (627, 832). The influence of his-
tamine on the human uterus may be illustrated by the fact that occasionally in 
the Indian countryside the latex of Calotrophis gigantea, which contains con-
siderable amounts of histamine, is applicated on the os uteri in order to procure 
abortion (842). In the guinea-pig the smooth muscles of the ileum also are 
extremely sensitive to histamine. The isolated terminal ileum of the guinea-pig 
is the best-known test-organ for histamine: concentrations down to io_ 8M can 
be demonstrated (407, 809). 
2. The action of histamine on the circulation is a very important aspect of 
its toxicity : introduced into or liberated in the body it can bring on circulatory 
insufficiency, collapse and lethal shock. These phenomena are the combined 
results of the influence of histamine on the blood vessels and the heart. 
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The effect of histamine on the blood vessels is not uniform. The capillaries 
of nearly all mammalian species, humans included, are strongly dilated (163, 
178, 223, 224, 316, 431, 465, 609, 692, 837, 996, 1009J. Especially the capillaries 
of the organs which serve as blood-stores are affected. The exact mechanism of 
this dilatation is still a controversial subject. Histamine may have a direct effect 
on the capillary wall (252, 407), causing the endothelial cells to lose their 
normal tone, or it may cause the dilatation in an indirect way, its influence on 
the heart action, the arterioles and the venous system (see below) resulting in a 
stagnation of the blood in the capillaries and thus in a relative anoxia of the 
endothelial cells, followed by a capillary atony. Perhaps both mechanisms play 
a role, the stagnation of the blood in the capillary bed starting a vicious circle 
(691) so that a shock caused by injection of histamine may deteriorate further 
in spite of the fact that the causal agent is no longer detectable in the circulating 
blood. 
The dilatation of the capillaries is attended with a rise in permeability (4, 224, 
296,316, 638,925,939,1055), which may cause urticaria or - if the effect is more 
general - oedema and haemoconcentration. In humans an intracutaneous in-
jection of histamine causes a red spot at the site of the injection and a local 
oedema with an erythema around it; the latter represents a vasodilatation which 
probably is caused by an axon reflex (607, 608). This syndrome is called the 
triad of Lewis or 'triple response'. 
The action of histamine on arterioles and venules differs in character and in 
strength with the species examined. The arterioles of man and a number of 
experimental animals are dilated (146, 408,409, 601, 871) ; some data, however, 
suggest that also constriction may occur (990, rabbit/ A dilatation of the 
vessels in brain and meninges is supposed to be responsible for the headache 
following administration of histamine ( ¡93,340, 770, 771). In the venous system 
constriction of the vessels is the rule (146,296,304,316,317,328,409,488, 883), 
although dilatation is reported too (329, 795). The larger blood-vessels all react 
with a constriction. The influence of histamine on cardiac output and rhythm 
again is not uniform (223, 238, 241, 242, 296, 297, 403,431, 761, 976, 996,1008, 
1009,1010), its direct effect on the cardiac action is not very pronounced. 
The appreciation of the direct action of histamine on the vascular elements 
is hindered by the fact that injection or release of histamine results in a liber-
ation of catecholamines from the adrenal medulla (163,599, 807, 846, 921, 940, 
969, 973, 994) by a direct action on the chromaffin cells (892) and in a direct 
stimulation of the sympathetic ganglion cells (969, 970, 971). This means that 
the primary fall in blood-pressure caused by histamine is more or less com-
pensated or even overcompensated by an indirectly caused rise in blood-
pressure. On the other hand, in a number of cases adrenaline and noradrenaline 
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are found to cause liberation of histamine (20c, 252, 270, 564, 941,1015,103c). 
To these factors may be added that the activity of the vasomotor centre which 
tries to maintain a homeostasis of the blood-pressure may vary with the kind 
and the depth of the possible anaesthesia of the experimental animal, and that 
also the sympathetic centres in the central nervous system seem to be stimulated 
directly by histamine (972). It will be clear that the over-all effect of histamine 
on the circulation is extremely hard to analyse. 
3. Among the digestive glands the glands of the stomach are the most 
sensitive to histamine, but also the salivary glands (γ, J2,108,210,223,345,357, 
366, 647, 776, 923, 1022; cat, dog, monkey, manj and, to a lesser degree, the 
pancreas and the mucosal glands of the intestine (223) can be stimulated. The 
doses needed to cause a secretion of saliva are comparatively large, so that, 
besides a possible direct stimulating action of histamine on the glandular cells 
(60, 357, 647, 648, 733, 923), the effect may depend on the central stimulating 
action of histamine (776), on stimulation of sympathetic ganglion cells (292), 
and on liberation of catecholamines from the adrenals (295, 782, 931, 932). 
Atropine abolishes the histamine effect (223, 357, 1057), although not com­
pletely (733, 923) ; it may be that histamine acts partly via a release of acetyl­
choline, it may be that it is dependent in its action on the presence of acetyl­
choline which, for instance, only renders the effector organ more sensitive, and 
it has even been supposed that histamine has a direct effect on the muscarine 
receptors in the gland (223). Whether histamine has a specific direct effect on 
the salivary gland cells is still a controversial point. 
With regard to the stimulating effect of histamine on gastric secretion, known 
since 1920 (550, 55/, 776), the situation is different. It is not disputable that 
histamine very potently and specifically stimulates the acid-producing cells in 
man and in a great variety of animal species (113,176, 227, 342, 587, 657, 868, 
1054). The effect on the production of pepsin (155, 341, 367, 455, 774) and 
mucus ^570, 582, 583) is less clear; some authors deny that the increase in 
pepsin secretion that may be seen after administration of histamine is the result 
of a direct stimulation of the chief cells by the amine (61,134, 617,658,965,993, 
1004). 
The histamine-induced secretion of gastric acid will be discussed further in 
chapter VI. 
With this the more important aspects of the pharmacological action of 
histamine are briefly introduced. For the sake of completeness it may further 
be mentioned that histamine shortens the clotting-time of blood (934,1066) and 
that it may cause itch after intracutaneous application. 
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FORMATION 
The origin of the histamine in the tissues of mammals is not yet elucidated ; 
it seems that considerable differences between the species exist. It is sure that 
in many tissues histamine can be formed from free L-histidine under influence 
of the specific enzyme histidine decarboxylase (475, 477, 1016). This enzyme is 
thought to be present in the mast cells, which contain the larger proportion of 
the bound histamine in the body (179, 797, 799, 801, 1026). Probably it is 
identical with the non-mast-cell enzyme demonstrated in the rat foetus (952). 
According to Kahlson histamine may be formed outside the mast cells in a 
number of tissues, and this histamine is thought to have a function in the 
organism different from the mast cell histamine (520) (see below). 
Histidine decarboxylase uses pyridoxal-5-phosphate as a coenzyme (415, 
1020) as other decarboxylases and transaminases; a pyridoxine-free diet results 
in a decrease in the histamine content of the body tissues (352, 423) and in a 
decrease in its urinary excretion (526, rat,). 
Besides the specific histidine decarboxylase at least one other enzyme, 
aromatic-L-amino-acid decarboxylase, is capable to convert L-histidine to 
histamine (235, 635, ion; kidney of rabbit or guinea-pig). It is not clear 
whether this nonspecific enzyme plays an appreciable role in the histamine 
formation under physiological conditions; perhaps this is species-dependent 
again. Recently it has been suggested that in the rat at least three histamine-
forming enzymes are present (953). 
The possibility of local histamine formation is proved in kidney, liver, lung, 
skin, muscle, ileum, pancreas and stomach of various animal species, and also 
in the human stomach. In many cases the histamine-forming capacity may be 
associated with the mast cell population in the tissues in question, in which 
cells the decarboxylase seems to be formed (619, 851, 857). In blood and bone 
marrow the histidine decarboxylase activity is related to the number of basophil 
leucocytes (59, guinea-pigj, which may be called the mast cells of the blood 
(130). Also the thrombocytes of the rabbit, which carry relatively large amounts 
of histamine, are capable to form histamine (860). The presence of histidine de-
carboxylase is further demonstrated in the splenic nerves, in sympathetic ganglia, 
and - to a lesser degree - in the phrenic nerve and the N. vagus (478,1017,1024J, 
giving occasion to speculations about histaminergic elements in the autonomous 
nervous system. Also the hypothalamus contains relatively high concentrations 
of histamine which is probably formed locally from histidine (807, 1033; cat). 
Histidine decarboxylase is an adaptive enzyme; its formation may be in-
duced. The general level of histamine formation in the body seems to be con-
trolled by the adrenal cortex. Administration of corticosteroids decreases, 
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adrenalectomy enhances the production of histamine, most probably by an 
influence on the activity of the enzyme. It was found that glucocorticoids 
diminish the activity of the enzyme in the liver but enhance the activity of the 
enzyme in the pyloric antrum (950, 951; ratj. Also the hormones of the thyroid 
may have an influence on the formation of histamine. Treatment with thyroxin 
or liothyronine causes an increased formation of histamine from histidine, at 
least in the stomach (114,115, 450; rat,). It is possible that this effect is indirect: 
the thyroid hormones may cause a decrease in the concentration of corti­
costeroids in plasma and tissue f765, 918,966,1056). Cortisone antagonizes the 
influence of hyperthyroidism on the urinary excretion of histamine (116, tax). 
The formation of histamine is also influenced by local stimuli. Histidine 
decarboxylase is very active in regenerating mast cells and vessel walls, and in 
mast cells of tissues subjected to stress (853). The histamine-forming capacity is 
increased in the fast-growing tissue in skin wounds (521, rat; 524, 621, тип) -
in this case it does not seem to be associated with the mast cell content of the 
tissue (326, 524) - and it is very high in fast-growing Ehrlich ascites tumour 
cells of the mouse (523, tissue culture), in various tissues after physical exercise, 
oxygen want and injection of adrenaline (371; rat, mouse), and in anaphylaxis 
(rat). It is also high during gestation in mice (667, 819) - first in the stomach 
and kidney of the mother, later in the foetus -, in rat (161, 527, 525, 529) -
stomach of the mother, liver of the foetus -, and in the placenta of the hamster 
(820), but not in the foetus of a number of other species (531, 532, woo), in­
cluding man (686). Also in germinating seeds of a number of plants histamine 
formation is demonstrated (406). 
Kahlson supposes that 'nascent' histamine (520a) is associated with and even 
is a condition for growth, regeneration and healing of tissues; there are a 
number of arguments for this theory, but it does not seem to cover the facts 
for all species and for all tissues (530, 531, 532, 533, 646). Another theory is 
brought out by Schayer, who supposes that 'induced' histamine has an im­
portant function in the regulation of the microcirculation (853). The two 
theories overlap but are not coincidental. 
Not all histamine present in the tissues is formed by tissue enzymes. His­
tamine may be present in the food, or it may be formed in the lumen of the 
intestine from histidine in the food by bacterial histidine decarboxylase. A 
larger or smaller proportion of the histamine in the intestinal wall probably 
originates from this source (1038). In normal animals the histamine values in 
the intestinal wall are usually higher than in germ-free animals (94; rat, mousej. 
(On the other hand monoassociation with the histamine-producing C.perfrin-
gens, resulting in high histamine values in the coecum, failed to increase the 
histamine values in the intestinal wall.) 
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Under normal conditions the greater part of the intestinal histamine is in-
activated in the lumen of the gut (by acetylation) or retained as such (by 
binding to the mucine) (738, 748), but a smaller fraction may reach the portal 
blood (489, aog). The amount of free histamine excreted in the urine is in-
creased after a meat meal or after oral administration of L-histidine, and this 
rise in excretion is significantly smaller if the intestinal flora is previously re-
duced (490, 646,1000, 1001 ; man, dogj. Also in this respect important differ-
ences between the species are found : in the guinea-pig oral histidine causes also 
a rise in free histamine excretion with the urine, but here sterilization of the 
intestinal tract has no influence on this phenomenon; it is supposed that the 
excreted histamine was formed in the tissues from absorbed histidine. The 
mentioned observations are brought out in full relief by the fact, that - in 
contrast to the situation in rodents - no or hardly any histidine decarboxylase 
is found in most tissues of man, cat and dog (476, 999, 1000). Waton suggests 
that the histamine in these species is largely of intestinal origin (490,1001). 
The fact that certain amounts of histamine may enter the blood from the 
intestine and that this histamine, in common with parenterally administered 
histamine, may be bound in the tissues does not necessarily mean that it will 
be in a position analogous to that of histamine synthetized at the spot. This is, 
for instance, demonstrated by the fact that in neoplastic mast cells in culture 
(mouse), which are able to synthetize histamine as well as to bind exogenous 
histamine, the two 'kinds' of histamine are mainly found in different intra-
cellular fractions (373). Also the turnover rates of the two 'kinds' of histamine 
are different: the endogenous histamine is metabolized much faster than the 
exogenous histamine (237). Apart from this aspect, exogenous histamine is 
taken up very fast by tissues throughout the body (rat, cat) at binding sites out-
side the mast cells, and then shows a much higher turnover rate than mast cell 
histamine (504). Whether exogenous (intestinal) histamine has importance as 
far as the possible physiological actions of histamine are concerned remains 
questionable. In this context it should be stressed again that the situation in the 
much-used experimental rodents may differ considerably from the situation in 
cat, dog, and probably in man. 
DISTRIBUTION 
In most species the highest histamine contents are found in skin (91,312, 313, 
430, 805), lung (308, 310, 802, 817, 974), stomach (251, 294, 662, 901) and 
intestine (410, 901, woo) ; the content of the liver is very high in the dog (180, 
308, 697, 975). The greater part of the histamine in the blood is present in the 
leucocytes (80, 196) ; in man this has reference to the basophil leucocytes ^267, 
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j / o , pSpJ, maybe in some other species, especially in the dog, to the eosinophils 
(202). In the rabbit most blood histamine is found in the platelets (684). In the 
plasma only very small amounts can be demonstrated (291, 642). 
In most organs studied the histamine content is proportional to the amount 
of mast cells present (797, 799, 802, 803, 804, 805, 1026). The mast cells, first 
described by Paul Ehrlich in 1877 (268), contain most of the histamine in the 
body; they hold further heparin and other mucopolysaccharides (401, 474), 
several enzymes (589, 986) and in some species also serotonin ( 101, 554, 736; 
rat, mousej or dopamine ( 109, ruminants/ In the mast cells histamine is present 
in the so-called mast granules, probably mitochondria (393, 800). In these 
granules the histamine concentration is as high as 60 mg/ml (0.5 M) (986, тзА). 
About the proportion of the histamine in the body which is bound in the 
tissues outside the mast cells no common opinion exists. 
BINDING 
As mentioned before, the vast majority of the histamine in the organism is 
present in a bound and inactive form. If the total amount of histamine in the 
human body were liberated all at once the effect would be lethal. 
In the mast cell histamine is supposed to be bound to heparin by salt for­
mation. The possibility of such a binding was decisively demonstrated in vitro 
(21, 74, 742) ; about 20 molecules of histamine can be bound by one molecule 
of heparin (563, 1018, 1019). The results of histological staining and chromato­
graphy of an artificially prepared complex of histamine and heparin resemble 
those obtained with naturally occurring mast granules (of mouse and rat) (66). 
Zinc, which is known to promote complex formation between histamine and 
heparin in vitro, is present in the mast cells in relatively large amounts (558, rat). 
Heparin functions in the way of an ion-exchanger; histamine can be displaced 
by cations, by multivalent ions in preference to univalent ions (563). The 
histamine-heparin complex is not stable in salt solutions and heparin does not 
bind histamine in, e.g., a Tyrode solution. Thus the degree of binding of hista­
mine in the mast cells may be dependent on the cation concentration in the mast 
granules; further the fact that exogenous heparin, even in high doses, has little 
influence on the actions of histamine in vivo (168, 598) may be interpreted in 
this light. 
Histamine is supposed to be bound to several other substances in the tissues 
outside the mast cells, such as nucleic acids (probably RNA, 597, 751), ade­
nosine-triphosphate and glucose-i-phosphate. According to a group of French 
authors histamine is also bound to a γ-globulin, plasmapexin I, in blood serum 
of man, guinea-pig, rat, mouse, dog and cat (129, 739, 741, 743, 744, 749, 750). 
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The sera of a number of other species (rabbit, cattle, horse, pig) are devoid of 
histaminopexic action. The binding in question does not take place in absence 
of calcium (or magnesium) ions or in presence of an overmeasure of potassium 
ions (745, 747). Plasmapexin I binds also serotonin and acetylcholine (327,740) ; 
it seems to be absent from the blood of persons suffering from allergic diseases 
(740, 746, 749,997). Adrenalectomy or hypophysectomy causes the histamino-
pexy of the serum to disappear; it can be restored for the greater part by the 
administration of cortisone. 
In contradiction with the foregoing Beali concludes that binding of histamine 
by serum proteins cannot be the cause of histaminopexy. This conclusion is 
based on in vitro experiments with a number of serum protein preparations, 
including plasmapexin, in which experiments histamine was not found to be 
bound (83). 
RELEASE 
It is well-known that administration of an antigen to a sensitized subject may 
cause an anaphylactic shock which is the result - at least partly - of a sudden 
effusion of histamine into the circulation. This liberation of histamine is at-
tended with a degranulation of the mast cells (986) ; obviously a smaller or 
larger part of the histamine bound in these cells is set free in the anaphylactic 
process. 
Extensive study in this field has shown that a release of histamine from its 
binding sites in the mast cells can be brought about in many different ways. It 
can be caused by mechanical stimuli as, for instance, pinching of the skin (822), 
by high and low temperatures (689, 760, 823) and by some kinds of radiation 
(552, 1003) ; it can also be caused by application of a bewildering variety of 
chemical substances (421, 429, 751, 871). Under the last heading a number of 
basic substances with low molecular weights are found, such as, for instance, 
ammonium (863), octylamine (/40, 314), d-tubocurarine (798, 865, 962), mor-
phine (315, 502, 737, 962), papaverine (315), codeine (315, 962), strychnine 
(865), atropine (845), quinine (845), pethidine (845), tolazoline (845), strepto-
mycine (20), many antihistamines (58, 696), tryptamine (318), serotonin (318), 
adrenaline (270, 564, 941, 1015) and substance 48/80* (140, 314, 695, 835, 901, 
1028) ; also substances with high molecular weights like dextran (104,422,588), 
peptone (1035), protamine (140), polivinylpyrrolidone (412, 962), ovomucoid 
(100) and anaphylatoxin (812, 833) ; proteolytic enzymes like trypsin (808) and 
* a condensation product of p-methoxyphenylethyl-methyl-amine and formaldehyde (67), 
for the greater part in the form of a trimer. 
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papain (SII) ; tissue extracts of Ascaris (244, 987), Cyanea (984, 986) and other 
animals; surface-active substances such as Tween 20 (584), decylamine (468) 
and lysolecithin (682, 834), and toxins of bacteria (311, 553, 735), insects (309, 
955) and snakes (260, 307). The macromolecular histamine-releasing substances 
are species-specific in their activity: dextran and ovomucoid show their typical 
action in the rat, polyvinylpyrrolidone and Tween 20 in the dog, anaphylatoxin 
in the guinea-pig. 
So much seems sure, that no common liberation mechanism for all sub­
stances mentioned exists. As for the histamine release caused by simple mono-
or diamines, it may be that in those cases the releasing substances penetrate 
into the mast cells, displacing histamine from its binding sites by a simple com­
petition. In model experiments with synthetic cation-exchangers such a process 
proved to be possible (586). But in other cases a liberation of the mast granules 
from the interior of the mast cell seems to be the primary process; the histamine 
release then simply could be the result of a displacement by cations in the extra­
cellular fluid. In favour of this theory militates the fact that if isolated mast 
cells are degranulated in a cation-free medium the histamine release into the 
medium is low, the larger proportion of the histamine being liberated only 
after addition of NaCl (986). 
Liberation of mast granules may occur if mast cells are disrupted or damaged, 
as may happen under the influence of physical traumata, venoms, toxins and 
proteolytic enzymes. If the substances which may act in this way and the 
compounds which may compete with histamine for binding sites in the intact 
mast cell are set apart, a group of substances with very interesting properties 
remains : the histamine liberators in a more restricted sense. The substances, as 
e.g. substance 48/80, Ascaris-extract and dextran (in the rat) cause a degran-
ulation of the mast cells in a way that seems to correspond more or less to the 
process of histamine liberation by an antigen-antibody reaction (104, 424, 468, 
698). It is supposed that the liberation is caused by an enzymatic lysis of lipid 
membranes in the mast cell (466). The process is known to be energy-con­
suming (246) ; it is dependent on pH and temperature (184, 244,51 j , 986,1028) 
and the presence of calcium ions is conducive (468, 698). The liberation is 
prevented by enzyme inhibitors which are known to block SH- and NH2-
groups (184, 246, 51 γ, 698, 8зз, 986, I028) which seem to be essential for the 
enzymatic process (467, 468), as in most instances also by anoxia (244, 246, 
762, 986). A number of these blockades can be counteracted by addition of 
glucose (243, 244, 245, 246, 762, 833, 835, 1029). Phlorizin, which inhibits the 
biological transport of glucose, annuls the influence of moderate concentrations 
of glucose in the medium (245). Hypophysectomy induces a greater resistance 
of mast cells against the disrupting effect of 48/80 (893). Considering all these 
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data together the conclusion that the histamine liberators in question act via 
an active, metabolic process seems justified. 
ELIMINATION 
Histamine is catabolized via different pathways (fig. 2). The relative impor-
tance of these pathways varies with the species and even may be different in the 
two sexes of one species (405, 560, 1030, rat; 912, rat, mouse,). It is also de-
pendent on the kind of food ingested. 
A small amount of histamine is excreted as such in the urine. A close corre-
lation between the amount of free histamine in the urine and in the plasma 
exists (259, man,). Unchanged histamine is also present in bile (977, dogj and 
in gastric juice (9, 10, 199, 200, 294, 643; dog, cat, man). The concentration of 
histamine in gastric juice may be higher than that in the plasma (643), so that 
simple diffusion cannot be the only cause of its presence. The amine seems to 
be concentrated by the parietal cells or cells adjacent to the latter, as it is by the 
cells of the kidney. The amount of histamine eliminated via the gastric mucosa 
may be an appreciable proportion of the total amount eliminated from the 
tissues; there are indications, however, that this way of elimination has no 
primary function in a general homeostasis of the histamine concentration in the 
body fluid, but that it is a by-product of the process of gastric acid secretion. 
In the urine and faeces of many mammalian species 4(5)-(ß-acetylaminoethyl)-
imidazole is found (945, 978). This metabolite is formed in the lumen of the 
intestine; various intestinal bacteria are able to acetylate histamine. The acetyl-
histamine in the urine must be largely from this source, since little or no 
acetylation of injected histamine seems to occur (624, 848, 850; rat, guinea-pig, 
rabbit, cat, dog, monkey,). 
The catabolism of histamine in mammalian tissues mainly proceeds via two 
different pathways, one starting with an oxidative deamination of the side-
chain, the other with a methylation on the ring nitrogen remote from the side-
chain (fig. 2). Other ways of detoxification of histamine have been suggested, as, 
e.g., the formation of histamine dinucleotide (17, 700, 701) or histamine ribotide 
(324), but those possibilities have been demonstrated in vitro only. 
The oxidative pathway is involved in the catabolism of histamine in nearly 
all species studied. It is the main route in the rat (848) - although significant 
methylation may occur in male rats (1030) - and equals the importance of the 
methylation in the guinea-pig (854). The oxidation takes place under the in-
fluence of an enzyme which was introduced as histaminase (no, 112), and which 
is blocked by drugs known to be inhibitors of diamine oxidase (849). Its char-
acter, however, is a controversial subject. Some workers mean that it is not 
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specific for histamine and that, consequently, it should not be called histaminase 
but diamine oxidase (942, 1063, 1064), whereas others maintain the existence 
of a specific histamine oxidase, to be distinguished from diamine oxidase (125, 
555» 55P> 566). In some species two enzymes with histaminase activity have 
been demonstrated; the enzymes are closely related chemically but differ in 
substrate specificity (156, 157, ¡58, 536, 639; pig, manj. 
In the histaminase molecule two prosthetic groups are present, viz. pyridoxal 
phosphate and flavin-adenine dinucleotide (124, 535, 538). 
Injection of thyroxin causes the (intestinal) histaminase activity to be lowered 
(919, moused, probably as a result of a reduction in the tissue level of corti-
costeroids. In this connection the influence of thyroxin and of corticosteroids 
on histidine decarboxylase may be recalled (p. 10); although the evidence is 
incomplete and concerns different species the possibility seems not excluded 
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that thyroxin causes an increased formation of histamine as well as a decrease 
in its rate of catabolism. Hypothyroidism is known to cause a decrease in the 
histamine content in the skin of rat and man (312). 
The oxidative catabolism of histamine leads to the formation of imidazole-
4(5)-acetic acid (f31, 618, 670, 848, Ç13, 944; rat, mouse, guinea-pig, manj via 
the instable intermediate imidazole-4(5)-acetaIdehyde (534, 537). In the urine 
the imidazole-4(5)-acetic acid may be found as such, or conjugated with ribose 
to form i-ribosylimidazole-4-acetic acid (540, 542, 911,943; rat, mouse,) (fig. 2). 
The pathway of methylation, on the other hand, is the main route of cata-
bolism in the mouse, although oxidation comes to play an important role if 
histamine in larger amounts is fed to the animal (850, 913) ; it is also important 
in guinea-pig (854), cat (850, 859), dog (850) and man (716, 850, 856). Under 
the influence of the enzyme imidazole N-methyltransferase (148), also called 
histamine methyltransferase (616), 1 -methyI-4-(ß-aminoethyl)-imidazole is form-
ed. The presence of this histamine metabolite in tissue and urine could be 
demonstrated (336, 357, 858). Its histaminergic activity, compared with that of 
histamine as unity, is only 0.006 on the guinea-pig ileum and 0.002 on the cat 
blood-pressure (600), so that the methylation as such seems to be an effective 
detoxification mechanism. A smaller part of the i-methyl-4-(ß-aminoethyI)-
imidazole formed is excreted in the urine; the majority, however, is oxidized to 
i-methylimidazole-4-acetic acid(427,541,542,559,858; mouse, man,), probably 
with i-methyIimidazole-4-acetaldehyde as an intermediate (fig. 2). The metabo-
lite i-methylimidazoIe-4-acetic acid is a normal constituent of human urine but 
seems to be absent from the urine of patients in status asthmaticus (559) • The 
nature of the enzyme which catalyzes the oxidation in question is not quite clear : 
it may be histaminase (535) or it may be a monoamine-oxidase-like enzyme (852). 
An argument in favour of the last supposition may be that after pretreatment 
with iproniazid, known as a monoamine oxidase inhibitor, a large proportion 
of injected 14C-histamine is excreted as methyl-14C-histamine (618, manj. 
Also the main sites of catabolic activity vary from species to species. In the 
rat the oxidation takes place mainly in the intestine (849) and to a lesser degree 
in the liver; in the dog, however, the kidney is an important site of histamine 
oxidation (620). In man the histaminase activity was found to be high in the 
maternal side of the placenta; it is also enhanced in the serum during pregnancy 
(663, 664, 1065; guinea-pig, man,). In mouse and cat the methylation is known 
to be performed mainly by the liver (610, 849). The enzyme histamine methyl-
transferase was found in the livers of all vertebrates investigated except the rat 
(404, 616), whereas also other organs as brain, lung and kidney show significant 
enzyme activity. The cat brain was demonstrated to methylate histamine in vivo 
(1034). 
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With respect to the important role of the liver in the process of histamine in-
activation in various species the following accidental observation may be in­
teresting. As is well-known, in the cat (as in other animals) a dose of histamine 
which has a distinct effect on gastric acid secretion if administered in the form 
of a slow intravenous infusion has no or hardly any gastric secretory activity if 
injected rapidly into the blood stream. The reason is supposed to be that after 
injection no eifective histamine concentration in the blood is present during a 
sufficiently long period of time. In a series of experiments of the kind described 
in chapter IX one cat was found to behave abnormally in this respect: rapid 
injections of histamine were equally effective as slow infusions. In the animal 
in question the liver was found to be practically destroyed by a heavy infection 
with liver flukes. This finding tallies also with the finding in man, that in a group 
of patients with epidemic hepatitis the plasma level of histamine was about ten 
times higher than in healthy persons (89т). 
PHYSIOLOGICAL AND PATHOPHYSIOLOGICAL SIGNIFICANCE 
The supposition that histamine may play a part in the (patho)physiology of 
living organisms is mainly based on the fact that it is found in appreciable 
amounts in certain tissues, as well as on the presence of specific enzymes for its 
formation and breakdown and on the influence of some endocrine glands, as 
the anterior lobe of the pituitary, the adrenals and the thyroid on these pro­
cesses. In spite of the extensive body of data available, however, the question 
which functions in the body may be filled by histamine is still unanswered. 
Some theories, supported by more or less strong arguments, exist; but the 
arguments are indirect and no common opinion about any of the proposed 
functions of histamine has been reached. On this place no detailed discussion 
of the matters in dispute can be given ; the reader may be referred to literature 
(316, 349, 402, 407, 429, 522, 809, 1032). A short enumeration of the current 
theories, however, may be presented. 
A distinction should be made between stored histamine, as, e.g., present in 
the mast cells, and 'nascent' or 'induced' histamine which is supposed to be 
synthetized in order to act locally and immediately. The theory of Kahlson 
about a physiological role of 'nascent' histamine in conditions of rapid growth, 
like during pregnancy (histamine may also play a role in the process of nidation 
of the mammalian egg) and in the regeneration or healing of tissue or in 
malignant growth was already mentioned earlier. A related theory is that of 
Schayer, who supposes that 'induced' histamine plays an important role in the 
local regulation of the microcirculation. 
A function of histamine in the central (545, 681, j68) and peripheral nervous 
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system does not seem improbable. Stimulation of some nerves causes a release 
of histamine which seems to originate from the nervous tissue itself. It is sup-
posed by some authors that histamine has a function in the process of per-
ception of pain and itch. Also functions in the nervous regulation of circulation 
and of gastric secretion are proposed. 
As for the regulation of the microcirculation, not only a direct local and a 
nervous mechanism but also an indirect local role of histamine seems possible; 
in this connection the mutual liberation of histamine and (noradrenaline may 
be recalled. 
A physiological function of histamine in the secretion of gastric acid is rather 
widely accepted ; it is even supposed that the action of histamine is the common 
final step in all kinds of stimulation of gastric acid secretion. Less unanimity 
exists about the question whether a local liberation of stored histamine or a 
de novo synthesis outside the mast cells is the most important factor in this 
process; possibly both mechanisms play a role. These points will be discussed 
further in chapter VI. 
The pathophysiological significance of histamine may be found in a number 
of anaphylactic and allergic conditions. The amine may play a role in the origin 
of anaphylactic shock, Quincke's oedema, urticaria, etc., and also in some kinds 
of asthma. In connection with its influence on the secretion of gastric acid it 
is probable that it shares in the genesis of certain kinds of peptic ulcers, e.g. 
those associated with extensive bums of the skin and with liver diseases. 
Byssinosis is a disease with allergic aspects, but - as mentioned already -
histamine may also play a direct role in its genesis. A disturbance in the hista-
mine metabolism further is suspected to be a factor in certain psychiatric 
disorders, notably schizophrenia. 
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CHAPTER III 
INTRODUCTION TO SOME PRINCIPLES 
OF MOLECULAR PHARMACOLOGY 
THE AFFINITY BETWEEN DRUG MOLECULES AND RECEPTORS; THE CON-
CEPTS DRUG ACTIVITY AND RECEPTOR 
Pharmacology is the branch of natural science engaged in studying the inter-
action between a biological entity and certain chemical substances, in this 
connection called pharmaca, or drugs. In former days pharmacology was 
mainly descriptive. In most cases the processes underlying the observable 
effects were utterly untransparent, and only in the last decades a break-through 
has been made to some understanding of more fundamental events. As early as 
1925 Storm van Leeuwen stated: 'The real site of action (Angriffspunkt) of 
drugs is unknown but it is certain, that each drug before being able to exert an 
action must enter into a chemical or physico-chemical reaction with substances 
of unknown origin, possessing definite physico-chemical properties. Without 
this assumption, specific drug action could not be explained' (928). Yet it took 
a relatively long time before it was generally appreciated that - since a bio-
logical object as well as a pharmacon is composed of molecules - an interaction 
between a living being and a chemical substance essentially is an interaction 
between molecules, obeying physical and chemical laws. 
Some drugs may cause alterations in the organism as a result of more general 
properties. In the case of many anaesthetics, for instance, the effect seems to be 
caused by an unspecific physico-chemical change in the biological milieu (757). 
For many other pharmaca, however, such a mechanism of action is rather im-
probable. Many pharmaca cause highly specific changes in the body - specific 
in this sense, that the effect in question proves to be dependent on the drug 
possessing a special molecular structure - when given in relatively low doses. 
Some substances even are effective when they are administered in doses of 
micrograms per kilogram body-weight. A simple comparison of the number of 
drug molecules and the number of molecules in the organism shows that in 
such a case only a very small fraction of the molecules of the organism can 
participate in the interaction with the drug molecules. Probably this fraction 
distinguishes itself in some way from other molecules in the organism : it may 
be assumed that there are molecules in the body to which the molecules of the 
drug have a special affinity. 
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These molecules - or perhaps parts of molecules or groups of molecules -
with which the molecules of a specific drug interact are called its receptors. The 
name is relatively young; it was Langley who used the term 'receptive sub-
stance' for the structure in the motor endplate with which curare combines 
(594). The concept behind it, however, is very old. Often it is carried back to 
the view of Ehrlich that 'corpora non agunt nisi fixata' (269), but indications 
of it are present already in the didactic poem De Rerum Natura, written by 
Titus Lucretius Carus in the first century before Christ. Lucretius supposed 
that all bodily sensations in essence are caused by the fact that certain parts of 
the body are 'touched' by certain 'atoms', and that the differences in shape and 
form of these atoms determine, for instance, whether they can cause the sen-
sation of taste by penetrating into the 'pores' of palate and tongue, and whether 
they cause there one kind of taste or another (637). 
Thus, if no receptors occur in the body for the molecules of a certain chemical 
substance, this substance cannot be an active and specific drug in the narrower 
sense of the word. Placebo effects, of course, are not considered to be pharma-
cological actions of a drug. 
Drug-receptor interactions are determinative for the greater part of drugs in 
use, and in the following the actions due to nonspecific properties are left out 
of consideration. With these limitations it may be stated that affinity to re-
ceptors is the first condition for activity, - though not the only one. 
Before going further into this, something more should be said about the 
concept 'drug activity'. Very strictly taken any drug that has affinity to re-
ceptors possesses activity, for having affinity to a receptor implies the ability to 
cause an alteration, however small, in this receptor. In this form, however, the 
concept has no use, since in research effects that cannot be measured, cannot be 
handled. This means that what is called 'drug activity' cannot be an objective 
concept but is something partly dependent on the observer. It can be defined as 
the ability of the drug to cause alterations in the biological system which are 
perceptible to the investigator. 
In this connection the concept 'receptor' should also be regarded with more 
accuracy. In the first place it will be clear that the concept is closely related to 
that of the 'active site' in enzymology, As stated before, the fact that interaction 
between two molecules takes place means that changes occur in both molecules. 
In the case of an interaction between a substrate molecule and an active site on 
an enzyme, the alteration in the former is essential with respect to the effect; 
in the case of a drug-receptor interaction the alteration in the receptor is the 
essential phenomenon. Nevertheless both situations have much in common, 
and in what follows some approaches known from the field of enzymology will 
be recognized. 
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Secondly, it is not very probable that the molecules of a specific drug only 
have affinity to the receptors on which the effect can be induced. The drug may 
also have affinity to other structures in the body, an interaction with these 
structures being not effective in the sense of the definition of effect given before. 
According to some authors these structures should not be called receptors; they 
prefer to use terms like 'binding sites', 'acceptors' (183), 'sites of loss' (181,300, 
991), and such. Another possibility is to distinguish this kind of receptors as 
'secondary receptors' (928, 929, 930), 'silent receptors' (365) or 'unspecific re-
ceptors' ('des récepteurs non spécifiques') (132), and to call the receptors from 
which an effect can originate 'dominant receptors' (928, 929) or 'specific re-
ceptors' ('des récepteurs spécifiques') (132). This seems preferable, since the 
difference does not lie in the factor 'receptivity'. In connection with what was 
said about 'drug activity' it will be clear that the question whether a site of 
interaction is a specific or an unspecific receptor only depends on the question 
whether the consequence of the interaction is regarded as 'effect'. The dis-
tinction, therefore, cannot have absolute value, but it is certainly of practical 
use. Whenever receptors are mentioned in the following text, specific receptors 
are meant. 
INTRINSIC ACTIVITY; THE CONCEPTS AGONISM, COMPETITIVE ANTA-
GONISM AND DUALISM 
The dependence of drug activity on affinity is obvious, but the question arises 
whether this is the only factor determining activity. This point may be illustrated 
with the following set of simple experiments. 
A well-known effect of the drug histamine (fig. 3) is that it can cause a contrac-
tion of smooth muscle fibres. This can be demonstrated on a piece of guinea-pig 
ileum, which may be used as an isolated organ preparation; this procedure is 
described in detail in the next chapter. The organ is suspended in a bath with 
a suitable fluid, and if an adequate dose of histamine is added to this fluid, the 
organ reacts with a certain degree of contraction. Let us suppose that such an 
amount of histamine is added that a distinct but submaximal contraction of the 
organ results. 
The bath fluid is changed several times, so that all histamine is removed and 
the organ is relaxed again. Then 3-(ß-aminoethyl)-pyrazole, a close structural 
analogue of histamine (fig. 3), is added in the same molar amount as the his-
tamine in the first experiment: no contraction of the organ follows. An obvious 
explanation of this result is, that this analogue has no - or much less - affinity 
to the histamine receptors in the organ, as a result of its slightly different mo-
lecular structure. If this is so, the presence of the 3-(ß-aminoethyl)-pyrazole in 
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the medium should have no demonstrable influence. And indeed, if the original 
dose of histamine is added, without removing the analogue first, a contraction 
results equal to the original effect of the histamine alone. 
So far everything seems clear. Now the experiment is repeated with another 
derivative of histamine, viz. N-(N'-phenyl-N'-benzyl-ß-aminoethyl)-histamine 
(fig. 3). Again no contraction results from the addition of an equimolar dose 
of this compound, and so it could be supposed that it has no affinity to the 
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receptor either. But if the original dose of histamine is added now, the inactive 
compound still being present in the medium, the effect of the histamine is found 
to be reduced considerably. Only if higher doses of histamine are added the 
original degree of contraction ensues. 
Clearly the derivative in the third experiment does have an influence on the 
organ: it hinders the action of histamine. This fact may suggest that the com­
pound still has affinity to the histamine receptors,- a supposition that can be 
confirmed by other means to be discussed afterwards. If this is true, why is the 
substance inactive by itself? Evidently it differs from histamine in a factor 
distinct from affinity: it interacts with the receptors, but the interaction is not 
effective in the sense that contraction of the muscle results from it. 
In presence of the derivative part of the receptors is not available for inter­
action with histamine. The interactions should be seen not as static, but as 
dynamic, reversible processes, and therefore it is also clear that if in the third 
experiment a larger dose of histamine is added, the percentage of the receptors 
that is in interaction with it will increase, and that the contraction of the organ 
will become greater. 
These experiments illustrate a fact of essential importance. Among the drugs 
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that have affinity to a receptor there may be substances that have the ability 
to cause such a change in the receptor that - as an ultimate result - an effect is 
observable, and others lacking this ability. Drugs that possess both affinity as 
well as this ability are called 'receptor-activators' (451) or 'agonists' (793) and 
the ability itself is given the name of 'intrinsic activity' (39) or 'efficacy' (926) *. 
From the foregoing it follows that the concept of agonism is different from 
drug activity, potency, effectivity or stimulant action. A drug without intrinsic 
activity but with affinity to the receptors of a certain agonist may show its 
presence in the organism by clear effects. In the physiological situation many 
'receptor-effector systems' are activated to a certain degree as a result of the 
presence of an endogenous agonist. (With receptor-effector system is indicated 
the whole body of identical receptors plus the structures in which the caused 
effect, and the chain of events leading to it, take place.) If an endogenous 
agonistic substance is continually present and interacts with its receptors, ad-
ministration of a pharmacon that blocks the influence of this agonist causes an 
alteration in the level of activation. 
For instance, if atropine is administered to the eye, the pupil is known to 
dilate. Atropine causes this effect by blocking the receptors for acetylcholine, a 
substance secreted by the parasympathetic nerve fibres. Interaction of acetyl-
choline with its receptors leads to contraction of the constrictor muscle of the 
pupil. Disappearance of this physiological constricting action is the cause of 
the observed dilatation, and though it could be said that atropine stimulates 
a dilatation of the pupil, yet the drug is not an agonist itself, but a so-called 
antagonist (counteracting substance) of the normally present agonist acetyl-
choline. 
The kind of antagonism introduced here is named competitive antagonism, 
and it is only one of the different kinds of antagonism that are usually dis-
tinguished. The term speaks for itself: this antagonism is based on a competition 
between an antagonist and an agonist for receptors to which both of them have 
affinity. The agonist, having intrinsic activity, causes its effect by interaction 
with the receptors as such; the competitive antagonist which does not possess 
* The differentiation between the two factors which are essential for the action of an agonis-
tic drug is older than the names 'intrinsic activity' and 'efficacy'. In 1937 already Clark for-
mulated the hypothesis that the selective action of drugs as acetylcholine and adrenaline 
depends firstly on the power to combine with the receptor, and secondly on the power to 
produce an effect after they have combined, and in this connection he refers to older, corres-
ponding views in enzymology (190). Âberg made the same distinction in a study on the effects 
of auxins, differentiating between affinity and the 'activity of the substance when bound' (2). 
As for the name 'intrinsic activity', this term had its predecessors in the terms 'intrinsic 
toxicity' and 'intrinsic action' (220,323), which, however, did not have the same purport as 
the present-day concept. 
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intrinsic activity cannot cause an effect except in the presence of the agonist. 
On 'empty' receptors it is inactive. 
Among the pharmaca which have affinity to a receptor the choice is not 
merely between substances with a certain intrinsic activity and others without, 
but theoretically the intrinsic activity can have all values between maximal and 
zero. In fact it has been shown that many substances by themselves act as 
agonists but at the same time are competitive antagonists with regard to agonists 
possessing higher intrinsic activities (39, 42, 48, 53). Such drugs may be called 
'partial agonists' (926), or, with the same right, 'partial antagonists'; also the 
name 'competitive dualist' is used. 
In practice, actions of drugs on the total organism being in play, it may be 
very hard to tell whether a drug acts agonisticly or by competitive antagonism, 
since the situation on the level of the receptor is not known. As will be shown 
later, the practical classification can be made with greater probability by means 
of experiments on isolated organs. For the moment one should bear in mind 
that a drug can be called an agonist only in relation to a certain receptor-
effector system, and that the differentiation between agonist and competitive 
antagonist has sense only on the level of the receptors concerned, and in re-
lation to each other. In other words, when a pharmacon is called a competitive 
antagonist, this means that it antagonizes a definite type of agonist competitively 
on a definite kind of receptors. 
DIFFERENT KINDS OF ANTAGONISM 
Any drug that counteracts the effect of an agonist can be called an antagonist. 
Since there are different levels on which the antagonism may occur, the follow-
ing classification may be useful. The different kinds of antagonism are special 
forms of more general kinds of interaction which can be classified in a corre-
sponding way. 
1. Chemical antagonism. The antagonist does not cause its effects by virtue 
of an interaction with molecules of the organism, but it interacts with the 
agonist itself, which in consequence loses its ability to be effective ('antagonism 
by neutralization'). The antagonism of protamine against the anticoagulant 
activity of heparin (188) may serve as an example : protamine, a low-molecular-
weight protein with a strongly basic character combines with the strongly acidic 
heparin to form a stable salt, so that the anticoagulant activity of heparin is lost. 
The antagonism, of course, is mutual. In the guinea-pig heparin as well as 
protamine sulphate have a strong histaminase-liberating effect on the liver, 
5 mg of the latter being as effective as 50 LU. of the former. When given si-
multaneously by two different intravenous routes the two substances neutralize 
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each other (with a dose relationship of ι mg of protamine sulphate to 50 I.U. 
of heparin) and no histaminase is liberated (411). Another example of chemical 
antagonism is the counteraction of d-tubocurarine by suramine. Here the 
neutralizing agent reacts with an antagonistic drug; if the latter was blocking 
the action of an agonistic drug the neutralizing agent now seems to have an 
action which, in reality, is caused by the unblocking of the original agonist (44). 
The principle of antagonism by neutralization is used extensively in the treat­
ment of intoxications by heavy metals: the action of dimercaprol against 
arsenic compounds and of sodium versenate against lead are attributable to it. 
2. Competitive antagonism. In the preceding text it was shown that this kind 
of antagonism takes place on the level of the receptors of one receptor-effector 
system. Of course it is quite possible that the competitive antagonist also has 
antagonistic or even agonistic properties with regard to other kinds of re­
ceptors (VJ,). 
5. Noncompetitive antagonism. Different kinds of antagonism come under 
this heading. They have in common that the antagonist interacts with its own 
receptors, different from those of the agonist. However, the interaction of the 
noncompetitive antagonist with its receptors does not lead to an independent 
effect; instead it causes a change in the relation between the agonist concen­
tration in the direct vicinity of the agonistic receptors and the resulting (ago­
nistic) effect. This model is formally analogous to the more recent model of 
allosteric effects in enzymology (690). Two essentially different possibilities can 
be distinguished : 
a. The change in the receptors of the antagonist results in a change in the 
receptors of the agonist. This change causes the affinity between the agonist 
molecules and their receptors to be reduced (45). The type of antagonism in 
question will further be indicated as metaffinoid antagonism. A metaffinoid 
system has a formal similarity with what in enzymology is indicated as a 'pure 
K-system'. 
b. The change in the receptors of the antagonist interferes with the ability of 
the receptor-effector system of the agonist to respond to the interaction between 
the agonist and its receptors ; in other words : it seems as if the intrinsic activity 
of the agonist is decreased. This kind of antagonism is generally meant when 
the term noncompetitive antagonism is used as such. It will further be indicated 
as metactoid antagonism. It seems that a term for the analogous system in 
enzymology (which, for instance, could be called a 'pure V
m
aX-system') has not 
been introduced. 
It seems not unlikely that the levels on which various metactoid systems inter­
fere with the receptor-effector system of the corresponding agonists may be 
different. The result of the interaction between the antagonist and its receptors 
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could be that the effector organ of the agonist partially or completely loses its 
possibility to react on stimulation; on the other hand it could be that the inter-
action between the agonist and its receptors results in a smaller stimulus, or 
that the chain of events between stimulus formation and effect is interrupted 
at some level, again partially or completely. So far these kinds of differences 
cannot be demonstrated experimentally except in a few cases only, so that the 
metactoid antagonists for the present are classified in one group. 
4. Physical antagonism. Two drugs activate two independent receptor-
effector systems and the resulting effects counteract each other. The pupil of 
the eye may again serve as an example. The parasympathetic nerves secrete 
acetylcholine, which causes contraction of the musculi constrictores pupillae: 
the pupil narrows. But at the endings of the sympathetic nerve fibres another 
substance, noradrenaline, is secreted and this causes a contraction of the mus-
culi dilatatores pupillae, resulting in widening of the pupil. Both substances are 
agonists for their own receptor-effector systems, but in view of the ultimate 
effect they are antagonists of each other. Another example of physical anta-
gonism is the antagonism between a substance which causes an increase of the 
blood-pressure by stimulation of the hart action and another substance which 
causes a decrease of the blood-pressure by vasodilatation. 
5. Functional antagonism. The position of this kind of antagonism is some-
what ambiguous. One possibility is to define it in a negative way: functional are 
those cases of antagonism which express themselves in a parallel shift of the 
agonistic concentration-effect curve along the concentration axis, in this respect 
corresponding with a competitive antagonism (see p. 41), but which do not 
come under one of the headings mentioned so far (41). But also another defini-
tion is used, having many features in common with that of physical antagonism: 
it is then supposed that two agonists, interacting with two independent receptor 
systems, cause effects which counteract each other, but that, in contrast with 
the physical antagonism, both effects are realized in the same effector system 
(46, 55)-
The name functional antagonism was originally used for the antagonistic 
relation between a sympathetic and a parasympathetic nerve impulse on one 
effector organ, thus, for instance, in connection with the antagonism between 
the effects of acetylcholine and noradrenaline on the smooth muscle fibres of 
the gut. From this example the second definition follows almost by itself. It is 
rather questionable, however, whether both definitions are equivalent. It seems 
not unprobable that the second definition applies only to one certain kind of 
'functional antagonism' according to the first definition, which, by the way, 
hardly means anything more than 'antagonism e causa ignota'. Anyhow it is 
not advisable to use the term without agreeing on its exact meaning previously. 
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For the rest it may be stressed that formally the model behind the second 
definition is not essentially different from that of the physical antagonism ; an 
effector organ that is considered a unit may yet be composed of separate sub-
units, one being responsible for the positive effect, another for the negative one. 
The distinction between physical antagonism and this kind of functional anta-
gonism, therefore, is of a different order as that between physical antagonism 
and, e.g., competitive antagonism. 
To complicate things further it may be mentioned that if experimental con-
centration-effect curves are made with the cholinomimetic drug furtrethonium in 
presence of various concentrations of the ß-adrenergic compound isoprenaline 
on the isolated jejunum of the rat, the results tally rather well with the theoret-
ical curves based on the formula for metaffinoid antagonism (see p. 57), whereas 
the formula proposed by Ariens et al. for functional antagonism according to 
the second definition (46, 55) does not cover the experimental results unless 
additional suppositions are made. The conclusion that the position of the so-
called functional antagonism is still far from clear seems justified. 
CLASSIFICATION OF DRUGS IN FAMILIES 
For many purposes it is useful to classify drugs in pharmacological families. 
Such a family includes all drugs which are able to interact with the same type 
of receptor-effector system, and which, by doing so, can cause the same kind of 
effect. By determining to which family a new drug belongs some predictions 
about its behaviour in the organism may become possible and valuable clues 
may be obtained for further research. 
This basis for classification is serviceable especially for agonists and com-
petitive antagonists. Agonists and competitive antagonists with affinity to the 
same receptors have quite different effects, and in consequence may be con-
sidered to belong to different families. Yet pharmacologically the members of 
two such group may be related, since they have affinity to the same receptors. 
This relationship of agonists and corresponding antagonists finds expression 
in the fact that often a gradual transition from one group to the other may be 
found via compounds with intermediate properties, the previously mentioned 
dualists. 
The families are often named after some typical member ; a family of anta-
gonists may also derive its name from a typical member of the corresponding 
family of agonists. For families with agonistic properties there are such names 
as, for instance, 'histamine-like drugs' or' histaminomimetics', 'adrenergic drugs' 
etc.; for the antagonists names like 'atropine-like drugs' or 'anticholinergic 
drugs', 'antihistamines' or 'histaminolytics', etc. exist. 
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In the case of the noncompetitive antagonists a proper division is often more 
difficult, since in a number of cases it is not known whether all drugs that 
counteract a certain effect do so via the same receptors. For reasons of con-
venience investigators may indicate drugs as being, e.g. 'papaverine-like' or 
having 'papaverine-like action', but this does not necessarily mean that these 
drugs belong to one family, as defined above. 
In practice the limits are not always as sharp as in theory. There are two 
reasons for this. First, the molecules of a drug may have affinity to more than 
one kind of receptors. If this is so, the affinity to one kind is usually far the 
greater, so that the interactions with other kinds of receptors do not play a 
role, - unless the drug is administered in an unusual way or in doses much higher 
than customary. It may be stated that this holds for many of the drugs in use. 
The expression 'Any effect can be caused by any drug, if only the dose is high 
enough' reflects, with some exaggeration, a certain amount of practical ex-
perience. A drug is classified in accordance with its highest (or 'specific') 
affinity, but in the cases that the difference between the affinities to the different 
receptors is not too large, such a drug is considered to belong to different 
families at the same time. Examples are the so-called a- and ß-action of adrenal-
ine (15), the muscarinic and nicotinic action of acetylcholine (221), etc. 
Secondly not all receptors and effectors of one kind are completely identical. 
It is well-known, for instance, that the interaction of histamine with its re-
ceptors may cause the contraction of smooth muscle fibres. The receptors and 
the contractile elements in question may be situated in a number of different 
organs and the different organs may belong to different kinds of animals. It is 
hardly probable that in all cases the receptor-effector systems would be ab-
solutely identical. Nevertheless they are equal to a very high degree, enough to 
consider them one kind when classifying pharmaca. But then it is not surprising 
when the ratio of the affinities of two members of one family to the common 
receptor appears somewhat different in different organ systems. It may even 
happen that a drug has a low but distinct affinity to the receptors in one case 
and so belongs to the family, but in another case - the affinity being still lower -
is considered inactive; of course the limit between 'low affinity' and 'no affinity' 
is something arbitrary. Yet another possibility is that a drug is agonistic in one 
animal species, but belongs to the corresponding family of competitive anta-
gonists if tested in another kind. Fortunately all such phenomena are details 
that cannot obscure the over-all image. 
EXPERIMENTS ON ISOLATED ORGANS 
The family to which a certain drug belongs may be determined with a com-
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paratively easy pharmacological technique: that of establishing the relation 
between the concentration of the drug and its effect - the making of 'con-
centration-effect curves'-with the aid of simple isolated organs. Also for 
finding further data about affinity ratios and intrinsic activity ratios within a 
family this kind of experiments is of much value. 
The attraction of using isolated organs lies, of course, in the reduction of the 
amount of variables which have to be taken into account. What is really of 
interest is the relation between the concentration of the drug in the direct 
vicinity of the receptors and the change caused in these receptors, but what is 
learned from experiments is something quite different, namely the relation 
between the dose administered and some measured effect. Is it possible to 
deduce the first relation from the second? 
When a dose of a certain pharmacon is administered to a patient or an ex-
perimental animal, the chain of events leading to the final effect consists of three 
main parts with different characters (fig. 4). 
D R U G TRANSFERENCE 
absorption 
circulation 
transport through 
membranes 
(active and passive) 
fixation to and 
liberation from 
binding sites 
metabolic activation 
and inactivation 
excretion 
PHARMACON-RECEFTOR 
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of effector system 
initial state 
of effector system 
contraregulalions 
(local and systemic) 
-PHARMACOLOGICAL EFFECT 
FIG. 4. Schematic representation of the chain of events leading from the administration of 
a drug to a pharmacological effect. Three consecutive steps with different characters can be 
distinguished. 
I. The administration results in a certain concentration in the so-called bio-
phase (301, 502, 325, 347)9 i.e. the direct vicinity of the receptors, or, more 
exactly, that compartment of the system in which interaction with the receptors 
takes place. This concentration depends on the amount of the drug given but 
also on many other factors, partly unknown. There are, among other things, 
the way of administration, the location of the receptors in the organism and 
the amount of silent receptors for this drug, properties of the drug such as 
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water- or fat-solubility, surface tension and the ratio of dissociated and un-
dissociated molecules at the existing pH, and also the possible influence of the 
metabolism on the drug; - an influence that may result in a bioactivation (if the 
product of metabolism is more active than the original drug) or, more com­
monly, in an inactivation. 
2. The presence of the drug int he biophase leads to interactions between drug 
molecules and receptors and thus to a change at receptor level. The magnitude 
of this change depends on the concentration of the drug in the biophase, and 
further on its affinity to the receptors and its intrinsic activity. The result of the 
drug-receptor interactions at receptor level is the formation of a so-called 
'stimulus' (926). The stimulus formation should not be seen as a phenomenon 
that occurs subsequently to the drug-receptor interaction; the stimulus is a 
purely theoretical magnitude and its formation just is an aspect of the inter­
action of an agonist with its receptors*. 
By definition the stimulus has a linear relationship to the number of Occupied' 
receptors**. In another vision the stimulus is supposed to be directly propor­
tional to the number of drug-receptor interactions taking place per unit of time 
('rate model', 752, 755, 754, 755; cf. also 595, 792). Since the concentration-
effect curves from which the affinity values and the intrinsic activity values are 
calculated (see chapter IV) are assumed to represent equilibrium responses, 
and in a situation of equilibrium the number of drug-receptor interactions is 
directly proportional to the number of 'occupied' receptors, the difference 
between the two models has no consequences with regard to the subjects to be 
discussed in what follows. 
Originally the 'rate model' was set against the Occupation model', but this 
seems hardly justified ; both models give a physico-chemical interpretation of 
the concepts intrinsic activity and stimulus formation which may have its 
counterpart in reality. Many authors have published more detailed models for 
certain cases of drug-receptor interaction (95, 172, 2ΐγ, 547, 644, 8io) or for 
drug-receptor interaction and stimulus formation in general (96,97,98, 99,185, 
186, 189, 480, 543, 579, 644, 645, 753, 794, 1002). Among these are the occu­
pation theory introduced by Clark (189), the flux-carrier hypothesis of Mackay 
* This is overlooked by Changeux (186) when he states that in his model of drug-receptor 
interactions 'the introduction of an 'intrinsic activity' of the drug is no longer necessary'. 
** Stephenson introduced the stimulus S as a relative magnitude, and thus defined it as 
having a linear relationship to the proportion of the receptors which are occupied, whereas 
the definition given here applies for the absolute stimulus. Stephenson's S equals the quotient 
SA/Spmax, in which SA represents the stimulus caused by a certain concentration of the drug 
A and Spmait the stimulus which causes the effect i Emax in the same receptor-effector 
system (see p. 39). 
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(644), the rate theory and the dissociation theory of Paton and Rang (753), the 
theory of induced conformational perturbation of Belleau f96, 97, 98, 99J, pat-
terned in part after Koshland's induced-fit theory of enzyme action (579), and 
the model of Changeux et al. (185, 186) which is patterned after the model for 
allosteric oligomers in enzymology (690^ and which is closely related to 
Belleau's model. It should be realized, however, that the concepts under dis-
cussion can be handled without any definition of the physico-chemical pro-
cesses which find an expression in them. Although in this chapter the occupation 
model is used in order to illustrate the concepts in question, these concepts are 
by no means dependent on the model used. 
3. The stimulus results in the measured effect. However, there may be many 
steps in between, and all kinds of relations between them are conceivable: 
linear, all-or-none, or other kinds of non-linear relations. The character of the 
stimulus-effect relation may depend on the question which phenomenon is 
chosen as 'effect' ; in the case of a spasmogen, for instance, the 'effect' can be 
the contraction of a muscle, the depolarization of a membrane, the flux of 
potassium and sodium ions, etc. Anyhow, when the stimulus formation is 
accomplished, the process is no longer drug-dependent: a certain stimulus 
always gives a certain effect, if, atleast, the effector system itself remains constant. 
The situation now is the following: phase 2 is the object of study, but the 
known magnitudes that can be controlled or measured are at the beginning of 
phase 1 (the dose) and at the end of phase 3 (the effect). The only possible way 
out is either to keep phase 1 and phase 3 constant, or to eliminate them. As 
for phase 1, keeping this phase constant over some time in the total animal is 
extremely difficult. Factors as redistribution and breakdown cause the drug 
concentration in the biophase to change from moment to moment; not only 
the maximal concentration reached but also the time in which this concen-
tration is reached may vary from occasion to occasion, so that the making of 
comparable quantitative measurements is nearly impossible. Administration of 
the drug by means of an intravenous infusion of longer duration may result 
in an equilibrium in the biophase for some time, but also then the situation 
remains difficult to handle. 
The solution is found in experiments on isolated organs. The only deter-
mining factor in phase 1 now becomes the concentration of the pharmacon in 
the bath fluid, the influence of factors as metabolism being considerably re-
duced, and generally a situation of equilibrium is reached easily and rapidly. 
Also, but in smaller measure, phase 3 will be less disturbing, since usually 
simpler effects can be studied than in the total animal. All facts considered and 
in spite of their limitations, isolated organ experiments are the main tool of 
molecular pharmacology,- although not the only one. 
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THE MODEL OF AGONISM 
The technique of making concentration-effect curves with the use of isolated 
organs will be discussed in the next chapter. To conclude this theoretical part, 
further consideration of the hypothesis of drug-receptor interaction is necessary 
in order to elucidate the conclusions drawn from the characteristics of these 
curves. 
With a few assumptions the calculation of theoretical graphs of agonist con­
centration and effect becomes possible,- and also the prediction of the influence 
of different concentrations of an antagonist, and of different kinds of anta­
gonists, on the position and shape of these curves. At this point it may already 
be stated that up to now the curves found in experiments tally surprisingly well 
with these theoretical predictions. 
The hypothesis starts with the supposition that pharmacon molecule and 
receptor interact in the way of an uncomplicated reversible bimolecular re­
action : 
R + А ч± RA 
in which A is a drug molecule, R the free receptor, and RA their interaction 
product. It is assumed that in this system the law of mass action holds (190) : 
[R] [A] 
IRÄT = KA (I) 
[A] being the concentration of the drug molecules in the biophase, [R] the 
concentration of the free receptors, [RA] the concentration of the occupied 
ones, and KA the dissociation constant of the pharmacon-receptor complex. 
KA is inversely proportional to the affinity of A to R, so that I /KA can be used 
as a measure for the affinity (affinity constant) (190, 191). 
The concentration of the free receptors plus that of the occupied ones is equal 
to the total receptor concentration [r] : 
[R] + [RA] = [r] (2) 
Now the question arises: in what way does the concentration of the occupied 
receptors [RA] depend on [A]? However, [RA] not only depends on [A], but 
as appears from the foregoing, also on the total amount of receptors present, 
therefore on [r]. This factor being unknown the question can better be for-
mulated as follows: in what way does the fraction of the receptors which is 
occupied, [RA]/[r], depend on the pharmacon concentration [A]? 
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According to (2) 
[RA] 
[г] 
[RA] 
[г] 
and since according to (1) 
[R] 
[RA] 
it follows that 
[RA] 
[r] 
[RA] 
[RA] + [R] 
I 
i + t R ] [RA] 
KA 
[A] 
I 
L. K A 
(3) 
[A] 
In the experiment with simple isolated organs it is assumed that the con­
centration in the biophase is equal to, or at least directly proportional to the 
concentration in the bath fluid. This is a permissible assumption if the system 
is given time to reach an equilibrium. It is further assumed that the concen­
tration in the bath fluid is directly proportional to the dose given. This is true 
only if the concentration of the drug molecules is very high in comparison with 
the total amount of receptors in the organ,- both specific and silent -, so that 
the concentration does not change notably by the formation of the pharmacon-
receptor complexes. Within the usual dose ranges this is actually the case, 
so that for [A] the concentration in the bath fluid, as calculated from the dose 
added, can be taken. 
The other unknown in equation 3 is the receptor occupation. From the de­
finition of the stimulus given before it follows that the stimulus generated is 
directly proportional to the concentration [RA] : 
SA=g[RA] (4) 
in which SA is the stimulus caused by a certain concentration of drug A. The 
maximal stimulus that possibly can be caused by drug A on the receptors in 
question (SAmax) will be reached when [RA] has its maximal value. This is the 
case when all receptors are occupied, thus when [RA] equals [r]. From this 
follows that 
SAmax=g[r] (5) 
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and combination of the equations 4 and 5 gives 
SA _ [RA] 
SAmax [rJ 
Combination of this equation with equation 3 results in 
S A I 
SAmax K A 
! + • 
(6) 
(7) 
[A] 
It would be possible to calculate the affinity constant from this formula if the 
stimuli could be measured directly, but this is not the case. Only the effects 
resulting from the stimuli can be determined ; the relation between stimulus and 
effect, however, is unknown and in many cases it surely is a nonlinear function. 
(The stimulus-effect relation characterizes the receptor-effector system.) 
If the simplest case, a linear relationship between stimulus and effect is 
assumed, the following equations hold : 
Е А = Ь 8 А (8) 
and 
Едтах = h SAmax (9) 
in which EA is the effect caused by a certain concentration of A, and Едтах is 
the maximal effect that can be reached with this drug in the receptor-effector 
system in question. Equations 8 and 9 may be combined to give: 
EA SA 
Ь д т а х bAmax 
so that in this case the equations 6 and 7 may be changed into : 
EA [RA] 
and 
Елтах [г] 
E A I 
Елтах K A 
(10) 
00 
In equation 11 the only variables are the drug concentration and the relative 
effect, and since these are measurable values, theory and practice can be com­
pared. As will be discussed in chapter IV, equation 11 is the basis for the cal­
culation of the so-called pDa-value, a frequently used (but rather inexact) 
measure for the affinity of an agonistic drug. 
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INTRINSIC ACTIVITY IN THE AGONISTIC FORMULA 
In equation u which gives the relation between drug concentration and 
relative effect the factor intrinsic activity is not found. The constant g in equa­
tion 4, however, which gives the relation of [RA] and SA, contains this factor. 
Yet g does not represent the intrinsic activity itself. The intrinsic activity of a 
pharmacon determines to which extent the interaction between this pharmacon 
and its receptors results in a stimulus. The stimulus SA, however, is not a 
relative magnitude (cf. p. 31). Each pharmacon-receptor interaction in the test 
organ contributes to it; consequently SA is directly proportional to the number 
of interaction products - in an absolute sense - in the organ. If this number is 
called QRA, the relation may be formulated as 
S A = a Q R A (12) 
and this proportionality constant a actually represents the intrinsic activity. 
The concentration of RA in the biophase is [RA], and if this term is multi­
plied by the volume V of the biophase in the organ used, the product is QRA. 
Equation 12 therefore can be written as 
S A = a V [ R A ] (13) 
It follows that the factor g in equation 4 represents the intrinsic activity multi­
plied with the volume of the biophase in the organ. 
Since the volume V and the concentration [RA] are unknown and also the 
stimulus SA cannot be measured directly, the absolute value of the intrinsic 
activity a cannot be determined. If, however, two agonists Ai and A2 which 
belong to one family are tested on the same preparation, the ratio of their in­
trinsic activities, аі/аг, is independent from the volume of the biophase and the 
receptor concentration. Substitute g in equation 5 by aV : 
SAimax= ai V [r] 
SA2max = аг V [г] 
therefore ai SAimax 
7" = ^ ( I4) 
It will be demonstrated that a practical estimation of the value of such a quotient 
is possible (see p. 73-77). 
If the intrinsic activities of the members of an agonistic family are all ex­
pressed in relation to the intrinsic activity of one reference compound from the 
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same family, the relative intrinsic activity values thus obtained are a suitable 
basis for comparing the intrinsic activities within the family in question. In 
principle it is immaterial which drug serves as a reference; the choice only 
determines the scale on which the relative intrinsic activities of the members of 
a family are expressed and has no influence on their mutual ratio. Theoretically, 
however, it seems preferable to express the intrinsic activity of a drug in relation 
to the highest intrinsic activity in the family. The relative intrinsic activity of a 
drug A, expressed in this way, is indicated as a. It follows that α may be defined 
as 
amax 
(15) 
in which a is the (absolute) intrinsic activity of drug A and amax the highest 
(absolute) intrinsic activity in the family. 
A drug with intrinsic activity amax is able to cause the maximal stimulus that 
can be brought about via the receptor system in question. If this absolutely 
maximal stimulus is called S
ma
x, the equations 14 and 15 can be combined to 
give 
ûAmax . ,. 
α = (ι6) 
The advantage of the definition of the (relative) intrinsic activity constant given 
above is that the intrinsic activities of all agonistic families would uniformly 
range from о to 1, so that a given value of α holds a direct information about 
the position of drug A within its family. On the other hand the practical diffi­
culty arises that it is generally not yet known which drug has the highest in­
trinsic activity in a family (especially since a maximal effect does not neces­
sarily mean a maximal stimulus ; see p. 53-56). Moreover, only effects and not 
stimuli can be measured directly. In view of these limitations the use of other, 
practical expressions of the intrinsic activity is necessary. 
At present two practical expressions of the intrinsic activity are in use, either 
having its own field of application. The older one, introduced by Ariens (39) 
may be defined as 
„ Ьлтах 
α Ε = — ( I 7 ) 
This magnitude was introduced as a,- under the assumption, however, that 
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Stimulus and effect are directly proportional*. If this is really the case it follows 
that 
öAmax i^Amax 
Ьшах Ь'Шах 
and thus that a E equals α indeed. If, however, the stimulus-effect relation is not 
linear a E is a value with an unknown relation to the α defined above. 
If the stimulus-effect relation is linear, equation и was shown to apply 
(p. 35). Under the same supposition equation 17 can be transformed into 
ËAmax 
= α 
¿•max 
and combination of this equation with equation 11 gives a formula in which the 
affinity as well as the (relative) intrinsic activity is represented : 
-gi-- α OS) 
Emax K-A 
The determination of a E is relatively easy. It seems acceptable to take the 
maximal effect of the most effective drug known in a family as E
m a
x with respect 
to the receptor-effector system in question, since in most families of agonists 
the number of members tested is considerable and in each family the maximal 
effect can be reached with a number of them. 
The merit of the a E is that it indicates directly whether a drug is a full agonist, 
a partial agonist or a competitive antagonist. The value of a E ranges from о to 
1 ; an a E with the value 1 designates a drug as a full agonist whereas for a 
competitive antagonist a E equals zero. Drugs with an intermediate value of a E 
are the earlier mentioned partial agonists or competitive dualists. 
In the study of structure-activity relations, however, the a E has a very limited 
value. In this kind of study one of the relevant informations would be the ratio 
* In his earliest publications (39, 42, 43, 44, 47, S3) Ariens defined the intrinsic activity 
of a pharmacon as 'the contribution to the effect per unit of drug-receptor complex' and 
identified it with the proportionality constant α in the relation EA = a[RA] Formally this 
α is the product of the factors g and h in the equations 4 and 8, and thus represents the in­
trinsic activity of the drug - in an absolute sense - multiplied with some factors which are not 
drug-dependent. From the practical applications of the formula, however, it is evident that 
the intrinsic activity constant α was considered a dimensionless relative magnitude from the 
beginning: Ел is always expressed as a percentage of Emax and [RA] as a percentage of [r]. 
Thus the 'unit of drug-receptor complex' in the definition should not be understood as an 
amount of drug-receptor complex with a defined magnitude but as a defined fraction of the 
total amount of receptors in the organ used, and the definition itself has reference to the 
relative intrinsic activity and not to the intrinsic activity in an absolute sense. 
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of the true intrinsic activities in a family of agonists. If the stimulus-effect re­
lation is not linear, however, the ratio between the respective aE 's is different 
from the ratio of these true intrinsic activities. Therefore the use of another, 
recently defined intrinsic activity constant, a s , is indicated for this purpose (82j, 
828). A method for the calculation of this a s will be discussed in chapter IV 
(p. 73). The essential difference with a E is that under certain general suppositions 
(cf. p. 43-45), but without any presuppositions about the character of the stimu­
lus-effect relation, a s has the same fixed relation to α for all members of a family. 
Instead of a special supposition concerning the character of the stimulus-effect 
relation comes the more general assumption that in a certain receptor-effector 
system the magnitude of the effect is dependent only on the magnitude of the 
stimulus and not on the way in which the stimulus was created. (The stimulus-
effect relation is 'system-dependent' and not 'drug-dependent'.) 
a
s
 is no approximation of α itself but of α multiplied with a certain factor. 
It is thus defined that if the general suppositions made agree with reality, the 
following relation holds : 
in which Spmax is the maximal stimulus that can be generated by a (hypothetical) 
partial agonist of the same family, which maximally can cause an effect equal 
to \ Emax. (Since within a family equal effects are supposed to correspond with 
equal stimuli (see above), Spmax indicates the stimulus which corresponds with 
the effect \ Emax, no matter by which agonist this effect is caused.) Comparison 
of equation 19 with equation 16 shows that 
a
s
= Ι φ a 
in which φ is a family constant representing the ratio of S
m
ax and Spmax and 
thus being dependent on the stimulus-effect relation in the receptor-effector 
system in question. It follows that every family of drugs has its own scale for 
the as-values; an isolated a s does not indicate whether the drug in question has 
a high or low intrinsic activity, but the ratio of the as-values within the family 
is the same as the ratio of the corresponding true values of a,- again if the 
general suppositions made are true. 
If the relation between stimulus and effect is linear 2 Spmax equals Smax so 
that φ = 2 and a s = a. 
The a s is analogous to the constant e ('efficacy') introduced by Stephenson 
(926). From the convention adopted by this author that 'a drug which occupies 
all receptors to produce an effect which is only 50 % of the true maximum has 
an efficacy e = 1', it follows that e = 2 a s . 
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THEORETICAL CONCENTRATION-EFFECT CURVES; DIFFERENTIATION 
BETWEEN TWO ESSENTIALLY DIFFERENT TYPES OF ANTAGONISM 
The relation between the concentration of an agonist in the biophase and the 
resulting stimulus - or the resulting effect, supposed that stimulus and effect 
are linearly related - depends on the two magnitudes affinity and intrinsic 
activity, and on these two magnitudes only. By substituting different values for 
[A] in equation 18, with given values of α and KA, a theoretical concentration-
effect curve can be calculated. Another curve will be obtained if the same value 
for α but a different KA are filled in and if then again a series of different values 
for [A] are substituted in the formula. Repeating this procedure a number of 
times, a set of curves representing the concentration-effect relations for a 
.10"eM [A] [A] 
FIG. 5. Theoretical concentration-effect curves based on equation 18. The path of the curves 
is given from [A] = ί ο - 8 M to [A] = ιο_ <·5 M ( = 3162· ίο - 8 M). 
Fig. 5A and 5в: Sets of curves made with different values for KA and the same value for a. 
In fig. SA the curves are plotted on a linear concentration axis, in fig. 5B on a logarithmic 
concentration axis. 
Fig. sc and 50: Sets of curves made with different values for α and the same value for KA. 
In fig. sc the curves are plotted on a linear concentration axis, in fig. 50 on a logarithmic 
concentration axis. 
40 
hypothetical family of drugs differing in affinity only will be acquired. The same 
may be done with constant KA and different values for a; another set of curves 
will be produced, this time for a hypothetical family of drugs differing only in 
intrinsic activity. The two sets of curves show essentially different characteristics 
so that it may be expected that the two possibilities, a change in affinity and a 
change in intrinsic activity, will be discernible also in practice. 
It is recommendable to plot the curves on a linear scale for the relative effect 
but to use a logarithmic scale for the concentration of the pharmacon. This 
procedure has a practical advantage, since a linear scale does not offer the 
possibility to draw a whole set of curves on a single graph,- unless it is made 
awkwardly long -, but its chief merit is that it shows very clearly the character­
istic difference between a set of curves made with different values for KA, and 
one made with different values for α (fig. 5). 
If the affinity is kept constant but different values are substituted for the 
intrinsic activity, the curves occupy the same part of the concentration axis but 
are different in shape, differing particularly in their slopes and maximal heights. 
Suppose that equal concentrations are used of a drug Ai and a drug A2, having 
the same KA but different intrinsic activities : 
E A I _ 0.1 E A 2 _ 0.2 
Emax K A I E
m t tx K A 2 
JÄH IÄÜ 
Since K A I = KA2 and [Ai] = [A2] it follows that 
EAI _ Oi 
EA2 _ Иг 
The ratio of the effects of equal concentrations is constant, in other words : 
the concentrations corresponding respectively with the beginning, middle and 
end of the curves (i.e. in practice 1 %-, 50 %- and 99 %-points) are equal. Of 
course this holds regardless of the character of the concentration axis (fig. 5c, D). 
If, however, the intrinsic activity is kept constant and only the affinity differs, 
the curves are all identical in shape; the only difference is their respective 
position on the concentration axis. This is true if a logarithmic concentration 
scale is used, but does not hold if the scale is linear (fig. 5A, в). Suppose that 
the concentrations [Ai] and [A2] of the drugs Ai and A2 cause effects of equal 
magnitude: 
E A I _ E A 2 
Emax Emax 
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and thus, according to equation 19: 
αϊ ai 
. ΚΑΙ , KA2 
1
 + ΓΛ~Ί l + ТГ~л [Αι] [A2] 
Since the drugs have the same intrinsic activity, it follows that 
KAI _ KA2 [A2] _ KA2 . . 
[ A J - [ A j o r [Ä7]_Ki; ^20' 
This means that the ratio of equieffective concentrations of the two drugs has 
a constant value. Thus, if the curves are plotted on a linear concentration scale, 
they will not be identical in shape. From equation 20, however, it follows that 
log [A2]-log [AJ = log £±2 
i t Al 
- in other words the difference between the logarithms of the equieffective con-
centrations is constant and independent of the concentrations. Thus, if the data 
are plotted on a logarithmic concentration scale, graphs with identical shapes 
will result. 
The foregoing gives occasion to observe an important fact regarding the 
possible kinds of antagonism between different drugs in relation to the same 
effector organ. The chemical and the physical antagonism do not come under 
this heading, since the former bears upon the drug transference only and the 
latter is effected via different effector organs. For the other kinds of antagonism 
it holds that, if the relation between stimulus and effect of the agonist remains 
linear, formally the antagonist can express its influence only either as a change 
in the affinity of the agonist or as a change in its intrinsic activity, whatever its 
true mechanism. Of course also combinations of the two possibilities are to be 
expected, but that does not alter the principle. 
It follows that a formula relating concentration and effect of an agonist A 
in presence of an antagonist В will have one of the two following basic shapes, 
or a combination of them : 
EAB _ / ( B ) a EAB _ a 
Emax . K-Α Emax . ƒ (Β) KA 
+
 [A] ' + [A] 
If the presence of drug В results in a perfectly parallel shift of the agonistic 
curve, the phenomenon will be covered by the second formula ; if it results only 
in a change in the slope of the curve (the maximal height being reduced), the 
first one will be applicable. 
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In practice the phenomenon of the parallel shift often is called 'competitive' 
and that of the change in slope 'noncompetitive', since the competitive inter-
action and the noncompetitive metactoid interaction, respectively, are the best-
known causes of the two phenomena. It should be realized, however, that the 
expressions 'competitive' and 'noncompetitive', if used in this sense, have 
nothing to do with the mechanism of the interaction. As for a shift of the con-
centration-effect curves, in practice it is often impossible to determine whether 
a shift is perfectly parallel as defined earlier. But even when it is sure that the 
shift has all characteristics of a 'competitive picture' it does not necessarily 
mean that the interaction is based on a competition for receptors which com-
pletely or partially coincide : the same picture may be found when the agonist 
and antagonist have totally different receptors (see p. 61). 
On the other hand it is true that the pure 'noncompetitive picture' of a change 
in the slope of the curve without a shift cannot result from a competition 
between two drugs for the same receptors, but even here some caution is 
necessary. Theoretically a competitive drug may be imagined which (formally) 
causes a change in the affinity of the agonist (by virtue of the competition) and 
at the same time a change in its intrinsic activity (by means of an influence on 
formation or propagation of the stimulus resulting from the interaction of the 
agonist with the receptors). The presence of various concentrations of such a 
drug would result in a set of curves with 'noncompetitive' as well as 'competitive' 
features, whereas the interaction mechanism would be really competitive. 
The conclusion should be that competitive interaction and noncompetitive 
interaction in the proper sense of the word are very different, but not always 
discernible, and surely not in the first instance. The only differentiation that 
can be made at sight with passable safety is between interaction resulting in a 
(formal) change in affinity, and interaction resulting in a (formal) change in 
intrinsic activity. 
DISCUSSION OF THE PRESUPPOSITIONS IN THE AGONISTIC MODEL 
A few words should be devoted to the presuppositions made so far in the 
model of agonistic action and to the conditions for their validity. A number of 
general suppositions and a few special assumptions with respect to experiments 
on isolated organs were made : 
i. The specific effect of a drug is caused by the interaction of the drug 
molecules with their receptors. 
2. The same extent of interaction between the receptors and a certain agonist 
always results in an effect of the same magnitude.-This may be not absolutely 
true, since as a result of growth, illness, involution and such the properties of the 
43 
receptor-effector system may change, but in any case there should be a re-
cognizable regularity in this relationship, otherwise a scientific approach of 
pharmacological problems would be impossible. Anyhow, in well-executed 
experiments on isolated organs, lasting a relatively short time, such factors need 
not be disturbing. 
3. The drug concentration in the biophase is equal to, or at least linearly 
related to that in the bath fluid.- Since simple isolated organs are used, this 
supposition is not too improbable; it should be taken into account, however, 
that in certain cases the relation may be less simple. 
4. For practical reasons only, the concentration in the bath fluid is supposed 
to be calculable directly from the volume of the bath fluid and the dose given. -
This is made acceptable by the conditions that drugs should be used which are 
stable in aqueous solution for some time and that the number of drug molecules 
should be very large compared with that of the receptors (specific and silent 
receptors together), so that the formation of drug-receptor combinations does 
not influence the concentration of the free drug molecules appreciably. If need 
be, the concentration in the bath fluid may be determined directly. 
5. The interaction between drug molecule and receptor can be described as 
a reversible, bimolecular reaction. 
6. If equilibrium is established, the relation between the concentration of 
the drug in the biophase and the percentage of the receptors which are in inter-
action with the drug is governed by the law of mass action.- This will be per-
fectly true only if the reaction between drug molecules and receptors is re-
versible and if all drug molecules on the one hand, and all receptors on the other 
have equal chance and equal ability for interaction. The drug molecules may be 
homogeneously distributed in the biophase but it does not seem very probable 
that this holds also for the receptors ; there may be cases where the receptors 
are concentrated on the surface of a membrane, or are grouped in another way 
deviating from the regular. So long as all receptors have more or less equal 
ability and chance for interaction, however,- and the condition that the amount 
of drug molecules should be large in comparison with the amount of receptors 
gives a greater probability to this supposition - the law of mass action will give 
a usable description of the system. The Langmuir isotherm that describes the 
relation of the concentration of a chemical substance and the amount of it 
absorbed on a surface formally answers to the mass action law,-which may 
describe the situation only approximately, but apparently well enough for most 
practical purposes. Likewise the supposition that the law of mass action gives 
a usable description of the situation in the biophase cannot be rejected on 
theoretical grounds. 
7. The relation between stimulus and effect is supposed to be dependent only 
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on the nature of the receptor-effector system and not on the agonist by which 
the stimulus is generated. If separate values for affinity and intrinsic activity 
should be derived from the experimental concentration-effect curves this is the 
minimal supposition about the stimulus-effect relation that has to be made. 
It may be recalled here that the stimulus is linearly related to the number of 
Occupied' receptors by definition (see p. 31). 
8. In the derivation of the equations 11 and 18 it was assumed that the 
relation between stimulus and effect is linear. In this more special assumption 
the preceding one is implied. 
In reality, a direct proportionality of stimulus and effect does not seem to be 
the rule ; in a number of cases the experimental results are not explicable on the 
basis of a direct proportionality of stimulus and effect. If the assumption is 
maintained that in one kind of receptor-effector system equal effects always 
originate from equal stimuli, but if the relation between stimulus and effect is 
not further defined, equation 18 should be written as 
E A
 -fi 
/ ί
 ^ · (21) (-¿) 
The consequences of some kinds of nonlinear relationship between stimulus 
and effect have been discussed in further detail elsewhere (57) and - some 
aspects of the so-called receptor reserve excepted - will not be dealt with in this 
introduction. 
THE MODEL OF COMPETITIVE INTERACTION 
In the foregoing it was discussed what the hypothesis used predicts about the 
form of the concentration-effect curves, and how the factors affinity and in-
trinsic activity are represented in these curves. The next question is: what are 
the consequences of the hypothesis in the case of competitive interaction? 
Presume that two drugs A and В with relative intrinsic activities α and β are in 
interaction with the same receptor-effector system. Then holds 
[
ТКАТ^
 = K A
· ^ T R I F = K B ' a n d [ r ] = [ R ] + [ R A 1 + [ R B 1 
The combined effect of [A] and [B], EAB, is composed of the effect of [A] in 
presence of [B], increased by the effect of [B] in presence of [A] : 
E A B = EA(B) + Ев (A) 
45 
For the part of the effect caused by [A] holds, according to the equations ю 
and 17: 
EA(B) _
 α
 [RA] 
Emax [г] 
This equation is developed as follows: 
EA(B) _ [RA] 
Emax [R] + [RA] + [RB] 
[R] [A] 
KA 
= α — [R] [A] [R] [B] [R] + + 
KA K B 
= a-
ΚΑ , , [B] KA 
l· ι Η · —^ 
[A] K B [A] 
r
 + ( I + ^ ) ^ T V
 ^ К в Ч А ] 
(22) 
An analogous reasoning holds for EB(A), SO that 
EAB α β 
E
- ~ I + ( I + Í B ] ) K A + I + ( I + [ A ] K B W ) 
^
 K +
 Кв^ [A] * 1- ^ f к
А
;
 [B] 
Comparison of equation 22 with equation 18 which refers to the effect of [A] 
in absence of a competitor makes it clear that the influence of В on the receptor 
occupation of A finds expression only in the factor with which К A is multiplied. 
The value of this factor is greater than one ; in other words, the presence of В 
seems to enlarge the dissociation constant KA. This could be expected, since 
the competition that A experiences from В reduces its receptor occupation, just 
as would be caused by a diminution of the affinity of A. In the same way the 
receptor occupation by В is hindered by the presence of A (equation 23). 
IMPLICATIONS OF THE MODEL OF COMPETITIVE INTERACTION 
Three types of competitive interaction between an agonist A and a competing 
drug В are distinguishable, depending on the intrinsic activity of the latter. If 
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ßE equals or approaches о, В behaves as a competitive antagonist of A; if ßE 
has about the same value as aE or is larger, В is a competitive synergist of A. 
If the value of ßE lies between that of aE and о, В is called a competitive dualist; 
depending on the concentration of A the action of В will be either synergistic or 
antagonistic (fig. 9A, в). 
In the case of competitive antagonism, β being zero, equation 23 becomes 
E A B 
•+ii+g>ra 
(24) 
The presence of the antagonist results only in an apparent diminution of the 
affinity of the agonist. As shown before, this causes a shift of the concentration-
effect curve along the (logarithmic) concentration axis, without influence on the 
shape and the height of the curve (fig. 6). It will be shown, that this is true 
regardless of the nature of the stimulus-effect relation in the concerned receptor-
effector system. 
Suppose that in absence of В a certain effect is caused by the agonist con­
centration [A]i, but in its presence the same effect is caused by [AJz: 
E A I E A 2 B 
EAB/E 
no. 6. Competitive antagonism. Theoretical concentration-effect 
curves of the agonist A in presence of increasing concentrations 
of the competitive antagonist В (equation 23). 
KA = ίο-
6
 Μ, α = ι, KB = ΙΟ"
7
 Μ, β = о. 
The concentration-effect curve is shifted along the concentration 
axis to higher concentrations, without a change in the shape and 
the height of the curve. 
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Application of the equations 18 and 24 gives 
α α 
It follows that 
1 + 
KA 
[A]! I + ( I 
[Ab
 = I , [B] 
[A], K B 
[Bl K ^ 
K B [A]2 
(25) 
10" З м 
FIG. 7. Theoretical concentration-effect curves of an agonist 
A in absence and in presence of a certain concentration of a 
competitive antagonist B. 
The shift is 1.33 units. Since it is measured in the scale unit, 
it equals log [AJ2— log [A]i and this equals log (1 + [В]/Кв) 
(equation 25). It follows that the relation between stimulus 
and effect has no influence on the magnitude of the shift. 
Since the axis along which the curve is shifted is logarithmic for the con­
centrations, it is linear for the logarithms of the concentrations. The unit of this 
axis is the distance between two successive degrees of ten, and if the shift is 
measured in this unit, the result s equals log [A]2— log [AJj (fig.7). It follows 
that 
s = log f-^ and thus s = log (1 + j ^ ) 
lAJi K.B 
from which can be seen that the magnitude of the shift depends only on the 
concentration and the affinity of the antagonist. The relation between stimulus 
and effect in the receptor-effector system stimulated by the agonist does not 
play a part. 
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The model of competitive interaction started with the supposition that the 
agonist and the competitive antagonist interact with the same receptors. For­
mally this is not necessary. As discussed on p. 61, competitive antagonism can 
be seen as a special case of metaffinoid antagonism. This follows from the fact 
that equation 24 can be obtained from equation 35, but apart from this, it is 
easily understandable that if the interaction of the antagonist В with its re­
ceptors R' results in a complete disappearance of the affinity between the 
agonist A and its receptors R, and vice versa, the situation will be undistinguish-
able from a 'normal' competitive antagonism. 
As for competitive synergism and dualism, it may suffice here to present the 
sets of theoretical curves, based on equation 23 (figs. 8 and 9). 
THE MODEL OF METACTOID INTERACTION 
The next subject of discussion is the noncompetitive interaction of drugs. 
The concept 'noncompetitive antagonism' was introduced earlier (see p. 26), 
and it was shown that two essentially different possibilities come under this 
heading. First the metactoid interaction will be discussed. 
It is supposed that two drugs, A and B, interact with two different kinds of 
receptors. These receptors, R and R ', are independent of each other as for their 
interactions with A and В respectively, but the receptor-effector systems are 
interrelated beyond the level of the receptors. В as well as A is an agonist on its 
E A B / E
m a x
 , 
1.0 
0.Θ 
0.6 
0.4 
0.2 
ιό
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 id - 7 ιό" 6 ιό"5 м 
[A] 
по. 8. Competitive synergism. Theoretical concentration-effect curves of the full agonist A 
in presence of increasing concentrations of the full agonist B, A and В interacting with the 
same kind of receptors (equation 23). 
K A = Ι Ο - « Μ , a = 1, K B = I O - ^ M , β = ι. 
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FIG. 9. Competitive dualism. 
FIG. 9A : Theoretical concentration-effect curves of the full agonist A in presence of increasing 
concentrations of the partial agonist B, A and В interacting with the same kind of receptors 
(equation 23). 
KA = ί ο - ' Μ, α = I, KB = ί ο - 5 Μ, β = 0.5. 
In presence of lower concentrations of A the drug В acts as a synergist (cf. fig. 8), in presence 
of higher concentrations of A as an antagonist (cf. fig. 6). 
FIG. 9B: Theoretical concentration-effect curves of the partial agonist В in presence of in­
creasing concentrations of the full agonist А, В and A interacting with the same kind of 
receptors (equation 23). 
KB = 10-5 Μ, β = 0.5, ΚΑ = ΙΟ"« Μ, α = ι. 
own receptors, but the stimulus caused by the interaction of В and R ' (indicated 
as S Ή) does not find expression in a directly measurable effect, but only in an 
alteration of the effectiveness of the interaction of A and R. This alteration is 
here supposed to be directly proportional to the stimulus S'в. If the alteration 
is a diminution, В may be called a metactoid antagonist; if it is an enlargement, 
SO 
however, the name 'metactoid sensitizer' may be preferable to 'metactoid 
synergist'. 
If the effect of [A] is called EA, the effect of [A] under influence of [B] may 
be called EAB' and the effect of [A] in presence of the maximal stimulus in the 
metactoid system Елз'тах· The effect of В can now be seen as the insertion of 
a multiplication factor between the receptor occupation by A and the effect 
caused by this interaction. The extreme value Елз'тах therefore has a certain 
fixed relation to the original EA - the same relation as found between the 
maximal effect of the agonistic system under the influence of a maximal 
stimulus from the metactoid system (Emaxs'max) on one hand, and the original 
Emax of the agonistic system on the other. This relation depends only on the 
nature of the interrelation between the two systems, and not on the actual value 
of EA. This fact is represented in the equation 
EAS'max = ρ E A (26) 
in which the constant p, or EAS'IMX/EA, is the value that characterizes the in­
terrelation between the agonistic and the metactoid system. 
As for the stimulus formation the noncompetitive drug does not distinguish 
itself at all from a normal agonist, and therefore the following equation de­
scribing the relation between the stimulus on the one side and the concentration, 
affinity and intrinsic activity of the agonist on the other side is applicable (com­
bination of equations 7 and 16): 
S
'
B
 ß' ,
 λ 
öï = Чр- (27) 
>> max . 1>- В 
Since the alteration caused by the metactoid drug was supposed to be directly 
proportional to the stimulus, instead of S 'в/ S 'max may be written the change 
caused by [B] in the effect of a certain concentration of A, divided by the 
maximal change in this effect that can be caused via the receptors of the met­
actoid system in question. The realized change is E A — EAB' if the metactoid 
drug is an antagonist, and E A B ' — EA if it is a sensitizer. In the same way the 
maximal change possible is E A — Елз'тах for the antagonist or EAS'max— EA 
for the sensitizer. In the case of a metactoid antagonism holds 
S'в E A — E A B ' 
S max E A — EAS'max 
and in the case of a metactoid sensitization 
S'в _ E A B ' — E A 
S max EAS'max— Ел 
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Since these two quotients have the same value, for both kinds of metactoid 
interaction equation 27 can be written as 
E A B — EA β' 
EAS'max— Е д 
I + 
Κ Ή 
[В] 
(28) 
It follows that 
EAB' = EA + (EAS'max— EA) • ß' 
I + 
or EAB' = 1 + 0 
EAS'max 
EA 
О-
ß' 
ι + 
K*i 
[B] 
Κ Ή 
[В] 
EA 
The fraction EAS'max/ EA was introduced before as the constant ρ : 
ß' 
EAB' = i + ( p — 1 ) . 
I + 
Κ Ί 
[B] 
EA (29) 
Division of both terms by E
m
ax and application of equation 18 gives the final 
formula: 
EAB' 
i + (p — I ) - ß' 
ΚΊ 
[В] ι + 
KA 
[A] 
(30) 
Attention may be drawn to the fact that β ' and К 'в are 'drug constants' on 
which comparison between individual members within one family may be 
based, but that ρ is a 'family constant' ; if two metactoid drugs have different 
values for ρ in equation 30 this means that they do not belong to the same family. 
In this respect the role of ρ is analogous to that of Emax where agonistic drugs 
are concerned. 
The intrinsic activity of a noncompetitive pharmacon can be defined ac­
cording to 
P / S Bmax 
э max 
this being the ratio of the maximal stimulus that can be generated by В on R' to 
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the maximal stimulus that can be provoked via these receptors by any sub­
stance. This equation holds for both metactoid and metaffinoid drugs; it is 
analogous to equation 16 for the intrinsic activity of agonistic drugs (p. 37) and 
is subject to the same limitations. For a metactoid drug a derived intrinsic 
activity constant β ' E can be used. This constant is calculated according to 
p > E = E A B W - E A ( З І ) 
t A S ' m a x — Ь А 
in which the numerator represents the maximal change of EA that can be caused 
by B, and the denominator the maximal change of EA that can be caused via the 
receptors of В by any member of the same family. The constant β ' Ε equals β' 
if the relation between stimulus and effect is linear. As may be seen from 
equation 31, β ' Ε only can have values from zero to one, both for sensitizers 
and antagonists. 
The difference between these two possibilities finds expression in the value of 
p. If this value equals 0 or lies between 0 and 1 the noncompetitive system is an 
antagonizing one; if ρ is larger than 1 it is sensitizing. As follows from the 
definition: 
EAS'max 
ρ cannot have a negative value. 
A complete antagonism of the effect of A will be possible only if ρ equals zero 
and В has an intrinsic activity β' = 1. If these values for ρ and β' are substituted 
in equation 30 the latter can be written in a simplified form 
ΕΑΒ' Ι α
 ( з 2 ) 
L [B] L KA 
1 + -ггг 1 + 
К ' в [A] 
This equation can be derived also from the formulae without p, presented earlier 
by Ariens et al. (45,53,55), in which no differentiation was made between drugs 
belonging to the same family but differing in intrinsic activity on the one side, 
and drugs belonging to different families on the other. 
IMPLICATIONS OF THE MODEL OF METACTOID INTERACTION; THE CON­
CEPT RECEPTOR RESERVE 
Equation 30, derived for the action of an agonist in the presence of a me­
tactoid compound, may be compared with equation 18 which describes the 
uncomplicated action of an agonist. As may be seen, the metactoid interaction 
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FIO. io. Metactoid interaction. Set of theoretical concentration-effect curves based on equa­
tion 30. 
Curve a : Theoretical concentration-effect curve of the agonist A in absence of other substances. 
K A = I O - 6 Μ, а = ι. 
Curves b, с, d: Theoretical concentration-effect curves of the agonist A in presence of in­
creasing concentrations of the metactoid antagonist B. 
KA = ю - 4 M, а = i, K'B = ю - 4 M, ß' = ι, ρ = о. 
Curves e, f: Theoretical concentration-effect curves of the agonist A in presence of increasing 
concentrations of the metactoid sensitizer C. 
K A = I O - ' M , а = I, K ' c = i o - 4 M,y'= ι, ρ = 3. 
Note, that the concentration-effect curves a-f are all in the same position in relation to the 
concentration axis, but that their maximal heights differ. 
Curves g, h: Theoretical concentration-effect curves of the agonist A in presence of the same 
concentrations of the metactoid sensitizer С as in the cases of the curves e and f but with the 
difference that the effect cannot become larger than the original Ema* (the stimulus-effect 
relation in the agonistic system is supposed to remain linear up to 85 % of Emax). 
A practically maximal effect is caused by interaction of the agonist with less than 100% of 
its receptors : the sensitization results in the formation of a receptor reserve (see text). 
finds expression only in a factor with which α is multiplied, so that it seems as 
if the intrinsic activity of A is changed. According to the conclusions reached 
earlier (p. 41-42) this means that the concentration-effect curves of an agonistic 
drug made in the presence of various concentrations of a metactoid drug arc 
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all in the same position in relation to the concentration axis, but that they 
differ in their maximal heights (fig. io, curves a-f). It may be stressed that this 
holds only if the relation of stimulus and effect in the system of A is not changed 
by the presence of B. If В is a metactoid antagonist this supposition is not 
particularly improbable; in the case of a metactoid sensitization, however, it is 
obvious that the physiological possibilities of the effector organ may set a limit 
to the enlargement of the effect. 
What will happen then depends on the question where in the chain of events 
from receptor interaction by the agonist to the ultimate effect the sensitizing 
stimulus has its influence. If the effector organ itself is sensitized and formation 
and propagation of the stimulus SA are unaffected, an existing direct propor­
tionality of stimulus and effect does not disappear, no matter how large the 
sensitization is. It may, however, be different if the sensitization has influence 
on formation and propagation of SA, so that the final stimulus reaching the 
effector organ is changed. In that case it becomes possible that already a sub-
maximal stimulus corresponds with a practically maximal effect; the stimulus 
may surpass this value, but the effect cannot increase any further. In such a 
case the relation between growing stimulus and effect will lose its direct pro­
portionality when the effect approaches its maximum. The sensitization now 
results in the formation of a so-called receptor reserve: interaction with only 
a part of the receptors suffices to cause the maximal effect. If formation of a 
receptor reserve is the only result of the metactoid interaction, the maximal 
height of the concentration-effect curve does not change but the slope becomes 
steeper, since the ι %-point of the curve remains in more or less the same 
position whereas the 99 %-point is shifted to the left (fig. 10, curves g and h). 
It will be evident that if growing concentrations of a metactoid antagonist 
are added to an agonistic system with a receptor reserve of its own (713, 714, 
926), and if this metactoid antagonist has no influence on the reactivity of the 
effector organ but causes a diminution of the final stimulus reaching the latter, 
the reversed phenomenon will be seen. At first the curve will not be depressed, 
the slope, however, will become less steep - the 99 %-point shifting towards 
higher concentrations -, and only when the receptor reserve is exhausted de­
pression of the curve will follow. As discussed above, the metactoid antagonist 
seemingly causes the intrinsic activity of the agonist to decrease: the contri­
bution of a single interaction of agonist and receptor to the total stimulus 
formation seems to become smaller. But, since there is reserve in the system, 
the loss can be made up by augmenting the agonist concentration, so that the 
number of interactions increases. As long as the receptor reserve lasts, the 
original maximal effect can be brought about. 
As discussed before (p. 48) the shift of an agonistic concentration-effect 
55 
1.6-
1.4-
1.2-
1.0-
0.Ö-
0.6-
0.4-
α2-
ιο-β ι ό '
7
 ι ό
- 6
 ιό"
5
 ιό"
4
 ΙΟ"
3
 Μ 
[Α] 
FIG. п . Competitive antagonism in presence of a receptor reserve. Theoretical concentration-
effect curves of the agonist A in presence of increasing concentrations of the competitive 
antagonist В (equation 23). 
KA = ю-« M, a E = i, Kn = 10-7 Μ, β = о. 
Up to 85 % of Em»* the stimulus-effect relation is supposed to be directly proportional. The 
interrupted lines indicate the further path of the curves for the case that the stimulus-effect 
relation would have been directly proportional along the whole range. As for a competitive 
antagonism the presence of a receptor reserve in the agonistic system is of no consequence 
(cf. fig. 6). 
curve caused by a competitive antagonist depends only on concentration and 
affinity of the antagonist. Needless to point out, therefore, that as far as com­
petitive antagonism is concerned, the presence or absence of a receptor reserve 
in the receptor-effector system of the agonist is of no consequence (fig. 11). 
THE MODEL OF METAFFINOID INTERACTION 
As for the other type of noncompetitive interaction (metaffinoid interaction, 
see p. 26) a formula relating EAB' to the concentrations of A and В can be ob­
tained with reasonings quite analogous to those for the metactoid interaction. 
This time the supposition is that the interaction between В and R' results in 
a change in the affinity between A and R. When the stimulus via the system of 
R' is maximal the affinity between A and R will acquire its extreme value; the 
ratio between the latter and the original affinity is a constant which depends 
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only on the interrelation between both systems. This is expressed in the follow­
ing equation, which is analogous to equation 26 for the metactoid interaction: 
1 1
 / 4 
ν
 =
 4 F " 03) 
The value of the constant q characterizes the interrelation between the 
metaffinoid system and the system of the agonist. 
From equation 27, which holds unaltered, together with the supposition made 
earlier, viz. that S 'в corresponds linearly with the resulting change in the affinity 
between A and R, it follows that 
P' _ KA KAB' 
K ' B
 _ — i ~ 
[Β] ΚΑ К AS'max 
in which I/KAB' represents the affinity between A and R in presence of [B]. 
This equation can be developed into a form analogous to equation 29 : 
KAB' 
β 
l + ( q - i ) -
Κ Ί 
KA 
(34) 
[B]' 
For the effect of [A] in presence of [B] holds, according to equation 18: 
EAB' _ α 
Emax KAB' 
I + [A] 
and with application of equation 33 this can be written as 
EAB' α 
ι KA 
Ι Η 
(35) 
I + ( q - i ) _ E _ M 
I +
K
'
B 
[B] 
The objection could be raised, however, that the model used here is the 
simplest one possible as for its formal aspects, but that a real situation tallying 
with it would be far from simple. It is rather probable that, if the interaction 
57 
between В and R' causes a change in the affinity between A and R, the inter­
action between A and R will also cause a change in the affinity between В and 
R'. As a matter of fact, a one-way influence will be possible only if energy is 
supplied to or withdrawn from the total system in a special, directed way ; other­
wise the influence on the affinity surely will have a mutual character. 
It seemed therefore useful to consider also another model in which the in­
fluence doubtlessly is mutual, viz. the case that R and R' are directly coupled. 
Suppose that any receptor for A is coupled to a receptor for B, and vice versa. 
In presence of given concentrations of A and В a situation will result for which 
holds that 
[rr'] = [RR'] + [ARR'] + [RR'B] + [ARR'B] 
and 
[A] [RR'] 
[ARR'] A 
[A] [RR'B] _ 
[ARR'B] A B ' 
[B] [RR'] 
[RR'B] B 
[ B ] [ A R R ' ] _ 
[ARR'B] B A 
Since it follows from these equations that 
KA _ К ' в 
KAB' К'BA 
the mutuality of the changes in affinity is well established and its character is 
known. 
Again the effect of A is supposed to be linearly related to the receptor 
occupation by A: 
EAB' [ARR'] , [ARR'B] 
Б —
 = α
— i - M — г - α — j — г ; — = 
Emex [ГГ ] [ГГ ] 
K A К А [ В ] К А [ В ] К А В ' К ' В К А В ' К ' В К А В ' 
+ I + , + 777- г., + „ + , . , + I [А] [А]К'в К А В ' К ' В [А] [В] К
А
[В] [А] 
=
 а ( [ А ] К
А
в ' К '
в
+ [ А ] [ В ] К
А
) 
K A K A B ' K ' B + [ А ] К А В ' К ' В + [ B ] K A K A B ' + [А] [ В ] К А 
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α 
ΚΑΒ'Κ'Β + [BJK.AB' ΚΑ 
ΚΑΒ'Κ'Β + [Β]ΚΑ ' "[Äf 
ι •+ 
ι JCA 
Κ Α — ΚΑΒ' [Β] ' [Α] 
(36) 
ΚΑΒ' Κ ' Β + [ Β ] 
Now return for a moment to the first model. For the intrinsic activity ß ' in 
equation 35 holds that 
η / S Bmax 
Ρ ς/ 
э max 
and thus, if the stimulus-effect relation is linear: 
1 1 
K A KAB'max K A S ' I M X K A — К л в ' т а х . . 
I I К д в ' т а х K A — Кдв 'тах 
K A КдЗ'тах 
in which i/KAB'max is the extreme value which the affinity between A and R ob­
tains when all receptors R' are in interaction with B. Further it follows from 
equation 33 that 
K A — KAs'max 
q—1 = — γ 
rw-AS'max 
and from this formula together with equation 37 that 
( q - i ) ß ' = K A — KAB'max 
К л в ' т а х 
It should be realized, however, that ΚΑΒ' in the second model has exactly the 
same meaning as Клв'тах in the first one, both representing the extreme value 
to which KA can be changed under the influence of the drug B. Therefore in 
equation 36 the term ( K A — KAB')/KAB' can be substituted by ( q — ι ) β ' and 
this makes equation 36 identical with equation 35. The two starting-points so 
lead to identical conclusions. 
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IMPLICATIONS OF THE MODEL OF METAFFINOID INTERACTION 
In the foregoing the various aspects of the metaffinoid interaction are by no 
means treated exhaustively. However, equation 35 seems to be a suitable basis 
for further discussion. 
In the first place it will be clear that what was said about the character of the 
constant ρ as a 'family constant' (see p . 52) holds also with regard to q : if two 
metaffinoid drugs have different values for q they do not belong to the same 
family. If the value of q equals 0 or lies between 0 and 1 the drugs in the group 
in question are antagonists of the drug A and if q is greater than 1 they are 
sensitizers; q cannot have a negative value. 
Then it may be observed that the only difference between equation 35 and 
equation 18 for the effect of an agonist present alone, is the factor with which 
K A is multiplied. As discussed before this means that the presence of В will 
cause the concentration-effect curve of A to undergo a parallel shift along the 
logarithmic concentration axis (see p. 40-43) ; in this respect the situation re­
sembles a competitive interaction. In the case of the latter, however, an en­
largement of the concentration of В always corresponds with an enlargement 
10"' ισ5 io"1 1er3 м ίο"' ю-* кг 7 ισ 6 м 
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FIG. 12. Metaffinoid interaction. Sets of theoretical concentration-effect curves based on 
equation 35. 
FIG. I 2 A : Theoretical concentration-effect curves of the agonist A in presence of increasing 
concentrations of the metaffinoid antagonist B. 
KA = ί ο - 6 Μ, α = ι, К ' в = ί ο - 6 Μ, β' = ι, q = ο.οοι. 
FIG. І2в: Dito in presence of increasing concentrations of the metaffinoid sensitizer B. 
K A = I O - 6 M , 0 = 1, K ' B = I O - 4 M , ß ' = 1, q = 100. 
The concentration-effect curve is shifted along the concentration axis to higher (fig. І2А) or 
lower (fig. I 2 B ) concentrations, without a change in the shape of the curve; the maximal value 
of the shift (measured in the scale unit) equals — log q (see text). 
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of the shift (cf. equation 25), whereas in the case of a metaffinoid interaction 
the maximal shift may be finite (fig. 12). A reasoning analogous to the one 
presented on p. 41-42 but applying the equations 18 and 35 may show that 
[ A l 2 I
 (38) [Α]! β' 
ι + (q—1) - K' 
I + [B] 
The shift will be maximal if β' = ι and [B] is infinitely large. Under these con­
ditions the foregoing formula can be simplified to 
^ = - (39) 
[A]! q Ü 9 J 
and it follows that the maximal value of the shift, if measured in the scale unit, 
equals —log q. The foregoing also implies that formally the maximal shift that 
can be caused by a metaffinoid antagonist may be infinite, viz. if β' = ι and q 
is infinitely small. If the indicated values of β' and q are substituted in equation 
35 the latter becomes identical with equation 24, so that formally a pure com­
petitive antagonism results (see also p. 49). 
Equation 37, defining the intrinsic activity ß' in terms of affinities, is no 
suitable basis for the calculation of this value in practice. The equations 38 and 
39 are better starting-points. Suppose that in the absence of the metaffinoid 
drug В a certain effect is caused by the agonist concentration [A]i. The same 
effect is caused by another agonist concentration, [A]2, if all receptors of В are 
in interaction with the latter drug, so that the shift of the agonistic curve is the 
maximal shift that can be caused by B. Still another agonist concentration is 
needed for the effect in question if all metaffinoid receptors interact with the 
molecules of a reference compound which possesses a full intrinsic activity 
(β' = ι). From equation 38 it follows that 
[Ab 1 
[A], i + ( q - i ) ß ' 
since in this case [B] can be considered infinitely large. The same holds for the 
concentration of the reference compound, and since moreover in this case β' 
equals 1 equation 39 applies: 
[ А Ь
=
 _L 
[A], q 
On this basis a derived intrinsic activity constant β ' Ε can be calculated. This 
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constant will equal β' if the relation between stimulus and effect in the non­
competitive system is linear (and if the other, general suppositions hold ; see 
p. 43-45), and it may be defined as 
[A]!
 w 
β ' " = ^ _ (40) 
JAJi _ 
[А]з I 
Finally it may be interesting to compare equation 35 with the equation for 
antagonism presented by Ariens et al.(45,55) which is also based on the model 
with coupled receptors. In this equation a constant KAB' represents 'the mutual 
interference of the drug molecules on their respective receptors'. Since the two 
formulae represent the same model they should be identical, and thus it is 
possible to express KAB' in 4 a n d ß ' : 
( q - i ) ß ' 
KAB' = i + ( q — ι ) β ' 
The formula with KAB' does not show the essential difference between drugs 
belonging to the same family but differing in intrinsic activity and drugs be­
longing to different families; for this reason equation 35 may be preferable. 
DUAL AFFINITY 
As mentioned before, many drugs have affinity to more than one kind of 
receptors. In this connection there are many possibilities (144), one of which 
will be discussed here, viz. the case of a drug being a competitive antagonist 
of a certain agonist and at the same time being able to antagonize the effect of 
this agonist by means of a metactoid antagonism. If it is supposed that the 
affinity to the receptors of the metactoid system is higher than to the receptor 
of the agonist, and if the metactoid system has the possibility of nullifying the 
effect of the agonist completely (as is usually the case), then the competitive 
antagonism will stay undetected in the experiment: the effect of the agonist 
will be reduced to zero before the competition can express itself. If, however, 
the affinity to the receptors of the agonist is the higher one, a complicated set 
of concentration-effect curves is obtained, showing mainly a shift with lower 
concentrations of the antagonist, but a shift plus a depression at the same time 
with higher ones. 
Theoretical curves demonstrating these phenomena (fig. 13) may be obtained 
on the basis of an equation which is a simple combination of equation 24, de-
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FIG. 13. Dual antagonism. Theoretical concentration-effect curves of the agonist A in pre­
sence of increasing concentrations of the drug В which is a competitive antagonist and a 
metactoid antagonist (equation 41). The affinity of В to the receptors of the agonist is higher 
than to the receptors of the noncompetitive system. How far the curve is shifted to the right 
before a measurable depression occurs depends on the ratio of KB and К'в (see text). 
FIG. 13A: KA = ί ο - 6 Μ, α = 1, KB = 10-7 M, К'в = ю - 6 Μ, β' = ι, ρ = о. 
FIG. 13Β: Κ Α = I O - 6 Μ, α = Ι, Κ Β = I O - 7 M, К ' в = ю - 5 Μ, β '= ι, ρ = ο. 
FIG. 13c: Κ Α = I O - ' Μ , α = ι, Κ Β = m - 7 M, K ' D = 10-4 Μ, β '= ι, ρ = ο. 
scribing the competitive antagonism, with equation 30 which represents the 
noncompetitive interaction: 
-ABB' 
ι + ( ρ — Ο ­
ι + 
Κ ι 
[B] K B [A] 
(41) 
Theoretically it is possible also that a pure noncompetitive antagonist would 
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have both metaffinoid and metactoid effects; the presence of increasing con­
centrations of such a drug would give a similar picture. Theoretical curves can 
be obtained on the basis of a combination of the equations 30 and 35. 
In practice sets of curves as presented in fig. 13 are often found. The question 
now arises whether in all such cases the tested antagonist is a drug with a 
double affinity or with a dual noncompetitive action. This is not necessarily the 
case. As shown earlier, the action of a pure metactoid antagonist on an agonistic 
system with a receptor reserve also may result in a shift of the curve - although 
not an exactly parallel one - before depression occurs. Although it is true that 
the respective sets of theoretical curves representing the two situations show 
certain differences (compare fig. 13 and fig. 10, curves h-g-a-b-c-d), the ex­
perimental sets of curves may look rather similar. 
If the antagonist has very different affinities to the two kinds of receptors the 
situation will be clear, for in this case there will be a perfectly parallel shift of 
the curve over a considerable distance before depression occurs (fig. 13c). This 
is a phenomenon that cannot be imitated by a metactoid antagonist in presence 
of a receptor reserve. If, however, the affinities do not differ very much (see 
fig. 1 ЗА) it may become rather hard to detect the underlying mechanism from 
the set of experimental concentration-effect curves. Fortunately the mechanism 
can also be elucidated by other means. The experiments may be repeated with 
a partial agonist as a reference compound, so that the existence of a receptor 
reserve in the system is excluded ; or else the receptor reserve may be nullified 
beforehand by incubation of the isolated organ with an irreversible competitive 
antagonist (346, 347), a technique also known as 'nonequilibrium blockade' 
(7'3-, 7f4) or 'unsurmountable blockade' (350). (See also chapter IV.) But even 
without experiments of this kind a reasonable surmise about the underlying 
mechanism may be obtained by comparing the sets of curves in question with 
the curves obtained in the presence of close structural analogues of the an­
tagonist. 
CONCLUSION 
In conclusion of this chapter it should be stressed that the techniques de­
scribed in the foregoing pages are useful expedients for the estimation of in­
trinsic activities and affinities of drugs, but that they should be rated at their 
true value. It was pointed out before that if the stimulus-effect relation in the 
agonistic receptor-effector system departs from linearity, the values of the 
affinity constant and the intrinsic activity constant of the agonist calculated on 
the basis of the presented formulae may differ from the true values. The same 
applies for noncompetitive antagonists, which formally are agonists with 
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respect to their own system. In the case of a competitive antagonism the stimulus-
effect relation has no influence on the calculated values but, as will be clear from 
the foregoing, other factors may complicate the situation just as well. It is ne-
cessary to keep these facts in mind when studying the results presented in 
chapter V. The values found should not be interpreted as giving the true mag-
nitude of the affinity in the proper sense of the word ; their main significance 
lies in the fact that they form a basis for comparing closely related compounds 
within one family, whereas the general characteristics of the sets of experimental 
curves are the basis for differentiations between various families. Usually the 
meaning of isolated values will be very limited. 
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CHAPTER IV 
T H E M A K I N G O F C O N C E N T R A T I O N - E F F E C T C U R V E S 
W I T H T H E C U M U L A T I V E C O N C E N T R A T I O N T E C H N I Q U E . 
D E T E R M I N A T I O N O F T H E aE-, pD2-, as-, рКл
5
-, pAî- A N D pD2 '-
VALUE. T H E STATISTICAL H A N D L I N G O F T H E S E VALUES 
CUMULATIVE CONCENTRATION-EFFECT CURVES 
In the preceding chapter the importance of experimental concentration-effect 
curves made on isolated organs was indicated: they are among the main tools 
for studies in molecular pharmacology. Different techniques for making con-
centration-effect curves exist. We employed the so-called cumulative con-
centration technique (42, 826, 831), a technique which is applicable only if the 
compounds used are rather stable and the obtained responses are sustained 
during some time without fading. In our experiments on isolated organs the 
responses are smooth muscle contractions which are practically isotonic. With 
these the phenomenon of fading is exceptional : the responses remain constant 
for long periods of time if the drug concentration in the bath fluid is not altered. 
Under the conditions named above the cumulative technique has a clear ad-
vantage over the older method of measuring the responses of the organ on 
single doses separately: it provides the same amount of information in a 
fraction of the time. 
Cumulative concentration-effect curves are made by augmenting the drug 
concentration in the bath fluid step by step without washing out after each 
addition. The isolated organs primarily used in the present study are the ileum 
of the guinea-pig and the jejunum of the rat. On the former organ the drugs 
under investigation were tested for possible histamine-like or antihistaminic 
properties, whereas the rat jejunum is suitable for testing cholinergic or anti-
cholinergic properties. In some cases the drugs were tested on adrenergic or 
antiadrenergic properties as well ; for this examination the vas deferens of the 
rat is a good test object. 
An animal is killed and the small intestine or vasa deferentia are immediately 
removed and kept in a beaker of Tyrode solution at 37 0C. When kept under 
these conditions the organ remains usable for four to six hours. The intestine 
should be empty; animals are not fed during 24 hours preceding the experiment. 
The gut is rinsed out with warm Tyrode to remove possible contents. A piece of 
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1.5 to 2 cm in length, cut from this intestine, is suspended in an organ bath, 
again in Tyrode solution kept at body temperature. One liter of Tyrode solution 
contains 8 g NaCl; 0.2 g CaCh; 0.1 g MgCh; 1 g NaHCOj; 0.05 g NaHzPO* 
and 1 g glucose. 
The organ bath used (fig. 14) has a capacity of 10 ml. This size represents a 
compromise: it is profitable to use the smallest bath possible to work sparingly 
with the test compounds, often available only in small samples, but on the other 
hand, the smaller the amount of Tyrode solution in which the organ is sus-
pended, the sooner auto-intoxication of the tissue occurs,- which may lead to 
spontaneous contraction of the organ or to loss of its contractility. 
The Tyrode in the bath is kept at a constant temperature by circulating water 
of the desired temperature from a thermostat vessel through the water jacket 
surrounding the bath. The organ is supplied with oxygen by bubbling air 
through the bath fluid via an opening in the hook at the bottom of the bath. 
The intestine is suspended between this hook and an isotonic lever weighted 
with about 0.5 gram, which records the responses of the organ on a slowly ro-
tating sooted drum. 
The organ is left undisturbed for about 10 minutes, allowing it to reach 
FIG. 14. Longitudinal section and cross-sections of organ bath used. Air is introduced via 
the air inlet; water from thermostat vessel is circulated through the outer jacket. 
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ne . is. Kymographion records of the contractions of the isolated guinea-pig ileum caused 
by histamine (Hist) and by some histaminomimetic drugs, viz. 2-(ß-aminoethy])-pyridine 
(PyretH), the N-ethyl derivative of 2-(ß-aminoethyl)-pyridine (PyretEt) and betazole. In the 
given concentrations the N-propyl derivative of 2-(ß-aminoethyl)-pyridine (PyretPr) does not 
cause a contraction of the organ. 
For each cumulative concentration-effect record the concentration of the agonist in the bath 
fluid is increased stepwise in geometrical progression. The next dose is introduced when the 
contraction caused by the preceding dose has reached a steady value; when the next dose 
docs not cause a further contraction the drug is washed out. (From van Rossum and van den 
Brink, 831.) 
equilibrium with its new surroundings. During this period the Tyrode is 
renewed several times; the last time the bath is filled with exactly 10 ml of 
Tyrode. To this amounts of spasmogen which are in the proportions 
1:2:7:20:70:200 etc., are added successively. Solutions of the drug with various 
concentrations are previously prepared, so that the desired amount can be 
added in a volume not exceeding a maximum of 0.2 ml. In this way the con-
centration of the drug in the bath fluid increases step by step in the proportions 
1:3:10:30:100:300 etc. In the preceding chapter it was explained that it is 
recommendable to plot the concentration-effect curves on a logarithmic con-
centration scale. The sequence of concentrations takes this into account: by 
increasing the concentration in a geometrical progression, the measuring-points 
are at regular intervals on the concentration axis. 
With each increase in concentration the organ contracts further until the 
response is maximal (fig. 15). A new dose is introduced into the bath after 
equilibrium for the preceding dose has been reached. When further increase of 
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concentration does not elicit further increase in response anymore, it is assumed 
that the maximal effect of the spasmogen in question has been obtained, and 
the drug is washed out. It is generally possible to perform the described proce­
dure from beginning to end in about 2 minutes. After the organ has been washed 
for 2 to 5 minutes the next record can be made. With one piece of intestine 10 to 
30 records may be obtained. 
The experiments should be started with a full agonist of which the affinity 
to the system in question has been determined previously and which in this 
way may serve as a standard reference compound, e.g. histamine. With this 
drug two or three consecutive records are made in order to check whether the 
preparation is stable and whether the responses on equal stimuli are equal every 
time. Other agonists may then be compared with the reference compound and 
with one another; the fact that it is possible to test a number of agonists on the 
same organ is one of the advantages of the method. Usually the agonists 
produce records that are essentially corresponding, but they may differ in 
maximal height and in the range of the concentrations. Every few records the 
reference record is repeated, to establish whether the properties of the organ 
remain constant. The sensitivity of the organ may decrease slowly during the 
experiment. As long as this decrease is small, it is not disturbing since every 
2000 
Hist -Ю"» -10 
Diphnhydrmnin· 3-10' 
FIG. 16. Kymographion records of the contractions of the isolated guinea-pig ileum caused 
by histamine (Hist) in absence and presence of diphenhydramine, a competitive antagonist 
of histamine. The cumulative concentration-effect records of histamine were made in the 
same way as those in fig. 15. (From van Rossum and van den Brink, 831.) 
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FIG 17 Concentration-effect curves calculated from the records presented in figs 15 and 16 
FIG 17A The maximal effect of the reference compound (histamine) is placed at 100% and 
the effect of each cumulative concentration of the compounds tested is expressed in percen-
tages of the maximal height of the preceding curve of the reference compound 
The curves of the various histammomimetic drugs are in different positions in relation to the 
concentration axis (different affinities), moreover the maximal effect of the N-ethyl derivative 
of 2-(ß-aminoethyl)-pyridme is smaller than that of histamine (different intrinsic activities) 
(cf ρ 4i) 
FIG 17B The presence of diphenhydramine causes the concentration-effect curve of histamine 
to be shifted to higher concentrations without a change in the shape of the curves, this 
picture is in keeping with a competitive antagonism between histamine and diphenhydramine 
(cf fig 6) (From van Rossum and van den Brink, 831 ) 
record is evaluated in relation to the preceding reference record. 
When antagonistic drugs are tested the procedure is somewhat different As 
discussed in the preceding chapter, the antagonist itself does not elicit a response 
of the organ, but it shows its presence by a change of the effect of the agonist. 
In such cases the reference records are made, the organ is washed, a certain 
dose of the antagonist is added and then - without replacement of the Tyrode -
another record with the reference compound is made, the kind and measure of 
its change giving information about the type and effectivity of the antagonist. 
(Fig. 16 gives an example of competitive antagonism.) 
From the data obtained m the described manner concentration-effect curves 
are calculated and drawn in a standardized way. The concentrations used are 
expressed in molars and plotted on the abscissa on a logarithmic scale; the 
corresponding responses are plotted on a linear scale on the ordinate. The 
reference compound is a full agonist; therefore its maximal response can serve 
as a standard. In this laboratory the distance between two successive degrees 
of ten on the abscissa is routinely taken as 1 unit of length while the responses 
are expressed on the ordinate, on a scale whereby the maximal response of the 
reference compound is 2І units of length (fig. 17) 
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NUMERICAL EXPRESSION OF INTRINSIC ACTIVITY AND AFFINITY 
It was shown already that the activity of a drug depends on two properties: 
its affinity to certain receptors, and the intrinsic activity which determines to 
what degree the interaction with the receptors results in a stimulus, and thus in 
an effect. In practice it proves convenient to express these magnitudes as 
numbers. It may suffice to illustrate here how such numerical expressions may be 
derived for agonistic drugs, competitive antagonists and metactoid compounds. 
In chapter III a numerical expression of the (relative) intrinsic activity was 
introduced, viz. the constant a. The affinity on the other hand has been intro­
duced as a concept only, so that in the first place a measure should be chosen in 
which this property can be expressed. Since the affinity is the tendency of the 
drug to associate with the receptor, it is inversely proportional with the tend­
ency of dissociation of the pharmacon-receptor complex. In the law of mass 
action, and in all equations that were derived from it, this tendency is expressed 
in the dissociation constant, a magnitude with the dimension of a concentration. 
It is plausible, therefore, to express the affinity as the reciprocal of this dis­
sociation constant, in other words, as I/KA. Since, however, the concentration-
effect curves from which KA may be derived are plotted on a logarithmic con­
centration scale, it is more practical to use a logarithmic measure of the affinity, 
viz. log I/KA or —log KA (PKA). Thus the negative logarithm of the molar 
concentration that corresponds with the dissociation constant of the drug is 
used as a measure of the affinity. 
As may be clear from the discussion of the presuppositions in the agonistic 
model (cf. p. 43-45) it is rather improbable that the exact values of α and рКл 
(β and рКв, etc.) can be found from the experimental curves. It is possible, 
however, to calculate practical affinity and intrinsic activity constants from 
these curves, constants which approximate the true α and рКд and which equal 
these magnitudes if a number of conditions are fulfilled. These constants are 
a
E
 (39, 825), a s (827,828), pDz (43, 683) and р К л 8 (827, 828) for the agonists, 
рАг (86i, 862) for the competitive antagonists, and β ' Ε and рог ' (43, 864) for 
the metactoid antagonist*. The a s , рКд 8 and рАг are better approximations 
of the true values than the others since the degree of approximation is indepen­
dent from the stimulus-effect relations in the systems in question (p. 39, 48 
and 75). 
* a
E
 was introduced by Ariens as α (see foot-note on p. 38). The pKAs-value was introduced 
by van Rossum as рКвА ; this notation is not adopted here since it might give the false im­
pression that this value, as determined experimentally, would simply be the negative logarithm 
of the dissociation constant. 
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CALCULATION OF α Ε AND рОг 
The value of a E may be calculated according to equation 17 (p. 37): 
Елтах 
1 E = 
Елтах 
K A 
[A] 
1 + 
Елтах 
E A 
KA 
[A] 
— 1 
Under the conditions discussed before, including a linear stimulus-effect re­
lation, рОг equals —log KA. Under the same conditions equation 11 applies: 
E A I 
From this it follows that 
log KA = log [A] + log ( % ^ - 1) 
Ь А 
p D 2 = - log [A] - log ( 5 g K - 1) (42) 
Since [А], Елтах and EA are known, the value of the p D 2 can be found from 
this equation. 
It may be noted, that if 
EA = i Едтах 
it follows that Едтах 
EA 
— 1 = 1 
j ! /t-Amax
 ч 
and log (—= 1) = 0 
Ь А 
In this case the рОг is identical with the negative logarithm of the given con­
centration of A. The рог may be defined on this basis: it is the negative 
logarithm of the molar concentration of the agonist which produces 50 % of 
the maximal effect of the drug on the receptor-effector system concerned. If, 
for instance, the concentration corresponding with the effect i Елтах is ю - 8 
molar, the рОг- аІие is 8. On this basis the рОг can be determined more readily. 
The 50 %-point of a concentration-effect curve is projected on the concentration 
axis; probably the projection will be found somewhere between the points in-
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FIG. 18. Determination of the рОг- аІие from a (theoretical) concentration-effect curve of 
the agonist A. The pD2 is identical with the negative logarithm of the molar concentration 
corresponding with the effect 0.5 Едгав*. 
dicating the whole degrees of ten. The distance to the nearest point at the left 
is measured, and is e.g. 0.4 unit, whereas the distance between two successive 
degrees of ten is 1 unit (see before). Since the axis is logarithmic for the con­
centrations, it is linear for the exponents, so if the nearest point at the left in­
dicates a concentration of ю - 7 molar, the sought concentration is ю-7*0·"' or 
io- 6 · 6 . The p D 2 is 6.6 (fig. 18). 
CALCULATION OF рКл 8 AND a s 
As discussed already on p. 39, a s equals ¿φα if certain general suppositions 
are fulfilled. The stimulus-effect relation should be 'drug-independent', but 
special presuppositions about the character of the stimulus-effect relation have 
not to be made. Likewise the рКл 8- value will equal the рКл if these conditions 
are fulfilled (apart from measuring faults). 
The calculation of the рКд 8 and a s of an agonistic drug is possible with the 
aid of a technique of reducing the concentration of reactive specific receptors 
in the organ. This may be accomplished by incubating the organ with an irre­
versible competitive antagonist of the agonist in question during an appropriate 
period of time (346, 347, 350, 713, 714). First a normal concentration-effect 
curve is made; the agonist is washed away and the organ is incubated with the 
irreversible competitive antagonist; then after washing away the molecules of 
the latter which are not irreversibly bound to the organ, the agonistic curve is 
made anew. If the stimulus-effect relation of the agonistic system is perfectly 
linear, the second curve will be less steep and reduced in height but otherwise in 
the same position on the concentration axis as the original one; if, however, 
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по. ig. Determination of the magnitudes from which the pKAs-value and as-value of the 
agonist A can be calculated. In calculating the theoretical concentration-effect curve a in 
FIG. 19A it was supposed that the stimulus-effect relation is linear up to an effect of about 
85 % of Emai and that a receptor reserve exists, whereas the interrupted line indicates the 
further path of the curve for the case that the stimulus-effect relation would have been directly 
proportional along the whole range; curve b is the concentration-effect curve of the same 
agonist after elimination of 50 % of the specific receptors by means of an irreversible competi­
tive antagonist. 
FIG. 19A: Determination of the concentrations [A] and [A]i which correspond with effects of 
the same magnitude before and after elimination of a proportion of the specific receptors. 
FIG. 19B: Determination of gi, being the ratio of the total concentration of the specific recep­
tors which are not occupied by the irreversible competitive antagonist after incubation with 
this compound and the total concentration of the specific receptors before this incubation 
(for further details see text). 
the stimulus-effect relation is nonlinear the slope of the second curve may be 
less steep with or without a reduction of the maximal height and the curve may 
be shifted to higher concentrations. Fig. 19A gives a theoretical example: in 
calculating the original curve (a) it was supposed that the stimulus-effect 
relation is linear up to an effect of about 85 % of Emax and that a receptor 
reserve exists, whereas the interrupted line indicates the further path of the curve 
for the case that the stimulus-effect relation would have been directly propor-
tional along the whole range; curve b is the concentration-effect curve of the 
same agonist after elimination of 50 % of the specific receptors (cf. fig. 10). The 
suppositions made here are arbitrary, the stimulus-effect relation does not play 
a role in what follows. 
If an effect with a given magnitude was caused by the concentration [A]i 
before the incubation, a higher concentration, [A]u, will correspond with this 
effect after that (fig. 19A). According to equation 3 the connection of these con-
centrations with the corresponding relative receptor occupation will be as 
follows : 
[RA], 1 
+
 [A]! 
and ß ^ i 
+
 [A]!! 
in which [r] is the total concentration of specific receptors and [r]i the total 
concentration of specific receptors which are not occupied by the irreversible 
competitive antagonist after the incubation. The ratio of these two concen-
trations ([r]i/ [r]) will be called gi. 
Since equal effects in the same organ may be supposed to correspond with 
equal values for [RA], [RA]i equals [RAJn and thus 
I I 
= gi· 
. ΚΑ , KA 
1 + ¡ τ τ 1 + [A]! [A],! 
This equation may be generalized to hold for all pairs of concentrations corre­
sponding with effects of the same magnitude, one concentration before and the 
other after the incubation: 
gi 
+
 [A] + [A], 
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The equation is further developed as follows: 
All terms are 
g l + g i 
о
 K A 
ß l [ A ] -
divided by KA and 
KA 
[A] 
KA 
[A], 
• + м 
= I — g l 
multiplied with [A] 
». tA]
 r i л π I - gl 
6
 [A], l J KA 
й+^ІАІ-в.-о (43) 
As follows from this equation, the connection between the two variables 
[A]/[A]i and [A] can be represented by a straight line (fig. 19B). The point of 
intersection of this line with the ordinate represents gi, the intersection with the 
abscissa KA. 
1 — g i 
Thus in practice the [A] and [A]i belonging to an effect of a certain magnitude 
may be determined from a pair of experimental curves and may be used to give 
one point of the line representing equation 43 ; if this procedure is repeated for 
a number of different effects a number of points will be obtained, a straight line 
can be drawn through these points and the values of gi and — - — Кд can be 
1 — g i 
found by extrapolation. By substitution of the value of gi in the other term a 
value for KA can be determined (a value which can be considered right only 
under the before-mentioned conditions); the negative logarithm of KA de­
termined in this way is the рКл 8 (827, 828). 
gi 
The value of KA can also be found directly from the experimental 
1 — gi 
curves: it is the value of [A] which corresponds with [A]/[A]i= 0 and thus 
with [A]i being infinitely large. If before the incubation [A]c is the concentration 
which corresponds with the effect that equals the maximal effect after the in­
cubation (fig. 19A), then 
K A = 1 Z Z l i [ A ] e 
gi 
In the example given in fig. 19 the g i = 0.5 and the P K A S = 6.0, whereas the 
pDa equals 6.30. In practice often much larger differences between рКд 3 and 
рОг are found. 
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The procedure can be simplified by the use of tables connecting the ratio of 
the concentrations [A]i and [A] directly to the magnitude of the shift. 
The р К л 8 being determined, the calculation of a numerical value of the a s 
presents little difficulty. According to equation 19 
as = 
SAD 
2 ¡jpmftx 
Spmax is the stimulus which corresponds with the effect ^ Emax. The concen-
tration of A needed to create this stimulus and thus the effect i Emax may be 
called [AJso. Application of equation 7 leads to 
'Pmax 
SAmax . K-A 
[A] so 
and thus 2 a s = 1 +
 r . _ (44) 
[Ajso 
According to the foregoing the negative logarithm of the KA in this formula 
is the P K A S ; the negative logarithm of [Ajso may be called the P K A E . 
log (2 as— 1) = P K A E — P K A S 
a 5 = H i + i o p K A E - p K A S ) (45) 
The P K A E can be defined as the negative logarithm of the molar concentration 
of the agonist which produces 50 % of the maximal effect that can be caused by 
any member of the family in question. For full agonists this constant is equal to 
the pDz, for partial agonists, however, it will have a different value. 
By application of equation 45 to the example given in fig. 19 an a s which 
equals 1.5 is found. 
CALCULATION OF PA2-VALUES 
If the affinity constant of a competitive antagonist should be calculated, 
equation 25 applies and may serve as starting-point (see p. 48): 
[Ah
 = T . Ш1 [A]! "*" K B 
It follows that K B = — ~ — [A]_2_ 
[A]i 
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l o g K B = l o g [ B ] - l o g ( í ^ - i ) 
pA2 = - log [В] + log ( щ - i ) (46) 
If logarithmic concentration-effect curves are used, the value of ρ-γ may 
be found directly from the shift. On p. 48 it was demonstrated that the shift, 
measured in the correct unit, is equal to log —ρ (fig. 7). The correct unit is 
lAJi 
the distance which represents a difference in concentration of a factor 10. If 
the shift, measured in this way, is called s, from the equation 
. [A]2 
s =
 logÏXh 
it follows that \-^ = 10s 
[AJi 
A table directly correlating the distance of the standardized curves with the 
[A] 2 
corresponding value of log ( r - y —1) is a useful help. In the table published 
by van Rossum (826) the distances are given in mm, one unit being 30 mm, 
whereas г—у is indicated as x.) 
LAJi 
As can be seen from the equation derived above, the рАг is equal to the 
negative logarithm of the given concentration of the antagonist if log 
( ттгр — ι ) equals zero. This is the case if [A]2 = 2 [A]i. This datum offers 
the possibility of a practical definition of the рАг: it is the negative logarithm 
of the molar antagonist concentration, in the presence of which twice the 
original agonist concentration is needed for the original effect. 
It is inevitable that a certain experimental error is made when the shift of the 
concentration-effect curves is measured. For this reason it is desirable to use 
no shifts of less than a certain magnitude as starting-point for the calculation, 
otherwise the influence of this error may be too large. In practice shifts of less 
[AI2 
than a factor three ( p r y < 3) should not be used and, if possible, a shift of 
a factor ten or more is advisable. 
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CALCULATION OF ß ' E AND рОг' 
The intrinsic activity constant of a metactoid sensitizer or antagonist can be 
calculated according to equation 31 (p. 53): 
a 1-p. Ьдв 'тах t'A 
EAS'max— E A 
The calculation of the pDa' of a metactoid compound may start from 
equation 28: 
E A B ' — EA β' 
EAS'max— EA . К'в 
In the derivation of this equation it was supposed that the metactoid 'effect' 
is directly proportional to the magnitude of the metactoid stimulus (cf. p. 50), 
and thus β'Ε can be substituted in equation 28: 
E A B ' — E A I 
EAB'max— E А К ' в 
[В] 
К ' в Е л в ' т а х — Е А 
[В] Е А В ' — ЕА 
log К ' в = log [В] + l o g ( Е А
р
в
'
т а х
~
Е А
- і) 
Ь А В ' —
 Ь
А 
ην ' i roí 1 /ЕАВ'тах— Е А
 Ч
 (4?) 
p D 2 = — log [В] — log ( Е А В Е А і) 
As was to be expected, this equation is quite analogous to the one derived 
for the рОг. The рог' is equal to the negative logarithm of the given concen­
tration of the metactoid drug, if the caused change in the effect of the agonist 
equals the half of the maximal change in this effect that can be caused with 
the metactoid drug in question. (If (Едв'тах — EA)/(EAB' — Ед) = 2, the last 
term of the equation equals zero.) 
It should be appreciated that the value of (Едв'тах — EA)/(EAB' — EA) is in­
dependent of the actual value of EA. It has practical advantages to compare 
the maximal values of EA, therefore to use equation 47 in this form : 
τ-. / ι
 Г
т 1 ^EAmaxB'max Едтах
 ч
 ,
 D 4 
p D 2 = — log [В] — log (-= 1) (48) 
EAmaxB'— I^Amax 
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This is especially true if the compound used is an antagonist with a dualism 
in action (see below). 
If the metactoid compound is a 'complete' metactoid antagonist (cf. p. 53), 
Елв'тах equals zero and equation 47 may be written as 
pD 2 ' = - log [B] - log ( E A ^ A E A B , - О (49) 
Further remodeling leads to the original equation presented by Ariens and 
van Rossum (43, 826) : 
, , EA
 Ч
 . EAB' , E A — E A B ' , , EA , 
so that pD 2 ' = — log [B] + log ( - ^ - — 1) 
EAB' 
Since the form of this equation suggests that the рог ' corresponds more with 
the рАг than with the pDz it may obscure the fact that the noncompetitive 
compound formally can be seen as an agonist with regard to its own system. 
Therefore equation 47 is thought to be preferable, at least in theoretical consi­
derations. 
рАг AND рОг' OF AN ANTAGONIST WITH A DUALISM IN ACTION 
A final word may be devoted to the calculation of рАг and рОг' from the 
curves obtained with a dual antagonist. Since either kind of antagonism results 
from interaction with a different kind of receptors, each one expresses itself 
as if the other component does not exist: the shift of the curve is as large as 
would correspond with the competitive antagonism alone, the depression is the 
same as would be caused by the metactoid antagonism in absence of a compe­
titive one. The рАг therefore can be found from the shift and the pDz' from the 
depression, as discussed for the competitive and the metactoid drugs, respec­
tively. 
In case of a mere competitive antagonism the shift is an unequivocal concept: 
the curves are parallel, so that the distance between the points indicating equal 
effects is independent of the actual magnitude of the effect. As may be seen 
from fig. 20, this does not apply for a dual antagonism. This difficulty is over­
come by defining the shift as the distance of the points indicating relatively 
equal effects, - so that the metactoid influence is eliminated. 
Suppose that in absence of В the concentration [A]i of the agonist causes an 
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E A B B / E
m
a x 
FIG 20 Determination of the magnitudes from which the pAj-value and the pDi'-value of 
an antagonist with a dual action (competitive and metactoid) can be calculated 
The pAi can be found from the shift, in this case the distance between the points indicating 
relatively equal effects (cf also fig. 7), by application of equation 46, the pDi' can be found 
from the depression of the curve (Елтах— Елтахвв') by application of equation 50, -premised 
that drug В is a 'complete' metactoid antagonist so that Едтахвв'тал equals 0 
effect EAI, and in its presence the concentration [A]2 causes a different effect 
EA2BBS for which holds that 
E A 2 B B ' E A I 
ЕАтахВВ' Едтах 
Application of the equations 11 and 41 leads to 
1 + ( P - I ) 
ß' 
К'; 
[В] ^іг + Ш.)
 К А 
•Е
п 
Кв [А]2 
К-
[А]і ι + ( Р - І ) 
ß' 
ι + 
ΚΊ 
[В] i+O + g-V К А K B [А]
т
ах 
Theoretically [А]
т
ах is infinitely large, and thus (1 + ——) -¡-^ is infinitely 
K B [A]max 
small and may be neglected. It follows that 
1 1 
•
 +
 s t •+<- + ^ ш ; 
8i 
^ KB [A], 
Since this is the same relation as found in case of a single competitive anta-
gonism, for the dual antagonist therefore likewise applies: 
pA2 = - log [B] + log (|£J2 - i) (see p. 78) 
Here the рАг may be defined as the negative logarithm of the antagonist 
concentration (in molars) in presence of which twice the original agonist 
concentration is needed to cause an effect that is relatively equal to the original 
effect. It may be remarked that contrary to the situation with a purely compe­
titive antagonist where the possible existence of a nonlinear relation between 
stimulus and effect of the agonist does not disqualify the definition given on 
p. 78, the definition of the рАг of a dual antagonist as given above is not valid 
if the concentration-effect relation of the agonist includes a threshold or a 
receptor reserve. The possible existence of these two phenomena may be detected 
with other techniques (57), which, however, fall outside the scope of this 
introduction. 
The calculation of the рог ' does not present special problems, since the 
depression of the curve can be measured in the same way as if no shift had 
taken place. Equation 49 may be applied in this form: 
p D 2 ' = - l o g [ B ] - l o g ( - ^ψ - ι ) (50) 
üAmax— í-'AmaxBD' 
STATISTICAL CONSIDERATIONS. THE AFFINITY VALUE AS A SAMPLE 
MEAN; THE VARIABILITY OF THE INDIVIDUAL VALUES 
The derivation of individual pD2-, рАг- and pD2'-values being elucidated, 
it should be discussed how the obtained values could be used. One of the pur­
poses of the present study of affinity values was to learn more about the general 
relations between structure and affinity in a certain family of drugs by compa­
ring the affinities of structurally related members of this family to their recep­
tors. Possible conclusions in this direction would have to be based on the 
presence or absence of a difference between these affinities. 
If, however, the pA2 of a certain competitive antagonist is determined a 
number of times, the values obtained tend to differ in magnitude, so that the 
series of values shows a certain variability. If follows that the meaning of an 
isolated, individual affinity value is limited. The affinity value of each com­
pound has to be determined a number of times ; the arithmetical mean of the 
individual values obtained with a certain drug then can be used as the affinity 
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value of the drug in question. It will be clear that a difference between two mean 
pAi-values of two different drugs can only be evaluated if the variability in 
the series of individual values is considered. An answer to the question how 
large a difference between two mean affinity values should be to justify con­
clusions can be provided only with the aid of statistics. 
The part of statistical knowledge that is of importance here has to do with 
the possibility of basing valid conclusions on a sample - in this case the limited 
series of affinity values that could in fact be collected - about the population 
from which the sample is taken - in this case the practically unlimited hypo­
thetical set of possible affinity values that might be obtained under comparable 
conditions. The variability in the population is reflected by the variability of 
the values in the sample. A statistical measure for the degree of variability 
in a population of numerical items is the so-called standard deviation of the 
population (σ). For a population of N items it is defined according to the 
equation , 
i/ JL 
σ= [/ j^y (xi-μχ)2 (50 
i = r 
in which xi is the i t h individual item of the population in which the individual 
items are numbered in an arbitrary order, and μχ the arithmetical mean of the 
items. The square of this standard deviation is known as the population vari­
ance. 
As may be seen from the equation given, the exact value of σ can be calcu­
lated only if the population is completely known, - a situation which rarely 
occurs. It is possible, however, to get an estimate (s) of the true value of σ 
from a sufficiently large sample taken from the population. This s is calculated 
according to the equation , 
i/ — 
s =
 I -¿¡У ( χ ι-*)2 (52) 
i = I 
in which η is the number of items in the sample, xi the i t h individual item of 
the sample and χ the arithmetical sample mean. 
Comparison of this equation with the preceding one shows one essential 
difference. In both equations the sum of the squares of the differences between 
each individual value and the mean value occurs in a corresponding way, but 
in the equation for σ this factor is divided by the total number of items in the 
population, whereas in the formula for s the denominator n-i represents the 
so-called number of degrees of freedom in the sample. (In a set of η items with 
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a given mean value maximally n-i items can be varied independently with 
maintenance of the original mean.) 
It is important to realize that s is only a reliable estimate of σ if the sample 
from which s is calculated meets certain conditions. A sufficient condition is 
that the sample is randomly taken from the population; then all sources of 
variability in the population express themselves in the sample in a way that is 
not systematically different from their representation in the population. Before 
conclusions are based on differences between sample means, it should be exa­
mined whether this condition is fulfilled. 
POSSIBLE SOURCES OF VARIABILITY 
Many possible sources of variability in the samples could reasonably be 
suggested beforehand. A biological variation in the material is to be expected ; 
further each sample consists of values collected by several analysts trained to 
perform the experiments, in each sample several experimental animals are 
represented, various pieces of gut ('organs') derived from each animal are 
used, on each piece of gut a number of single experiments are performed and, 
finally, different periods of time may pass between the collecting of two sam­
ples to be compared. In addition to these factors which all may have their 
influence, other, less obvious sources of variability may exist. 
It is, of course, desirable to minimize the possible influence of the suspected 
sources of variability beforehand. Therefore the experimental procedure was 
standardized as much as possible (see before). Albino guinea-pigs and albino 
Wistar rats from the Central Institute for the Breeding of Laboratory Animals 
TNO at Zeist were used as experimental animals. The animals were provided 
for by the experienced staffof the Central Animal Laboratory* of the University 
of Nijmegen, where they were kept under standardized conditions of housing, 
feeding and health care. Only young-adult animals (3-4 months old) were used. 
Further it was considered whether the effect of some possible sources of 
variability could be reduced by a special design of the experiments, adapted 
for the comparisons to be made. Generally speaking such an approach is 
highly desirable, but practical difficulties may render it less feasible. For optimal 
results it would have been necessary to decide previously which drugs would 
be compared in the same group of experiments, how many observations would 
be made on the same piece of gut, how many pieces of gut of the same animal 
would be used, etc. In our case such conditions could not be fulfilled. 
For instance, it was an important point of consideration whether it might 
• Director: Dr. M. Dobbelaar. 
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be possible to avoid the biological variation within one animal species as a 
source of variability in the samples. For one drug it would be possible to collect 
a series of values of sufficient extent using only one experimental animal, but 
if two or more mean pA2-values of different drugs should be compared the 
extent of the required material is such that the use of several animals becomes 
unavoidable. Since the individual animals may differ considerably in sensitivity, 
a comparison between the mean affinity values of two compounds would be 
meaningless if each mean value is based on a sample derived from one single 
animal. It follows that material from different animals should be present in 
each series of pA2-values. 
Theoretically the effect of the 'between-animal variability' thus introduced 
in the material, could be eliminated if all drugs to be included in the compari­
sons were tested once on each animal used. It could be supposed that, whereas 
a certain affinity could differ from individual to individual, the ratio of the 
pA 2-values of drugs belonging to one family would not be influenced by the 
variability between the animals. Apart from the fact, however, that the suppo­
sition that two drugs belong to the same family cannot be based on a more or 
less close structural relationship only but should be confirmed experimentally, 
this approach can be realized only if the number of drugs to be compared is 
relatively small and known when the experiments are planned. In our case the 
total number of drugs was too large; moreover, new compounds with structures 
chosen on the basis of the results that were obtained with the drugs studied 
before had to be included in the study as they became available. Thus the 
possible 'between-animal variability' could not be avoided and consequently 
had to be implicated in the analysis. 
PRELIMINARY ANALYSIS OF VARIANCE 
The necessity to analyse the variability in the samples in order to determine 
whether s (calculated according to equation 52) is a reliable estimate of the 
standard deviation of the population, caused considerable difficulties. An 
inherent difficulty is that a reliable analysis asks for an extensive material; 
the first indications that the chosen set-up produces (or does not produce) 
usable samples can be obtained only when the set-up in question has been used 
for some time. In the present study an extra problem was created by the fact 
that each sample of individual pA2-values represented a different compound. 
The sources of variability to be analysed could be supposed to have their 
influence in each sample, but the samples could not be combined for the ana­
lysis. 
The circumstance that almost every individual рАг- аІие was determined 
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together with a pDa-value of the reference agonist offered a solution for this 
problem. It seemed rather probable that possible sources of variability as the 
time of the year, the technique of the analyst performing the experiment, the 
'between-organ variability' and the 'between-animal variability' would find 
analogous expression in the sample of pAi-values and in the corresponding 
sample of pDz-values. It was supposed, therefore, that the results of an analysis 
of the pDz-values of the reference agonists would be relevant to the affinity 
values of the antagonists. 
After about a year of value-collecting a tentative analysis of variance was 
made. The material available at that time consisted of several hundreds of 
pD2-values of the reference compounds, being histamine for the guinea-pig 
ileum and furtrethonium for the rat jejunum (acetylcholine itself being too 
unstable). Furthermore a larger-than-usual number of pAz-values of some 
antihistaminic and anticholinergic substances had been determined. This 
sample consisted of fifty to sixty values, derived in different months and by 
different analysts. 
The analysis of this material, performed by the Mathematical Service 
Institute* of the University of Nijmegen, led to the following conclusions: 
i. The рог-values subsequently obtained from one piece of gut showed a 
slight but significant tendency to decrease. This tendency was demonstrated 
by testing the mean of the rank correlation coefficients of Kendall (557, 838) 
between the pDz-values and the order of experiments for each organ. 
2. With the one-way analysis of variance developed by Fisher (416) it was 
found that in a high percentage of the samples of pD2-values (the sets of pDz-
values corresponding to the different samples of pA2-values) the results of the 
F-test for 'between-animal variability' was significant. The same held for 
the larger sample of pA2-values used in the analysis. The percentage of signi­
ficant results with the pD2-values of histamine on the guinea-pig ileum was 
higher than that with the pD2-values of furtrethonium on the rat (69 % and 39 %, 
respectively); it is not known whether this difference is due to chance or to a 
really existing difference between the species - the rats used may belong to a 
more inbred strain than the guinea-pigs. In any case for both species the con­
clusion had to be that the 'between-animal variability' should be taken into 
account in further statistical investigations. 
3. It was not possible to demonstrate a contribution to the overall variability 
by a 'between-analyst variability', (i.e. a variability caused by the fact that the 
experiments were performed by different persons), nor by a 'between-season 
variability' (a variability caused by the time of the year) nor by a 'between-
* Director: Drs. Ph. van Eiteren. 
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organ variability' (a variability caused by the fact that, simultaneously and by 
the same analyst, different pieces of the gut of one animal were tested). Also 
these three possibilities were tested with the one-way analysis of variance men­
tioned above ; it may be stressed that the absence of significant results in these 
tests corresponds with a verdict of 'guilt not proved' and not with one of 
'innocence proved'. 
THE 'BETWEEN-ANIMAL VARIABILITY' 
The results of this tentative analysis of variance necessitated a reconsideration 
of the way in which the experimental affinity values could be used. As for the 
fact that the affinity values subsequently obtained from the same organ had a 
tendency to decrease (demonstrated for the pD2-values), this phenomenon was 
not unexpected, and, from the onset of the experiments, a systematic influence 
of this factor was excluded by testing the different antagonists on the individual 
organs in a random order. Thus a possible slow deterioration of the organ in the 
course of the experiment could not cause systematic differences between the 
mean affinity values (sample means). Apart from the foregoing it may be men­
tioned here that more recent data suggest that the tencency in question, already 
small in the case of the pDi-values, would be still smaller or completely absent 
in the case of pA2-values (145). 
As for the 'between-animal variability', first it was studied whether it would 
be possible to eliminate or at least to reduce the influence of this factor in the 
material of the collected pAz-values. Since the competitive antagonists are 
supposed to have affinity to receptors which, at least partially, coincide with 
the receptors of the reference agonist it seemed not improbable that if, in a 
particular animal, a relatively high pDz-value for an agonist, e.g. histamine, 
was found, also the pAi-value for an antihistaminic drug would be relatively 
high, whereas a low pDi-value would coincide with a low рАг- аІие for the 
antagonist. If this were true it would be possible to rule out the greater part of 
the 'between-animal variability' by subtracting from each рАг- аІие the 
difference between the corresponding pDz-value and the mean pDz-value of 
the agonist, the latter to be calculated from the large number of pDz-values 
available (826). This correction was tentatively applied to the individual рАг-
values of sixteen different samples, but the results did not affirm the expectation : 
in the majority of the samples the total variability did not diminish*. On the 
whole, it even seemed to have a tendency to increase. Consequently it was 
decided that the proposed correction should not be applied. 
* For a possible explanation see p. 110-111. 
87 
THE AFFINITY VALUE AS A MEAN OF ANIMAL MEANS 
From the foregoing it follows that the 'between-animal variability' in the 
material could not be avoided. If indeed values obtained from different animals 
together tend to have a greater variance than values obtained from one animal, 
it must be accepted that in a sample of data from several animals the values 
from one animal usually are not independent. In the statistical techniques in 
question, however, independence of the elements of the sample is necessary. 
For this reason it was decided to use the arithmetical means of the values of 
the individual animals as the elements of the sample, instead of the individual 
values themselves. 
Suppose that the sample contains η items (individual affinity values), whereas 
the number of animals used is к and m experiments have been performed on the 
і
ш
 individual animal. The j t b item from the і ш animal is indicated as xi,j (i = i, 
2, к ; j = i, 2, ni). The arithmetical mean of the items determined on 
the i t h animal is indicated as χι and calculated according to 
m 
j = i (53) 
The sample mean χ now is calculated according to 
к 
χ = i ^ j n 
i = i (54) 
As the animal means (χι) are based on different numbers of observations they 
do not have the same accuracy. Nevertheless, the arithmetical mean x, calcula­
ted according to equation 54, is an unbiased estimate of the mean affinity value 
of the population. 
As a consequence of the foregoing it was necessary that a sufficient number 
of animals was represented in each series of determinations. The use of about 
10 animals for each sample was considered desirable, whereas the number of 
6 animals was chosen as the absolute minimum to be used. Of course a number 
of drugs can be tested on each animal, so that this condition does not lead to a 
greater consumption of animals on the whole. An animal should be represented 
in a series by at least two values, so that each element of the sample minimally 
would be based on an in duplo determination. As mentioned, these insights 
could be acquired in a sufficiently early stage of the study, so that all samples 
readily could be conformed to the conditions made. 
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THE STANDARD ERROR OF THE MEAN; CONFIDENCE INTERVALS 
The calculation of the sample means being discussed, it should be stressed 
again that, properly speaking, not the means of the samples but the true 
population means are the desired data. Since the latter are not obtainable we 
have to content ourselves with the former, but very probably the two will not 
be exactly identical. It is a relevant question, therefore, with which probabilities 
various differences between the two quantities may occur. 
If a number of samples of fixed size are taken at random from a normally 
distributed population, their means will be distributed around the population 
mean according to chance. Such a series of means can be considered a random 
sample from a new normally distributed population with the same mean value 
as the original population. The standard deviation of this new population is 
smaller than the original standard deviation σ; it is called the standard deviation 
of the mean and indicated as σ
Α
. If the original population is known this value 
can be calculated exactly according to the equation 
in which η is the size of the samples. 
Since the new population of sample means is normally distributed, the inter­
vals μ χ ± σ
Α
, μ χ ± ι σ * and μ
χ
± зст* contain 68 %, 95.5 % and 99.7 % of the 
population, respectively; consequently the probability that μχ is present in the 
interval χ ± σ^, χ being an arbitrary sample mean, is also 68 %, the probability 
that μχ is present in the interval χ ± 2 σ^ is 95.5 %, etc. The intervals in question 
are called 'confidence intervals' for μχ, the corresponding probabilities are the 
confidence coefficients of these intervals. The standard deviation of the mean, 
therefore, is a measure of the accuracy of the sample mean and fundamental 
for obtaining confidence intervals for the latter. 
Since the exact value of σ is unknown the same holds for σ
Α
. It follows that 
also the standard deviation of the mean has to be estimated from the sample 
η 
\ (xi— χ)2 (56, cf. equation 52) 
i = i 
The quantity s
x
 is usually called the standard error of the mean, and is normally 
calculated according to equation 56. However, since in our case the animal 
means instead of the individual determinations were used as the elements of the 
sample, the calculation had to be correspondingly adapted. The equation used 
is the following: 
Vn 
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1 1 к ni к m 
І = І j = I І = І j = I 
The meaning of the symbols used in this equation corresponds with those in 
the equations 53 and 54. 
The degree of probability that an interval χ ± ts^ contains the population 
mean μχ is dependent on the value of t; a certain value of t can be selected in 
order to obtain a certain desired confidence coefficient. How large the value of 
t should be for a certain confidence coefficient depends on the number of 
degrees of freedom in the sample. The exact values can be found in the tables 
for Student's t-distribution. The limits χ ± 2s
x
 will include the true mean with a 
probability of 89.8 % for η = 6, increasing to 95 % for η = 6o. In our material, 
η being at least 6, the confidence coefficient of the interval x ± 2sÄ would be at 
least about 90 %, provided that the conditions mentioned in the beginning of 
this paragraph, viz. that the samples are taken at random from a normally 
distributed population, are fulfilled. 
CHECK ON THE BASIC CONDITIONS 
Whether the samples of animal means really could be considered to be 
samples taken at random from a normally distributed population could now 
be checked on the samples of pD2-values (the sets of pD2-values corresponding 
to the diflerent samples of pAz-values, modified to be composed of animal 
means) with the aid of the calculated standard errors of the mean. Altogether 
62 samples of pD2-values of histamine on the guinea-pig ileum and 69 samples 
of pDi-values of furtrethonium on the rat jejunum had been collected. If the 
conditions mentioned were fulfilled, the intervals x ± 2 s Ä should include the 
population mean with a probability of at least 90 %. The expected number of 
intervals not containing the population mean, therefore, would be 6.2 for 
histamine and 6.9 for furtrethonium at most. In reality it was found that the 
maximal number of intervals that contained a value in common was only 50 for 
histamine and 55 for furtrethonium. Thus, if there exists one population mean 
for each species, at least 12 intervals for histamine and 14 for furtrethonium do 
not contain this value. According to the Poisson-distribution the probabilities 
of these high numbers of 'failing' intervals are about 2.5 % for histamine and 
about 1.5 % for furtrethonium. These probabilities have to be considered the 
upper limits of the real probabilities, as the expected numbers 6.2 and 6.9 are 
based on the number of animal means in the smallest samples of pD2-values. It 
would not be justified, therefore, to assume that the results in question are due 
to pure chance. 
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(57) 
The conclusion has to be that the pD2-samples in our material could not be 
considered random samples from a normally divided population. In conse-
quence, it would not be justified to use the samples of pAz-values as if, in their 
case, these conditions were fulfilled. It follows that the variability of the sample 
means cannot be estimated from the standard error sÄ; with regard to a certain 
difference between the mean affinity values of two compounds it is not possible 
to claim significance at a certain exact level. Nevertheless it seemed indicated 
to present the mean affinity values in table I together with their sx; the latter 
value should be seen as a rough indication of the reliability of the mean affinity 
values. 
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TABEL I 
COMPOUND HISTAMINERGIC SYSTEM IN THE GUINEA-PIG ILEUM CHOLINERGIC SYSTEM IN THE RAT INTESTINE 
Structural formula 
p D 2 
or Sx n-k a E pDi' 8χ n-k 
PA2 
p D 2 
or Sx n-k a E ρΌι 5χ n-k 
рАг 
Q-
- N - C H 3 
•N-CjHs 
- N - C H t C H j ) ! 
5.47 0.05 31-10 100 
5.44 0.06 36-10 100 
4.51 0.07 23- 8 91 
4.01 0.04 31-23 
3.53 0.05 14- 9 13 
3.14 0.11 21- 9 1.86 0.10 8- 6 
3.71 
3.32 
'3.31) 
3.57 
3.58 
0.16 
0.06 
0.05 
0.09 
14- 9 
19- 9 
5-4 
29-13 
27-12 
13 
3 
1.89 
(1.86) 
(2.13) 
0.11 7- 6 
7- 5 
6- 5 
- N - C 1 H 7 4.17 0.12 38-24 3.55 0.07 26-11 (2.44) 
CV 
Q-
-H-Ct»3 
—-H-CiHn 
- N - C e H , 7 
4.24 0.16 27- 6 
4.65 0.12 44-23 
5.41 0.08 46-21 
(2.29) 11-5 4.04 0.05 26-13 
3.53 0.15 34-19 4.44 0.08 22-10 
4.30 0.07 35-19 5.34 0.05 15- 8 
2.75 0.06 10- 7 
3.58 0.10 19-10 
4.32 0.06 11- 6 
10 
- N - C , o H 2 , 
y^V /снз 
/ C 2 H 9 
N ч С
а
Н 5 
12
 О — н, 
5.75 0.06 45-30 
5.65 0.21 37-11 96 
4.43 0.16 17- 9 22 
4.37 0.09 25- 8 
5.61 0.13 56-10 
4.88 0.06 48-29 5.70 0.06 19- 6 
3.61 0.06 36-12 
(2.37) 
3.69 0.12 18- 8 
3- 2 4.26 0.04 48-13 
4.57 0.12 25- 9 
4.72 0.05 18- 6 
(3.09) 
3.63 0.11 29-13 
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TABEL I 
COMPOUND HISTAMINERGIC SYSTEM IN THE GUINEA-PIG ILEUM CHOLINERGIC SYSTEM IN THE RAT INTESTINE 
pD2 pDi 
nr. Structural formula or 8χ η-k αΕ ρΌι' S* η-k or Sj η-k aE pDj' 8χ n-k 
pA2 рАг 
26 ¿ ~ \ • • / " " У / ' Л - а 6.S1 0.09 54- 7 (4.42) 22- 5 4.41 0.13 17-10 3.62 0.07 33-15 
27 / ^ . . . / " " V / ^ V g 6.39 0.09 22-13 4.96 0.05 11-7 (5.41) 10-5 4.76 0.09 30-14 
28 <\} . . Ν • • N 6.51 0.18 27- 6 (5.31) 12- 5 (5.45) 9- 4 5.08 0.08 68- 7 
9 
29 <\ // · ' y——-N 7.96 0.16 28-11 5.94 0.07 14- 8 (5.95) 12- 3 5.38 0.10 34- 7 
CH, 
ГУ- 0 30 <.\ /> • ' N • • N 6.44 0.09 39- 9 5.18 0.06 31- 9 (5.26) 7- 5 5.00 0.09 35-10 
31 Q -
CHj 
7.46 0.17 35-10 5.63 0.10 28-10 5.90 0.04 19- 9 5.3S 0.09 27-10 
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TABEL I 
COMPOUND mSTAMINERGIC SYSTEM IN THE GUINEA-PIG ILEUM CHOLINERGIC SYSTEM IN THE RAT INTESTINE 
p D î p D j 
nr. Structural formula or 8χ η-k αΕ ρΌι' 8χ η-k or 8χ η-k a E pDj' 8χ n-k 
рАг рАг 
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 V N / > ^ ? ^ M 
С г Н
э 
CL 0 7.76 0.10 47-11 5.87 0.11 28-10 6.00 0.10 15- 8 5.71 0.07 48-16 
39 Q- C H j 6.42 0.04 22- 8 5.81 0.08 33-10 6.17 0.05 12- 8 5.98 0.15 25-10 
40 ^ — 
ρ 
6.95 0.15 25- (5.38) 15- 5 5.95 0.13 31- 9 5.27 0.07 59-13 
41 V/ ι 
" си, 
7.18 0.08 34-12 5.64 0.08 22- 9 6.10 0.05 40- 8 5.10 0.17 49- 8 
42 
о— 
6.02 0.10 54-12 5.17 0.06 42-12 (5.74) l i - 5 5.37 0.12 48-12 
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TABEL I 
COMPOUND HISTAMINEROIC SYSTEM IN THE GUINEA-PIG ILEUM CHOLINERGIC SYSTEM IN THE RAT INTESTINE 
pDi pDi 
nr. Structural formula or 8χ η-k aE рОг' 8χ η-k or 8χ η-k aE pDi' 5χ n-k 
pAi pAj 
49 4 Jf · · N - ~ - N 6.14 0.08 40-12 5.20 0.08 37-12 (5.86) 6- 4 5.20 0.08 36-13 
О 
50 / \ . .
 N - - M 6.83 0.04 27-10 (5.74) 7- 5 5.57 0.07 17-10 5.29 0.09 34-13 
51 ^ Л . .
 Ν
 . , ,( 6.47 0.09 24-20 4.93 0.05 24-20 (4.62) 4- 4 4.41 0.07 22-22 
52 ci-S~)i • . N . . / 5.67 0.10 36- 7 4.91 0.16 38- 7 5.38 0.11 9- 6 5.02 0.08 59-14 
53 /^Ч . , M . . ρ ( 6.84 0.06 41-13 6.18 0.07 44-13 6.38 0.20 11- 6 6.03 0.18 41- 9 
54 h N 6.7« 0 02 1773-390 100 
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TABEL I 
COMPOUND HISTAMINERGIC SYSTEM IN THE GUINEA-PIG ILEUM CHOLINERGIC SYSTEM IN THE RAT INTESTINE 
pD2 ρΌι 
nr. Structural formula or Sj η-k aE PD2' 8χ η-k or 8χ η-k aE pDj' 8χ n-k 
рАз рАг 
9 
63 СНз-N · · Ν 7.71 0.17 35-13 4.73 O.Il 24-11 5.43 0.06 32-13 4.54 0.12 33-13 
C H , 
Cl 0 
64 c H i - N · · N 6.80 0.10 44-13 4.93 0.09 35-10 5.34 0.09 2 2 - 8 4.85 0.10 28-10 
Cl 
H 
65 CH3—N · • N 8.24 0.12 37-12 5.17 0.08 2 0 - 8 5.39 0.09 1 5 - 9 4.78 0.09 22-11 
C H , 
CL 
66 C H j - N — — - N — — N 4 8.05 0.14 39-9 5.46 0.15 3 0 - 9 5.86 0.11 2 0 - 9 5.15 0.13 44-14 
CHj CHj 
Cl 
-•-I 
C H j C H J 
67 CHj-N · • . N — — — \ 7.45 0.20 33-11 5.06 0.06 19-11 5.41 0.10 7 - 7 5.02 0.12 31-13 
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TABEL I 
COMPOUND 
α-ADRENERCIC SYSTEM IN THE RAT VAS DEFERENS 
p D î 
nr. Structural formula or Sx η-k aE PD2' Sx η-k 
pAi 
Q 8 <\ /> • • N-C,H,7 4.75 0.11 24-11 3.74 0.08 19-11 
13
 Q—f—O 3.87 0.10 16-10 27 4.44 0.09 13-8 (3.62) 12- 5 
33 
v¿ 
5.69 0.09 12- 5.14 0.04 22-12 
44
 {)~"Γ-° (4.79) 1- 1 4.55 0.06 29-12 
50
 \j~-x* 
CH. 
CI 0 5.26 0.07 29-15 4.71 0.08 33-16 
59 І > — N - 4.67 0.13 21-10 3.71 0.07 20-10 
70« C H -f 
CH. 
· · d-form 
1 0 2 
4.64 0.05 23-11 36 
TABEL I 
COMPOUND 
α-ADRENERGIC SYSTEM IN THE RAT VAS DEFERENS 
nr. Structural formula or 8χ η-k α Ε ρΌι' 8χ n-k 
PA2 
71 
73 
C H ^ N 
C2HS-N r 
ν 
О 
(5.08) 
(5.56) 
4 - 3 
2 - 2 
4.85 0.14 27-10 
4.78 0.05 59-17 
75 'ОН^ сн, 4.57 0.11 63-14 
Э.14 0.18 27-11 
The compounds 28-53 and 57-67 were obtained by courtesy of the Research Department of 
N.V. Organon, Oss, the Netherlands, 
compound 56 by courtesy of the Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, 
Ind., USA, 
compound 72 by courtesy of Ciba N.V. Amhem, the Netherlands, 
compound 74 by courtesy of A. H. Robins Cy. Inc., Richmond, Va., USA. 
The compounds were used in the form of the following salts: 
chloride : compounds 14, 19, 53, 55, 68, 71 
dichloride : compounds 15-17, 28, 29, 41, 46-48, 51, 54, 56-58, 62, 63 
bromide : compounds 20, 74 
dibromide : compounds 1-13, 18, 25-27 
tribromide : compounds 21-24 
sulphate : compound 75 
maléate : compounds 31, 32, 35, 40, 42, 45, 49, 50, 52, 60, 61, 64, 65, 69, 70, 72 
dimaleate : compounds 30, 33, 34, 36-39. 59. 66, 67 
dioxalate : compounds 43, 44 
citrate : compound 73 
The following compounds are known under generic names: 
compound 54: histamine 
compound 56: betazole 
compound 63 : phenbenzamine 
compound 68 : p-methyl-diphenhydramine 
compound 70: dexchlorpheniramine 
compound 71 : cyproheptadine 
compound 72 : dimethindene 
compound 73 : alverine 
compound 74: glycopyrronium 
compound 75 : atropine 
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CHAPTER V 
RESULTS OF THE EXPERIMENTS ON ISOLATED ORGANS 
GENERAL REMARKS RELATING TO TABLE I 
In table I the affinity values calculated for the compounds tested are listed. 
The pA2-values, referring to competitive antagonistic compounds, are printed 
in normal type, whereas the pD2-values referring to fully or partially agonistic 
compounds are given in italics. In the last cases also a mean intrinsic activity 
value (aE) is given. The intrinsic activity values (histaminomimetic, cholino­
mimetic or α-adrenergic) are the means of the mean values per animal. They 
are expressed in the form of percentages, the intrinsic activity or the reference 
compound being 100 %. 
For each compound the affinity to the histamine receptor in the guinea-pig 
ileum and, whenever possible, also the affinity to the acetylcholine receptor in 
the rat jejunum was determined ; in ten cases also the affinity to the noradrenal­
ine receptor in the vas deferens of the rat was measured. If the number of ani­
mals in the sample is at least 6 (usually it is larger), the рОг or pAz is given 
together with the standard error of the mean (s
x
), calculated according to 
equation 57 ; the same holds for the corresponding pD2'-values. For reasons to 
be discussed below, a certain proportion of the pA2-determinations on jejunum 
and vas deferens of the rat and of the pD2'-determinations on all three receptor-
effector systems had to be based on a smaller number of animals. In these cases 
the mean affinity value is given in parentheses and without s^; it should be 
considered a rough indication only of the magnitude of the affinity. With each 
affinity value the number of the observations (n) and of the animals (k) in the 
sample in question is given. 
THE INTRINSIC ACTIVITY VALUES AND AFFINITY VALUES OF PARTIAL 
AGONISTS 
With respect to the intrinsic activity values of the partial agonists it should 
be mentioned that the animal means scatter widely around the general mean; 
in the case of compound 57, for instance, (general mean 45 %) the lowest and 
highest means in the sample are 11 % and 88 %, respectively. In this light it is 
questionable whether it is correct to give the mean a E of the compounds 3, 10 
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and 56 as 91 %, 96 % and 90 %, since full agonism ( a E = 100 %) was found in 
3 out of 8 animals, 7 out of 11 animals and 2 out of 12 animals, respectively. 
An a E of 100 % may indicate that the compound in question is just able to 
cause Emax, but it may also mean that the maximal response is reached when 
the system still has a receptor reserve (see chapter III). Therefore it is not quite 
satisfactory to combine these values with those smaller than 100 % to one mean 
value ; however, a better alternative is not available. 
Some of the compounds tested behaved as partial agonists in certain animals 
but were competitive antagonists in other ones. This holds for the compounds 
11 and 55 (histaminergic and competitively antihistaminic), compounds 1, 2 and 
3 (cholinomimetic and competitively cholinolytic) and compound 13 (adren­
ergic and competitively adrenolytic); in these cases bothapD2- and a рАг- аІие 
are given. 
The intrinsic activities of the compounds in question are calculated from the 
whole sample. Compound 11, for instance, was found to be a partial agonist 
in 9 animals and a competitive antagonist with a E = 0 in 8 animals; in the mean 
a
E
 of 22 % both these categories are represented. 
Theoretically it could be expected that the рОг- and the pA2-value of the 
drugs discussed here would be identical, since both values are equivalent 
measures of the affinity of the drug to one and the same kind of receptors. As a 
matter of fact the differences found are relatively small, in spite of the fact that 
the group of animals on which the рОг- аІие was determined is not identical 
with the group that could be used for the determination of the рАг- аІие. If 
the two groups would form selections from the population not only with 
respect to the intrinsic activity but as to the affinity as well, the pDz-value and 
the pAz-value could depart from the mean affinity value of the population in 
different, systematic ways. The values actually obtained do not suggest that 
such a deviation, if existing, plays an important role. 
METACTOID ANTAGONISM HINDERING OR PREVENTING THE OBSERV­
ATION OF COMPETITIVE ANTAGONISM 
With respect to the рАг- аІиез presented in table I another point should be 
considered. If possible both the рАг and pDz' were determined on each animal 
used. This, however, was not always the case. 
In the first list of affinity values referring to the histamine receptor 4 pAz-
values are based on a smaller number of animals than the accompanying pDa'-
values (compounds 36, 39, 45 and 73). In the first three cases the difference 
between the numbers of animals is small. It was caused by accidental factors; 
in principle the differences between рАг and рВг' are sufficiently large to allow 
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determination of both values in each animal. In the case of compound 73, how­
ever, the рАг is not much higher than the рОг'. Here in 7 out of 14 animals used 
it was impossible to determine a pAi-value, since the curves were depressed too 
far before an appreciable shift to higher concentrations could manifest itself. 
The same factor plays a much more important role with regard to the рАг-
values referring to the acetylcholine receptor. This is not surprising, since most 
compounds tested in this study have a considerably lower affinity to this re­
ceptor than to the histamine receptor, whereas their pD2'-values with respect 
to the two systems differ much less. In 19 cases the рАг is based on less than 
6 animals and consequently is given in parentheses and without s ,^ whereas 
on the average the accompanying pD2'-values are based on samples of about 
12 animals. In another 23 cases the рАг is based on 6 or more animals, but the 
number of animals is smaller than that on which the accompanying рог ' is 
based. This holds also for the рАг- аІие of compound 33 regarding the nor­
adrenaline system. 
It is an interesting question whether the pA2-values determined in these cases 
may depart from the population affinity value in a systematic way. The animals 
on which a рАг- аІие could be determined cannot be considered an aselect 
sample from the population; obviously in their cases the difference between 
рАг and рОг' is greater than on the average. A study of the whole material 
available did not show that the animal pAz-values and the accompanying animal 
pD2'-values would be scattered around their means in analogous ways; in other 
words, it is not so that, as a rule, relatively high рАг- and pD2'-values would 
be found in one animal and relatively low рАг- and pD2'-values in another. If, 
however, both a high and a low affinity to the receptor of the agonist can be 
accompanied by a high or low affinity to the metactoid receptor, whereas the 
рАг can be determined only if it is higher than the corresponding рВг' and the 
difference has at least a certain minimal value, the chance that the рАг is 
sufficiently higher than the pDz' is better if the рАг- аІие itself is relatively 
high. It follows that the mean pA2-values determined on these 'incomplete 
samples' may tend to be somewhat higher than the true population mean. 
pD2 '-VALUES BASED ON A SMALLER NUMBER OF ANIMALS THAN THE 
ACCOMPANYING PA2-VALUE 
Also a number of pD2'-values are based on 'incomplete samples'. In these 
cases the reason is that in a certain proportion of the determinations the highest 
drug concentration used was too low to cause a sufficient reduction of the 
maximal height of the agonist curve. 
Again it is to be supposed that the mean affinity values determined in these 
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cases are somewhat higher than the true population means, since the higher 
items in the population of pDz'-values have a better chance to be determined 
at all. 
THE INTERACTION OF HISTAMINOMIMETIC COMPOUNDS AND OF COM-
PETITIVE ANTAGONISTS OF HISTAMINE WITH THE HISTAMINE RECEPTOR; 
THE CONCEPT ADDITIONAL RECEPTOR AREA 
The majority of the compounds tested are competitive antagonists of his-
tamine. As discussed before, a competitive antagonism is supposed to be based 
HISTAMINOMIMETICS 
histamine 
N
^N 
3-(5-ammoethylpyrazole 
4-(3-mninoethylpy razóle 
2- p-aminoelhylpyridine 
FIG. 2i. Structural formulae of some histaminomimetic drugs and some competitive anta-
gonists of histamine. 
Note the structural relationship between the compounds with histaminergic action and the 
lack of a clear structural relation between the antihistamines. 
107 
ANTIHISTAMINES 
p-methyldiphenhydramine 
phenindamine 
S N • 1 Ν ' 
Η 
^ ^promethazine 
.S 
on the fact that the molecules of the agonistic drug and of the antagonist have 
affinity to the same receptors (p. 24). The affinity of a compound to a certain 
type of receptor is dependent on certain physico-chemical properties of its 
molecules. It could be supposed, then, that a tendency to interact with a certain 
type of receptors would be reflected by a certain similarity of the structural 
features of the compounds in question. The majority of the antihistamines 
shown in table I are closely related indeed, but they form a selection ; if the 
whole family of competitive antihistamines is considered, the structural 
relationship is not evident. (The same holds, mutatis mutandis, for some other 
families of competitive antagonists.) 
In fig. 21 the structural formulae of a few histaminomimetics and competitive 
antagonists of histamine are given. The structural relationship between the 
histaminomimetics is quite evident but the antihistamines have no clear 
structural relation with the agonistic drugs nor with each other. They resemble 
each other only in the presence of two unsaturated rings and of an amino-
group situated at approximately the same distance from this ring system. This 
would hardly seem to be a sufficient basis for a common affinity of agonists 
and antagonists to the same receptors. 
How can these drugs behave as competitive antagonists of histamine? The 
affinity values with respect to the histamine receptor of some of the compounds 
tested in this study may suggest an answer to this question. To begin with, 
attention may be drawn to the compounds 1-9 and 14, a series of alkyl- and 
aralkyl-substituted derivatives of the histaminomimetic drug 2-(ß-aminoethyl)-
pyridine (compound 1). The methyl- and ethyl-substituted derivatives are 
histaminomimetic compounds themselves, but from the isopropyl-substituted 
derivative the substances are competitive antihistamines, although their 
structure contains the structure of the original agonist. At first the affinity de-
creases - this effect may be (partly) caused by a disappearance of the receptor 
reserve - but from the isopropyl-substituted derivative it grows again. The 
ρ A 2-values of the decyl-substituted and the diphenylpropyl-substituted deriv­
atives (compounds 9 and 14) are even higher than the рог of 2-(ß-aminoethyI)-
pyridine itself. 
It is quite evident that this increase in the affinity, which finds expression in 
the increase of the рАг- аІиез, cannot have been gained on the original receptor 
area, since this was already Occupied' by the pyridylethylamine-moiety of the 
molecule. New, additional receptor areas must have been used: structures 
present in the direct environment of the original receptor, but outside the 
agonistic receptor area proper (56). Further it may be clear that the pyridyl­
ethylamine-moiety of the derivatives does not interact with the original receptor 
in exactly the same way as 2-(ß-aminoethyl)-pyridine itself, since otherwise the 
108 
loss of the intrinsic activity would be unexplicable. It is a relevant question, 
then, whether the agonistic receptor area still plays an appreciable role with 
respect to the affinity of the derivatives substituted with relatively large alkyl-
or aralkyl-groups. 
This question could be answered by comparing some antihistaminic com-
pounds (compounds 58, 60, 28 and 45) in which an N-phenyl-N-benzyl-
ß-aminoethyl-group (as present, for instance, in the antihistaminic drug phen-
benzamine, compound 63) was substituted to the side-chain amino-group of 
histamine, 3-(ß-aminoethyl)-pyrazole, 2-(ß-aminoethyl)-pyridine and phenyl-
O—N-
Q—N^^ 
pA2 
6.43 
6.61 
6.51 
6.21 
6.94 
SR 
0.14 
0.07 
0.1 β 
0.07 
0.09 
η - к 
29-10 
36-15 
2 7 - 6 
26-14 
29-12 
—η 
по. 22. The affinity values with respect to the histaminergic system in the guinea-pig ileum 
of the compounds 58, 60, 28, 45 and 62 (cf. table I). The values in the column Sx give the 
standard errors of the mean calculated according to equation 57 ; η is the number of obser­
vations and к is the number of animals in the sample from which the corresponding pAi 
was calculated. 
Note: the nature of the ring in the 'mimetic moieties' of the molecules has little influence on 
the affinity values, and removal of the ring in question does not cause a decrease of the рАг. 
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ethylamine, respectively (fig. 22). As may be seen from the pAa-values, the 
nature of the ring in the 'mimetic moiety' of the molecule has little influence 
on the affinity of these antihistamines, although in the corresponding agonistic 
drugs (compounds 54, 56, 1 and 55) it is quite important. (The pDz-values are 
6.78, 3.85, 5.47 and 3.83, respectively; these differences may be due partly to 
differences in receptor reserve, but this cannot be the whole explanation, the 
P K A S of histamine being about 5 (145).) To this must be added that compound 
62 (secondary phenbenzamine), which lacks the 'mimetic moiety', has a higher 
affinity than any of the four antihistamines in question (fig. 22). Obviously the 
'mimetic moiety' in the structure of these substances does not essentially con-
tribute to their affinity to the receptor; on the contrary, it might even have a 
negative influence (see also p. 123). 
In view of these data it may be supposed that antihistamines may block the 
histamine receptor without really using this structure for their own binding. 
It may be that only a small (but essential) part of the histamine receptor is 
screened. 
The concept is illustrated schematically in fig. 23. The agonist optimally 
'fits' the agonistic receptor. The antagonist mainly uses additional receptor 
areas. The 'mimetic moiety' is not essential for the receptor blockade ; it may 
be over the agonistic receptor area, it may be in another position, or it may be 
absent. 
According to this hypothesis, which may be applicable to a number of 
systems besides that of histaminomimetic and antihistaminic drugs, a close 
structural relationship between agonistic drugs and their competitive anta-
gonists is not necessary (40, 49, 50, 56, 896, 933). It is not necessary either to 
suppose that all competitive antagonists of a certain agonist would use identical 
additional receptor areas, so that it is not difficult to give a possible explanation 
for a lack in structural relationship within the group. 
An interesting consequence of the hypothesis presented here is the possible 
existence of drugs which could interact with the additional receptor area 
essential for the binding of a given competitive antagonist, but without inter-
fering with the interaction between agonist and agonistic receptor. A drug of 
this kind would be without visible effect if given alone or in combination with 
the agonist, but it could potentiate the agonist if added to a combination of 
agonist and competitive antagonist. It would seem worth while to look for 
compounds with this type of action. 
The supposition that the agonistic receptor area proper may not play an 
appreciable role with respect to the affinity of certain types of competitive anta-
gonists further may explain why it was impossible to diminish the 'between-
animal variability' discussed in chapter IV by subtracting from each pAz-value 
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the difference between the corresponding pD2-value and the mean pDz-value 
of the agonist (cf. p. 87). If indeed the receptors of the agonist and the com-
petitive antagonist are largely different structures, there is little reason to expect 
that the proposed correction would produce the desired result. 
Receptor 
for antagonist 
FIG. 23. Schematica! illustration of the concept 'additional receptor area'. The agonistic drug 
optimally 'fits' the agonistic receptor; the competitive antagonist mainly uses additional 
receptor areas. 
Note, that in this view the antagonist may block the agonistic receptor by screening only a 
small but essential part of it. Here the 'mimetic moiety' in the molecule of the antagonist is 
not essential for the receptor blockade; it may be over the agonistic receptor area, it may be 
in another position, or it may be absent. A close structural relationship between agonistic 
drugs and their competitive antagonists is not necessary. 
I l l 
THE pAi/pDi'-RATios IN THE HiSTAMiNERGic SYSTEM - A. In the whole 
material studied 
On first inspection of the affinity values listed in table I the impression may 
be got that рАг- and pDa'-values are more or less correlated. In the series of 
alkyl-substituted derivatives of 2-(ß-aminoethyl)-pyridine (compounds 1-9) 
the increase in the affinities to the specific histamine and acetylcholine receptors 
is attended with an increase in the affinities to the receptors of the respective 
metactoid systems. Also in the further material the relatively high pAî-values 
rather often are accompanied with relatively high pD2'-values. This aspect 
deserved a closer examination. 
pDi' gulnta-ptp-
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FIG. 24. The relation between рАг- and pD2'-values with respect to the histaminergic system 
in the guinea-pig ileum. Each point represents the рАг/рОг'-гайо of one compound; all 
antagonists listed in table I except the compounds 4 and 5 are included. 
Note: all points are found in a band-shaped area between two parallel lines. The left-hand 
interrupted line may represent the minimal difference and the right-hand interrupted line may 
represent the maximal difference between pAi and pDz' allowing determination of both 
values (see text). 
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In fig. 24 the relation between рАг- and pD2'-values with respect to the his-
taminergic system in the guinea-pig ileum is shown. In this figure all antagonists 
in table I except compounds 4 and 5 are included. Each point represents the 
рАг/рОг'-гайо of one compound. As may be seen, all points are found in a 
band-shaped area between two parallel slanting lines, affirming that low рАг-
values tend to be associated with low pDa'-values and high pA2-values with 
high pD2'-values. However, the width of the band shows that the correlation 
is not very strong. 
Does the finding in question hold information about a possible correlation 
of more general nature between the affinities to the two different types of 
receptors? On reflexion this appears not to be the case. Both margins of the 
band-shaped area in which the points are situated can be explained by factors 
which have nothing to do with the affinities between the drugs and the two 
types of receptors. 
The left-hand margin of the band-shaped area represents the minimal differ­
ence between рАг- and pD2'-value allowing determination of both values. The 
left-hand interrupted line in fig. 24 indicates a difference between рАг and pDi' 
of 0.2 unit. No points are situated on the left side of this margin, since the term 
рАг—рог' never has a value smaller than about 0.2 units, let alone a negative 
value. If the affinity of the antagonist to the specific receptor is very little higher 
or if it is lower than that to the metactoid receptor, the antagonist will cause a 
depression of the agonist curve without an appreciable shift, or without any 
shift, to higher concentrations. In such cases no рАг- аІие can be determined, 
although the drug may have a considerable affinity to the specific receptor. 
The other margin of the band-shaped area represents the maximal difference 
between рАг- and pDz'-value allowing determination of both values. The right-
hand interrupted line in fig. 24 indicates a difference between рАг and pDi' 
of 3.5 units. If the difference would be greater the concentration of the anta­
gonist necessary for the manifestation of the affinity to the metactoid receptors 
by depression of the agonist curve is so high, that it would cause a shift of the 
histamine curve to the concentrations where the auto-inhibition of histamine 
starts to play a role. In the course of the present study it was found that in 
general a depression of the agonist curve to about 50 % of the original height 
can be accompanied with a shift up to about 3.5 units without complications 
caused by this auto-inhibition phenomenon. From the equations 46 and 50 
(p. 78 and 82) it follows that 
pA2- pD2' = log (EJJ2 - 1) + log L ^ f = 1) 
\lAJi / \fcAmax—bAmaxBB' / 
If the maximal value of the shift (equaling log jr-— ) is 3.5, whereas 
ПЗ 
^ ^ equals 2, the maximal difference between рАг and рог ' 
allowing an accurate determination of both values also is about 3.5. Again 
this does not mean that drugs with a larger difference between the affinities 
to the two types of receptors cannot exist, but their pD2'-value cannot be deter­
mined. Consequently in fig. 24 no points can be found on the right side of the 
right-hand margin; the figure only shows the visible segment of a cloud of 
points which, in principle, may be much larger. 
THE pAz/pDi'-RATios IN THE HiSTAMiNERGic SYSTEM - B. In a series of 
compounds with a close structural relationship 
From the foregoing it follows that no correlation between рАг and pDz' 
can be deduced from the whole material shown in fig. 24. The matter looks 
different, however, if a more selected material is studied. Fig. 25 shows the 
part of fig. 24 which refers to a series of compounds with a close structural 
relationship, viz. the compounds 28 - 44 (compound 39, in which the structural 
difference is more important, excluded). The positions of the points representing 
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FIO. 25. The part of fig. 24 which refers to a series of compounds with a close structural rela­
tionship (compounds 28-38 and 40-44). 
Note, that within this group the pAj- and pDj'-values are rather closely correlated. 
114 
the рАг/рОг'-гаиоз of these 16 compounds clearly show that within this group 
the рАг- and pD2'-values are rather closely correlated. This is the more con­
vincing as a regression line through the points in question has a smaller angle 
of inclination than the lines representing the minimal and the maximal diffe­
rences between pAz and рВг'. 
How is this finding to be interpreted? If structural variations have analogous 
consequences with respect to different affinity values, two basal possibilities 
exist. As may be clear from the discussions in the chapters III and IV, the 
affinity values used are no pure expressions of the interaction tendency between 
drug molecule and receptor. Also possible factors influencing the relation 
between dose and biophase concentrations (drug transference; see fig. 4) may 
find expression in these values. Changes in the physico-chemical properties 
of the drug molecule which have little or no influence on the interaction ten­
dency of the drug with its receptor yet may influence the affinity value if, for 
instance, the partition of the drug molecules between bath fluid and biophase 
is changed (cf. p. 44). If different types of receptors are present in biophases 
with similar characteristics, these 'unspecific' changes may influence different 
affinity values in analogous ways. 
The second basal possibility is that the structural variations in question have 
analogous influences on the interaction tendencies of the drugs with different 
receptors. Even if this is the case the influence of the structural variations may 
be rather 'unspecific'. Of course the interaction tendency proper may be depen­
dent on highly specific, structural features in the drug molecule, which, for 
instance, may be essential for a point-to-point interaction of complementary 
polar groups ('receptor complementarity'), but also less specific factors like 
the more diffusely acting hydrophobic forces may play a role, especially on 
additional receptor areas. Only if the structural differences cause changes in 
the affinity values as a result of an amelioration or deterioration of the receptor 
complementarity, the differences may render essential information about the 
structure of the original receptor. 
With respect to the series of compounds under discussion the last-mentioned 
condition does not seem to be fulfilled. It is not very probable that the molecular 
modifications in this series would influence the affinity to the two types of 
receptors in a parallel way by virtue of an ameliorated receptor complementarity 
of the compounds. This would be plausible only if a rather high degree of 
similarity in the structures of the specific and the metactoid receptor would 
exist. In that case, however, a more general relationship between the рАг- and 
pD2'-values of antihistaminic compounds would be expected. Moreover, the 
noncompetitive spasmolytic action of higher concentrations of all kinds of 
compounds, belonging to different families of competitive antagonists and 
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possessing very different structures, is so general a phenomenon, that it is not 
plausible that the metactoid receptors would make very specific structural 
demands. Since the specific receptors proper do make such demands, the struc­
tural similarity of the specific and the metactoid receptor cannot be very striking. 
At best some similarity may exist between certain additional receptor areas 
of the specific receptor and (parts of) the metactoid receptor. 
The conclusion, then, must be that the molecular modifications in question 
mainly have their influences on the drug transference and/or the less specific 
binding forces, and that they cannot be expected to produce much information 
about the structure of the histamine receptor. Of course this conclusion, 
although probable, is not compelling. A few possible counter-arguments may 
be discussed here. 
First, the supposition that the metactoid receptor would be more or less 
devoid of specific structural features may be attacked on the ground of the 
finding that the optical isomers of chlorpheniramine (compounds 69 and 70) 
have different affinity values not only with respect to the specific receptor, but 
also with respect to the metactoid receptor. If stereoisomerism has a considera­
ble influence on the affinity values this argues for an important role of the 
receptor complementarity. (Theoretically also certain aspects of drug trans­
ference, like enzymatic catabolism or active transport mechanisms may be 
stereospecific, but such factors hardly have to be considered here.) The fact, 
however, that no difference in affinity with respect to the metactoid receptor 
in the rat intestine is found may raise some doubt about the great difference with 
respect to the metactoid receptor in the guinea-pig ileum. The рог ' of com­
pound 70 is about 3.3 units smaller than the accompanying рАг, meaning that 
an influence of the auto-inhibition by histamine cannot be excluded completely, 
the more so as in 8 out of 15 animals no pDz' could be determined at all. 
Possibly the difference between the affinities to the two receptor types is greater 
than found here, meaning that the difference between the true pDz'-values 
of the compounds 69 and 70 may be smaller or even non-existent. Therefore 
this point will stay undecided until рАг- and рОг'-values of more stereoisomers 
of antihistaminic compounds have been determined. In general, the use of 
stereoisomers in the study of this kind of problems seems promising. 
Another counter-argument turns on the possibility that different types of 
metactoid receptors could be present in the guinea-pig ileum. In that case it 
would be possible that the metactoid receptor relevant for the series of com­
pounds in fig. 25 would be structurally related to the histamine receptor, but 
that this would not hold for the metactoid receptors relevant to a number of the 
other antihistamines. Since attendant arguments in favour of this notion are 
lacking, the other, simpler explanation of the experimental results is preferable. 
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THE рАг/роі'^RATIOS IN THE CHOLINERGIC SYSTEM 
The more general considerations in the Jast paragraph also are applicable 
to the relationships of the pAz- and pD2'-values of the compounds collected 
in table I with respect to the cholinergic system in the rat intestine. In fig. 26 
the pA2/pD2'-ratios of the compounds in question are given. Comparison with 
fig. 24 shows that the situation is very different from that found with respect 
to the histaminergic system. The great majority of the points (in fact, the pAi/ 
pD2'-ratios of all compounds except 69-72, 74 and 75) are found in a narrow 
band-shaped area. In the upper half of this band-shaped area the left-hand 
margin coincides with the line representing the minimal difference between 
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FIG. 26. The relation between pAj- and pDi'-values with respect to the cholinergic system in 
the rat intestine. Each point represents the pAilpOi'-Tntio of one compound; all compounds 
listed in table I except the compounds 11, 45, 54 and 56 are included. 
Note that, with a few exceptions, a rather close correlation between pA2- and pD2'-vaIues 
exists. 
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рАг and pDi', but the line representing the maximal difference is situated on a 
considerable distance from the right-hand margin. (In the cholinergic system 
in question a shift of at least a factor 10,000 is possible without auto-inhibition.) 
It must be concluded that, with a few exceptions, a rather close correlation 
between рАг- and pDz'-values exists. 
If the reasonings in the preceding paragraph are correct, the explanation 
of this finding is obvious. With only a few exceptions the compounds in table I 
are histaminergic or antihistaminic substances. The structural changes were 
introduced in the hope that they would influence the affinity of the compounds 
to the histamine receptor; they were not selected with a view to their possible 
effect on the affinity to the cholinergic system. If nevertheless the structural 
differences between the compounds have their influence on this affinity, it is 
not very probable that changes in the complementarity between the compounds 
and the acetylcholine receptor would be the main factor: none of the compounds 
in the band-shaped area will have a good 'receptor fit'. On the contrary, the 
association between the pAz- and pD2'-values argues for the supposition that 
the changes in these values are mainly caused by changes in the drug trans­
ference and/or the less specific binding forces, factors which may influence 
both the рАг and рОг' in an analogous way, even if the receptors of the two 
systems have different characteristics. 
This interpretation is supported by another aspect. It is suggestive that the 
few compounds in the series which have high affinities to the acetylcholine 
receptor, viz. cyproheptadine, glycopyrronium and atropine (compounds 71, 
74 and 75) have pAi/pD2'-ratios far outside the range of the narrow band-
shaped area in which the other points are concentrated. Here the affinity of the 
compounds to the specific receptor probably is dependent on more specific 
binding forces, so that the correlation between рАг and рОг' is small. 
COMPARISON OF THE pDz'-VALUES IN THE HISTAMINERGIC AND THE 
CHOLINERGIC SYSTEM 
In one of the preceding paragraphs it was argued that 'it is not plausible 
that the metactoid receptors would make very specific structural demands' 
(p. 116). This can be interpreted in different ways. The metactoid receptor may 
be seen as a structure to which a number of different compounds have a mode­
rate affinity on account of less specific binding forces, and to which no drug 
will have a very high and specific affinity since the structure is so indifferent 
that a typical receptor complementarity hardly plays a role. The extreme sup­
position in this direction is that the metactoid receptor would not be a receptor 
proper, but a phase in which the molecules of the metactoid antagonist are 
118 
dissolved. On the other hand the metactoid receptor may be seen as a true 
receptor to which a high and specific affinity on account of a perfect 'receptor 
fit' may exist, but which nevertheless is sufficiently indifferent to allow a 
moderate degree of interaction with numbers of differently structured com­
pounds. 
In view of these different possibilities it is worth while to compare the PD2'-
values of the compounds in table I with respect to the histaminergic system in 
the guinea-pig ileum and with respect to the cholinergic system in the rat 
intestine. If the metactoid receptor is devoid of characteristic structural features 
or even is just a receptive phase, it is not to be expected that much difference 
between these two values would be found. And indeed, in the majority of the 
cases the pD2'-values are moderate and the differences between the two pDj'-
values in the different systems are small ; for the compounds 28-68 the mean of 
the absolute values of the differences is only 0.31 unit. However, there are 
important exceptions (compounds 21, 24, 68-72, 74 and 75). 
Especially the results obtained with the compounds 71 and 75 (cyprohep­
tadine and atropine) are strong arguments against the hypothesis in question. 
In the case of compound 71 the pDz' found in the histaminergic system (7.12) 
is 1.33 unit higher than that found in the cholinergic system, whereas the 
difference between the рАг and рог ' in the histaminergic system is only 1.64, 
so that the high pDa'-value seems reliable (influence of histamine auto-inhibition 
being out of the question). In the case of compound 75, on the other hand, 
the ρΌζ' found in the histaminergic system is 4.80 units lower than that found 
in the cholinergic system. Also here the difference between the higher pDi' 
(7.60) and the accompanying pAz is moderate (1.59), so that auto-inhibition 
in the cholinergic system cannot have played a role. 
In view of these data the conclusion must be that the metactoid receptors 
in the histaminergic system in the guinea-pig ileum and in the cholinergic 
system in the rat intestine are different structures which, as for higher affinities, 
both have their own, specific structural demands. 
INFLUENCE OF SOME MOLECULAR MODIFICATIONS ON THE AFFINITY 
VALUES 
A. The influence of the substitution of a methyl-group to the secondary N-atom. 
The so-called rule of Pfeiffer 
Among the compounds tested 7 pairs of compounds with molecular struc­
tures differing only in the presence or absence of a methyl-group substituted 
to the secondary N-atom are found. In table II the differences between the 
affinity values of the analogous compounds are shown. 
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Pairs of Histaminergic system Cholinergic system 
compounds guinea-pig ileum rat intestine 
I 
29 
33 
41 
47 
50 
63 
65 
II 
28 
30 
40 
45 
49 
62 
64 
рА2І-рА2ІІ 
1.45 
1.89 
0.23 
i.o8 
0.69 
0.77 
1.44 
pD 
Л-рОЛІ 
о.бз 
о.8з 
0.26 
о.З ι 
0.54 
O.Ol 
0.24 
pAîI-pAjII 
0.50 
0.47 
0.15 
— 
—0.29 
о.об 
0.05 
pDi'I-pDî'II 
0.30 
0.4З 
— 0 . 1 7 
0.30 
0.09 
— 0 . 0 6 
— 0 . 0 7 
TABLE п. Comparison of the affinity values of compounds with analogous structures. Each 
compound in column I only differs from the corresponding compound in column II in the 
presence of a methyl-group substituted to the secondary N-atom. 
The substitution in question causes an increase in the affinity values determined on the gui­
nea-pig ileum (see text). 
Obviously in the material in question the substitution of a methyl-group 
to the secondary N-atom increases the affinity values found with respect to 
both the specific and the metactoid receptor of the histaminergic system in the 
guinea-pig ileum. The influence on the affinity value with respect to the metac­
toid receptor is smaller than with respect to the specific receptor, but in both 
cases the tendency to increase is significant (P = 0.016, according to the two-
tailed Wilcoxon's signed rank test). No systematic influence of the structural 
change in question on the affinity values found with respect to the specific 
and the metactoid receptor of the cholinergic system in the rat intestine could 
be demonstrated (P = 0.22 and 0.30, respectively, according to the same test). 
The fact that the differences between the pD2'-values measured in the hista­
minergic system in the guinea-pig ileum clearly indicate a trend, whereas the 
differences between the pDz'-values measured in the cholinergic system in the 
rat intestine do not allow a conclusion, may be an additional argument in 
favour of the supposition that the metactoid receptors in the two systems should 
not be seen as identical structures (cf. p. 119). 
For several pairs of compounds the difference between the рАг- аІиез 
determined on the histaminergic system is great so that the interaction tendency 
between the compound and its receptor seems to be considerably increased by 
the substitution in question, but in some other cases the difference is much less 
important. An explanation of this discrepancy was sought in the so-called rule 
of Pfeiffer. In 1956 Pfeiffer published a study on optical isomerism and phar­
macological action (767). He studied a series of 14 compounds with very 
different structures and found that the difference in the pharmacological effec-
tivity of the optical isomers was greater as the effective dose of a drug was lower 
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(i.e. as its potency was higher). His explanation for this finding was that with 
a non-potent drug 'the degree of geometric conformation to the locus of action 
must be relatively poor, and, hence, would not be greatly influenced by the 
optical isomerism of the compound'. 
The 'rule of Pfeiffer' was demonstrated to hold in several other groups of 
pharmacologically active optical isomers (51, 52, 274, 275). As suggested by 
Ellenbroek et al. (274, 275), however, the relationship in question will only be 
found if the centre of asymmetry is located in a part of the drug molecule that 
plays an important role with respect to the interaction, whereas the influence 
of the steric configuration will be low if the centre of asymmetry is located in 
a part of the drug molecule that is only slightly or not involved in the inter­
action (so-called critical and non-critical drug moieties, 40, 897). 
If Pfeiffer's explanation of the relationship is correct, it is to be expected 
that the same kind of reasoning would apply to the influence of certain small 
structural modifications in larger molecules. In fact a relationship reminiscent 
of that reported by Pfeiffer was found in a series of cholinomimetic compounds 
composed of pairs with small differences in the structure of the onium head 
(40,897). However, analogous changes in a series of anticholinergic compounds 
had little influence on the activity (i.e. the ratios for activities of pairs of com­
pounds were close to unity, 40, 897). It seemed of interest, therefore, to check 
whether the higher pA2-values with respect to the histaminergic system in the 
guinea-pig ileum of the methyl-substituted compounds in table II would coin­
cide with greater differences between these pA2-values and the pAz-values of 
the corresponding non-substituted compounds. 
In table III the relevant data are shown: column A gives the pA2-values of 
the methyl-substituted compounds, column В the differences with the рАг-
values of the corresponding non-substituted compounds. The correlation expec-
Compound A В 
33 8.33 1.89 
65 8.24 ι-44 
29 7.96 1.45 
63 7.71 0.77 
47 7.29 1.08 
41 7.18 0.23 
50 6.83 0.69 
TABLE in. Comparison of the pAi-values of the methyl-substituted compounds collect­
ed in table II, determined on the guinea-pig ileum (column A) with the differences 
between these pAa-values and the pAi-values of the corresponding non-substituted 
compounds (column B). 
The values in the two columns are correlated (see text). 
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ted on the basis of the proposed generalization of 'Pfeiffer's rule' indeed is 
found; the result is significant (P = 0.015 according to the one-tailed Kendall's 
rank correlation test). In this way the very different magnitudes of the changes 
in the affinity values caused by the molecular modification in question find an 
unforced explanation. 
B. The influence of the presence or absence of an N-atom in the ring in the 
'mimetic moiety'1 (pyridyl- or phenyl-ring) 
The compounds 28-44 c a n be seen as derivatives of 2-(ß-ammoethyl)-
pyridine, the compounds 45, 47 and 49-53 as derivatives of phenylethylamine. 
Five pairs of compounds have structures differing only in this respect that one 
compound has a pyridyl-ring where the other has a phenyl-ring. The influence 
of this difference on the affinity values is shown in table IV. 
Pairs of 
compounds 
I II 
28 45 
29 47 
30 49 
33 50 
37 51 
Histaminergic system 
guinea-pig 
рАД-рАШ 
0.30 
ο.6η 
о.зо 
I.So 
I.II 
ileum 
pDî'I-pDj'II 
—0.16 
0.16 
—0.02 
0.27 
0.87 
Cholinergic system 
rat intestine 
ΡΑ2Ι-ΡΑ2ΙΙ 
0.08 
— 0 . 6 0 
0.16 
1.06 
рОзЪрОг'И 
—O.I4 
— 0 . 1 4 
— 0 . 2 0 
0.14 
I.OI 
TABLE iv. Comparison of the affinity values of compounds with analogous structures. Each 
compound in column I only differs from the corresponding compound in column II in the 
presence of an N-atom in the ring in the 'mimetic moiety'. 
The presence of the N-atom in question seems to have a positive influence on the pA2-values 
determined on the guinea-pig ileum (see text). 
As compared with the phenyl-ring, the pyridyl-ring seems to have a positive 
influence on the pAz-values determined in the histaminergic system of the 
guinea-pig ileum; however, the number of pairs is too small to call the result 
statistically significant. The differences with repect to the other receptors are 
not suggestive for a definite influence. The relatively great positive differences 
with respect to all four receptor systems found in the case of the pair 37-51 
is remarkable but unexplained. 
Again a correlation between the magnitude of the higher pA 2-value and the 
magnitude of the difference between the higher and the lower pAz-value, as 
expected on the basis of the generalized 'rule of Pfeiffer' (cf. p. 120) is found. 
The data are shown in table V (column A gives the pAi-values of the compounds 
containing the pyridyl-ring, column В the differences with the pAz-values of the 
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Compound A В 
33 8.33 1-50 
29 7.96 ο.6η 
37 7-58 M I 
28 6.51 0.30 
30 6.44 0.30 
TABLE v. Comparison of the pAi-values of the compounds collected in table IV which 
contain a pyridyl-ring, determined on the guinea-pig ileum (column A) with the dif­
ferences between these pAz-values and the pAi-values of the corresponding com­
pounds which contain a phenyl-ring (column B). 
The values in the two columns are correlated (see text). 
corresponding compounds containing a phenyl-ring); the correlation is statis­
tically significant (P = 0.042 according to the one-tailed Kendall's rank 
correlation test). 
In view of the foregoing it may be clear that the conclusion reached on p. 110, 
viz. that the 'mimetic moiety' in the molecules of some structural analogues, 
among which the compounds 28 and 45, does not essentially contribute to 
their affinity to the receptor cannot be generalized. Obviously in certain other 
structurally related compounds the nature of the ring in the 'mimetic moiety' 
may be rather important (although the question whether a difference in affinity 
is caused by an increase of a positive influence or a decrease in a negative influ­
ence remains open). 
C. The influence of para-substitution of a Cl-atom to the phenyl-ring in the 
N-phenyl-N-benzyl-ethylamine-group 
In table VI the influence on the different affinity values of para-substitution 
of a Cl-atom to the phenyl-ring in the N-phenyl-N-benzyl-ethylamine-moiety 
is shown. The way in which the data are presented is analogous to that in the 
sections A and В (cf. tables II and IV). 
The differences between the affinity values of the paired compounds are 
rather small and do not give an indication that the substitution in question 
would exert a systematic influence. As for the correlation expected on the basis 
of the generalized 'rule of Pfeiffer', the data under discussion do not allow 
a conclusion in this respect either. Nevertheless it is worth noticing that the 
pA2-values of the p-Cl-substituted compounds are found in two ranges: five 
compounds have moderate pAi-values between 6.14 and 6.83, but the рАг-
values of the compounds 33 and 65 are 8.33 and 8.24, respectively. Only these 
two high affinity values are adversely affected by the removal of the para-sub­
stituted Cl-atom. 
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Pairs of Histaminergic system Cholinergic system 
compounds guinea-pig ileum rat intestine 
I 
30 
33 
49 
50 
59 
64 
65 
II 
28 
29 
45 
47 
58 
62 
63 
pAjI-pA2II 
— 0 . 0 7 
0.37 
— 0 . 0 7 
—0.46 
—O.II 
— 0 . 1 4 
0.53 
pD2'I-pD: 
— 0 . 1 3 
0.07 
- 0 . 2 7 
— 0 . 0 4 
0.03 
0.21 
0.43 
рАгІ-рАгІІ 
— 0 . 1 9 
— 0 . 2 2 
— 
—O.30 
0.28 
— 0 . 0 3 
— 0 . 0 4 
pD2'I-pD: 
— 0 . 0 8 
0.05 
— 0 . 0 2 
—О.23 
О.ЗЗ 
О.25 
О.24 
TABLE vi. Comparison of the affinity values of compounds with analogous structures. Each 
compound in column I only differs from the corresponding compound in column II in the 
para-substitution of a Cl-atom to the phenyl-ring in the N-phenyl-N-benzyl-ethylamine-moiety. 
The substitution in question does not seem to have a systematic influence. 
D. The influence of para-substitution to the phenyl-ring of N-(N'-phenyl-N'-
benzyl-§-aminoethyl)-N-methyl-{2-($-aminoethyl)-pyridine} 
The positive influence of the para-substitution of a Cl-atom to the phenyl-
ring of compound 29 (cf. table VI compounds 33 and 29) does not stand alone. 
Analogous substitution of a Br- or F-atom likewise causes an increase of the 
affinity value of the drug with respect to the histaminergic system in the guinea-
pig ileum. Para-substitution of an I-atom, however, causes a decrease of the 
рАг, whereas substitution of a methoxy-group was found to have little influence 
(table VII). 
The compounds in table VII are arranged in order of their pAz-values with 
respect to the histaminergic system ; of course the difference between the com­
pounds 35 and 29 and between the compounds 32 and 33 are insignificant. With 
respect to the metactoid receptors in the guinea-pig ileum the influence of the 
substitutions is smaller, but the sequence of the compounds is the same. The 
differences between the affinity values with respect to both types of receptors 
in the rat intestine are too small to allow any conclusion. 
The sequence of the para-substituted compounds in table VII is not explained. 
On the basis of Hammett's σ-values (428) the following sequence would be 
expected: OCH3—H—F—(Br and CI)—I. It seems that the influence of the 
para-substitions in question on the pA2-values with respect to the histamin­
ergic system in the guinea-pig ileum is not directly dependent on a possible 
change in the electron density on the neighbouring N-atom. 
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Ο—τ 
Com­
pound 
Зі 
35 
29 
32 
33 
34 
R 
I 
OCH3 
Η 
Br 
CI 
F 
Histaminergic system 
guinea-pig 
pAi 
7.46 
7.91 
7.96 
8.26 
8.3З 
8.85 
ileum 
PD2' 
5.63 
5.62 
5-94 
5-95 
6.01 
6.16 
Cholinergic system 
rat intestine 
PA2 PD2' 
5.90 5.35 
6.07 5.02 
5-95 5.38 
5-68 545 
5-73 5-43 
6.27 5.49 
TABLE vn. The influence of para-substitution of various small substituents to the phenyl-ring 
of compound 290η the affinity values determined on the guinea-pig ileum and the rat intestine. 
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CHAPTER VI 
THE PHYSIOLOGY OF GASTRIC ACID SECRETION 
THE PARIETAL CELL 
A. Introduction 
Two types of glands are found in the gastric mucosa: the pyloric glands 
located in the pyloric antrum and the fundic or oxyntic glands which are present 
in the mucosa of the main body of the stomach. One of the differences between 
the two types of glands is that in the pyloric glands no or hardly any parietal 
(or border, or oxyntic) cells are found, whereas in the fundic glands these cells 
are abundant, especially in the prepyloric region. Since all available evidence 
indicates that the parietal cells are the sole source of the HCl in the gastric 
juice, this differentiation is essential with respect to the present subject. 
B. Structure and distribution 
The parietal cells were first described by Heidenhain in 1870 (443)- They are 
more or less pyramidal in form, with the apical pole directed towards the 
glandular lumen; the nucleus is centrally placed. The cytoplasm, which contains 
many mitochondria, is transversed by a tubular system, the intracellular 
canaliculus, which opens onto the free surface of the apical pole. In the non-
stimulated parietal cell the lumen of the canaliculus is filled by numerous mi­
crovilli protruding from its wall. 
A great number of vacuoles are present throughout the cytoplasm, especially 
in the apical pole and in the vicinity of the intracellular canaliculi; further a 
number of vacuole-containing bodies may be present. The structure of the 
parietal cells is broadly the same in all vertebrates studied (141, 419, 445, 492, 
493,596, 611,815, 874, 875, 876,878,992; dog, cat, man, rat, mouse, frog, ЪгХ). 
The distribution pattern of the parietal cells in the stomach also shows a 
certain similarity in the various species (722, 723; man, dog, cat, rabbit, guinea-
pig, ratj. In man, the number of the parietal cells in the normal stomach is 
about 109 (214). Their density is not homogenous but decreases gradually 
around an area of maximal density which in man, cat and dog is situated in 
the central portion of the gastric body. In the cat, the animal on which most of 
the present experiments were performed, the situation is as follows. The pyloric 
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antrum is practically devoid of parietal cells over a distance of about 4-6 cm 
measured from the gastro-duodenal junction along the stretched lesser curva-
ture. Few parietal cells are present both in the mucosa of the cardia for a dis-
tance of about 2 cm measured from the oesophago-gastric junction along the 
stretched lesser curvature and an area of similar width adjoining the antrum, 
whereas such cells are numerous throughout the rest of the mucosa (785). 
C. Function: the secretion of gastric acid 
Evidence that gastric acid is produced by the parietal cells has been obtained 
by a variety of techniques. For example, electron microscopy of the gastric 
mucosa has revealed differences between the ultrastructure of the parietal cells 
in resting state and that observed after administration of histamine or betazole, 
drugs known to stimulate specifically the secretion of HCl in the stomach 
(420, 815, (S77, 992; frog, mouse, rat, cat, dog, man / The intracellular canaliculi 
are seen to be enlarged, the microvilli are decreased in number and size and the 
vacuole-containing bodies are larger and more abundant. 
Evidence has also been obtained from experiments with indicator dyes. 
Various basic dyes are transported by isolated, actively secreting gastric mucosa 
and are concentrated in the secretion product. Some of these dyes are acid-base in-
dicators. Microscopic study of preparations which were excreting such indicators 
showed that during histamine-induced acid secretion the pH was lower than 
1.4 not only in the crypts and tubules but also in the intracellular canaliculi. 
It was concluded that the site of origin of the gastric acid is the pericanalicular 
zone of the oxyntic cells (137; frog, toad, cat, polecat,). 
Other, more indirect arguments implicating the parietal cells as the source 
of the gastric acid are the fact that HCl-secretion can be induced in a fundic 
gastric pouch but has not been observed in an antral gastric pouch, and the 
finding of a linear relationship between the amount of acid that can be measured 
titrimetrically in slices of the fundic mucosa (cut in a plane parallel to the sur-
face) and the number of parietal cells present in these slices (622, p ig / Further, 
a highly significant correlation exists between the total number of parietal cells 
in the gastric mucosa and the maximal rate of acid production (after stimulation 
with histamine) (¡75, 215, 658, 659, 705, 791, 967; guinea-pig, dog, manj ; a 
similar correlation has been shown between the number of parietal cells and 
the rate of acid production of the 'resting' stomach (705). Continuous stimu-
lation by histamine for some weeks causes hypersecretion of gastric acid and 
results in parietal cell hyperplasia (215, 967; guinea-pig, dog,) while repeated 
injections of human gastric juice or stomach extracts in dogs may result in a 
hypochlorhydria (118, 120, 150, 152, 909) accompanied by a reduction in the 
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number of parietal cells (908). Finally, it is known that greater-than-average 
numbers of parietal cells are found in many patients with duodenal ulcer (175, 
214, 680), a condition which tends to be associated with an increased produc-
tion of gastric acid (358, 561, 605). The same association is found in cases of 
the Zollinger-Ellison syndrome (1069; see also p. 151J. 
CONTROL OF THE SECRETORY MECHANISM 
As already indicated in the foregoing section gastric acid is not secreted 
continuously; in many species, including the dog, cat and man, little or no 
acid is produced in the inter-digestive periods (758), at least under physiological 
conditions. During these periods the pH in the gastric lumen may even be 
slightly alkaline, possibly as a result of the secretion of alkaline mucus; Shay 
found gastric mucus to have a pH of 8.2 (886, dogj. But even under conditions 
of maximal activation not all parietal cells are active simultaneously; the 
secretory activity of the mucosa occurs in patches and even within an active 
tubulus some parietal cells may be found in the resting state (137, 879; dog, 
frog, toad J. 
Acid production thus seems to be dependent on the presence of a stimulus 
and, indeed, a great variety of substances and conditions stimulating the resting 
mucosa and causing the production of HCl are known. Many of these stimuli 
cause their effects via the pathways that also play a role in the physiological 
production of gastric acid, namely a neural pathway via the vagal nerve and a 
hormonal pathway, dependent on the liberation of the antral hormone gastrin. 
Many investigators believe that these two pathways converge to one common 
process at the level of the parietal cells, a process in which histamine may play 
a leading part (197) • The neural and the hormonal system appear to co-operate 
and to influence each other during all 'phases' of the physiological acid 
secretion process. Thus, the classical scheme dividing acid secretion during 
the digestive period into a cephalic (vagal), a gastric (antral) and an intestinal 
phase, which are supposed to occur successively and to operate more or less 
independently, is now considered to be out of date. But, although the neural 
and the hormonal secretory mechanisms are closely associated, it is essential 
to distinguish between them. In the following sections, therefore, the two 
mechanisms first will be discussed independently. 
NEURAL INDUCTION OF GASTRIC ACID SECRETION 
A. Introduction 
Neural impulses which induce gastric acid secretion may exert their influence 
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on the stomach in two different ways: they have a direct action, sensitizing and/ 
or stimulating the parietal cells, and also an indirect action via the release of 
gastrin from the wall of the antrum pyloricum and perhaps also from duodenum 
and ileum. The indirect action will be discussed further in a subsequent section 
(p. 152). 
B. Neural structures involved in the stimulation of gastric acid secretion 
It is generally accepted that the neural impulses stimulating gastric secretion 
reach the stomach by parasympathetic pathways, i.e. mainly via the vagal 
nerves. (It should be borne in mind that both the vagal and the splanchnic 
nerve contain parasympathetic as well as sympathetic fibres, although in quite 
different proportions.) The branches of the trunci pneumogastrici which reach 
the stomach divide further to form intramural networks in the gastric wall 
(plexus of Meissner, plexus of Auerbach). Synapses between pre- and post-
ganglionic neurons are present in these networks. 
The vagal induction of gastric secretion is controlled by the parasympathetic 
bulbar centres, which, in their turn, are influenced by the anterior hypothala-
mus. As shown by Beatty et al., stimulation of the anterior region of the 
hypothalamus activates the parasympathetic nervous system, whereas stimu-
lation of the posterior hypothalamic region gives rise to sympathetic responses 
(84, 85, 86, 8j, 88). In conformity with these findings, a number of authors 
has shown that electrical stimulation of the anterior hypothalamus results in 
enhanced gastric acid secretion (448, 602, 603, 880; cat; 575, 665; dog; 777, 
monkeyj, whereas inhibition of acid production is observed after stimulation 
of the posterior hypothalamus (448, 602, 603, 880; cat). 
The experimental results, however, are not uniform, especially not with 
respect to the latter facet. Kosenko, for instance, found that both anterior and 
posterior hypothalamic stimulation caused an increase in free gastric acid with 
parasympathetic responses from both areas (578, dog). Zukoski et al., using 
unanaesthetized dogs, was unable to demonstrate any effect on gastric secretion 
of anterior or posterior hypothalamic stimulation (1073). In acute experiments 
on anaesthetized cats, the group of Feldman found a significant increase in 
gastric secretion, free and total acidity and peptic activity following stimulation 
of the posterior hypothalamus, as contrasted to anterior hypothalamic and 
preoptic stimulation, which in some cases caused no increase in free HCl 
(320, 321). The same group found no consistent changes in gastric secretion 
following posterior hypothalamic stimulation in conscious dogs with chroni-
cally implanted electrodes (319) • 
The partly conflicting results may be explained by differences in the areas 
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stimulated, in the type, frequency and intensity of the stimulation and in the 
methods used for measuring gastric acid secretion, whereas the question 
whether anaesthetized or conscious animals were used also may be important. 
Anyhow a distinct role of the hypothalamus in the regulation of gastric acid 
secretion seems well established. 
Increases in gastric secretion, acidity and peptic activity have also been 
reported to follow stimulation of cortical areas situated in or laterally to the 
gyrus sygmoideus anterior ^229,562; dog, cat,) and of parts of the limbic system 
(23,888,1060,1061; cat, monkey,). Both regions are known to have connections 
with the hypothalamus. 
C. How effective is direct vagal stimulation of the parietal cells in absence of 
hormonal influences? 
Direct proof that an efferent excitation via the vagal fibres can induce gastric 
acid secretion comes from experiments in which the vagal nerve was stimulated 
electrically (134, 434, 448, 617, 758; dog, cat,). The production of a highly acid 
juice can be caused by stimulating the peripheral end of the previously severed 
nerve. The question, however, as to whether this effect can also be caused by 
direct vagal stimulation of the parietal cells in the absence of simultaneous 
hormonal excitation is more difficult to answer. Elimination of the antral 
part of the mechanism (resection of the antrum, ligation of the arteries supplying 
the pyloric region or cocainization of the pyloric mucosa) caused a considerable 
decrease in the effect of efferent vagal stimulation, but, in the majority of the 
cases, did not completely abolish the secretory response (63, 6/7,979;dog, cat,). 
Yet it is not certain that the residual secretion was solely caused by direct vagal 
stimulation of the parietal cells. Since, in the experiments in question, the vagal 
nerve was stimulated in the neck, the possibility that the remaining response 
was dependent on vagal liberation of a gastrin-like substance from the intestine 
cannot be ruled out (cf. p. 152-153). 
The possibility that the secretory response was partly dependent on the 
presence of non-antral gastrin should also be considered in the case of some 
experiments described by Olbe (726, 727; dogj, in which secretion of gastric 
acid was caused by sham-feeding or insulin hypoglycaemia (procedures which 
bring on vagal stimulation, see p. 134 and p. 136) and in which removal of the 
antrum reduced the secretory response but did not abolish it. To a lesser degree 
the same may hold with respect to another experiment of the same author in 
which a response to hypoglycaemia was still present after resection of the 
antrum and the duodenal bulb (728, dog,). In the last-mentioned experiment 
the response to sham-feeding was almost reduced to zero. 
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The possibility of a gastrin-induced sensitization of the parietal cells would 
seem to be minute, however, in an older experiment of Pevsner and Grossman 
(766, dog), in which it was shown that a copious acid secretory response to 
insulin occurred in dogs after resection of the pyloric segment of the stomach 
together with the entire small intestine. On the other hand, in this experiment 
the secretory response to insulin was demonstrated on the day after the excision 
of the antrum and the small intestine. It is known that, during situations of 
severe stress, for instance after major surgery, the synthesis of histamine is 
enhanced (855). Moreover, during stress enlarged multivesicular bodies are 
found in the parietal cells, indicating that these cells are activated (364). 
In the experiment of Pevsner and Grossman, then, the possibility exists 
that, although gastrin may not have played a role, yet the secretion mechanism 
was sensitized. Moreover, from the functional point of view a sensitization by 
histamine may be tantamount to having gastrin present. According to different 
investigators (22, 294, 5/9, 902) gastrin acts by liberation of histamine in the 
gastric mucosa. If this is so, the condition of the stomach in the above-mentio-
ned experiment may well be analogous to that of a normal stomach under the 
influence of gastrin. 
In conclusion, it seems that strict proof for the assumption that gastric acid 
secretion can be induced by direct vagal stimulation alone is still lacking. 
D. The neurotransmitter in the vagal pathway of secretory stimulation 
The neurotransmitter in the junctions between the postganglionic neurons 
in the gastric wall and the secretory eflector organs is believed to be acetyl-
choline. This is assumed on the analogy of the function of this substance in 
parasympathetic stimulation of the gastric muscles, proved by Dale and Feld-
berg in 1934 (222). Many years earlier the pharmacological actions of choline 
itself had been studied extensively by the group of Magnus and le Heux, who 
showed it to be a stimulant of the vegetative nervous system. Secretory effects 
of choline and acetylcholine were known. Already in 1931 Kellermann recom-
mended the administration of bromocholine ((2-bromoethyl) trimethyl ammo-
nium, Pacyl) as a treatment for achlorhydria (555). 
Many different ways of stimulating gastric secretion are known. Some of 
these stimuli act directly via the vagal nerve, but even if this is not the case, 
the presence of a background of parasympathetic stimulation, sensitizing the 
parietal cells to other stimuli, may play a more or less important role. The 
well-known fact that in many instances the administration of atropine will 
inhibit gastric secretion, either completely or to a certain degree, fits in with 
the supposition that parasympathetic stimulation of the secretory process is 
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dependent on the liberation of acetylcholine from the postganglionic nerve fibres. 
Also in the synapses between pre- and postganglionic secretory neurons the 
transmitter substance is supposed to be acetylcholine. This is supported by the 
results of experiments with tetraethylammonium and hexamethonium, drugs 
known to be antagonists of acetylcholine in the autonomic ganglionic synapses 
(5, 162, 756). 
Tetraethylammonium practically eliminates basal secretion and decreases 
the response to histamine (712, 1074; manj; hexamethonium is reported to 
depress volume and acidity of gastric juice secreted spontaneously or in response 
to vagal stimuli (549, 615; dog, man,). 
E. Can vagal stimulation be imitated completely by exogenous acetylcholine 
and by cholinomimetic drugs? 
If acetylcholine is the neurotransmitter of secretory impulses to the stomach 
it might be supposed that the introduction of cholinomimetic agents into the 
blood stream would cause the production of gastric juice similar in composition 
to the juice produced after vagal stimulation. The results of experiments in 
this direction, however, are rather divergent. 
Intravenous infusion at continuous rate of acetylcholine in doses of 25 mg/h 
up to 60 mg/h resulted in the secretion of small amounts (maximally 0.5 ml/ 
io min) of a thick, mucous fluid with low acidity but high peptic power (617, 
dog,). Likewise single subcutaneous injections of 100 and 400 mg acetylcholine 
had little effect: secretion of maximally 1.3 ml/15 m in> highest acidity 52 mN. 
Acetylcholine combined with prostigmine, which blocks acetylcholine esterase, 
(50 mg acetylcholine + 1 mg prostigmine, s.c.) did somewhat better: secretion 
of maximally 3.3 ml/15 Π"11, highest acidity 88 mN. With repeated subcutaneous 
injections of acetylcholine (50 mg acetylcholine every io min, 40 times) a 
maximal acidity value of 138 mN could be obtained (708, Heidenhain pouch 
dogs,). In man acetylcholine administered via subcutaneous or intravenous 
routes seldom raised the acid secretion of the stomach (355). 
It could be argued that intravenous or subcutaneous injection of acetyl­
choline could not be very effective, since the ester is very rapidly destroyed by 
the enzyme acetylcholine esterase. On the other hand, the doses administered 
in the above-mentioned experiments are extremely high and in one experiment 
an acetylcholine-esterase-blocking agent was given simultaneously. Anyhow 
this argument would seem hardly valid with respect to experiments in which 
acetylcholine is administered intraarterially close to the stomach. 
Intraarterial injection of acetylcholine into a resting stomach resulted in 
the secretion of juice of low acidity but rich in mucus and pepsin, or even in 
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the production of an alkaline juice (pH 7.6 - 8.9) (694, 924; dog). Altamirano 
reports that intraarterial injection of 5-30 μg acetylcholine close to an isolated 
piece of mucosa of the greater curvature also caused secretion of an alkaline 
fluid (19, dog,). According to this author, however, the rate of injection would 
determine whether the juice was acid or alkaline: small doses usually produced 
an acid juice, which rapidly became alkaline if the rate of injection was increa­
sed. This tallies with the earlier finding of Pevsner and Grossman (766, âog) 
that acetylcholine infused into the arteries of the gastric fundus after pyloro-
fundic separation at a dosage rate of 7-700 μg/h caused secretion of acid, but 
that higher rates suppressed or abolished this acid secretion. From the data 
presented by the last-mentioned authors it can be calculated that the acidity 
of the gastric juice during maximal acid response ranged from 11-95 mN with 
a mean value of 42 mN (5 dogs). Altamirano did not report which amounts 
of gastric juice and which acidity could be obtained with his 'small doses'. 
If the results obtained with acetylcholine administered in different ways and 
in various dosage ranges are compared with the results of electric stimulation 
of the vagal nerve (maximal acidities of 131 mNf/j^, dogj, 125 mH(448, àog), 
122-130 mN, in one case 150 mN (617, cat,)), the conclusion that exogenous 
acetylcholine cannot fully duplicate the results of vagal stimulation seems 
inevitable. Under certain conditions the two ways of stimulation even may 
have opposite results. 
The experiments with other, stable cholinomimetic agents do not change 
the over-all picture (708,1014,1025; dog, methacholine; 787, dog, bethanechol; 
211, cat, pilocarpine^. Werther and Hollander determined the optimal dose of 
a single subcutaneous injection of methacholine (acetyl-ß-methylcholine) in 
dogs, and using such doses (0.025-0.075 mg/kg) could report a maximal total 
acidity of about n o mN (1025). Higher acidities were obtained by Wener et 
al. after intramuscular injection of maximally tolerated ('sub-shock'-) doses 
in a mixture of beeswax and mineral oil; they report that some dogs were 
completely refractory to methacholine, whereas others responded with a 
scanty alkaline secretion ( 1014). After high doses of methacholine the gastric 
mucous membrane often is found to be oedematous and haemorrhagic. As 
for pilocarpine, it may be remarked that the effect of this substance (partly) 
could be caused by stimulation of parasympathetic centres in the central ner-
vous system, since the drug in question readily passes through the blood-brain 
barrier. 
The difference between the effect of electrical vagal stimulation and injection 
of cholinomimetic agents is an interesting point. The situation is not unique; 
in several systems the maximal effect of the liberation of an endogenous 
substance cannot be duplicated by administration of the same substance. A 
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theoretical possibility is that in these cases local liberation of the activating 
substance results in a higher concentration in the biophase than the maximal 
concentration reached in this compartment after administration of the substance. 
As for the case in question, another possible explanation might be found in 
the fact that the vagal nerve contains both cholinergic and adrenergic fibres 
^702; dog, cat), so that electrical stimulation probably will not only result in 
the liberation of acetylcholine but also in the release of some noradrenaline. 
As discussed in greater detail on p. 144-145, noradrenaline may potentiate the 
effect of cholinergic stimulation on gastric acid secretion. 
PHYSIOLOGICAL STIMULI ACTING VIA THE VAGAL NERVE 
A. Sensory and cerebral stimuli 
Sensory perceptions associated with feeding may cause vagal induction of 
gastric secretion, especially in a hungry subject. In the first place this holds 
true with respect to smelling or tasting of food (in this context it should be 
remembered that what is called tasting of food for the greater part depends on 
stimulation of the olfactory sense) (165, 216, 499, 758, 900; dog, man,). Also 
other sensory stimuli which are not directly associated with feeding may induce 
gastric secretion via conditioned, Pavlovian reflexes. Gastric secretion can 
also be stimulated by agreeable thoughts about food (1043, man) and even by 
dreaming about tasty food (247). 
The secretory response to the above-mentioned stimuli can be blocked by 
vagotomy and by intravenous administration of atropine, so that the para-
sympathetic character of the stimulation seems well established. 
B. Stimulation of the gastric wall. Vago-vagal reflexes 
With their conditioned reflex experiments and sham-feeding experiments 
(in which the food eaten leaves the animal through an oesophageal fistula 
without reaching the stomach) Pavlov and his co-workers decisively showed 
that entering of food into the stomach is not necessary for a secretory response 
(758). This does not mean that the presence of food in the stomach does not 
play a role in the vagal induction of gastric acid secretion. Pavlov's theory 
was that in later stages of digestion impulses flowing along afferent fibres of 
the abdominal vagal and splanchnic nerves to the centres in the brain stem 
would maintain gastric secretion. At present it is known that local stimulation 
of the antrum resulting in a direct liberation of gastrin is the major factor in 
later stages of digestion. However, impulses travelling via vago-vagal reflex 
arcs also may play their part in the regulation of gastric secretion. 
Arguments for this notion have been provided by Harper et al. They showed 
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that secretion of acid (and pepsin) occurred when, after cutting the splanchnic 
nerves extraperitoneally, one or other of the abdominal vagal trunes or their 
contributory branches was severed and the central end was stimulated electri­
cally (433, 434, саХ). Repetition of the stimulation after section of the vagal 
nerves in the neck was ineffective, whereas stimulation of the peripheral end 
of the nerve still caused a well-marked production of acid. Transsection of the 
spinal cord at the level of the second cervical vertebra did not prevent the 
secretory effect of afferent stimulation. The effect could not be related to changes 
in gastric motility and, according to the authors, it seemed unlikely that the 
reflex effects were secondary to vasomotor changes. 
The proportion of afferent fibres in the vagal nerve is considerable (14, 29g, 
435). For instance, Agostoni et al. showed that 90% of the 31,000 fibres in the 
abdominal vagus of the cat are afferent. Further the existence of gastric tension 
or stretch receptors (485, 486, 734; cat, goatj and of receptors sensitive to 
pH-changes (48J, catj have been demonstrated. They are not only found in the 
pyloric antrum but also in other parts of the stomach (487, 734). During 
distension (e.g. by inflation of an intragastric balloon) and during application 
of either acid or alkaline solutions on the gastric mucosa electrical activity 
in vagal afferent fibres arising from these receptors could be recorded. 
Paintal suggested that the normal function of the gastric stretch fibres might 
lie in the immediate satiation of hunger. This notion is supported by the recent 
findings of Anand and Pillai, who showed that distension of the stomach or 
stimulation of the gastric vagal branches resulted in an increase in the electrical 
activity of the medial hypothalamic satiety centre and in a decrease of the 
activity of the lateral feeding centre (24, cat). Further it is known that hypotha­
lamic lesions in the area of the satiety centre which produce hyperphagia cause 
an increase in gastric acid production (796, ratj. This increase is also present 
if food intake is restricted to normal levels. Electrical stimulation of the satiety 
centre via an implanted electrode causes inhibition of feeding in starved rats, 
whereas stimulation of the feeding centre causes feeding in satiated rats. The 
first response is accompanied by a reduction of the gastric acid output, whereas 
the second response is attended with an increase of acid production (685, таХ). 
On the other hand it has been demonstrated that distension of the vagally 
innervated oxyntic gland area after resection of the antrum stimulates the 
secretion of acid and pepsin (395, dogj. 
It seems plausible, then, that the stretch receptors and the pH-receptors in 
the gastric wall play a role in the regulation of gastric secretion. It is not quite 
clear whether activation of the stretch receptors will always result in stimulation 
of the gastric secretion or whether, under different circumstances, it also can 
cause an inhibition via activation of the satiety centre. 
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LOCAL REFLEX MECHANISMS 
A. Local reflexes in the acid-producing part of the stomach 
Some investigators have shown that distension of a Heidenhain pouch and 
an autotransplanted fundic pouch may cause small acid secretory responses 
(494, 613; dog). Grossman (394, dog) demonstrated that distension of dener-
vated fundic pouches with 0.9 % NaCl caused a slight stimulation of gastric 
acid secretion and a marked augmentation of the responses to injection of 
histamine or gastrin and to a test meal. The author interpreted this finding into 
a representation of a local cholinergic reflex. Since the dogs used had totally 
extrinsically denervated pouches prepared according to the method of Gregory 
(377) and the effect of distension was abolished by atropine, this conclusion 
seems well founded. 
B. Local reflexes in the wall of the pyloric antrum 
Mechanical or chemical stimulation of the mucosa of the pyloric antrum 
may induce gastric acid secretion by liberation of the hormone gastrin. Also 
this mechanism depends on a local, cholinergic reflex. For further details the 
reader is referred to p. 152 et sqq. 
THE SECRETORY RESPONSES TO INSULIN ADMINISTRATION 
A. Hypoglycaemia-induced gastric secretion 
Besides sensory perceptions associated with feeding and gastric vago-vagal 
reflexes a third type of stimulus is known to cause gastric secretion via the 
vagal pathway, namely hypoglycaemia. This mechanism, however, does not 
play a role in the physiological regulation of the gastric secretion. 
Administration of insulin in sufficiently high doses provokes secretion of 
gastric acid and pepsin (76, 127, 171, 206, 212, 231, 233, 240, 325, 339, 482, 
679, / / J , 814, 895, 906, 937, 954; dog, cat, various species of monkeys, man,), 
and also stimulates gastric motor activity (159,160,632). The same phenomena 
can be produced by the insulin-releasing substances chlorpropamide and 
tolbutamide (775, Pavlov pouch dog; /007, man,) and are also associated with 
spontaneous hypoglycaemia in cases of organic hyperinsulinism caused by 
ß-cell tumours of the pancreas (905, ¡012; man,). For reasons yet unknown 
insulin fails to stimulate gastric secretion in goats and sheep (452, 464). 
The following data suggest that the gastric response to hypoglycaemia, or at 
least its 'early phase' (see below) is mediated by the vagus nerve (64). First, 
there is the observation that the composition of the gastric juice secreted in 
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response to insulin hypoglycaemia is similar to that produced by parasympathe-
tic nervous stimulation (1013, man). The ability of atropine to block the 
response in question suggests the presence of a cholinergic step in the secretory 
mechanism (128, 248; dog; 446, 725; man). Further it has been shown that 
degrees of hypoglycaemia which consistently produce gastric acid secretion in 
Pavlov pouch dogs (innervated gastric pouches) are ineffective in Heidenhain 
pouch dogs (denervated gastric pouches) (775) and that bilateral vagotomy 
abolishes the secretory effect of insulin (77, 470, 499, 873; dog, man). 
From the following observations it may be concluded that the stimulus for 
the gastric acid secretion is the state of hypoglycaemia and not insulin as such : 
1. the'early'gastric secretory response is independent of the insulin dosage 
over a wide range (232, 234; dog) but seems to depend on the degree of hypo-
glycaemia reached; depression of the blood sugar level to 55-50 mg per cent or 
less is necessary for this effect to be produced (470, 471, 499, 775, 814, 1012; 
man, dog) ; 
2. not only the hypoglycaemia caused by injection of insulin but also the 
hypoglycaemia following hepatectomy is associated with vagal hyperactivity 
(75, dog; ; 
3. the secretory response (as well as the gastric motor response) can be pre-
vented or arrested by intravenous glucose, provided that the blood sugar level 
is raised above 50 mg per cent (632, 725, 775; dog, man). The same holds in the 
case of organic hyperinsulinism (1012, man). 
Hypoglycaemia activates parasympathetic centres in the brain (78, dog). 
Recent data seem to throw light on the mechanism involved. Administration 
of 2-deoxy-D-glucose causes powerful vagal stimulation of gastric secretion 
(256,271,284,290,459,460; dog, cat, man), apparently by the same mechanism 
as insulin hypoglycaemia. The secretory effect can be eliminated by truncal 
vagotomy (289, dog) or by atropine and is absent in dogs with denervated 
pouches. The parasympathetic stimulation seems to be caused by the situation 
in the brain cells which results from the formation of non-metabolized 2-deoxy-
D-glucose-6-phosphate and which is tantamount to an effective cytoglycopoenia. 
It seems probable, therefore, that also in the case of insulin-induced vagal 
stimulation the stimulus proper is a cytoglycopoenia of the brain. Insulin, 
which promotes glucose uptake by a number of tissues, has no influence on 
the glucose uptake of the brain; consequently, severe hypoglycaemia may 
result in an insufficient supply of glucose reaching the cells of this organ. 
According to Hirschowitz and Sachs the vagal secretory centre is specifi-
cally glucose- (and mannose-) dependent (459, dog). Desiraju et al. have shown 
that slow intracarotid infusion of 2-deoxy-D-glucose specifically caused a 
decrease of the activity of the hypothalamic satiety centre and an increase of 
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the activity of the feeding centre (23g). On the other hand, the finding of 
Bralow et al. (138, тгХ) that light surgical anaesthesia with urethane prevents 
the secretory effect of insulin hypoglycaemia might suggest that the cortex 
cerebralis also plays a role in the induction of the stimulus. Likewise, de Corral 
Saleta states that anaesthesia suppresses the central action of insulin (212, 
allobarbital- or chloralose-anaesthetized catsj. There is no strict evidence, 
however, that depression of the vagal secretory centre and/or the effector organ 
is not produced directly by the anaesthesia, so that this point requires further 
analysis. 
B. Insulin-induced inhibition of gastric secretion 
The vagally mediated stimulation is not the only effect of insulin on gastric 
secretion. An inhibitory action may precede it or may be present simultaneously 
(164, 212, 248, 334, 651, 710, 731, 732, 847; dog, cat, man,). The inhibition may 
cause a delayed onset of the secretory response (732, man) or may limit its 
magnitude; indeed, in the dog active inhibition of electrolyte secretion was 
shown to occur in the period between the two secretory peaks of the biphasic 
response following larger doses of insulin (453, 457). The inhibition counteracts 
not only the stimulatory effect of insulin itself but it also inhibits gastric acid 
secretion evoked by other means (499, 731, 937; basal secretion, man, dog; 
709, 731; hypersecretion in duodenal ulcer patients; 164, psychic stimulation, 
insulin-positive Heidenhain pouch dogs; 710, meat meal, Pavlov pouch dogs; 
164, cholinomimetic drug, dog; 511, exogenous and endogenous gastrin, dog; 
212, 273, 453, 454, 456, 544, 806; histamine, dog, catj. The degree of inhibition 
is dosage-dependent (454, 457, 501) and may be complete with higher doses 
(453, histamine-stimulated àog). 
The mechanism of the inhibition is different from that underlying the secre-
tory response, since the inhibition is demonstrable in the denervated pouch 
('65, 332, 356, 511; dog) and cannot be blocked by atropine. Further, the 
inhibitory effect is not an aspect of the response to 2-deoxy-D-glucose (460, 
dog). A few other possibilities can be ruled out immediately: the inhibition was 
proved not to be dependent on the possible occurrence of glucagon in the 
insulin preparation used, nor on the presence of the pyloric antrum (273, dog), 
indicating that the effect is not caused by the liberation of an antral inhibitory 
hormone (the existence of which is in any case still unproven, cf. p. 154). 
As for the remaining possibilities, an essential question is whether the inhi-
bition is dependent on a change in the blood sugar level or on another effect 
of insulin. Karvinen and Karvonen, for instance, suggested that inhibition is 
mainly dependent on hypoglycaemia, since they could not demonstrate inhi-
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bition of histamine-induced acid secretion when they prevented hypoglycaemia 
by giving glucose simultaneously with insulin (544, aog). However, the existence 
of a hypoglycaemia as such does not seem to be decisive. Jordan and Quintana, 
using gastrin-stimulated dogs (511), found that the inhibition normally follo-
wing an insulin injection did not occur if, as a result of glucose infusion, the 
blood sugar concentration remained at a stable level of around 300 mg per 
cent. In cases, however, in which insulin administration caused a sudden 
reduction of the elevated blood glucose concentration to normoglycaemic 
levels, the gastric secretion was inhibited, even though hypoglycaemia did not 
develop. Several other workers have also demonstrated the inhibitory pheno-
menon, although hypoglycaemia was prevented by infusion of glucose (273, 
458, 806; histamine-induced secretion in dogsj. 
The evaluation of some of these experiments is complicated by conflicting 
data concerning the influence of high doses of glucose and A>y?erglycaemia on 
gastric secretion. The majority of workers in this field report inhibition (236, 
249, 250, 343, 7/7, 724, 916). The question as to whether the inhibition of 
gastric secretion which occurs after insulin and associated glucose admini-
stration (in several cases considerably overcompensating the tendency of insulin 
to produce hypoglycaemia) is caused by the insulin or by the administered 
glucose should be considered in the light of the folllwing observations: 
1. hyperglycaemia mainly affects the nervous pathway of secretion (236, 
249, 250; dogj, 
2. intravenous infusion of a 30% glucose solution or a blood sugar level of 
300-400 mg per cent produces no or hardly any inhibition of histamine-induced 
secretion (236, 249; dogj, 
3. hyperglycaemia will even enhance histamine-induced acid secretion (273, 
Heidenhain pouch dogs with blood glucose levels up to about 200 mg per cent,). 
On the other hand it has been reported that 
1. histamine-induced acid secretion is inhibited slightly but definitely by 
intravenous infusion of glucose (a 40% solution produces up to 25 % inhibition) 
or by intraduodenal administration of glucose (100 ml of a 50% solution effects 
an average inhibition of about 15%) (236, aog), 
2. histamine-induced acid secretion is inhibited considerably by glucose- or 
sucrose-induced hyperglycaemia ( 12, ratj, 
3. histamine infused in a 5 % glucose solution has no gastric secretory effect 
(581, ratj. (It may be important that the last two results were obtained in a 
species that is exceptionally insensitive to histamine. The doses needed for the 
induction of gastric secretion in the rat are in the range of 1-16 mg/kg (593)). 
The afore-mentioned experiments in which the presence or absence of 
insulin-induced inhibition of gastric acid secretion was studied were all perfor-
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med on dogs. Some data obtained in other species may be added. For example, 
it has been observed that insulin inhibited acid production in guinea-pig gastric 
mucosa secreting in vitro in the presence of 100 mg per cent glucose (458). In 
the pigeon insulin did not lower the blood sugar level, yet inhibited histamine-
induced gastric secretion (580). 
Considering all the data together it does not seem very probable that insulin-
induced inhibition of gastric secretion depends on hypoglycaemia. The situation, 
however, is not clear and a certain importance of the blood sugar level cannot 
be excluded. If indeed the inhibition is not related to the existence of a low 
blood sugar level it would follow that not only hypoglycaemia as such, but 
also consequences of hypoglycaemia are ruled out as possible mechanisms. 
Theories which indirectly depend on hypoglycaemia are liberation of serotonin 
(763) or glucagon (65, 615a) and also sympathetic or adrenergic activity. The 
theory based on an adrenergic mechanism of inhibition was widely supported 
(173, 257, 258, 2ç8, 331, 481). It has heen shown, however, that the inhibition 
is not prevented by adrenalectomy and/or total sympathectomy (332, 356, 
721; âog), so that this hypothesis seems no longer tenable. 
At present most authors agree that insulin-induced inhibition of gastric 
secretion is a peripheral effect, and probably caused by a direct influence on 
the parietal cells. Attention has recently been focused on the role that potassium 
ions may play in the mechanism. The potassium concentration in gastric juice 
secreted in response to insulin is lower than that found after stimulation with 
histamine (840, 1059; manj and a reduction of the K+-concentration in the 
gastric juice is the earliest evidence of insulin-induced inhibition of histamine-
stimulated secretion (454, dogj. Insulin is known to cause a shift of potassium 
ions into the intracellular space (438). Hirschowitz and Sachs were able to 
reverse insulin-induced inhibition of gastric acid secretion during histamine 
infusion by an intravenous injection of KCl or RbCl (rubidium is known to 
be an effective substitute for potassium in several systems), but not with sodium, 
magnesium or calcium ions (461, 462, 556; dogj. The authors suggested that 
the insulin inhibition might be caused by a redistribution of intracellular 
potassium with depletion of potassium ions from sites essential to secretion. 
The relief of inhibition brought about by exogenous potassium or rubidium 
may be caused by the replenishment of these sites. 
C. The late phase in the gastric secretory response to insulin 
The so-called late or delayed phase of the gastric secretory response to 
insulin is still a rather controversial issue. Many of the experimental results in 
this field are contradictory or can be explained in different ways; as yet no 
generally accepted conclusion can be presented. 
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In 1953 French et al. published a study on the gastric secretory response to 
insulin hypoglycaemia in anaesthetized rhesus monkeys (339). They found that 
the response which started within 30 to 60 min after the injection and lasted 
about 4 h could be divided into two phases. The early phase (i s t and 2nd h) 
was absent in vagotomized animals and the late phase (3rd-5 th h) did not occur 
after adrenalectomy. 
These responses are analogous to the responses observed by the same group 
of workers after electrical stimulation of the anterior and posterior part of the 
hypothalamus, respectively (777, monkey^. Anterior hypothalamic stimulation 
caused a prompt increase in gastric acid production, reaching its maximum 
within 30 to 60 min. The response was abolished by vagotomy but was unaffec-
ted by adrenalectomy or section of the cervical cord. Posterior hypothalamic 
stimulation, on the other hand, resulted in an increase in gastric acidity which 
developed later and reached its peak only after 2 to 3 h. This response was 
completely blocked by adrenalectomy, but was not influenced by vagotomy or 
section of the cervical cord. In view of these results the authors concluded 
that the early phase of the gastric secretory response to insulin was dependent on 
the anterior hypothalamus via the vagal nerve and the late phase on the poste-
rior hypothalamus via hypophysis and adrenal cortex. 
The occurrence of the late phase and its dependence on the presence of the 
adrenal glands was affirmed by Sun and Shay (887, 935, 937; dog, ma.n). They 
found that the response during this phase was also considerably diminished 
after vagotomy. A severe hypoglycaemia (e.g. 40 mg per cent) was necessary 
to evoke the late phase of gastric secretion. A diphasic secretory response to 
insulin hypoglycaemia has also been found by Fausnaugh et al. in monkeys with 
innervated gastric pouches (303). These authors, however, reached a quite 
different conclusion. They found that the adrenergic blocking agent dibenzyline 
was capable of blocking the 'depressive phase' separating the early phase 
from the late phase, and they supposed that the resulting monophasic curve 
was due to a loss of the inhibition which adrenergic substances exert on the 
acid secretion. 
However different the interpretation, it is at least sure that under certain 
conditions a late phase in the secretory response to insulin may occur. It seems, 
however, that the response in question is highly variable. It cannot be evoked 
equally clearly in all individuals (920, 937, 1037; man). A number of workers, 
studying the phenomenon in experimental animals, either could not produce 
reliable evidence of the late phase (775, Heidenhain pouch dog; 171, pigtail 
monkeyj, or report significantly variable results (231, dog; 906, spider monkey,). 
All these experiments were performed on conscious animals. In view of this 
fact Cammock et al. suggested that certain cerebral stimuli may interfere with 
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the late phase of secretion ( / / /J . On the other hand, the significant observations 
of Sun and Shay were made in conscious subjects. 
Although the results of the last-mentioned authors may seem to leave no 
doubt about some role of the adrenal glands in the production of the late 
response, there are a number of arguments against the theory that this response 
would be due to the adrenocortical hormones (64, 65, 900). The observation 
that administration of ACTH or adrenal corticoids may cause a (weak) stimu-
lation of gastric acid production or may potentiate other stimuli (936, 1062; 
Heidenhain pouch dogsj is in keeping with this theory, but in a review article 
published in 1963 (65) Bachrach discussed the results of ten different groups 
of authors who have studied the effect of ACTH and a number of corticoste-
roids (cortisone, hydrocortisone, corticosterone, corticotropin, metacortelone, 
prednisolone, methylprednisolone and aldosterone) in mice, rats, pigs, dogs, 
cats and men and pointed out that none of the experiments produced consistent 
evidence of a stimulation of gastric secretion during the relevant period of time 
after the administration. More recently, Williams et al. (1037) administered 
Cortisol to humans as a continuous infusion at a dose range corresponding 
with the peak range after insulin. They did not observe stimulation of gastric 
secretion even after 5 h. Likewise, Zukoski et al. (/073, dog) found no increase 
in HCl-production during and after a period of increased secretion of adrenal 
cortical steroids, nor during a two hours period of ACTH-infusion and a 
subsequent period of four hours after this infusion. 
Similarly, the fact that the plasma level of adrenocortical substances is 
temporarily elevated after insulin administration (126, 233, 344, 935, 963; dog, 
manj is in keeping with the theory. The gastric response, however, could not 
be correlated with the plasma steroid concentration (233, 234; dog; 907, rhesus 
monkeyj. Zukoski and Hume found that the increase in steroid concentration 
in blood from the adrenal vein occurred during the first hour after 
insulin administration (1072, dog). It was back at control levels after about 
100 min, long before the possible occurrence of the late phase of gastric 
secretion. 
It is not surprising, then, that the theory that the late response is due to a 
neuroendocrine secretory stimulus has been called in question and that alter-
native explanations have been put forward. Bachrach (65) interprets the 
occurrence of a delayed response to hypoglycaemia after vagotomy as evidence 
of persisting parasympathetic innervation of the stomach, either via overlooked 
components of the vagus nerve or via parasympathetic fibres reaching the 
stomach with the splanchnic nerves. He supposes that the small stimulus trans-
mitted by these fibres cannot show its presence before the passing of the inhibi-
tory phase, - hence the delay of the response. It may be remarked that, whatever 
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the virtues of this theory, it does not seem to account for the absence of the 
late phase after adrenalectomy. 
Another theory which has much in common with the former was proposed 
by Sircus et al. (900). The results of their experiments on dogs with Pavlov or 
Heidenhain pouches would seem quite incompatible with the pituitary-adrenal 
theory about the late secretory response : they found that the late phase of the 
secretion was not abolished by bilateral adrenalectomy but that the response 
was absent after antrectomy. Further the late phase was found to be dependent 
on a prolonged contact of the antral mucosa with the acid juice of the main 
stomach. 
It is widely accepted that the secretory effect of vagal stimulation is at least 
partly dependent on the liberation of the antral hormone gastrin (cf. p. 152). 
In connection with this view the authors suggest that the late phase is caused 
by a delayed liberation of gastrin occurring after a period during which this 
liberation was inhibited by the high acidity of the gastric juice on the mucosal 
surface of the antrum (cf. p. 153-154). If the antrum is continuously drained this 
inhibition would not occur and 'the whole of the gastrin component of the 
hypoglycaemic secretogenic effect is discharged within the first two hours': 
the late phase will be absent. 
In their publication Sircus and co-workers are referring to 'the second 
phase' of the acid secretory response. There is a possibility, however, that they 
did not study the same phenomenon as Sun and Shay : these authors define the 
late phase as the response during the 3 r d and 4Ш h (935, 937) whereas Sircus 
and co-workers found the second secretory peak between the 4 t h and 6 t h h, 
being separated from the first peak by some hours. 
If nevertheless the phenomena are identical, Sircus' theory as such fails to 
explain the occurrence of the late phase of secretion in vagotomized animals, 
unless it is combined with Bachrach's view about persisting parasympathetic 
innervation of the stomach or else is supplemented with the supposition that 
a non-vagal gastrin-releasing mechanism triggered by insulin or hypoglycaemia 
would exist. Even if one of these possibilities is accepted, however, also this 
theory does not explain the absence of the late phase after adrenalectomy found 
by others. 
Recently Williams et al. (1037) studied the response to insulin during 6 to 8 h 
after administration in Heidenhain pouch dogs. The late response, if present 
at all, came from the pouches and not from the vagally innervated main 
stomach, which would be in a better position to respond to gastrin. The authors 
concluded that there is little evidence to support vagal gastrin release as the 
cause of the late response. 
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If the facts and opinions reviewed above are weighed against each other, one 
is forced to wonder whether the late phase in the gastric secretory response to 
insulin could not be caused by adrenaline. Since the experiments of French and 
co-workers and of Sun and Shay showed the late phase to be dependent on the 
presence of the adrenal glands, whereas it is rather improbable that the products 
of the adrenal cortex would cause the secretory response in question (see before) 
there is reason for considering a possible role of the adrenal medulla. 
Here two questions should be posed : does an enhanced secretion of adrena­
line occur during the 3 r d and 4 t h h after insulin administration, and is it possible 
to stimulate gastric secretion with this amine? As for the first question, accor­
ding to a number of authors the adrenaline level is enhanced after admini­
stration of insulin (139, 173, 257, 258, 479, 481, 938; blood levels in cat, dog, 
man; 298, urine level, man), although Weil-Malherbe and Bone reported a 
drop in adrenaline blood level (1005, 1006) and Tietz observed very little 
change (964). However, these blood level measurements were limited to the 
first two hours after insulin injection. Yet, there is indirect evidence that 
adrenaline is secreted during the late phase and that the gastric response is 
dependent on it. Shay and Sun found that if the α-adrenergic blocking agent 
phentolamine 'in the dosage and at the rate at which its action should have 
been almost entirely if not entirely adrenergic blocking alone' was administered 
simultaneously with insulin the late phase of the secretory response was absent, 
and that in a vagotomized subject the already diminished insulin-induced 
secretion was abolished completely by this drug (887, man). The authors 
concluded that an adrenergic step was involved in the late phase of insulin-
induced secretion, but they supposed that the amine would act by stimulating 
secretion of adrenocortical hormones via liberation of ACTH. 
The answer to the second question posed above may explain why the possi­
bility of a direct adrenaline action has not been given serious attention: both 
adrenaline and noradrenaline are reported to be inhibitors of gastric secretion 
(331, 413,436,449, 604, 617, 813; cat, dog, manj. On the other hand. Gumming 
et al. reported that adrenaline usually caused an increase of histamine-induced 
secretion (219, dogj and Haigh and Steedman found that adrenaline increased 
gastric secretion during bethanechol infusion (414, dog,). Likewise our own 
results, obtained in cats with the technique described in chapter VIII of this 
study, show that under certain conditions both adrenaline and noradrenaline 
cause an increase of gastric acid secretion. If in the pentothal-anaesthetized cat 
(normotensive) a low rate of gastric acid production was induced with a stimulus 
not much stronger than the threshold value, and also in the rare cases that a 
low acid secretion occurred spontaneously, intravenous infusion of adrenaline 
or noradrenaline (e.g. 2 μg/kg/min during io min) regularly resulted in a 
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distinct rise in acid output. Different kinds of stimuli were used to cause the 
'background secretion'; i.a. a secretory peak was observed if adrenaline was 
infused when the gastric response to insulin nearly was over. The last experi-
ment might correspond with the situation in vivo if at the end of a period of 
enhanced vagal activity a rebound activity of the sympathetic system would 
occur. Usually the amount of acid secreted in response to catecholamine admi-
nistration was small, but the same holds for the late phase of insulin-induced 
secretion. 
As for the discrepancy between the data in literature and these findings, it 
would not be surprising if a gastric secretory effect of the catecholamines, e.g. 
caused by the liberation of a secretagogue or by a direct stimulation of the 
metabolism of the acid-secreting cell, would be demonstrable only at low levels 
of secretion. The catecholamines have been reported to have inconsistent 
effects on the total gastric blood flow, although generally a decrease in this 
flow is found (715, 764, 836, 961'; dog, catj. More important still is the finding 
that they decrease the flow through the mucosal capillary bed (715, 764; àog). 
At low secretory levels this flow, although decreased, may nevertheless be 
sufficient, so that the stimulation can show itself. At higher rates of secretion, 
however, the acid production in response to secretagogues is blood-flow-limited 
(496, dogj. The depressing effect of a decrease in blood flow then may outdo 
the facilitation of the secretion, so that the over-all effect would be inhibition. 
Further experiments in this direction seem to be indicated. For the moment 
it would appear that definitive experiments have not excluded a role of adrena-
line, even a direct role, in the induction of the late response to insulin. 
HORMONAL INDUCTION OF GASTRIC ACID SECRETION 
A. Introduction 
As early as 1905 Edkins propounded the hypothesis that secretion of gastric 
juice might be induced by a substance originating from the cells of the mucous 
membrane of the stomach (265). Since he (incorrectly) assumed that liberation 
of this substance would be dependent on resorption of digested food from the 
stomach he considered the pyloric antrum a more probable place of origin 
of the hypothetical 'gastrin' than corpus and fundus of the stomach. This 
suggestion proved to be right: Edkins could demonstrate that extracts of the 
pig antrum indeed stimulated gastric secretory activity and that extracts of 
the oxyntic gland area did not show this property (266, cat J. 
Soon, however, it was found that many other tissue extracts also contained 
a principle capable of stimulating gastric secretion (612), a principle that 
eventually was shown to be histamine (73, 223). After some time it was clear 
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that histamine occurs in many tissues of the body, including the pyloric antrum 
of the stomach (83c), and that the amine is a very powerful stimulant of gastric 
secretion (776). Moreover several workers failed to find any substance stimu-
lating gastric secretion but histamine in extracts of the pyloric mucosa (354, 
83c). Thus the gastrin hypothesis became discredited and remained so till, 
many years later, histamine-free tissue extracts were prepared and studied. 
At the time the fact was overlooked that the type of gastric secretion caused 
by histamine is different from that caused by a gastrin-containing extract: 
the latter stimulates the secretion of acid, pepsin and mucus, whereas in most 
species studied histamine seems to be a stimulant of the parietal cells only. 
Although many controversial data obscured the field one thing remained 
clear, viz. that the pyloric antrum plays a special role in the regulation of 
gastric secretion. Under certain conditions a chemical or mechanical stimulation 
of especially this part of the stomach results in a stimulation of the gastric 
glands. For a long time, however, it remained questionable whether this 
mechanism was humoral indeed. It was found, e.g., that an antrally induced 
gastric secretion could be blocked by atropine (382, 843), a result lending colour 
to the idea that this kind of secretion was caused by a vagal reflex directly 
acting upon the gastric glands. 
The existence of a humoral mechanism for gastric secretion was proved 
in 1943 by Butler et al. (167), who demonstrated that the feeding of a meal 
caused a secretory response in a subcutaneously transplanted and thus extrinsi-
cally denervated gastric pouch. The next question to be answered was whether 
the pouch was stimulated by certain absorbed constituents of the food or by a 
true hormone. In 1948 Grossman et al. showed that distention of the pyloric 
portion of the stomach causes acid secretion by the fundic glands even after 
interruption of all nervous connections between the stimulated and the res-
ponding portion of the stomach, especially so if the response is potentiated by a 
background dose of the cholinomimetic compound bethanechol (398, dogj. 
Interruption of the nervous connections was accomplished by subcutaneous 
transplantation of either the pyloric or the fundic part of the stomach. Thus 
it was definitively proved that the antral mechanism acts via the liberation of a 
hormone. A nervous, cholinergic mechanism in the wall of the antrum seems 
to be responsible for the liberation of the hormone in response to a stimulus 
(718), a situation explaining the blocking effect of atropine. 
B. The nature of gastrin 
In 1938 Komarov had published work suggesting that the antral secretagogue 
might be a protein (567). This led to the development of a number of techni-
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ques for the preparation of antral tissue extracts with 'gastrin activity' (28, 
29, ¡23, 330, 359, 383, 384, 385, 432, 514, 568, 569, 699, 979, 980, 981, 982, 
1041; generally hog antral mucosa, in some cases material from cat, dog, 
sheep, cattle or man). These techniques were sufficiently refined to exclude the 
presence of significant amounts of free histamine in the extracts prepared, as 
confirmed by the observation that doses which strongly stimulated gastric 
secretion were devoid of activity with respect to the blood pressure. 
This, however, did not exclude the possibility that gastrin might contain 
histamine more or less firmly bound to another substance and thus rendered 
inactive, and that it would stimulate gastric acid secretion only because his-
tamine would be disengaged from it in the wall of the gastric fundus. For in-
stance, chemical analysis of a 'gastrin' prepared according to the method of 
Wojciech and Ivy (1041) - an extract without influence on the blood pressure 
and also devoid of free histamine in paper chromatography (546, 1041) -
yielded an amount of histamine which could easily account for the whole 
secretory response (1058). The character of gastrin thus remained unclear, the 
more so as different extraction methods apparently yielded materials with 
rather different properties: dialysable or non-dialysable (62), with an effect 
that was strongly inhibited by atropine (385; dog, manj or not influenced by the 
presence of this substance (123, cat), etc. (Today it would seem that the last-
mentioned discrepancy was connected with the use of experimental animals 
of different species rather than with the different extraction methods : also if 
pure gastrin is used, atropine has little influence on the acid response in the 
cat but is a strong inhibitor in conscious dog and man (378).) 
In the last few years new data have become available. In the early sixties 
Gregory and Tracy isolated an active principle from hog antral mucosa in a 
pure form and showed it to be a heptadecapeptide (386, 387). This gastrin 
consists of two closely related substances with the same quantitative amino 
acid composition. The two substances, indicated by the authors as Gastrin I 
and Gastrin II, have identical effects on the alimentary tract; i.a. they promptly 
and strongly stimulate the secretion of gastric acid (69, 484, 652, 653, 654; man, 
0.5-2 μg/kg ex., 5-50 μg/kg i.v. or 0.03-0.1 ng/kg/min i.V.; 387, 388, 574, 968; 
dog, 0.25-8 μg/kg s.c. ; 102, 426; rat, 0.5-64 μgy). The influence of the hormone 
on acid production is complex. It was shown, for instance, that in the conscious 
dog stimulation occurs only within a certain dosage range. Supraoptimal doses 
cause inhibition, not only of gastrin-induced secretion, but also of histamine-
induced secretion (287, 290, 379, 387, 572, 574). On the other hand, the inhibi­
tion is not observed in man or in the conscious or anaesthetized cat (287, 290, 
378). 
The structure of hog Gastrin I was shown to be as follows: Pyroglutamyl-
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Gly-Pro-Trp-Met-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe · N H 2 (376). Gastrin 
II has the same structure except that the tyrosine is present in a sulphated form. 
Both gastrins have been synthetized (26, 27), together with a large number 
of peptide derivatives (228, 968). It was found that all actions of the natural 
gastrins also can be evoked by the C-terminal tetrapeptide, Trp-Met-Asp-Phe 
•NH2 (388, 968; dog), although it is less active quantitatively. The amide-
group masking the C-terminal residue is essential. In this context it is interesting 
that pure natural cholecystokinin-pancreozymin, an intestinal polypeptide 
hormone which contains 33 amino-acids and which exhibits the combined 
properties previously held to be exerted by cholecystokinin and pancreozymin 
(516, 703), also stimulates gastric secretion (106, 230). The C-terminal pen-
tapeptide of this hormone is identical with that present in Gregory's gastrin 
(515, 704). Also caerulein, a decapeptide occurring in extracts of the skin of 
the Australian amphibian Hyla caerulea (177) has the C-terminal pentapeptide 
in common with gastrin (25) and stimulates the flow of gastric juice and the 
output of acid and pepsin ( 106, 881). 
In 1966 Gregory et al. announced the isolation of two gastrins from human 
antral mucosa (391). As shown by degradative analysis {103) and subsequent 
synthesis (82), these substances, like the hog gastrins, are heptadecapeptides; 
they differ from hog Gastrin I and II, respectively, only in that the methionine 
residue in position 5 is replaced by leucine. The human gastrins show the same 
range of actions as the hog gastrins, as could be expected from the fact that the 
only structural difference with these gastrins is situated in the 'non-essential' 
part of the molecule (968). 
The same holds for the gastrins which have since been isolated from dog 
antral mucosa and from the antral region of the ovine and bovine abomasum. 
Dog gastrin differs from hog gastrin in having one of the glutamine residues 
(position 6-10) replaced by alanine; the same is the case with the gastrins 
from sheep and cow, but here in addition the 5-position is occupied by valine 
(13, З78, 379, 389)-
C. One type of gastrin or more? 
Although the progress in the field is impressive, the gastrin puzzle is not yet 
solved. From the same source originally used by Gregory and Tracy, the hog 
antrum, another gastrin was isolated by Tauber and Madison (947, 948, 949). 
Acid hydrolysis of this substance yielded 107 amino-acid residues; the minimum 
molecular weight was calculated to be 12,514. 
The following possibilities now should be considered. 
1. As suggested by Gregory (379), the activity of Tauber's preparation might 
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be due to the presence of a small amount of Gregory's gastrin. On weight 
basis, the lowest effective dose of Tauber's gastrin is 200 times higher than that 
of Gregory's gastrin. 
This hypothesis could be countered by the argument that Tauber's prepara­
tion behaved as one single polypeptide in electrophoresis, paper chromato­
graphy and ultracentrifugai analysis, and that no tryptophan could be demon­
strated in Tauber's gastrin, although it was especially looked for (Ehrlich 
reaction, spectrophotometry). Gregory argues that the presence of a small 
amount of the tryptophan-containing heptadecapeptide in Tauber's prepa­
ration would not have been detectable by the methods used. 
Another counter-argument could be that the eifects of the two types of gastrin 
seem to be qualitatively different: as mentioned, a supraoptimal dose of 
Gregory's gastrin causes inhibition of gastric acid secretion in the dog, whereas 
Tauber's gastrin was not reported to do so. The log-dose response relation 
remained linear up to doses of 37 μg/kg (i.v. infusion over 30 min). On the 
other hand, if 0.5 % of this amount (on weight basis) would consist of Gregory's 
gastrin (see above) and this would be the active principle, its maximal blood 
concentration in Tauber's experiments might well be lower than that reached 
after the doses reported to cause inhibition (0.4-2 μg/kg i.V., 387). 
2. Tauber's gastrin might be a progastrin, meaning that the heptadecapep­
tide would be present in Tauber's peptide, not as a contamination but as a 
part of the molecular structure. This would tally with Tauber's claim that the 
isolated material is one single polypeptide; as for the other points raised under 1, 
the same arguments and counter-arguments would hold. 
To these considerations could be subjoined that even if Gregory's and 
Tauber's gastrins indeed behave differently with respect to gastric acid inhibition 
in the dog, this would not be a definitive argument against the hypothesis in 
question ; it could be explained, for instance, by the assumption that the maxi­
mal rate of conversion of Tauber's gastrin to Gregory's gastrin in the body 
would be such that supraoptimal stimulation of the acid production could 
not occur. 
Here it was assumed that Gregory's gastrin would be formed physiologically 
from Tauber's gastrin in the body. Theoretically it would even be possible that 
Gregory's gastrin is just an artefact, created by the purification procedure 
applied, which, as remarked by Wilding et al. (1036), could fragment a peptide. 
The last-mentioned authors, extracting a protein fraction with gastrin activity 
from hog antral mucosa by ultracentrifugation, thus minimizing the possi­
bility of fragmentation of protein-like substances, came to the conclusion that 
gastrin, as it exists in the antral mucosa, is a larger protein than the hepta-
decapeptides isolated by Gregory and Tracy. 
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3- The theoretical possibility remains open that both Tauber's and Gregory's 
gastrins are gastric secretory hormones and that the two are not biochemically 
connected to each other. 
D. Pentagastrin 
From the series of gastrin derivatives tested by Morley et al. (693) the 
pentapeptide N-t-butyloxycarbonyl-ß-Ala-Trp-Met-Asp-Phe · NH2 (pentagas-
trin, ICI 50,123, Pentavlon) was selected for marketing as a stimulant of gastric 
acid secretion. During the last few years it has been tested rather extensively 
(68,333, 361, 447, 508,575, 759, 889,1053; man; 413, 693; dog; 591, mini-pigj. 
In the rat it was reported to be about 10 times less potent than Gregory's 
gastrin on a molar basis (79). In man doses from 0.01 to 0.1 μg/kg/min i.v. or 
6 μg/kg s.c. elicit peak stimulation of gastric acid production (i.e. a production 
rate that cannot be enlarged by increasing the dose) (3, 508, 571, 655, 1053). 
The drug can also be given in the form of a snuff (1 mg every io min) with the 
same results (500, 1051). 
Dose rates equal to or greater than 0.1 μg/kg/min i.v. or doses greater than 
8 μg/kg s.c. tend to cause side-effects, which generally are rather mild. Gastro­
intestinal symptoms are most frequently observed (3, 518, 628, 655, 1053). 
This finding was to be expected, since peptagastrin, like gastrin itself, enhances 
intestinal motility (629, man; 711, cat,). Also transient hypotension has been 
reported (3, 1053). 
The question whether pentagastrin can cause acid responses as great as 
those following supramaximal doses of histamine or betazole is not answered 
unanimously. Some authors find maximal responses of equal magnitude (3, 
207, 425, 491, 500; man; 79, rat,), others report a somewhat larger or smaller 
acid secretory capacity of pentagastrin. This discrepancy may be due partly to 
different definitions of the concept 'maximal response'. Some authors under­
stand by maximal response the response to a certain high dose of histamine or 
betazole which is routinely given in clinical tests, without strict proof that the 
upper level of the acid secretory capacity of the subject actually was reached ; 
some take into account the peak response measured in one of the sampling 
periods, others the level of sustained secretion during infusion of the secre-
tagogue; some work with a 'calculated maximal response' and others with 
a measured response which cannot be increased further by doubling the dose. 
(As for the last-mentioned difference the reader may be referred to the discussion 
of the data of Makhlouf et al. (655) by Grossman (396).) 
Taking the present data together the conclusion of Konturek (571) that the 
gastric secretory test with pentagastrin has an obvious advantage over all 
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previously used secretory methods in sofar as it provides a reproducible, safe, 
and physiologic stimulant to examine the capacity of the human stomach to 
secrete acid seems justified. 
E. Occurrence of gastrin 
The main source of gastrin is the pyloric antrum (266, 286, 432, 567, 56c, 
979, 98З; cat> dog, hog, manj. Gastrin-like activity has further been found in 
the duodenal mucosa (285,286,432,567,569,590,980,983; cat, dog, hog, manj 
and, to a still lesser degree, in jejunal, ileal and colonic mucosa (590, man), -
although other investigators obtained negative results with extracts of the last-
mentioned tissues of other species (286, 432, 567, 569, 980; cat, dog, hog). 
Traces of gastrin-like action have also been found in the cardia (266, 286, 
385, 612; cat, hog). At present it is not yet known whether the secretagogue 
present in the duodenum and, possibly, in other parts of the digestive tract is 
identical with that isolated from the pyloric antrum. 
If the antrum is called the main source of gastrin, it only means that the 
gastrin-like activity, expressed per gram of extracted mucosa, is highest in the 
antral extracts. This finding may strongly suggest that the antrum plays the 
chief role in physiological hormonal regulation of gastric secretion, but it does 
not necessarily implicate it. The views on the possible physiological significance 
of the hormone in the duodenum are divergent. Some workers suppose that 
the concentration in the duodenal wall is too low to be of much importance, 
but, as correctly stated by Uvnäs (283), the relatively large area of the gastrin-
producing mucosa in the duodenum may compensate for the low concentration 
of the hormone. Some experiments of the group of Dragstedt seem to indicate 
that the antrum is the source of nearly all the gastrin which is involved in the 
stimulation of gastric secretion by a meal (254, 1044; âog). On the other hand 
Olbe (728) found that in some experiments resection of the duodenal bulb 
(and the distal 3-4 cm of the corpus) caused an important further decrease of 
the already low response of antrectomized dogs to sham-feeding. Also, Marks 
et al. (661) described a patient in which a gross hyperplasia of Brunner's glands 
was associated with a basal gastric acid secretion of 34-47 % of his maximal 
capacity. 
The only other tissue known to produce a substance with gastrin-like activity 
is a non-beta islet cell tumour of the pancreas (38, 381, 390,400,417, 660, 783, 
867, 995, 1068) and its metastases (201, 205, 400, 417, 463, 495). This type of 
tumour is associated with a marked gastric hypersecretion and a fulminating 
ulcer diathesis (Zollinger-Ellison syndrome, 279, /067, /069, /070, 1071). 
Probably the secretagogue in question is identical with Gregory's gastrin (381, 
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640). In experimental animals it has been shown that sustained administration 
of gastrin can be a cause of peptic ulceration (363, crude hog gastrin in gelatin 
s.c. every 12 h caused a duodenal ulcer incidence in guinea-pigs of 74% within 
14 days; 288, i.v. infusion of crude or pure hog gastrin for 24 h resulted in 
erosions or ulcerations in stomach and/or duodenum in 15 out of 16 conscious 
cats). In normal pancreatic tissue no gastrin-Iike substance could be demon-
strated (418; hog, dog, man,). 
The gastrin-producing cells in the antrum have not yet been identified. The 
highest gastrin activity is localized in the middle and basal parts of the gland 
crypts of the antral mucosa (147, 283; cat, dog,). It has been suggested that the 
ganglion cells of the submucous plexus of Meissner would be the cells of origin 
of the hormone (81,1046) ; further an endocrine-like cell with the morphological 
characteristics of a protein-secreting cell has been found in the antral mucosa 
(915)· 
F. Release of gastrin 
Gastrin can be liberated from the antral mucosa by stimuli of different kinds. 
The following three mechanisms can be distinguished. 
1. Parasympathetic impulses reaching the antrum via the vagal nerves (869). 
With various techniques causing central vagal excitation gastric acid secretion 
can be caused in a denervated pouch of the oxyntic gland area (Heidenhain 
pouch), on the condition that an innervated pyloric antrum is present (sham-
feeding, 166, 668, 66c, dog; insulin hypoglycaemia, 718, 720, 1047, dog; 
administration of 2-deoxy-D-glucose, 35, dogj. Further it has been demonstra-
ted that gastrin is released by topical application of acetylcholine to the antral 
mucosa (398, dog). 
2. Local mechanical stimuli. Distension of the antral wall was shown to 
result in gastrin-induced gastric secretion. Under physiological conditions 
such a distension may be caused by the presence of food in the stomach; 
experimentally it can be brought about by inflating a small balloon in the 
antrum, a technique clearly proving that a purely mechanical stimulus suffices 
to activate the mechanism in question. Since distension of a gastric pouch 
containing the pyloric antrum causes secretion in a transplanted fundic pouch 
and, moreover, distension of a transplanted antral pouch causes secretion in the 
remainder of the stomach (398, dogj it seems quite sure that the stimulus acts 
via the release of gastrin. 
3. Local chemical stimuli. Gastrin-induced gastric acid secretion also follows 
contact of the antral mucosa with certain amino acids (282, 283), extracts of 
meat and liver (631, 870) and alcohol (280, 281, 283, 1048). The hormonal 
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nature of the stimulation again is suggested by the fact that irrigation of an 
antral pouch with the secretagogue results in a secretory response of a Heiden­
hain pouch (283, 631, 870, 1048; dog). 
A normal meal may cause gastrin liberation via all three mechanisms. At 
1.5 h and 3 h after a meal the antral gastrin activity (amount of extractable 
gastrin) was found to be reduced to about 40%; after 12 h it was back to control 
level (348, cat,). 
The local stimuli cause liberation of gastrin via a cholinergic nervous mecha­
nism in the wall of the pyloric antrum. Mechanical and chemical stimulation 
can be blocked by application of local anaesthetics to the antral mucosa (614, 
786, 1049) and by ganglion-blocking drugs (142, 614) suggesting that these 
stimuli act on mucosal receptors which are connected with the gastrin-releasing 
cells by means of a nervous pathway containing a synapse. Probably this 
ganglion lies in the plexus of Meissner (870). Local anaesthetics also block the 
effect of vagal stimulation of the antrum (718, 786, 979; cat, dogj. Atropine, 
introduced locally into the antrum, blocks the effect of all stimuli, including 
vagal stimulation and application of acetylcholine (382, 614, 718, 789), whereas 
the effect of acetylcholine is not influenced by cocaine (788, 790) nor by gang­
lion-blocking drugs (789). These data suggest that the gastrin cell is stimulated 
directly by acetylcholine. 
Also distension of the intestinal wall (706, 898) or the presence of food in the 
intestine (167, 898) may cause gastric secretion, and again a hormonal mecha­
nism is concerned in the effectuation. It is not known, however, whether the 
hormone in question is identical with antral gastrin, nor whether it is liberated 
directly from the intestinal wall itself. Perhaps the intestinal stimuli (also) 
cause liberation of gastrin from the antrum via a nervous reflex mechanism; 
application of procaine to the intestinal mucosa blocked the responses to 
chemical and mechanical stimulation (898). With respect to the contribution 
of this so-called intestinal phase of the gastric secretion to the physiological 
secretory mechanism as a whole the opinions differ; most authors think it a 
minor factor. 
The effectivity of the antral gastrin-releasing stimuli seems to be pH-depen-
dent. As early as 1904 Sokolov observed that introduction of acid into the 
stomach blocked further gastric secretion (914). Many experiments have con­
firmed that if the pH in the antral lumen is below 3 the effectivity of all types of 
local antral stimuli and also of vagal stimulation (i.a. by sham-feeding or hypo-
glycaemia) is diminished to a greater or less extent, and that hardly any secre­
tory response follows at pH 1 (32, 187, 283, 369, 437, 656, 668, 669, 778, 
787, 956, 985; dog,). Many experiments (which, i.a., give indications that 
acidification of the antral mucosa inhibits gastric secretion only if the latter is 
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dependent on the release of gastrin) support the original suggestion of Wood-
ward et al. (1045) that a low pH in the pyloric antrum would block the release 
of gastrin (253, 255, 503, 631, 650, 882, 956). Other experiments, however, 
have been interpreted into supporting the theory that a sufficiently high con-
centration of acid in the antrum might (also) result in the liberation of an antral 
chalone (225, 261, 262, 263, 369, 437, 512, 513, 656, 673, 719, 781, 890, 922, 
957'> 95#> 959> 9^0, 1050). This hypothetical substance would inhibit the gastric 
secretion directly. The chalone-theory, however, fails to explain the observa-
tion that antral acidification did not inhibit gastric secretion caused by his-
tamine (34). Anyway, so much is certain that, under physiological circum-
stances, the regulation of the gastric secretion is subject to a very appropriate 
feed-back mechanism, which causes the gastric secretion to decrease strongly 
when the gastric contents reach their optimal acidity. 
THE INTERPLAY OF VAGAL AND HORMONAL STIMULATION OF GASTRIC 
SECRETION 
Not very long ago the vagal mechanism and the hormonal mechanism of 
gastric secretion were considered two largely independent processes. According 
to the classical scheme the physiological secretory process was divided into 
a 'cephalic phase', a 'gastric phase' and an 'intestinal phase'. The character 
of the first phase would be purely vagal, whereas the subsequent phases would 
be hormonal. More recent data clearly proved that this dualistic concept needed 
reconsideration. 
Under physiological conditions an interplay of the two secretory mechanisms 
is essential for the progress of the secretory response to a meal, from beginning 
to end (397, 988). The vagal stimuli are much less effective or even inactive 
if no gastrin is released simultaneously (729, 730) ; on the other hand the effect 
of administration or liberation of gastrin is diminished if the vagal innervation 
of the acid-producing mucosa is not intact (35, 442). Optimal secretory activity 
seems to take place only if the two stimulatory mechanisms co-operate. 
INHIBITION OF GASTRIC SECRETION 
A. Sympathetic nervous stimulation 
The influence of stimulation of the sympathetic nervous system or of ad-
ministration of catecholamines on the secretion of gastric juice is a controver-
sial subject. The influence of the sympathetic system on gastric secretion, if 
any, is usually considered to be inhibitory ( 149,174,688, 784). As discussed in 
some detail on p. 144-145, in most experiments adrenaline and noradrenaline 
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are found to be inhibitors of gastric secretion, but under certain conditions 
an enhancement of the secretion can be observed. 
B. Endogenous inhibitory substances 
In the course of the years names have been introduced for a few substances 
which inhibit gastric secretion but which have not yet been identified. The 
existence of physiological inhibitory mechanisms which would be dependent 
on these substances is as uncertain as the exact nature of the substances in 
question. 
Gastrone is the name given by Code to a principle which, in very different 
concentrations, is present in gastric juice and which causes inhibition of gastric 
secretion if administered intravenously (118, 119, 120, 150, 151, 152, 153, 154, 
548, 623, 673, 675, 687, 872, 909, 910, ¡042; rat, dog, manj. Probably we are 
dealing here with more than one substance. The gastric juice of achlorhydric 
patients suffering from pernicious anaemia or gastric carcinoma has the 
strongest inhibitory potency; as for the gastric juice of healthy experimental 
animals, the inhibitory action of the antral juice is stronger than that of the 
juice formed in corpus and fundus of the stomach. Some of the (unpurified) 
extracts cause atrophia of the gastric mucosa (cf. p. 127), others lack this power. 
Inhibitory activity is found also in extracts of gastric mucus (118, 119, 203) 
and in saliva (105, 203, 674, 909). 
Recently some fractions in which the inhibitory activity was mainly con-
centrated have been isolated from gastric juice. One of these fractions had the 
character of a sialomucin, which may indicate that the inhibitory substance 
is a product of the mucoid cells; another, more potent fraction seemed to be a 
γ-globulin-like material (362). The last finding may suggest that antibodies 
(possibly products of auto-immune processes) may play a role. Anyhow, there 
seems to be no indication for a physiological inhibitory process in which 
gastrone would be released into the circulation as a result of some specific 
stimulus. 
As mentioned earlier (p. 154) such a role in a physiological inhibitory process 
has been claimed for the hypothetical antral chalone, that would be liberated 
by acidification of the antral mucosa. However, definitive proof of the exis­
tence of this chalone has not been produced. 
The position of enterogastrone, the intestinal chalone, is different (380). 
Gastric secretion is inhibited by the presence of fats (322, 573, 577, 630, 672, 
884, 885, 899; dog, man,) or of hypertonic sugar or salt solutions (236, 884, 
885, 899; dog, manj in the duodenum. Also the presence of acid may block 
gastric secretion (30, 31, 32, 34, 36, 136, 392, 506, 507, 885, 914; dog, man; ; 
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however, inhibition occurs only when the pH of the duodenal contents is lower 
than 2.5 (η, 204, 722, 773, 899). There is little doubt that the intestinal inhibi­
tion is hormonal (33, 322, 510), but it is not certain that the effect is mediated 
by a special chalone. Possibly the inhibition of the gastric secretion is an aspect 
of the action of the duodenal hormone secretin (16, 360, 374, 505, 614, 1052) 
or of cholecystokinin-pancreozymin (360, 636). As for the inhibitory action of 
acidification, the possibility cannot be excluded that, analogous to the mecha­
nism in the gastric antrum, a low pH may (also) cause a blockade of the release 
of gastrin or a gastrin-like substance from the intestinal wall. It is questionable 
whether the inhibitory action of duodenal acidification on one hand, and of fat 
and hypertonic solutions on the other are effectuated by one and the same 
mechanism. The sensitivity for acidification is mainly localized in the duodenal 
bulb (perfusion of a jejunal loop with acid results in an enhanced gastric acid 
secretion, 573) whereas fat is effective throughout the small intestine. In con­
nection with the latter aspect it is worth mentioning that many conditions which 
interfere with the normal intestinal digestion or absorption cause gastric 
hypersecretion (277): recht shunting portal vein blood to the vena cava (194), 
exclusion of bile from the intestine (707), bile duct obstruction (894), diversion 
of pancreatic juice (208, 375), pancreatic obstruction (278), excision of the 
duodenum (780), resection or bypass of part of the jejunum or ileum (338, 
1027). Resection of the gastric antrum checks the effect of pancreatic ductal 
obstruction (276) but not that of portocaval shunting or other forms of liver 
damage (649). Although this may suggest that more than one mechanism is 
involved in the gastric hypersecretion caused by the conditions mentioned above, 
it seems plausible that a role is played by the disappearance of the inhibitory 
influence of enterogastrone. 
Finally a substance which inhibits gastric secretion has been found in extracts 
of urine which displayed gonadotropic activity (218). This substance is called 
urogastrone. Purified preparations of chorionic gonadotropin also are able 
to inhibit gastric secretion, so that a relationship of urogastrone and the 
gonadotropic hormones seems plausible (483). 
HISTAMINE AND GASTRIC SECRETION 
Histamine is known as a potent gastric secretagogue. In all animal species 
studied it causes production of gastric acid by a direct stimulation of the 
parietal cells. In some species, i.a. man, also the production of pepsin is enhan­
ced. 
Since the first study of the secretory activity of the amine by Popielski ^776^ 
the question whether histamine would play a role in the physiological mecha-
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nism of the gastric secretion, has been a controversial issue. Supporters (62, 
197, 198, 226, 294) and opponents (122, 192, 397) of the theory still disagree, 
but at present most workers in the field tend to answer the question in the 
affirmative. According to the theory of Code-Mclntosh (198, 643) histamine 
even would be the only physiological stimulant of the parietal cells and all 
other stimuli would be effectuated by the release of histamine in the immediate 
environments of these cells. 
The arguments for a physiological role of histamine in the secretion of 
gastric acid are indirect. Histamine is found in the gastric mucosa of all species 
studied, and the concentration of the amine is maximal in the area where the 
parietal cells in the mucosa of the gastric fundus and corpus have their maximal 
density (306, 904; dog, man). The histidine decarboxylase activity in the gastric 
mucosa increases considerably after a meal or after a gastrin injection, and this 
is associated with an increase in the urinary histamine excretion (525). Several 
authors reached the conclusion that gastrin may act by liberation of his-
tamine in the gastric mucosa (22, 294, 519, 902). Histamine is excreted in 
gastric juice secreted in response to various kinds of stimuli (200, dogj. 
In the recent years some of the arguments of the opponents are disproved ; 
for instance, enzymes for the formation and catabolism of histamine occur 
not only in the rat's stomach, but also in the stomach of guinea-pig, dog and 
man (633, 634, 1021). Everywhere else in the body the greater part of the his-
tamine is stored in the mast cells, where it has a low turnover rate; in the gastric 
mucosa, on the other hand, the great majority of the histamine present is not 
associated with the mast cells and its turnover rate is high. Moreover there are 
indications that the turnover rate increases as the secretory activity of the gas-
tric mucosa increases. It seems that the histamine level is kept constant by 
some regulatory mechanism (93, r a t / 
The question whether histamine is indeed the common final pathway of the 
gastric acid secretion could be answered immediately if the effectivity of the 
various secretory stimuli could be studied in the presence of a substance which 
would be able to block the action of histamine on the parietal cells in a specific 
way. However, up to now such a substance has not been found. As mentioned 
earlier, the antihistamines which block the other actions of histamine by means 
of a competitive antagonism have no inhibitory potency with respect to the 
histamine-induced gastric secretion. 
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CHAPTER VII 
EXPERIMENTS ON CONSCIOUS DOGS 
WITH A GASTRIC FISTULA 
INTRODUCTION 
In order to clarify the possible role of histamine in the physiology of gastric 
acid secretion a drug acting as a competitive antagonist of histamine in this 
respect would be very useful. With such a drug as an experimental tool it would 
be possible, for instance, to answer the question whether histamine might be 
the common final step in a number of stimulatory pathways (cf. p. 157). A 
specific antagonist of the gastric secretory action of histamine even might be a 
welcome addition to the therapeutic arsenal. Several of the new compounds 
listed in table I have been synthetized with these considerations in mind. Once 
the fact being established that they act as competitive antihistaminics in the 
isolated guinea-pig ileum, the next step had to be to determine whether they 
would exert any influence on the histamine-induced gastric acid secretion. It 
was decided to perform the planned experiments on conscious dogs with 
gastric fistulae. 
MATERIAL AND METHODS 
A. The fistula 
The fistula used is a modification of the apparatus described by Gautrelet 
(353)· A polyethylene tube (length 5 cm, inner diameter 1 cm) with an external 
screw-thread over its full length was furnished with three thin round collar 
plates of the same material (diameter 3 cm) (fig. 27). One of these (A), placed 
at the extreme end of the tube, is affixed to it; the other two (B and C) can be 
screwed up and down along the tube. The opposite opening can be closed 
with a screw-cap (D). 
B. Preparation of the experimental animals 
Two mongrel dogs, one male weighing 5.5 kg and one female weighing 
9.5 kg, were equipped with these fistulae*. The abdominal wall of the anaes-
thetized dog was opened between sternum and navel. Through a longitudinal 
* The operation was performed with the kind co-operation of the director of the Central 
Animal Laboratory, Dr. M. Dobbelaar. 
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incision along the greater curvature of the stomach the collar plate A was 
brought into the gastric lumen and the gastric wall was closed around the tube. 
Collar plate A was fixed to the gastric wall around the opening by means of 
ligatures through the small holes in the collar plate near its circumference. 
Collar plate В was screwed up until it rested against the serosa of the gastric 
wall. Thereafter the opening in the subcutaneous tissues was closed, collar 
plate С was screwed up against them, and the skin was closed over the latter. 
A length of about 2 cm of the tube protruded from the animal. The collar 
pieces В and С were intended to prevent any fluid from leaking along the outside 
of the fistula tube ; a purpose that they served perfectly. 
no. 27. Diagram of polyethylene gastric fistula. Collar plate A 
is affixed to the fistula tube, collar plates В and С can be screwed 
up and down. The collar plate A is brought into the gastric lumen 
and fixed to the gastric wall with ligatures through the small holes 
near its circumference; collar plates В and С are screwed up 
against the serosa of the gastric wall and against the subcutane­
ous tissue, respectively, thus preventing leakage along the outside 
of the fistula tube. The external opening of the tube can be closed 
with the screw-cap D. 
The polyethylene fistulae proved to be very well tolerated. The animals 
rapidly got accustomed to their presence and did not seem to be hindered 
by them at all. They had an undisturbed digestion, gained weight and behaved 
like normal, good-tempered dogs. The wound in the skin kept secreting small 
amounts of serous fluid, so that the skin in the environment of the fistula 
needed cleansing and greasing routinely, but further special care was not 
necessary. One of the dogs carried its fistula for one-and-a-half year, and when 
the animal had to be sacrificed at last, the gastric mucosa proved to be in normal 
condition. 
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С. Experimental situation 
After recovery from the operation the animals were trained to stand in a 
frame limiting their freedom of movement but allowing a normal standing 
position. Before the experiments were commenced the animals were positively 
conditioned to this situation by means of rewards, so that they were prepared 
to stand in the frame without compulsion.' A positive attitude with respect 
to the experimental situation was considered an important factor, since it is 
known that psychical disturbances may have a profound influence on the secre­
tion of the gastric juice (92). In the evening preceding an experiment the animal 
was not fed, so that the stomach was empty when the experiment started. 
Usually the duration of an experiment was 2 hours; if necessary this period 
of time could be extended to i1^ hours, but then a limit was set by the endu­
rance of the dog. 
D. Collection 0/ the gastric juice 
The gastric juice was collected in consecutive portions, each representing 
a 15 min period. An aid, especially constructed for this purpose, was used in 
collecting the fluid. It consists of a metal tube 2 cm long and with an inner 
diameter of 2.5 cm, affixed perpendicularly on the surface of a metal plate in 
which a round opening concentrica! with the axis of the tube was made (fig. 28). 
The diameter of this opening is 2.2 cm, so that the plate forms an inward 
protruding rim of 1.5 mm at the end of the tube. Cloth bandages are attached 
to the longer edges of the plate. 
This aid was placed over the fistula tube in such a way that the plate rested 
against the skin of the dog, being kept in place by means of the bandages which 
were tied around the body of the animal. Calibrated polyethylene tubes, having 
flat bottoms with protruding edges, were used as receptacles for the acid. Their 
diameter is such that they fit exactly in the metal tube. By means of a rubber 
band which is hooked over two projections on the outer surface of the metal 
tube and passes under the bottom of the receptacle the latter is pressed upwards 
inside the tube and kept firmly in place with its upper rim pressing against the 
protruding edge of the plate (fig. 28). It takes only a few seconds to replace one 
receptacle by another at the end of a sampling period. An advantage of this 
way of collecting is that a certain freedom of movement of the animal within 
the frame can be allowed without risk of losing gastric juice, whereas no 
traction on the end of the fistula tube is exerted. 
In most cases the fistula tube was found filled with partly digested food 
which could be removed without difficulty. If in the process of cleaning these 
remnants were partly pushed back into the stomach, as sometimes would 
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FIG. 28. Apparatus for collecting gastric juice in consecutive portions. 
FIG. 28A: Aid, to be placed over the fistula tube, and calibrated polyethylene collecting tube, 
The aid is kept in place by means of bandages around the body of the experimental animal. 
FIG. 28B: The collecting tube is attached to the aid by means of a rubber band. This way of 
fixation prevents traction on the end of the fistula tube, is dependable and allows replacement 
of one collecting tube by another within a few seconds. 
happen, or if the stomach contained much mucus, some draughts of water 
were given to the dog and this would cleanse both stomach and fistula. 
E. Administration of the test substances 
The substance to be tested was administered to the animal after a control 
period (usually 30 or 45 min) in order to determine the possible occurrence of 
spontaneous secretion; the amounts of acid produced during this time, if any, 
were always very small. The test substances were injected subcutaneously at 
the beginning of a new 15 min collection period. 
F. Determination of acid in the gastric juice 
A 1 ml sample of each portion was titrated against an NaOH-solution of 
100 mN, using methylorange as an indicator. Each determination was made 
in duplo, if possible. In a number of cases the determinations were hindered by 
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the presence of regurgitated duodenal contents in the collected fluid; in all 
cases, however, the portions were mixed well before the samples were taken. 
If the volume of a portion was less than ι ml the total amount was used for 
titration. 
DRAWBACKS OF THE EXPERIMENTAL SET-UP 
Although the experimental set-up in itself operated smoothly, it soon became 
clear that it had a number of serious limitations. These limitations were the 
reasons that after some sixty experiments, the results of which will be discussed 
later in this chapter, the method was abandoned in favour of a different one 
(see chapter VIII). The handicaps of the method were the following. 
The progress of the experiments was slow. When the series was started it 
was planned to perform two or three experiments per dog each week, but 
this tempo could not be maintained. After some weeks the response to the 
standard dosage of histamine, which had to serve as a basis for comparison, 
diminished to such low levels that, even considering the great variation occur­
ring in these values, it hardly could be ascribed to chance (see table VIII on 
p. 165). Indeed, the responses became normal again when a longer period 
of time was allowed between the experiments; three experiments in two weeks 
were found to be acceptable in this respect. 
Nevertheless the danger remained that compounds administered in a prece­
ding experiment would have protracted effects in the animal and thus would 
cause changes in the responses obtained in later experiments, either by a direct 
influence on the acid secretion mechanism or by a change in the metabolism 
of the drugs. As mentioned before, one of the purposes of the present study 
was to find a drug which could competitively antagonize the secretion induced 
by histamine. It was essential, therefore, that even a small antagonizing effect 
could be identified as such, since this could give a valuable indication of the 
direction in which the investigations should proceed. However, in addition 
to the great variability in the secretory responses to the standard doses of 
histamine, the possibility mentioned made it extremely difficult to rate smaller 
differences at their true value. 
The method had some further drawbacks, arising from the fact that the 
animals were conscious and should remain positively conditioned to the experi­
mental situation. Both for this reason and on ethical grounds it was necessary 
that the maximal doses of the test substances and the maximal duration of the 
experiments should not seriously interfere with the animal's sense of well-being. 
The maximal duration of the experiments was too short to allow the deter­
mination of the secretory response to histamine alone and to the same dose of 
histamine in presence of the test compound in one experiment. Also the fact 
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that only relatively small doses of the test compounds could be given was 
unfavourable, since, as already discussed, a possible inhibition of the histamine-
induced secretion should be substantial in order to be identifiable as such. 
Another disturbing factor was the regurgitation of duodenal fluid. This 
phenomenon took place occasionally and in some cases the regurgitated amount 
of the duodenal contents was not negligible. It is true that the alkalinity of 
this fluid is low in comparison with the acidity of the gastric juice, especially 
since the regurgitation tended to occur when the acid production was high. 
Yet, it was an unknown variable, to which may be added that unknown quan-
tities of gastric juice may have been lost via the pylorus. 
The points discussed in this paragraph were sufficient reasons to consider 
acute experiments on anaesthetized animals. Such experiments could have a 
longer duration and it might be possible to maintain a constant level of acid 
secretion for longer periods of time by means of an intravenous infusion of 
histamine, so that a possible small antagonizing effect of a test compound 
might be clearly demonstrable. Of course, intravenous infusions of histamine 
could not be used in the conscious dogs. Moreover, no influence of preceding 
experiments would have to be feared, higher doses of the test compounds 
could be given and the regurgitation of duodenal fluid, if still occurring under 
anaesthesia, could be prevented by ligation of the pylorus. 
The realization of the desired experimental set-up for anaesthetized animals 
(see chapter VIII) was difficult and required much time. In the meantime some 
sixty experiments were performed on the fistula dogs, the results of which 
are discussed in the following part of this chapter. 
THE SECRETORY RESPONSE TO HISTAMINE 
A. Experimental results 
In the course of the series of experiments the secretory responses to standard 
doses of histamine dichloride were determined a number of times. The course 
of the acid production caused by subcutaneous injection of histamine is shown 
in fig. 29; more detailed data are collected in table VIII. 
The following points may be noted : 
1. In the experiments 24, 31, 32 and 38 a spontaneous secretion of acid 
was observed during the control periods. The amounts of acid secreted were 
small; they amounted to (in the sequence of the control periods): 
Experiment 24: 0.26 mEq; 0.02 mEq 
Experiment 31: 0.22 mEq; 0.10 mEq; no secretion 
Experiment 32: 0.20 mEq; 0.07 mEq 
Experiment 38: 0.50 mEq; 0.21 mEq 
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n o . 29. Graphs of gastric acid production, collected in por­
tions of 15 min, after subcutaneous injection of 30 Mg/kg 
histamine dichloride (fig. 29A) or 50 Mg/kg histamine dichlo-
ride (fig. 29B). 
Drawn lines: Individual responses of dog I. 
Interrupted lines : Individual responses of dog II. 
Note : the responses to the two doses of histamine vary con­
siderably and even may overlap. 
The occurrence of spontaneous secretion in the contro] periods tended to 
coincide with larger secretory responses to the administration of histamine. 
An explanation may be found in the supposition that the secretory mechanism 
responds only if the stimulus surpasses a certain threshold value. In the case 
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of a completely resting stomach part of the histamine given may be needed to 
reach the stimulus threshold, whereas in the case of a spontaneous secretion, 
however small, the threshold stimulus is already present. 
2. The responses to 30 μg/kg histamine tend to be smaller than the responses 
to 50 μg/kg and they tend to be of shorter duration. The variability of the res­
ponses is considerable. The height of the maximal acid production and the 
duration of the effect seem to be correlated ; this may be a result of the fact 
that the histamine was administered by subcutaneous injection. The very 
small responses to 50 μg/kg histamine in the experiments 11 and 12 may be 
disregarded, since they probably were connected with the circumstance that 
the frequency of the experiments was too high (cf. p. 162). 
I 
Dog I, 30 Mg/kg 
Dog I, 5t^g/kg 
Dog II, 30 Mg/kg 
Dog II, 50 pg/kg 
Dog II, 65 ug/kg 
II 
9 
I? 
25 
4 
16 
31 
II 
12 
24 
32 
38 
22 
III 
7-9 
3-10 
28-10 
20-8 
30-9 
14-12 
12-9 
14-9 
25-10 
16-12 
6-1 
19-10 
IV 
— 
+ 
— 
+ 
+ 
+ 
— 
V 
1.44 
2.04 
3-74 
З.98 
4.03 
458 
0.80 
1.47 
2.14 
8.17 
5-73 
6.49 
VI 
0.66 
0.70 
1.69 
1.98 
1.40 
0.30 
0.60 
1.04 
2.25 
1.89 
2.38 
3 
2 
2 
2 
2 
2 
2 
3 
2 
2 
2 
2 
VII 
122 
I28 
130 
ІЗ7 
ІЗ8 
140 
ΙΟΙ 
112 
93 
139 
128 
142 
3 
4 
2-3 
3 
3 
3-4 
3 
3 
2-3 
3 
3 
3 
Vili 
6.5 
6.0 
13.0 
15.8 
I L I 
14.0 
7-2 
5-4 
11.2 
I7.6 
16.O 
19-3 
2 
2 
2 
2 
2 
2 
2 
3 
2 
2 
2 
2 
IX 
± 
— 
— 
+ 
+ 
+ 
+ 
TABLE vin. The secretion of gastric acid by two dogs with gastric fistulae in response to 
subcutaneous injection of histamine. 
I : animal and dose. 
II: number of experiment. 
Ill : date of experiment. 
IV: occurrence of spontaneous secretion during the control periods*. 
V: total amount of acid in mEq produced in response to the injection. 
VI : largest amount of acid in mEq produced in one period, with the number of this period *. 
VII: concentration in mN of the portion with the highest acidity, with the number of the 
corresponding period*. 
VIII: volume in ml of the largest portion, with the number of the corresponding period*. 
IX: occurrence of duodenal regurgitation. 
* With 'period' is meant the standard collection period of 15 min; the periods are counted 
from the moment of injection of the drug. The periods before the injection are the 'control 
periods'. 
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В. The upper limit of the gastric acidity 
The highest acid concentrations observed in the control experiments (the 
experiments with histamine alone) are about 140 mN. Still higher concentra­
tions were found in several other experiments. For all experiments performed 
on the fistula dogs the acidities of portions with an acid concentration sur­
passing 130 mN are collected in table IX. Thus in 5 experiments acidities over 
145 mN were found, the highest value being 155 mN. 
Dog 
Experiment 
nr. 
2 
4 
5 
16 
19 
26 
28 
31 
43 
48 
52 
22 
32 
47 
55 
61 
63 
65 
Acidities in mN 
148, 145 
137 
139 
138 
149,143, Mi 
145,142, 147, 140 
139, 150, 149.155.15З 
140, 140 
141, 140 
139, 139 
137. 137 
142 
139 
141 
141 
141 
149. 150 
138 
TABLE ix. Acid concentrations measured in the gastric 
juice of two dogs with gastric fistulae. The acidities of 
all 15 min portions of gastric juice with an acid concen­
tration surpassing 130 mN are listed. 
These findings correspond well with the data in literature. In experiments on 
dogs with gastric pouches Hollander and Cowgill collected samples of gastric 
juice the acidities of which were determined with the Potentiometrie method 
(473). The highest acidities were not distributed randomly, but seemed to have 
a sharp upper limit at pH 0.91, which corresponds with an acid concentration 
of about 155 mN. Gray, Bücher and Harman, also using dogs with gastric 
pouches, found a maximal acidity of 153 mN (372). James points out that 
155 mN is very close to the tonicity of the dog's body fluid and makes the sug-
gestion that 'the maximal concentration of acid which the stomach can secrete 
is that of a solution of hydrochloric acid equal to or at least dependent on the 
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tota] concentration of the plasma' (498) Anyhow, about 155 mN is the highest 
acid concentration observed in dogs, and it should be noted that this acidity 
could be maintained for at least 15 min in a test object in which the possibility 
of dilution with saliva or duodenal fluid was not excluded. 
C. Do the parietal cells produce acid with a fixed, maximal concentration? 
As shown in fig 30 the peak of the acid concentration tends to fall later than 
the peak of the total acid production. This is an interesting phenomenon in 
connection with the different hypotheses in literature regarding the acidity of 
gastric juice. According to Pavlov (758) and to Hollander (467, 472) the acid is 
secreted with a constant, maximal concentration, lower concentrations of the 
gastric juice being due to a secondary dilution with non-acid juice produced 
iriEq 
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FIG 30 Graphs of mean gastric acid production and mean acid concentration in the gastric 
juice after subcutaneous injection of histamine 
Graph A. Mean acid production after 30 Ug/kg histamine 
Graph B: Mean acid concentration in gastric juice after 30 pg/kg histamine. 
Graph C. Mean acid production after 50 μg/kg histamine 
Graph D Mean acid concentration in gastric juice after 50 pg/kg histamine. 
The graphs A and В give the mean values of the four expenments shown in fig. 29A; the 
graphs С and D give the mean values of the five experiments shown in fig 29B 
Note: the peak of the total acid production precedes the peak of the acid concentration 
separately. Rosemann supposed that the acid-producing cells could secrete 
fluid with any acid concentration between maximal and zero (818). Theorell 
and his co-workers suggested the possibility that the concentration of the secre­
ted acid could be altered secondarily by diffusion, Η-ions being exchanged 
for other cations, mainly Na + (444). The essential question is whether the 
parietal cell produces acid at a fixed, maximal concentration or at various 
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concentrations, for the diffusion mechanism proposed by Theorell will exert 
its influence in both cases. 
The results of the described experiments seem to argue against one of the 
theoretical possibilities, viz. that the acid would be secreted with a maximal 
concentration and that the acidity would decrease secondarily by diffusion 
only. Since the acid is in contact with the mucosa only during the time needed 
to flow down to the opening of the fistula, the influence of the diffusion process 
would be smaller when the secretion rate is high and greater when small amounts 
of acid are produced. It follows that the acidity of a collected portion would 
be higher as the total amount of acid present in it is larger. The found disso­
ciation of maximal acid production and maximal acidity contradicts this 
supposition. 
In the case of the present experiments diffusion anyhow could not play an 
important role, since the time of contact of the gastric juice with the mucosa 
was short. The differences in the acidity of the gastric juice therefore should 
be explained on the basis of one of the following hypotheses: 
i. the acid is secreted at a maximal concentration and subsequently diluted 
with non-acid fluid (Pavlov-Hollander), 
2. the acid is produced at various concentrations and, besides, diluted with 
non-acid fluid. (The last factor should be included even if the non-acid gastric 
secretion is negligible, since the animal undoubtedly swallows saliva during 
the experiment.) 
The experimental results under consideration do not allow a choice between 
the two possibilities mentioned. If, however, the data are interpreted in the 
light of the Pavlov-Hollander hypothesis the following observations can be 
made. In fig. 31 the mean volumes of the total amounts of gastric juice, secreted 
after administration of 30 μg/kg and 50 μg/kg histamine and collected per 
period of 15 min, are presented. If it is assumed that this juice is composed of 
gastric acid of maximal concentration (here put at 155 mN; cf. p. 167) and of 
neutral fluid, the volumes of these two components can be calculated on the 
basis of the mean acidity values given in fig. 30. The resulting graphs show that 
1. the productions of acid and of neutral fluid have different characteristics. 
The latter tends to reach its maximum earlier than the former; this corresponds 
to the dissociation of the maximal acid production and the maximal acid 
concentration in fig. 30. 
2. the acid production caused by 50 μg/kg histamine is considerably larger 
than that caused by 30 μg/kg histamine, but the amounts of neutral fluid 
secreted in response to the different doses of the drug do not appreciably differ. 
The same imaginary separation into components was also performed with 
the assumption that the acid had been diluted with a fluid with an alkali 
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concentration of 40 mN. The resulting graphs are analogous to the graphs 
shown in fig. 31 and allow the same conclusions. 
The observation that (if the Pavlov-Hollander hypothesis is correct) the 
amount of non-acid fluid secreted in response to 30 μg/kg histamine hardly 
differs from that secreted after 50 μg/kg of this drug may indicate that the 
smaller histamine dose is sufficient to cause a nearly maximal response of the 
cells which produce this fluid. Another possibility is that the non-acid secretion 
last ISmln-pertod ISmln-perlod 
before Injection after Injection 
FIG. 31. Graphs of the mean volumes of fluid produced after subcutaneous injection of 
histamine. 
Graphs A and B: Mean total fluid production after 30 Mg/kg and after 50 Mg/kg histamine, 
respectively. 
Graphs С and D: Corresponding volumes of acid juice, calculated on the basis of the mean 
acidity values given in fig. 30, with the assumption that the acid was secreted with a concen­
tration of 155 mN. 
Graphs E and F: Corresponding calculated volumes of neutral fluid. 
Note: the production of neutral fluid tends to reach its maximum earlier than the production 
of acid juice; the volumes of neutral fluid produced in response to the different doses of 
histamine hardly differ, whereas the volumes of acid juice differ considerably. 
is not stimulated by histamine but by the presence of acid in the stomach. It 
has to be supposed, then, that both doses of histamine cause the gastric acidity 
to reach a level at which a maximal non-acid secretion would occur; however, 
it should be noted that the production of non-acid fluid starts to diminish 
before the acid concentration decreases. Further research in this direction is 
indicated. 
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SEARCH FOR A COMPETITIVE ANTAGONIST OF HISTAMINE WITH RESPECT 
TO GASTRIC ACID SECRETION 
A. Introduction 
The classical antihistamines do not antagonize histamine-induced gastric 
acid secretion. As discussed already in chapter 1, this fact can be explained on 
the basis of two different suppositions. The gastric receptors of histamine may 
be essentially different from those in other organs, so that the classical anti-
histamines do not have affinity to them; it is also possible that the gastric 
receptors as such are not different but that the classical antihistamines cannot 
readily reach them. If administration of an antihistaminic drug in a high dose 
does not result in a sufficient concentration in the biophase of the gastric 
receptors of histamine, the drug will be considered inactive against histamine-
induced gastric secretion. 
The chance that a drug readily penetrates into the biophase and has a suffi-
cient affinity to the histamine receptor would seem best if its structure rather 
closely resembles that of histamine. Derivatives of histamine itself were not 
available at the time, and since 2-(ß-aminoethyl)-pyridine is a histamine-like 
drug which stimulates gastric acid secretion, the series of amino-substituted 
derivatives of this drug (table I compounds 1-14) was first considered for 
testing. Perhaps substitution to the amino-group of 2-(ß-aminoethyl)-pyridine 
would interfere with the intrinsic activity of the compound (as is the case regar-
ding the histaminergic system in the guinea-pig ileum), so that the substituted 
compounds would be competitive antagonists of histamine with respect to 
the gastric acid secretion. 
From the series of derivatives three compounds were selected for testing; 
one with a small, one with a medium-sized and one with a large substitution 
group. A compound with a small substitution group might have a chance 
since its structure more closely resembles that of histamine, but, on the other 
hand, in the guinea-pig ileum the compounds with smaller substituents have 
the lower affinities of the series. A compound with a larger substituent has a 
much higher affinity to the histamine receptors in the guinea-pig ileum (pro-
bably due to the interaction with additional receptor areas; cf. p. 108), but here 
the attainability of the secretory receptors or the possible structural differences 
between the gastric and the other histamine receptors may carry more weight. 
Another theoretical possibility is that the N-atom in the side-chain is not 
essential with respect to the intrinsic activity of histamine and 2-(ß-aminoethyl) 
-pyridine regarding gastric acid secretion, in which case all members of the series 
of derivatives might be able to cause secretion of acid. Such a result could be an 
indication that indeed the secretory histamine receptors would have charac-
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teristics essentially different from those in the guinea-pig ileum; however, its 
interpretation would be complicated by the possibilities that the test compounds 
might act as histamine liberators or might partially block the catabolism of 
histamine. 
B. Compound 2 
Experiment i, dog I 
Four control periods: acid secretion less than 0.015 mEq per period, acidity less 
than 10 mN. (Henceforth an acid production of less than 0.02 mEq per period 
will be indicated as 'no secretion'.) 
Dose: compound 2, 2 mg/kg s.c. During the hour following the injection the 
acid secretion did not increase and the acidity of the juice remained below 
10 mN. 
Experiment 2, dog I 
Two control periods: acid secretion 0.09 mEq and 0.04 mEq. 
Dose 1: compound 2, 2 mg/kg s.c. Acid secretion during the next three periods: 
0.48 mEq, 0.20 mEq and 0.25 mEq; highest acidity 83 mN in the third portion. 
Dose 2: histamine, 50 μg/kg s.c. The experiment had to be finished after the 
third period, when the secretion still was considerable. Total acid secretion in 
these 45 min: 6.18 mEq; largest amount 2.58 mEq (second period), highest 
acidity 139 mN (third period). At the end of the experiment the acid production 
was already larger than any of the standard responses to 50 μg/kg histamine 
observed in this dog (cf. table VIII). 
Experiment 3, dog I 
Three control periods: no spontaneous secretion. 
Dose: compound 2, 20 mg/kg s.c. Total acid secretion during the following 
six periods: 2.98 mEq; largest amount 0.92 mEq (second period), highest 
acidity 122 mN (fourth period). The first and second portion contained duode­
nal contents. The decline of the curve seemed to be slower than after a dose 
of histamine. 
Conclusion 
The experiments did not give any indication that compound 2 would anta­
gonize histamine with respect to gastric acid secretion. On the contrary, the 
drug seems to have a definite stimulating action by itself. This is in accordance 
with the agonistic character of this compound in the guinea-pig ileum. 
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С. Compound 5 
Experiment ι, dog I 
Three control periods: no spontaneous secretion. 
Dose: compound 5, 20 mg/kg s.c. During the next five periods no acid was 
secreted, but the production of mucous fluid was slightly increased (2-3 ml 
per period). 
Experiment 2, dog I 
One control period: no spontaneous secretion. 
Dose 1: compound 5, 20 mg/kg s.c; no acid secretion during the next period. 
Dose 2: histamine, 50 μg/kg s.c. Total acid secretion during the following 
six periods: 7.57 mEq; largest amount 2.04 mEq (second period), highest 
acidity 124 mN (third period). The fourth and fifth portion contained small 
amounts of duodenal contents. The response had the same general pattern 
as the standard responses to 50 Mg/kg histamine but was greater than any of 
these. 
Experiment 3, dog I 
Two control periods: no spontaneous secretion. 
Dose 1: compound 5, 20 mg/kg s.c; no acid secretion during the next period. 
Dose 2: histamine, 30 Mg/kg s.c. In the first period after this injection no acid 
was secreted; this was also observed in three out of the four experiments with 
30 Mg/kg histamine alone (fig. 29A). Total acid secretion during five periods 
following the histamine injection: 2.75 mEq; largest amount 1.02 mEq, highest 
acidity i n mN, both in the third period. Most portions were contaminated 
with duodenal contents. 
When this response is compared with the standard responses after 30 Mg/kg 
histamine alone, there is no indication that the preceding administration of 
compound 5 had any influence. The experiment, however, was performed in the 
period that the secretory responses were abnormally small, probably as a result 
of the frequency of the experiments being too high (three experiments weekly; 
see p. 162). Two days earlier a dose of 30 Mg/kg histamine caused a secretion 
of 1.44 mEq acid and three and five days afterwards the responses to 50 Mg/kg 
histamine amounted to 0.80 mEq and 1.47 mEq (see table Ш, experiments 9, 
и and 12). If the response in question is compared with the immediately 
preceding and following control experiments, therefore, it seems probable that 
compound 5 did enlarge the response to histamine. 
Conclusion 
In the guinea-pig ileum compound 5 is a competitive antagonist of histamine, 
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but the experiments described above do not give any indication that the drug 
in the administered doses would antagonize histamine with respect to the 
gastric acid secretion. It remains possible, of course, that the result would have 
been positive if the drug had been given in higher doses ; if the affinity ratio of 
the compounds 2 and 5 with respect to the secretory histamine receptors is 
of the same order as that determined in the guinea-pig ileum, the doses of the 
latter compound should have been about twenty times higher in order to be 
equipotent with the given doses of the former. The quantity of compound 5 at 
our disposal, however, was too small for such doses, - apart from the question 
whether the dog would have tolerated them. 
The experimental results suggest that compound 5 in the dose given enhances 
the gastric secretory response to histamine. This phenomenon may be caused 
by different factors (cf. p. 171). 
D. Compound 13 
Experiment 1 
As an orientating experiment a subcutaneous injection of 20 mg/kg of com­
pound 13 was given to a healthy male dog with a body-weight of 11 kg. The 
effects were unexpected. Five minutes after the injection the dog became resless 
and the secretion of saliva increased, then the animal vomited and immediately 
afterwards it had an epileptiform attack with clonic convulsions of the muscles 
of the extremities and the back, foam on the snout, incontinentia alvi et urinae 
and hyperventilation. The attack was suppressed with an injection of pento­
barbital; hyperventilation and light twitches in the legs lasted for some time. 
Afterwards the animal did not show any sign of permanent damage. 
In this connection it is relevant that compound 13 did not show any hista-
minergic, cholinergic or α-adrenergic activity in the experiments on isolated 
organs. It seems probable that the observed effect originated in the central 
nervous system. 
Experiment 2, dog I 
In view of the results obtained in experiment 1 the test dose for the fistula dog 
was decreased to 1 mg/kg. This dose did not cause manifest side-effects, perhaps 
with exception of a slight unrest. 
Two control periods: no spontaneous secretion. 
Dose: compound 13, 1 mg/kg s.c. Result: no secretion in the first, second and 
third period, 1 to 2 ml non-acid fluid in the fourth and fifth period, and in the 
sixth, seventh and eighth period secretion of 0.22 mEq, 0.50 mEq and 0.25 mEq 
acid, respectively (total amount 0.97 mEq); highest acidity 78 mN (seventh 
period). 
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Experiment 3, dog I 
It was not clear whether the late secretion in experiment 2 should be regarded 
as a response to the injected drug after a latent period or whether it was coin­
cidental. Perhaps it might be connected with the unusually long duration of the 
experiment. For this reason three days later the experiment was repeated in a 
modified form. 
Dose: compound 13, 1 mg/kg s.c, given 35 min before the beginning of the 
first collecting period. Ten portions of juice were collected, containing respec­
tively 0.39 mEq, 0.13 mEq, 0.30 mEq, 0.24 mEq, o. 16 mEq, 0.21 mEq, 0.32 mEq, 
0.30 mEq, 0.33 mEq and 0.80 mEq acid. The acidity varied from 65 mN to 
80 mN, reaching 98 mN in the last period. 
It seems less problable that the increase in the acid production during the 
tenth period, three hours after the injection, had to be ascribed to the adminis­
tered drug; as in experiment 2 the duration of the experiment may have played 
a role. 
Experiment 4, dog I 
The experiment was preceded by a resting period of eight days. 
Two control periods: acid secretion 0.39 mEq and 0.43 mEq. 
Dose 1: compound 13, 1 mg/kg s.c. Secretion during the next period : 0.20 mEq. 
Dose 2: histamine, 50 μg/kg s.c. Total acid secretion during the following 
five periods: 4.79 mEq; largest amount 1.61 mEq (second period), highest 
acidity 130 mN (second, third and fourth period). The portions of the control 
periods, the period after dose 1 and the first period after dose 2 were contami­
nated with duodenal contents. 
The response had the character of a normal histamine response. It was 
somewhat greater than the greatest response of the dog to 50 μg/kg histamine 
alone; this could be connected with the unusually high spontaneous secretion. 
Conclusion 
No indication that compound 13 in the dosage used would antagonize 
histamine with respect to gastric acid secretion was found. The affinity of 
compound 13 to the histamine receptor in the guinea-pig ileum is about three 
times greater than that of compound 2; on this basis the dose of 1 mg/kg 
would not seem inadequate. 
The character of the acid secretion in the experiments 2 and 3 is not clear. 
If compound 13 in the dosage used stimulates the gastric acid secretion, the 
effect is small and has a pattern different from a histamine response. 
E. Compound 24 
The next drug selected for a test as a possible histamine antagonist with 
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respect to gastric acid secretion is compound 24, a representative member of 
the series of compounds which contain a piperazine-ring (table I compounds 
15-27). The maximal dose that could be given without producing undesirable 
effects in the dog (unrest, later followed by drowsiness) was determined before­
hand in a dog without fistula. 
Experiment 1, dog I 
Three control periods: acid secretion 0.04 mEq, 0.03 mEq and 0.03 mEq. 
Dose: compound 24, 20 μπιοΐ/kg (10.9 mg/kg) s.c. During the next five periods 
no acid was produced. Some dilatation of the pupils was observed. 
Experiment 2, dog I 
Two control periods: no spontaneous secretion 
Dose 1: compound 24, 20 μηιοΐ/kg (10.9 mg/kg) s.c. Acid secretion during 
the next period: 0.10 mEq. 
Dose 2: histamine, 50 Hg/kg (0.27 ц т о і ^ ) s.c. Total acid secretion during 
the following five periods: 5.39 mEq; largest amount 1.89 mEq (second period), 
highest acidity 149 mN (fourth period). The second portion was contaminated 
with duodenal contents. 
The response was greater than any of the corresponding standard responses 
of dog I ; its characteristics are those of a normal histamine response. 
Conclusion 
The pAz-value of compound 24 determined in the guinea-pig ileum is 7.19, 
which is higher than the pD2 of histamine itself. On a molar basis the dose 
administered to the dog is 74 times higher than the dose of histamine. Never­
theless no indication that compound 24 would antagonize histamine with 
respect to gastric acid secretion was found. 
F. Compound 58 
The next drug selected for a test as a possible antagonist of histamine with 
respect to gastric acid secretion was compound 58. This substance was chosen 
on the ground of the fact that it can be regarded as a derivative of histamine 
itself. It was recognized that the 'histamine moiety' of the molecule probably 
is of little importance for the affinity of compound 58 to the histamine receptor 
in the guinea-pig ileum (cf. p. 110), but as for the secretory receptor the situa­
tion possibly might be different. The doses given to the fistula dogs were tested 
beforehand in other dogs; they did not seem to have any general effect. 
Experiment 1, dog II 
Two control periods: acid secretion 0.03 mEq and 0.02 mEq. 
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Dose: compound 58, 0.6 цтоІ/к§ s.c. Acid secretion in the following six 
periods: 0.04 mEq, 0.03 mEq, 0.06 mEq, 0.04 mEq, no secretion, no secretion. 
Highest acidity: 40 mN (fourth period). 
Experiment 2, dog I 
One control period: acid secretion 0.02 mEq. 
Dose 1: compound 58, 0.6 ц т о і ^ s.c. Acid secretion in the next two periods: 
0.39 mEq and 0.37 mEq; acidities of 78 mN and 111 mN. 
Dose 2: histamine, 50 μg/kg (0.27 ц т о і ^ ) s.c. Total acid secretion during 
the following seven periods: 10.09 mEq, largest amount 2.41 mEq (third period) ; 
highest acidities 150 mN, 149 mN and 153 mN in the third, fourth, fifth and 
sixth period. 
The secretory response in this experiment was more than two times greater 
than any of the corresponding control responses; the acid concentration 
reached was the highest measured in the whole series of experiments. 
Experiment 3, dog I 
Two control periods: acid secretion 0.07 and 0.31 mEq. 
Dose: compound 58, 1.5 μ ι η ο ΐ ^ s.c. Acid secretion during the following six 
periods: 0.24 mEq, 0.23 mEq, 0.13 mEq, 0.07 mEq, 0.02 mEq, no secretion. 
Highest acidity 138 mN (fourth period). 
Experiment 4, dog II 
Two control periods: no spontaneous secretion. 
Dose: compound 58, 1.5 цтоі/іф s.c. Acid secretion during the following six 
periods: 0.07 mEq, 0.24 mEq, 0.13 mEq, 0.06 mEq, no secretion, no secretion. 
Highest acidity 88 mN (third period). 
Experiment 5, dog I 
One control period: no spontaneous secretion. 
Dose 1: compound 58, 1.5 ц т о і ^ s.c. No acid secretion during the next 
period. 
Dose 2: histamine, 30 Hg/kg (0.16 ц т о і ^ ) s.c. Total acid secretion during 
the following six periods: 1.43 mEq, largest amount 0.64 mEq (fourth period), 
highest acidity 119 mN (fourth period). 
Experiment 6, dog II 
One control period: acid secretion 0.03 mEq. 
Dose l: compound 58, 1.5 ц т о і ^ s.c. No acid secretion during the next 
period. 
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Dose 2: histamine, 30 ЦЕ/І^ (о.іб ц т о і ^ ) s.c. Total acid secretion during 
the following six periods: 2.07 mEq, largest amount 0.86 mEq (third period), 
highest acidity 95 mN (third and fourth period). 
Conclusion 
The affinity of compound 58 to the histamine receptor in the guinea-pig 
ileum is about a factor 2 smaller than that of histamine itself. In experiment 2 
the ratio of the amounts of histamine and compound 58, expressed on a molar 
basis, is 1:2 and in the experiments 5 and 6 it is 1 :io; yet the experiments did 
not give any indication that compound 58 would antagonize histamine with 
respect to gastric acid secretion. The responses in experiment 2 and, perhaps, 
experiment 4 even suggest that compound 58 may have a positive influence 
on gastric acid secretion; however, the secretory responses in the experiments 
5 and 6 fall within the range of the corresponding control responses. 
THE RESPONSES TO SOME STIMULANTS OF GASTRIC ACID SECRETION 
In this stage of the study small samples of a series of histamine derivatives 
with alkyl-substitutions to the N-atom in the side-chain were placed at our 
disposal by courtesy of the N.V. Organon at Oss, the Netherlands. All com­
pounds in this series caused either complete or partial contraction of the guinea-
pig ileum. (As for the compounds with larger substituents there was reason to 
doubt whether the action was a direct histaminergic effect; however, the avail­
able quantities of the drugs were too small to allow an analysis of their mecha­
nism of action.) Only N-methyl-and N-ethyl-histamine could be tested on the 
gastric fistula dogs; the quantities of the other derivatives did not suffice for 
this purpose. Both drugs have been reported to cause gastric acid secretion 
(18, 50c) ; N-methyl-histamine would be 2.5-3 times more active than histamine 
itself. 
The doses of methyl- and ethyl-histamine administered to the fistula dogs 
were chosen to be equipotent to 50 μg/kg histamine on the basis of the affinity 
ratios determined on the guinea-pig ileum. Further a few experiments with 
other drugs stimulating gastric secretion, viz. the histaminomimetic drug 
betazole (compound 56) and the cholinomimetic drug carbachol were performed 
in order to have a wider basis for comparisons. 
A. N-methyl-histamine 
Experiment 1, dog I 
Two control periods: no spontaneous secretion. 
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Dose: N-methyl-histamine, 0.80 μιηοΐ/kg s.с. Total acid secretion in the follo­
wing eight periods: 6.35 mEq, largest amount 1.62 mEq (fifth period), highest 
acidity 126 mN (fourth period). The last four portions were contaminated with 
duodenal contents. The secretion still continued when the experiment had to 
be concluded. 
Experiment 2, dog I 
One control period: no spontaneous secretion. 
Dose: N-methyl-histamine, 0.80 μ π ι ο ί ^ s.с. Total acid secretion in the follo­
wing nine periods: 2.69 mEq, largest amount 0.64 mEq (eighth period), 
highest acidities 106 mN and 107 mN (eighth and ninth period). Most portions 
contained duodenal contents. The secretion still continued when the experiment 
had to be concluded. 
Experiment 3, dog I 
One control period: no spontaneous secretion. 
Dose: N-methyl-histamine, 0.80 μιηοΐ/^ s.c. Total acid secretion during the 
following nine periods: 7.51 mEq, largest amount 1.32 mEq (sixth period), 
highest acidities 145 and 147 mN (sixth and eighth period). At the end of the 
experiment the secretion still continued. 
N-methylhîst amine 
O.SO^mol/kg 
FIG. 32. Graphs of gastric acid production, collected in portions of 15 min, after subcutaneous 
injection of 0.80 цтоі/і^ N-methyl-histamine. The figure shows three individual responses 
of dog I. 
Note: the secretion pattern differs from that after subcutaneous administration of histamine. 
The acid production increases at a slower rate and continues longer. 
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Conclusion 
N-methyl-histamine stimulates the secretion of gastric acid. The secretion 
pattern differs from that after subcutaneous administration of histamine: the 
acid production increases at a slower rate and continues longer (fig. 32). 
Theoretically these differences may be caused by various mechanisms. It may 
be that the absorption of N-methyl-histamine from the place of subcutaneous 
injection is slower and, as for the longer duration, the derivative may be cata-
bolized at a slower rate than histamine. 
The statement of Alphin and Lin (18) that N-methyl-histamine is 2.5-3 
times more active than histamine may be true in terms of the total amount of 
gastric acid produced, but probably not in terms of affinity and/or intrinsic 
activity; the different secretory pattern is more suggestive for differences in 
the field of drug transference (cf. p. 30). 
B. N-ethyl-histamine 
Experiment 1, dog I 
Two control periods: no spontaneous secretion in the first control period, 
0.036 mEq in the second control period. 
Dose: N-ethyl-histamine, 5.4 μmol/kg s.c. Total acid secretion during the follo­
wing nine periods: 3.60 mEq, largest amount 0.81 mEq (sixth period), highest 
acidity 108 mN (sixth period). The dose given seemed to cause some discom­
fort to the dog. The secretion still continued when the experiment had to be 
concluded. 
Conclusion 
N-ethyl-histamine seems to have a type of action similar to that of N-methyl-
histamine. 
C. Betazole (3-($-aminoethyl)-pyrazole, compound 56) 
Betazole is used as a gastric secretagogue in man. In doses which cause 
maximal gastric acid secretion the drug is free of the side-effects which usually 
accompany a histamine-induced maximal secretion, such as flushing and head­
ache (143, 195, 824). 
Experiment 1, dog I 
Two control periods: acid secretion in the first period 0.07 mEq, no secretion 
in the second period. 
Dose: betazole, 2 mg/kg s.c. Total acid secretion in the following six periods: 
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3.48 mEq, largest amount 1.03 mEq (third period), highest acidity 128 mN 
(fifth period). 
The top rate of acid secretion in this experiment was of the same order as 
that after 30 μg/kg histamine but the secretory activity seemed to decline 
somewhat slower. 
Experiment 2, dog I 
Two control periods: acid secretion 0.26 mEq and 0.34 mEq. 
Dose: betazole, 3 mg/kg s.c. Total acid secretion in the following six periods: 
11.20 mEq, largest amount 2.44 mEq (second period), highest acidity 148 mN 
(fourth period). The secretion still continued when the experiment had to be 
concluded; the acid production during the last period was 1.58 mEq. Never­
theless the total amount of acid secreted was much larger than in any of the 
control experiments with 50 μg/kg histamine (cf. table VIII); the difference was 
mainly caused by the slower decline of the response to betazole. 
The dose of betazole given was tolerated by the experimental animal without 
any sign of discomfort. 
Conclusion 
According to the data of Lin, cited by Jones (509) betazole is a factor 100 
less active than histamine with respect to smooth muscle contraction, but in 
the present study the affinity ratio of histamine and betazole determined on the 
guinea-pig ileum was found to be in the order of ι :200ο. Rosière and Grossman 
found that in the anaesthetized dog betazole is about a factor 700 less potent 
than histamine with respect to blood pressure depression (824). In the experi-
ments on conscious dogs described above the stimulating action of betazole 
on gastric acid secretion was found to be only about a factor 60 smaller than 
that of histamine. This corresponds perfectly with the secretory potency deter-
mined by Rosière and Grossman (824). The decline of the secretory response 
caused by betazole is slower then that from a similar level of secretion caused 
by histamine. 
These data explain why betazole as a gastric secretagogue is relatively free 
of side-effects, and stress again that the gastric histaminergic system may 
differ considerably from other histaminergic systems. 
D. Carbachol (carbaminoylcholine) 
Experiment 1, dog I 
Two control periods: no spontaneous secretion. 
Dose: carbachol, 5 μg/kg s.c. Acid secretion during the following six periods: 
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о.оз mEq, o.oi mEq, 0.20 mEq, 0.08 mEq, 0.12 mEq, 0.10 mEq. Acid concen­
trations, respectively: 12 mN, 20 mN, 48 mN, 32 mN, 39 mN, 51 mN; volumes 
of the portions: 2.3 ml, 0.5 ml, 4.1 ml, 2.6 ml, 3.2 ml, 1.9 ml. 
Experiment 2, dog II 
Two control periods: acid secretion in the first period 0.05 mEq, no secretion 
in the second period. 
Dose: carbachol, 5 ц§/к§ s.c. No secretion of acid or non-acid fluid occurred 
during the following six periods. 
Experiment 3, dog I 
Two control periods: no spontaneous secretion. 
Dose: carbachol, 12 μg/kg s.c. (In preliminary experiments on dogs without 
fistula the dose of 12 μg/kg s.c. proved to be the highest dose tolerated without 
much discomfort; 25 μg/kg caused diarrhoea and vomiting.) Acid secretion 
during the next seven periods: 0.28 mEq, 0.53 mEq, 0.07 mEq, 0.19 mEq, 
0.59 mEq, 0.40 mEq, 0.31 mEq. Acid concentrations, respectively: 14 mN, 
31 mN, 70 mN, 86 mN, 98 mN, 112 mN, 99 mN. The amounts of fluid secreted 
during the first two periods were 23 ml and 17 ml, respectively; this may be 
compared to the largest amount of fluid secreted during one period after 
30 μg/kg histamine in four control experiments: 6.5 ml, 6 ml, 11.2 ml and 13 ml 
(in each case during the second period). Another difference was that the fluid 
secreted during the first two periods after carbachol was very viscous, whereas 
the larger portions of juice secreted in response to histamine always were thin 
as water. 
Experiment 4, dog II 
Two control periods: acid secretion 0.34 mEq and 0.13 mEq. 
Dose: carbachol, 12 μg/kg s.c. Acid secretion during the next six periods: 
0.18 mEq, 0.03 mEq, 0.08 mEq, 0.02 mEq, 0.07 mEq, 0.15 mEq; acid concen­
trations: 50 mN and 60 mN in the control periods, and after the injection 
20 mN, 15 mN, 44 mN, 32 mN, 50 mN, 61 mN. The amounts of fluid secreted 
during the six periods were, respectively, 9 ml (highly viscous), 2 ml, 1.9 ml, 
0.5 ml, 1.4 ml and 2.4 ml. 
Conclusion 
Dog I responded to the administered doses of carbachol with a small but 
definite increase of the gastric acid production. Dog II, however, did not show 
any reaction to the administration of 5 μg/kg carbachol, whereas the acid 
secretion after the injection of 12 μg/kg carbachol did not exceed the level of the 
spontaneous secretion before the injection. 
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The total amount of acid secreted by dog I in response to 12 ц§/к§ carbachol 
(2.37 mEq) is of the same order as the total acid secretion caused by 30 pg/kg 
histamine. The secretory pattern, however, is quite different; in the experiment 
in question the secretion had an irregular course with two peaks and continued 
much longer than a response to a subcutaneous injection of histamine. 
In both animals the higher doses of carbachol caused a marked increase in 
the production of gastric mucus. 
The above results correspond well with the literature data about other 
cholinomimetic agents discussed on p. 133. In the present experiments carbachol 
did not appear to be a usable stimulant of gastric acid secretion, at least not in 
doses which the experimental animals could tolerate without serious discomfort. 
THE INFLUENCE OF SEROTONIN ON THE HISTAMINE-INDUCED GASTRIC 
ACID SECRETION 
The 40 experiments discussed so far were performed in a period of six 
months. During the next four months a further series of 26 experiments was 
devoted to a study of the influence of serotonin (5-hydroxy-tryptamine) on the 
histamine-induced gastric acid secretion. 
The data in literature about the gastric secretory effect of serotonin do not 
concur. Cali and Cordova report a stimulant action which did not appear to 
be mediated by liberation of histamine (16c, 170, man^. In dogs, Sosin et al. 
and Whang et al. found either no effect or an increase of histamine-induced 
acid secretion (917, loji). The majority of the workers in this field, however, 
report a serotonin-induced inhibition of volume and acidity of both spontaneous 
and histamine-induced gastric secretion (439, 769, 8/6, 866; man; 117, 440, 
441, 903; dog; 213, cat;. 
In view of the theoretical possibility that serotonin, which is structurally 
related to histamine, might inhibit gastric secretion by competing with hista­
mine for the receptors of the histaminergic secretory system, it seemed of 
interest to study the effect of very high doses of serotonin on submaximal 
histamine-induced secretory responses. The highest subcutaneous dose tole­
rated by the dogs without discomfort was 1 mg/kg serotonin creatinine sulphate 
(4.14 mmol/kg). The secretory effect of this dose of serotonin alone was tested 
in the following experiments: 
Experiment 1, dog I 
Two control periods: no spontaneous secretion. 
Dose: serotonin, 1 mg/kg s.c. Acid production during the following six periods: 
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о. 19 mEq, 0.22 mEq, 0.08 mEq, 0.03 mEq, 0.08 mEq, 0.02 mEq; acid concen­
trations, respectively: 39 mN, 60 mN, 83 mN, 93 mN, 80 mN and 46 mN. 
Experiment 2, dog II 
Two control periods: acid secretion 0.25 mEq (63 mN) and 0.22 mEq (60 mN). 
Dose: serotonin, 1 mg/kg s.c. Acid production during the following six periods: 
0.28 mEq, 0.08 mEq, 0.10 mEq, 0.10 mEq, 0.03 mEq, 0.09 mEq; acid concen­
trations, respectively; 47 mN, 38 mN, 48 mN, 65 mN, 54 mN and 43 mN. 
Conclusion 
Dog I responded to the administration of serotonin with a small but distinct 
increase in the gastric acid production; the response of dog II cannot be inter­
preted in view of the pre-existing spontaneous secretion (cf. the experiments 
with carbachol). 
The possibility had to be taken into account that the influence of serotonin 
on the histamine-induced gastric acid secretion, if any, would be small. There­
fore it was decided to perform a series of experiments that would allow statis­
tical analysis of the results. Twelve experiments were performed on each dog; 
alternatively the secretory response to 30 μg/kg histamine s.c. and to 30 μg/kg 
histamine plus 1 mg/kg serotonin, given as one subcutaneous injection, were 
determined. Unfortunately in one of the experiments on dog II the portions 
H 
1.48 
1.28 
2.10 
O.5I 
З.26 
О.69 
DOG I 
H + S 
592 
1.60 
5-73 
6.20 
2.43 
2.97 
H 
5.62 
6.63 
10.82 
4.01 
5.76 
4.87 
DOG II 
H + S 
— 
8.94 
5-74 
9.68 
4.61 
4.41 
TABLE x. The secretion of gastric acid by two dogs with gastric 
fistulae in response to histamine and to histamine combined with 
serotonin. 
Column H: Total amount of acid in mEq secreted during 90 min 
after s.c. injection of 30 ug/kg histamine. 
Column H + S : Total amount of acid in mEq secreted during 
90 min after s.c. injection of 30 pg/kg histamine + I mg/kg sero­
tonin. In dog I the secretory response after the administration of 
histamine combined with serotonin tends to be greater than the 
response to histamine alone; the difference is significant. In dog II 
no significant difference was demonstrable. 
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of gastric juice were lost before titration. The total amounts of acid secreted 
during the six periods following the drug administration are collected in table X. 
Again the great variability in the secretory responses is striking. The mean 
acid production of dog I after administration of 30 μg/kg histamine alone is 
1.55 mEq; after 30 μg/kg histamine + 1 mg/kg serotonin it is 4.14 mEq. The 
mean values of dog II are 6.28 mEq and 6.67 mEq, respectively. The difference 
between the responses of dog I to 30 μg/kg histamine alone and to 30 μg/kg 
histamine combined with 1 mg/kg serotonin is significant (P = 0.026 according 
to the two-tailed Wilcoxon's two sample test); in the case of dog II, however, no 
significant difference was demonstrable. 
It will be clear that these results do not support the supposition that sero­
tonin would exert a competitive antagonism against histamine with respect 
to gastric acid secretion. 
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CHAPTER Vi l i 
DEVELOPMENT OF APPARATUSES FOR 
CONTINUOUS REGISTRATION OF THE RATE 
OF GASTRIC ACID PRODUCTION AND FOR REGULAR 
PERFUSION OF THE CAT'S STOMACH 
INTRODUCTION 
As discussed in the previous chapter, the experiments on conscious animals 
with gastric fistulae had certain drawbacks which made the performance of 
supplementary acute experiments desirable. It was decided to use anaesthetized 
cats for this purpose. In the experiments on conscious dogs with gastric fistulae 
it was no question which method should be used for the determination of the 
gastric acid production: the obvious approach was collection of the juice in 
samples and subsequent titration. In experiments on anaesthetized animals, 
however, the choice of possible measuring methods is wider. Since each method 
has its own limitations, the choice is not irrelevant. 
THE TITRIMETRIC AND THE POTENTIOMETRIC MEASURING METHODS; 
THE LIMITATIONS OF EITHER PROCEDURE 
The methods for the determination of gastric acid production may be divided 
into two groups: the acid juice is either collected in samples and the acidity of 
each portion is determined by means of titration, or the pH of the juice is 
measured continuously by potentiometry. The methods belonging to the first 
group are the older ones and are still by far the most frequently used; often 
they are applied in combination with various surgical preparations. Generally 
the juice is allowed to flow spontaneously through a fistula or cannula; some-
times the gastric mucosa is rinsed at set times with a known volume of a 
neutral fluid. 
The necessity to collect the gastric juice in samples limits the information 
that can be obtained with this approach. A reliable titrimetric determination 
is not possible unless a certain minimal quantity of gastric acid is available 
for titration ; in practice the gastric juice of the larger experimental animals, as 
dogs and cats, is collected in samples containing the production of at least 
io or 15 min. If smaller animals are used or if, in the larger animals, the level 
of secretion is low even sampling periods of this order are too small, so that the 
measuring points in a diagram of the secretion rate may be far apart. Worse 
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yet is the fact that rapid changes in the secretion velocity may not be detected : 
for instance, a high but short-lasting peak in the secretion will only show itself 
as a small enhancement during 15 or even 30 min. 
It follows that if detailed information about the course of the secretion is 
desired, a method allowing a continuous determination of the acid production 
is preferable. This requirement can be met by the techniques which belong to 
the second group. With suitable electrodes the pH of the gastric contents may 
be measured directly in the stomach. But if also the amount of the produced 
acid must be known, the stomach should be perfused and the pH of the fluid 
which leaves the stomach and contains the produced acid should be measured 
outside the stomach. If the rate of perfusion is carefully kept constant, and the 
volume of fluid in the stomach is great with respect to the amounts of acid 
produced, the changes of the pH of the perfusate correspond directly with the 
changes in gastric acid production. This type of continuous registration of 
acid secretion was employed first by Gosh and Schild (368). Compared with the 
titrimetric method it means a considerable saving of effort. 
As compared with the titrimetric determination the pH-registration has one 
important disadvantage, which is a consequence of the logarithmic scale of the 
pH-curve. Each change of the pH by one unit means an equal alteration of the 
difference in potential between the two electrodes, and therefore an equal 
distance in the registration. This means that as the gastric juice becomes more 
acid, the Potentiometrie method of determination becomes less distinctive. 
Suppose that the resting gastric mucosa responds to a stimulus with the pro-
duction of a certain number of HCl-molecules per unit of time, and that this 
production rate shows itself as a peak of 10 cm in the registration. If the same 
number of HCl-molecules is added to the gastric contents at pH 3, the change 
will correspond with a peak of 0.001 cm in the registration, - in other words, 
it cannot be perceived at all. But if a drug is studied with respect to its dose-
effect relation the change in secretion of HCl-molecules is as important as its 
original level. Consequently a linear registration is to be preferred to a logarith-
mic one. 
Of course Gosh and Schild were well aware of the limitations of their method. 
They employed it in rats, so that even at maximal secretion rates the quantities 
of acid were small, and, moreover, they perfused the stomachs of their experi-
mental animals with an NaOH-solution of ± 0.25 mN. In this way they 
attained that the pH-range in which the measurements had to be made was 
near pH 7. According to Gosh and Schild the perfusion fluid further takes up 
enough buffering substances in passing through the stomach to serve as a 
linear buffer system from pH 6.5 to 4.5. In a later modification of the method 
by Rosenoer and Schild (821) a phosphate-citrate buffer with pH 7.3 was used 
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for the perfusion. With this change the method can be used for measuring an 
acid production up to maximally 0.25 ml juice with an acidity of 100 mN per 
io min, but even in this form the range of the method is far too small to be 
useful for measuring the acid production in larger animals. Just as the titrime-
tric methods prove to be deficient at low secretory rates, so do the Potentio-
metrie ones if the rate of secretion is high. 
Summarizing, an ideal method of recording gastric acid secretion should 
1. be serviceable for all levels of acid secretion, 
2. render automatically a registration which is direct, continuous and linear 
to the number of acid molecules secreted, 
3. have an accuracy and a resolving capacity not less than one of the classic 
methods. 
It is plausible to seek the realization of these desiderata in some combination 
of titrimetric and Potentiometrie methods. This is not a new idea. An apparatus 
which works on the principle of such a combination exists : the automatic titra-
tor. Here the actual measurement is carried out by means of titration, but the 
zero-level is controlled by a pH-meter. The Potentiometrie zero-indication has 
the advantage that automatization is feasible, whereas the logarithmic character 
of the pH-scale does not matter in this case. 
Yet the commercially available automatic titrators have never been used for 
the registration of gastric acid secretion. A reason could be that these appara-
tuses are supplied with integrating registration systems. This makes them less 
suitable for the purpose. An integrated registration directly shows the total 
amount of acid secreted since a certain moment, but the rate of the acid pro-
duction is hidden in the slope of the registration curve. A change in the secretory 
level only finds expression in a change of this slope. 
In principle an integrated signal may be differentiated again, but if this 
cannot be done automatically, there is little sense in the whole automatization. 
Moreover, the differentiated values cannot be calculated very exactly: the 
whole range of secretion, from zero to maximal, is found within an angle of 
90 degrees. With the aid of electronic techniques an automatic differentiation 
of an integrated signal is not absolutely impossible, but it is not practicable 
over sufficiently long periods of time. 
AN APPARATUS FOR AUTOMATIC, CONTINUOUS REGISTRATION OF THE 
RATE OF GASTRIC ACID SECRETION 
A. Introduction 
In order to meet the requirements listed in the previous section, a new 
apparatus for the determination and registration of the rate of gastric acid 
187 
FIG. 33. Schematic representation of the apparatus for automatic, continuous registration of 
the rate of gastric acid secretion. 
secretion was realized. The determination is based on titration with Potentio­
metrie zero indication; the registration is automatic and produces a differentia­
ted record of the acid production. The mode of operation is represented schema­
tically in fig. 33. 
B. The perfusion fluid 
The perfusion fluid is a 0.9% NaCl-solution. Directly before an experiment 
this solution is prepared with deionized water and NaCl p.a., so that the pH 
does not deviate appreciably from 7. With this fluid a Mariotte bottle with a 
capacity of 3 1 is filled. The air inlet of this bottle is supplied with a CO2-
adsorber, without which the pH of the fluid may shift to 6 or 5.5 during longer 
experiments. The fluid enters the stomach of the experimental animal at a 
temperature of 38е С. 
С. The perfusion 
The perfusion of the stomach had to meet the following conditions: 
1. The perfusion fluid should leave the stomach at a perfectly constant flow. 
This is necessary since the apparatus registers the amount of acid leaving the 
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stomach per unit of time ; it cannot distinguish between a change m the acid 
secretion rate and one in the rate of transport to the measuring unit. 
2. The acid produced should be carried away by the perfusion fluid with 
perfect constancy. The reason is analogous : if an amount of acid accumulates 
in a fold of the gastric mucosa before entering the stream of the perfusate, the 
registration will show a false peak. 
3. The wall of the stomach, and especially that of the pyloric antrum should 
not be brought under tension, since this might stimulate the acid production 
(cf. p. 135 and 152). 
4. The amount of fluid present in the stomach should not be too large in 
proportion to the rate of perfusion. Changes of acid secretion result in changes 
of acid concentration in the perfusate; the characteristics of the latter, however, 
are not identical with those of the former. A peak is shifted on the time axis, 
" • 
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Reepoxific 
n c 34 Theoretical graphs illustrating the differences between a change in the rate of gastric 
acid secretion and the resulting change in the acid concentration of the perfusion fluid which 
leaves the stomach The degree of deformation of the primary curve depends on the time 
constant τ, being the ratio of the fluid volume in the stomach and the perfusion rate. 
FIG 34A * Deformation of the primary step function A to an exponential response curve B. 
FIG 34B Deformation of a gradually increasing and decreasing primary curve A to a response 
curve В which is shifted in the time and has a slightly different shape The part of curve В 
between the points Ρ and Q has an exponential character, like curve В in fig 34A. The de­
formation of curve A will be smaller as τ is smaller. 
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its slope may change, and if the primary phenomenon is relatively short-lasting, 
the maximal height is also considerably diminished. The degree of the defor­
mation with which the primary phenomena are represented by the changes in 
the perfusate concentration depends on the ratio of the fluid volume ν in the 
stomach to the perfusion rate i. The quotient v/i has the dimension of a time. 
If the change in acid secretion is a step function, the acidity of the perfusate 
changes according to an exponential curve (see fig. 34A). The time τ which 
equals v/i is that time in which the acidity of the perfusate acquires about 63 % 
of the limit value U. (More exactly: (e-i/e)U, e being the base of natural loga­
rithms, 2.7183....). After an elapse of 2τ and of 31 these values are ± 8 6 % 
and ± 95 %, respectively. 
In reality the changes in the secretion rate will be gradual. Suppose that the 
ideal curve has the shape A shown in fig. 34B. The curve actually obtained 
then will have a shape corresponding to В ; it is shifted in the time with τ, and 
also the difference in height of the two curves is dependent on this value. (The 
part of curve В between points Ρ and Q is exponential, like the curve В in 
fig. 34A.) The deformation of the ideal curve therefore will be smaller according 
as τ is smaller. It follows that the quotient v/i should preferably be as small 
as possible. 
Not only the ratio of ν to i but also the magnitude of the individual values 
is important. If, at a given secretion rate, the perfusion rate is made χ times 
higher, the acid concentration of the perfusate becomes χ times lower. Depen­
ding on the qualities of the measuring apparatus, the difference between two 
concentrations should have a certain minimal value to be detectable. The more 
the acid is diluted, the less distinguishing the resulting record will be. The 
maximal perfusion rate suitable for the purpose has to be determined experi­
mentally. The magnitude of i again decides about the amount of fluid in the 
stomach that is acceptable. 
In which way a satisfactory perfusion was obtained will be discussed later in 
this chapter. In the set-up eventually realized τ equals 3-4 min. 
D. The titration fluid 
The perfusate is titrated with an NaOH-solution of known concentration, 
- in our experiments usually 10 mN. This fluid is in a smaller Mariotte bottle, 
likewise supplied with a COz-adsorber. The lye flows out of this bottle through 
a thin, flexible polyethylene cannula. Its flow rate is dependent on the difference 
in level between the bottle and the cannula opening and on the resistance of the 
system. The latter being constant, the rate of the lye supply is directly propor­
tional to the difference in height between the two levels. 
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E. The titration 
The titration takes place in the neutralization chamber (fig. 35), a glass 
vessel with a flat sintered-glass bottom of 7 by 22 mm. Through this bottom a 
constant flow of pure nitrogen is led. The perfusate and the NaOH-solution 
meet at one side of the vessel and are mixed by the nitrogen bubbles; the 
mixture passes along the pH-measuring electrodes and is removed at the other 
side by suction. 
glass electrode 
acid perfusate 
from stomach 
to suction pump 
connection with 
calomel electrode 
NaOH 
bottom of sintered glass 
N2 
for bubble-mixing 
FIG. 35. The neutralization chamber, in which the perfusate is 
titrated. The perfusate and the NaOH-solution meet at one side 
of the vessel and are mixed by means of nitrogen bubbles; the 
mixture passes along the pH-measuring electrodes and is removed 
at the other side by suction. 
Mixing by means of the nitrogen bubbles has an important advantage, as 
it allows the volume of fluid constantly present in the neutralization chamber 
to be kept very small. This is necessary for the same reasons as discussed in 
connection with the perfusion of the stomach, since the larger the amount of 
fluid, the tardier the reactions of the apparatus and the smaller the resolving 
capacity. Moreover, a certain degree of slowness introduced at this point will 
give the apparatus a tendency to produce a self-reinforcing oscillation, conse-
quently drowning the signal. 
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With this method a sufficient degree of mixing is possible in an amount of 
fluid far too small for most other ways of mixing, and in a very short time. 
Furthermore, since the minute amount of fluid momentarily changes into a 
layer of froth, measurement is possible with normal macro-electrodes in some 
tenths of a millilitre. The fact that macro-electrodes can be used again has an 
advantage with respect to the velocity of the mixing, as it is not necessary to 
effect a perfect homogeneousness, but it is sufficient if the dimensions of the 
spectrum of inhomogeneity are smaller than those of the glass electrode. The 
latter strikes an average of the pH-values over its surface. In this way mixing 
and measuring is done in a volume of 0.3-0.5 ml and is completed within a 
few seconds. 
The pH-meter used is an apparatus supplied with a relay (Radiometer 
Titrator TTT ic), which produces a direct current of 125 V whenever the mea-
sured pH is below a pre-set limit (in this case pH 7). This current is utilized to 
operate a two-way relay, that in its turn controls the direction of rotation of a 
small 24 V D.C. motor (fig. 36). The height of the stock bottle of lye with respect 
to the outlet of the polyethylene cannula into the neutralization chamber can 
be increased or reduced by this motor. 
Whenever the pH of the fluid in the neutralization chamber is below 7, the 
S W l » 
J25V 
D.C. ^ 
frempH-metertíí. 
* 
Rei 
swi 1 
- fW,x 
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IOOJUF 
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. of motor 
FIG. 36. Diagram of electrical circuit controlling the rotation direction of the motor in the 
apparatus for automatic, continuous registration of the rate of gastric acid secretion (cf. fig. 3 3). 
Motor: E.M.W. type T.G.N. 70-20; 20 V, 0.4 A. 
Re 1 : Electromethods type 411 A. 
f 1 and f2: Τ 1/250. 
Sw 1, Sw 2 and Sw 3: 10 A/125 v · 
Switch 1 is a manual switch for reversal of the field connections, switch 2 a microswitch 
limiting the ascent of the NaOH-reservoir (opened when the reservoir reaches its highest 
position) and switch 3 a microswitch limiting the descent of the NaOH-reservoir (opened 
when the reservoir reaches the level of the neutralization chamber). 
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pH-meter actuates the two-way relay, the motor starts to operate and hoists 
the NaOH-reservoir to a higher level. This results in an increase of the amount 
of NaOH that flows into the neutralization chamber, and thus the pH of the 
mixture rises. At the moment the pH of the mixture surpasses 7 the actuation 
of the relay stops, and as a result the motor changes its direction of rotation 
and the NaOH reservoir descends, until the pH of the mixture passes 7 again. 
The NaOH-bottle therefore executes an oscillation around a position of 
equilibrium. 
It is desirable to suppress this oscillation to a certain degree. For this purpose 
the so-called 'proportional band', with which the titrator is supplied, could 
be utilized : this offers the possibility to select a pH-range within which the relay 
is intermittently powered. In our case this pH-range is fixed between 6.2 and 
8.2. When the pH reaches 6.2 the actuation of the apparatus will be interrupted 
regularly for short moments and as the pH rises further these interruptions 
increase in duration until, at pH 8.2, the powering does not take place but as 
pulses of short duration. At pH 7 the relay is powered 50 % of the time, so 
that the motor alternately gets impulses of equal strength to rotate clockwise 
and anti-clockwise. As a result of its inertia the armature remains immobile. 
The further the measured pH deviates from 7 the greater the speed of the motor 
until, when the deviation is about one pH-unit or more, it operates at full 
speed. In the region of 7 the pH-measurement has its maximal sensitivity, so 
that the apparatus will react upon the smallest disturbance of the equilibrium. 
F. The registration 
A registration of the acid production in the stomach of the experimental 
animal may now be obtained in a very simple manner. The string on which 
the lye reservoir has been suspended is wound once around a pulley, with which 
a linear, low-friction potentiometer (Helipot, 100 Ω) is operated. This poten­
tiometer is included as a resistance in a Wheatstone bridge, in which at the 
same time possibilities are introduced to adjust the zero level and the scale of 
the registration (fig. 37). A direct-writing millivolt recorder (Honeywell Brown 
Electronik) is used for the registration. In principle any voltage recorder 
is suitable. 
The registration obtained in this way is a continuous, differentiated and 
linear representation of the acid secretion in the stomach. This is apparent 
from the following facts: the registration is a linear representation of the 
movements of the NaOH-reservoir, the height of this reservoir is directly 
proportional to the rate of the lye inflow via the cannula into the neutralization 
chamber, and the rate of the lye supply in its turn is directly proportional to the 
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FIG. 37· Diagram of Wheatstone bridge (sec fig. 33 : 
'resistance bridge'). 
A: Measuring potentiometer (Helipot, 100 Ω). 
В : Scale adjustment. 
C: Zero adjustment. 
rate of acid production in the stomach. A standard record obtained by infusing 
HCI-solutions of various concentrations directly into the neutralization cham­
ber is shown in fig. 38. 
THE DEVELOPMENT OF AN APPARATUS FOR REGULAR PERFUSION OF 
THE CAT'S STOMACH 
A. Outflow dependent on controlled inflow 
To appreciate the necessity of the rather complicated apparatus used for 
the perfusion of the cat's stomach, the successive steps in its development 
should be described. The first condition to be met was that the outflow of the 
perfusate has to be constant. As the stomach has a variable capacity, a constant 
flow into the stomach does not necessarily result in a constant outflow. 
The ends of two flexible cannulae were placed in the stomach. Through one 
cannula a constant flow of the perfusion fluid was pumped into the stomach. 
When the conditions were favourable, there was a constant outflow through 
the other cannula during an appreciable length of time ; however, more often 
the rate of the outflow was extremely variable. This could be due to a number 
of causes. When, for instance, a small piece of mucus entered the exit cannula, 
the outflow immediately diminished or stopped until the pressure in the stomach 
became high enough to force it through. Then all at once the collected fluid 
flowed out. Also when the position of the cannula was changed or some internal 
movement occurred, disturbances might result. An outflow cannula with a 
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greater diameter - up to ι cm - was tried in the hope that it would not be 
clogged, and indeed it was not; but now the cannula did not remain filled with 
fluid: it filled, then drained itself totally, air entering from the outlet, and the 
outflow stopped until the cannula had filled again. When the end of the cannula 
was placed on a level higher than that of the stomach, the stomach became 
overfilled before any fluid flowed out; was the end placed on a lower level than 
the stomach, the system siphoned intermittently, or a fold of mucosa was 
sucked against the opening of the outlet cannula and the system was blocked 
again. The over-all conclusion was that this method was unreliable. 
B. Control of both inflow and outflow 
The next possibility considered was to control both the inflow and the 
outflow. This would mean that the volumes of fluid entering and leaving the 
stomach per unit of time would have to be exactly equal. The experiments may 
extend over 8 h or longer: even the smallest difference between the two rates 
100 min 
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FIG. 38. Standard responses obtained with the apparatus for automatic, continuous registra­
tion of the rate of gastric acid secretion by infusion of HCl-soIutions of various concentrations 
directly into the neutralization chamber. 
Note, that the registration has a perfectly linear character. 
would inevitably result either in an accumulation of fluid in the stomach or in 
a growing underpressure. Even if it would be possible to use two exactly equal 
pumping-rates, the changing rates of gastric secretion during the experiments 
would render this approach unsuitable. 
С Inflow dependent on controlled outflow 
As may be clear from the foregoing, the best prospects seemed to be offered 
by a perfusion method in which the outflow was controlled and the inflow was 
passively dependent on the former. However, such a method could be applied 
only if provisions were made to prevent that the gastric mucosa would be 
sucked into the opening of the outflow cannula. Some aid had to be introduced 
into the stomach which would keep the gastric walls apart in spite of the under­
pressure in the lumen. However, it seemed inadvisable to open the organ 
surgically, since this might interfere with its secretory responses. Furthermore 
the dead space in the stomach should not exceed 10-15 m l . ' n connection with 
the resolving capacity of the measuring method (cf. p. 189-190). 
A small basket was made from small-mesh nylon gauze, applied in a diagonal 
direction, so that it could be shaped into an oblong and thin form, but also into 
a short and thick form. An elastic thread, stretched inside the apparatus, 
forced it into the latter form (fig. 39). Both cannulae had one of their openings 
within the basket; the whole was attached to a slightly flexible polyethylene 
tube of 60 cm length, through which both cannulae were led. 
When the basket was brought in its oblong form, it had the same diameter 
as the polyethylene tube, and both fitted snugly in a thin-walled brass tube. 
FIG. 39. Gastric basket of small-mesh nylon gauze, ap­
plied in a diagonal direction. The basket can have an 
oblong, thin form and a short, thick form. An elastic 
thread, stretched inside the apparatus, gives it a tendency 
to the latter form. Cannulae for the inflow and outflow of 
the perfusion fluid have their openings within the basket. 
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The basket with its tube was positioned in the brass tube in such a way that 
the furthest end of the basket was level with the opening of the brass tube. 
The latter was passed through mouth and oesophagus of the anaesthetized cat 
until its tip was immediately beyond the cardia ; then the polyethylene tube was 
pushed further through it until the basket was situated in the middle of the 
stomach. Liberated from the brass tube it resumed its short, thick shape. The 
brass tube was retracted, the slightly flexible polyethylene tube remained lying 
in the oesophagus and mouth of the animal. 
By adjusting the level of the stock bottle with perfusion fluid it was possible 
to regulate the underpressure in the stomach. An underpressure of 1-2 cm 
water proved to be enough to ensure a good functioning of the apparatus, and 
no influence on the condition of the mucosa or on the acid secretion was seen 
to result from it. 
The results proved that this was a step in the right direction: the disturbances 
in the perfusion rate disappeared, but nevertheless in the majority of cases the 
registrations remained marred by unexpected sharp peaks which could not be 
supposed to represent real changes in the acid secretion rate. 
The probable explanation for the false peaks in the registration seemed to be 
that acid accumulated for some time in folds of the gastric mucosa before the 
depots thus formed joined the stream of the perfusion fluid. Since the nylon 
gauze basket contained not more than 10 ml of fluid, its volume was insufficient 
to unfold the gastric wall completely. Obviously the acid secreted did not pass 
into the perfusion stream in a sufficiently uniform way. 
D. The definitive form of the perfusion apparatus 
In view of this difficulty it was necessary to construct a different apparatus, 
with which it would be possible to unfold the gastric wall completely, yet 
without bringing it under tension. A basket that would meet this condition 
would introduce a dead space in the perfusion stream of 30 to 40 ml, and as 
discussed before, this is inacceptable. Only one possibility remained: to con­
struct a basket with the desired larger volume, but with a space-occupying 
body centrally placed within it, so that the whole gastric mucosa would be 
rinsed and yet the dead space in the perfusion stream would not be too large. 
As a further complication it remained necessary that such an apparatus should 
be introducable into the stomach without opening its wall. 
This problem was solved by the construction of the following apparatus 
(fig. 40). Two thin-walled metal cannulae A and В are placed concentrically 
within a third one, С (inner diameters 1.2, 3 and 5 mm, respectively). Space is 
left between the walls of the cannulae. The smaller cannula A is immovably 
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FIG. 40. Lengthwise section and side-view of the gastric perfusion apparatus. 
Two thin-walled metal cannulae A and В are placed concentrally within a third one, C. The 
perfusion fluid enters the apparatus through opening D, flows through cannula В into the 
stomach, rinses the gastric mucosa while flowing through the space left between the central 
rubber balloon and the gastric wall and leaves the stomach again through the cannula С and 
opening E. Cannula A connects the central balloon, which limits the dead space in the stomach 
to a minimum, with the outside. For further details see text. 
fixed within B. The opening of В is closed around A, which protrudes 4 cm 
from the former, but a small side-cannula D opens into the space between A 
and B. The other end of В is also closed, but 4 mm before this end two round 
openings (diameter 1 mm) connect the space within В with the outside. The 
smaller cannula A ends 32 mm before the end of В with a sidelong opening 
through the wall of B. 
The cannula В can be turned around its axis and moved to and fro within 
the outermost cannula C. The latter is much shorter than B, so that В protrudes 
from it on both sides. The opening of С is fitted around В by means of a water­
tight sleeve; another side-cannula E opens into the space between В and C. 
The other end of С is open. 
From small holes in the thicker part at the end of С sixteen pieces of stainless 
steel spring wire lead to corresponding holes in a round nut screwed onto the 
end of B. Each spring wire is fully covered by a polyethylene sleeve to prevent 
damage to the gastric mucosa by the sharp wires. 
With the aid of a screw mechanism the cannula В may be shifted through С 
without changing its orientation. The opposite ends of the springs are thus 
brought closer together and as a result the springs bend outwards (fig. 40). In 
this position they enclose a spindle-shaped space. When this part of the ap-
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paratus is brought in the described form after being introduced into the 
stomach, the gastric wall will be stretched around it, without being under 
tension. Around cannula В a thin-walled rubber balloon is fixed. This balloon 
occupies hardly any room when it is empty, but when it is inflated through the 
cannula A it also becomes spindle-shaped. The inflated balloon is smaller than 
the space enclosed by the spring wires in their bent-out position and is placed 
centrally within the latter (fig. 40). 
A nylon thread is fixed around the equator of the spindle formed by the wires. 
At equal distances it is knotted around the plastic sleeve of each spring wire. 
In this way it fixes the maximal circumference that the spool may reach, and it 
prevents two springs from being pushed apart by a fold of the gastric mucosa, 
which may be sucked inwards slightly by the underpressure in the stomach. 
The apparatus is introduced into the stomach in the following way. The 
FIG. 41. Successive stages in the application of the intragastric part of the transfusion appara­
tus shown in fig. 40. 
FIG. 41 A: The distance between the ends of the inflow and the outflow cannula is maximal, 
so that the spring wires are unbent. By turning the inflow cannula around its axis within the 
outflow cannula the spring wires are wound closely around the inflow cannula, over the empty 
balloon. In this shape the apparatus can easily be introduced into the stomach. 
FIG. 41B: The inflow cannula is turned back and the spring wires are unwound again. 
FIG. 41c: By means of a screw mechanism in the 'stem' of the apparatus (see fig. 40) the inflow 
cannula is shifted through the outflow cannula, so that the ends of the two cannulae come 
closer together. Consequently the spring wires bend outward. The gastric wall will be unfolded 
but not brought under tension. 
FIG. 41 D: The thin-walled rubber balloon is filled with water. The inflated balloon is some­
what smaller than the space enclosed by the spring wires in their bent-out position and is 
situated centrally within the latter. 
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distance between the ends of В and С is made maximal, so that the spring wires 
are unbent. Then В is turned as far as possible around its axis within C. As a 
result the spring wires wind closely around cannula B, over the empty balloon. 
In this shape the apparatus can easily be passed through cardia or pylorus 
(fig· 4i)· 
It proved to be most practical to introduce the apparatus into the cat's 
stomach via a small, latitudinal incision in the lateral wall of the antrum pylori-
cum. It would be possible to pass the apparatus through the oesophagus, but 
the longer dimension of the stomach is nearly perpendicular to the direction 
of the oesophagus, so that the apparatus would force the stomach into a very 
unphysiological position. Moreover it was necessary to open the abdomen of 
the animal anyhow, in order to ligate the outlet of the stomach. (If this would 
be neglected, acid could be lost via the duodenum, or alkaline fluid could be 
regurgitated from the intestine into the stomach.) 
The fact that the apparatus was introduced via an incision in the wall of the 
antrum instead of via the duodenum, had two reasons. A practical reason was 
the anatomy of the cat's stomach. If the stomach is empty the antrum has about 
the same diameter as the duodenum, it lies in line with the latter, and meets the 
corpus ventriculi, which is much wider, with a sharp flexure. Moreover it was 
attractive to exclude the antrum pyloricum from the perfusion as the presence 
of acid in the antrum may cause a decrease of the acid secretion (cf. p. 153). 
The antrum is ligated on either side of the incision, which is made close to the 
FIG. 42. The intragastric part of the transfusion apparatus in situ 
within the cat's stomach. The apparatus was introduced into the 
stomach through a small lengthwise incision in the wall of the 
pyloric antrum. 
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change of antrum to corpus. The proximal ligature, encircling also the 'stem' 
of the apparatus, separates corpus and antrum (fig. 42). Since the incision is 
made latitudinally in the lateral wall of the antrum, the circulation in the area 
in question is hardly disturbed. 
The preparations for the perfusion now are the following. The abdominal 
wall of the anaesthetized cat is opened by a median incision between sternum 
and navel and the perfusion apparatus is introduced into the stomach of the 
animal in the described way. The spring wires are brought in their bent-out 
position and the central balloon is filled with water (± 17 ml). Between the 
surface of the balloon and the gastric mucosa a peel-shaped open space with 
a uniform thickness is left. Under working conditions (small underpressure 
in the stomach) its volume is approximately 13 ml. The abdominal wall is closed 
around the stem of the apparatus, and the orientation of the latter is secured 
in such a way that the stomach lies in its physiological position within the cat. 
When the pump is in operation perfusion fluid passes from the stock bottle 
through a polyethylene cannula attached to D and via the space between A 
and B, finally entering the stomach via the openings in В between the round 
nut and the furthest pole of the balloon. After passing through the peel-shaped 
space, rinsing the acid-producing mucosa in doing so, the fluid leaves the 
stomach via the space between the cannulae В and С (fig. 42). Through a 
second polyethylene cannula attached to E it is pumped directly into the neutra­
lization chamber (rate 4 ml/min). The rest of the procedure has been described 
above (p. 191-195). 
Before the perfusion met all conditions, one more difficulty had to be solved. 
During the development of the apparatus described it was found that the per­
fusion fluid did not pass through the space between the gastric mucosa and the 
balloon surface in such a way that the secreted acid was evenly mixed with the 
total amount of fluid. As a result of the underpressure in the afore-said space 
the gastric mucosa bent slightly inwards between the spring wires, so that alleys 
were formed through which the greater part of the fluid passed. For this reason 
it was desirable to stir the fluid in some degree while it passed through the 
stomach. To this end the central rubber balloon was linked to a syringe via 
cannula A and a polyethylene tube. Two ml of fluid were removed out of the 
filled balloon at a constant rate in 14 seconds. Then the same amount of fluid 
was abruptly re-injected into the balloon. This procedure was continuously 
repeated. 
The slow retraction of fluid from the balloon is balanced by a slight increase 
in flow of the perfusion fluid to the increasing space between balloon and 
mucosa. The abrupt re-injection causes a disturbance of this regular flow, 
resulting in a better mixing of the perfusion fluid and the secreted acid. The in-
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FIG. 43. View from above and sidelong sections of the apparatus used for stirring the perfusion 
fluid during its passage through the stomach. The syringe is connected with the central rubber 
balloon of the gastric perfusion apparatus (fig. 40). Two ml of fluid is slowly retracted from 
this balloon and then abruptly re-injected ; this causes a disturbance of the regular flow of 
the perfusion fluid, resulting in a better mixing with the secreted acid. 
FIG. 43A: The handle of the plunger of the syringe has been lengthened with an oblong, flat 
metal strip A in which a medial slit has been made. The end of this strip moves in a bearing 
in block B. Two springs С keep the plunger pressed in. A small roller D is fixed vertically 
in the slit and presses against the circumference of a metal plate, the rim of which describes 
one winding of a spiral. This plate is fixed to the axle of a small motor and is placed vertically 
in the slit in strip A. 
FIG. 43B: The plunger is in its deepest position within the syringe. As the axle of the motor 
rotates, roller D is pushed in the opposite direction against the pulling force of the two springs. 
The plunger moves backward. 
FIG. 43c: When point E of the spiral rim passes roller D the springs will pull the plunger 
back to its original position with an abrupt movement. For further details see text. 
flow will stop momentarily, and the possibility that a certain quantity of the 
perfusate would be forced back into the supplying cannula was considered. As 
a precaution a long polyethylene cannula (inner diameter 2 mm) was inserted 
between the stock bottle and the perfusion apparatus, so that no mixing could 
occur between the stock fluid and the perfusion fluid that had been in the 
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stomach, but this did not prove necessary. As it is, the perfusion fluid hardly 
flows back; instead the stomach is somewhat dilated. 
The syringe with which the balloon is connected is part of a small apparatus, 
constructed for this purpose, which moves the plunger to and fro in the desired 
fashion. The handle of the plunger has been lengthened with an oblong, flat 
metal strip (A) in which a medial slit has been made (fig. 43A). The end of this 
strip moves in a bearing in block B, so that its orientation is fixed. The bearing 
is orientated with respect to the syringe in such a way that the whole of plunger, 
handle and strip can be moved to and fro in the horizontal plane. Two springs 
(C) pull the strip towards the syringe and thus keep the plunger pressed in. A 
small roller (D) is fixed vertically in the slit at its far end. A metal plate, the 
rim of which describes one winding of a spiral, is fixed to the axle of a small 
motor. This plate is placed vertically in the slit in A, with the axle just above the 
latter, in such a position that roller D presses against its circumference (fig. 43). 
When the spiral plate is in the position as shown in fig.43B the plunger is in 
its deepest position within the syringe. As the axle of the motor rotates, roller D 
is pushed in the opposite direction with a uniform motion, against the pulling 
force of the two springs. As a result the plunger moves backward in the syringe. 
When point E of the spiral rim has passed roller D, the springs pull the plunger 
back to its original position with an abrupt movement. Thus the apparatus 
causes the desired movements of the balloon wall in a completely automatic 
way. 
With the last modification in the technique the perfusion of the cat's stomach 
met all requirements discussed on p. 188-189. The perfusion apparatus, used 
in combination with the measuring apparatus described in the first part of this 
chapter, allowed a detailed study of the cat's gastric acid production over a 
wide range and during considerable periods of time. 
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CHAPTER IX 
EXPERIMENTS ON ANAESTHETIZED CATS 
WITH PERFUSED STOMACH 
INTRODUCTION 
As discussed already in chapter VII (p. 162) the experiments on conscious 
dogs with a gastric fistula had a number of drawbacks. Acute experiments on 
anaesthetized animals had much to attract, since some of these drawbacks 
(e.g., possible influence of preceding experiments and regurgitation of duodenal 
contents) could be excluded and especially since more complete experimental 
information could be obtained. If necessary, very high doses of the substances 
to be tested as possible competitive antagonists of histamine with respect to 
gastric acid secretion could be administered while a constant, submaximal level 
of gastric secretion was maintained by means of an intravenous infusion of 
histamine. Under these conditions even a low anti-secretory potency of the test 
substances would be noticed. 
MATERIAL AND METHODS 
A. Experimental animals 
Full-grown cats of either sex were used (body-weights from 2 to 3.5 kg). 
Thanks to the care by the staff of the Central Animal Laboratory of the Uni-
versity of Nijmegen the animals were healthy and in good condition. During the 
24 hours preceding the experiment the animal was not fed, so that the stomach 
was empty when the experiment started. Generally the secretory mechanism 
was inactive at the beginning of the experiment; in a very few cases a low level 
of spontaneous secretion was found. 
B. Anaesthesia 
In the first experiments of the series the animals were anaesthetized by intra-
peritoneal injection of urethan (1-1.5 g/kg body-weight). This method did not 
quite meet the requirements, since the level of anaesthesia following injection 
of a fixed dose of the anaesthetic was rather unpredictable. Moreover, in a 
number of cases the gastric secretory mechanism of the anaesthetized animal 
was found to be very insensitive to stimulation. 
204 
Better results were obtained with the three-stage technique adopted in later 
experiments. First an intraperitoneal injection of 30 mg/kg thiopental rendered 
the cat drowsy and sedate. Then a light surgical anaesthesia was induced by 
making the animal breath a mixture or oxygen and nitrous oxide, or, if ne-
cessary, of oxygen, nitrous oxide and halothane; this made it possible to per-
form a venasection and to introduce a polyethylene cannula into one of the 
femoral veins. Subsequently anaesthesia could be maintained at the desired 
level by means of an intravenous drip-infusion of thiopental, adjusted to the 
individual requirement of the experimental animal. 
C. Preparation and experimental conditions 
Besides the cannula used for the intravenous administration of the anaesthetic 
two more intravenous cannulae were inserted: one for the continuous infusion 
of histamine, the other for injection or infusion of the other test substances. An 
intraarterial cannula, placed in the A. carotis, was connected with a manome-
ter. The possibility had been considered that administration of a test substance 
might cause a decrease of gastric secretion as a result of an important decrease 
of the arterial blood pressure; continuous observation of the blood pressure 
would preclude that in such a case the anti-secretory effect would be mistaken 
for a specific action of the test substance. 
The abdominal wall of the experimental animal was opened between sternum 
and navel. The gastric perfusion apparatus was introduced into the stomach 
through a small longitudinal incision in the wall of the pyloric antrum, as 
described in detail on p. 200 (cf. also figs. 41 and 42). The perfusion rate was 
4 ml/min. 
It was necessary to pay special attention to the animal's body-temperature 
in the course of the experiment. The combination of anaesthesia and perfusion 
of the stomach with a fluid at room-temperature proved to result in a consider-
able under-temperature of the experimental animal. This problem could be 
solved partly by warming the perfusion fluid to 38 CC (the normal body-
temperature of a cat) before it entered the animal; to this end the inflow cannula 
was led through a small adjustable heating-apparatus. In later experiments a 
thermocouple was introduced into the rectum of the cat ; this thermocouple was 
connected with an apparatus, made for this purpose, which automatically 
switched on the heating in the preparation table to which the cat was fastened 
when the animal's body-temperature fell under 38 °C and switched it off when 
the temperature exceeded 38 °C. In this way the experimental animal was 
protected both against undercooling and overheating. 
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SOME CHARACTERISTICS OF THE ACID SECRETORY RESPONSE TO HISTA­
MINE 
A. The importance of a 'subthreshold stimulus'1 
In the course of the series of experiments on anaesthetized cats with perfused 
stomachs it was regularly observed that the secretory response of the 'resting' 
stomach to the first stimulus was smaller than the responses to subsequent 
stimuli (irrespective of the type of anaesthesia used). The first stimulus generally 
was a standard dose of histamine, 100 ця/І^, given as a io min intravenous 
infusion. If the same dose of histamine was administered when a preceding 
secretory response had just come to an end, and a fortiori if a very small rest-
secretion still continued, the effect of the secretagogue used to be considerably 
stronger than that following the first dose. An illustration of this phenomenon 
is given in fig. 44. 
It would seem that the indication 'a resting stomach' for a stomach during 
the periods in which no acid is secreted needs a refinement. A distinction should 
be made between a stomach which is 'not secreting and inactive' and a stomach 
which is 'not secreting but in activated state'. This 'activated state' wil exist for 
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FIG. 44. Registrogram of the rate of gastric acid secretion in an anaesthetized cat with per­
fused stomach. The secretion was stimulated with a series of separated intravenous histamine 
infusions of 10 min duration (50 ug/kg). 
Comparison of the first and the last secretory peak shows that the response is much smaller 
when the stomach is 'not secreting and inactive' than when the stomach is 'not secreting but 
in activated state' (see text). 
Note further that the determination method allows perception of the compound character 
of the secretory response to a series of 4 separated histamine infusions given with 12.5 min 
intervals. With a determination method based on collecting the gastric juice in portions of 
10 min (cf. p. 185) this aspect of the response would hardly have been perceptible. 
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some time after the end of a secretory response to histamine; in 2-3 % of the 
experiments it may have been present spontaneously, which might explain why 
in these cases the first response was relatively large and did not differ from later 
responses to stimuli of similar magnitude. 
The 'activated state' of the gastric mucosa may be caused by the presence 
of a subthreshold stimulus. It is supposed, then, that if at the beginning of the 
experiment the gastric secretory mechanism is really inactive, the greater part 
of the first stimulus would be needed to activate the stomach. If the stomach 
is stimulated at regular intervals the 'activated state' continues; if, however, 
during the experiment the stomach is not stimulated for some hours (with 
maintenance of the perfusion) the secretory mechanism becomes inactive again. 
It does not seem probable that an 'activated state' of the stomach would 
directly depend on a raised level of circulating histamine. The amine is removed 
from the blood and is catabolized at a very fast rate; it is not likely that 30-
60 min after the end of an infusion of 100 μg/kg histamine the blood level still 
would be higher than normal. Also, in our experiments the difference between 
'activated' or 'inactive' did not seem to be a difference in parasympathetic tone. 
In the majority of the experiments the cats were atropinized beforehand (1 mg/kg 
i.V.); moreover in the cases that atropine was given during the experiment the 
response to histamine generally was not decreased by it (cf. p. 213). The phe­
nomenon in question may be an aspect of the response mechanism of the parietal 
cells themselves or it may be connected with different levels of blood supply to 
the gastric mucosa. 
B. The beginning of the acid secretory response 
The observable acid secretory response starts between about 5 and 15 min 
after the beginning of the standard histamine infusion. As discussed already 
on p. 190 the measuring method causes a shift of the response on the time axis 
with 3-4 min, so that under favourable conditions the secretion promptly 
follows the beginning of the stimulation. In general the secretory peak is found 
to be higher as the response starts earlier and will be lower as the response 
follows tardier. 
C. How long can a constant level of gastric acid secretion be maintained? 
By administration of histamine as a continuous intravenous infusion (doses 
in the order of 1 μg/kg/min) a constant submaximal level of gastric acid se­
cretion could be maintained for many hours. Continuous secretory responses 
for periods up to 8-10 h could be obtained without difficulties. As illustrated 
in fig. 45, a very slow increase or decrease of the secretory level might occur in 
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FIG. 45. Registrogram of the rate of gastric acid secretion in an anaesthetized cat with perfused stomach. The secretion was stimulated by continuous in­
travenous infusion of histamine. The infusion rates of 5 Mg/kg/min and 1 pg/kg/min were too high ; the slopes of the ascending part of the curves representing 
the secretion caused by these infusions suggest that the gastric acid secretion would have reached higher levels than desired. With the third infusion rate 
(0.5 Hg/kg/min) it was possible to maintain a practically constant submaximal secretion level during 3.5 h. 
the course of the experiment; since such slow changes would not interfere with 
the recognition of the possible anti-secretory actions of the test substances they 
could be disregarded. 
For the sake of completeness it may be mentioned that in one orientating 
experiment a maximal secretory response was caused with a continuous his­
tamine infusion of io μg/kg/min. The secretory response in question is called 
maximal since doubling the dose for io min did not cause any change in the 
secretory level. The secretion rate obtained was in the order of 65 μΕς/ιηίη; it 
remained constant for 1.5 h but than the cat's blood pressure abruptly fell to 
60 mm Hg and the secretion strongly decreased. 
D. The descending part of the acid secretory response 
It was an important question what could be expected to happen with a 
continuous submaximal secretion of gastric acid caused by intravenous in­
fusion of histamine when the secretory histamine receptors would be blocked 
yuE<j acid/min 
2 0 
70 min 
FIG. 46. Combination of 6 registrograms of the gastric acid secretion caused by a io min 
intravenous infusion of histamine (50 Mg/kg or 100 Mg/kg) in 6 different cats with perfused 
stomachs. 
Note, that the secretory responses are rather different in duration and height, but that the 
character of the descending part of all curves is so similar, that these parts perfectly cover 
each other when the ends of the curves are placed in the same position. For a possible inter­
pretation of this phenomenon see text. 
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abruptly by a competitive antagonist of the secretagogue. It seemed a rational 
supposition that the secretion would come to an end and that the descending 
leg of the secretory curve would be similar to that which is seen when the in­
fusion of histamine is abruptly decreased or stopped. The points which deserved 
study, therefore, were whether the descending leg of the registration obtained 
after termination of a histamine infusion would have characteristics of shape and 
slope which would be easily recognizable, and whether the character of the des­
cent would depend on the height of the preexisting secretory level or on the du­
ration of the preceding secretory period. (Theoretically it could be supposed, for 
instance, that the descent would be less steep after a histamine infusion of several 
hours that after a io min infusion, in connection with the saturation of possible 
histamine stores.) 
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FIG. 47. The descending parts of the registrograms of gastric acid secretion in 2 cats with 
perfused stomachs. 
FIG. 47A: Descending part of a secretory response of more than 5 h duration, caused by con­
tinuous intravenous infusion of histamine (5 μg/kg/min). The descent of the curve follows 
the conclusion of the histamine administration. 
FIG. 47B: Descending part of a secretory response of more than 2 h duration, caused by 
continuous intravenous infusion of physostigmine (2 μg/kg/min). Physostigmine blocks the 
action of the enzyme acetylcholine esterase and thus causes a raised level of cholinergic 
stimulation. The descent of the curve follows the administration of a high dose of atropine 
(1 mg/kg i.V.). 
Comparison of figs. 47A and в with the descending parts of the curves in fig. 46 shows that 
the duration of the preceding secretory period does not influence the character of the descent. 
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In the course of the experiments these questions could be decisively answered. 
The secretory responses to the standard histamine stimuli (io min infusion of 
50 or 100 μg/kg) in different experimental animals were rather different in 
duration and height, but the character of the descending leg of the curves was 
similar to a very high degree. As shown in fig. 46, the descending parts of the 
curves cover each other when the curves are combined in such a way that their 
ends are in the same position. 
The descending legs of the curves have a more or less exponential shape. 
If it is correct that the descending part of the curve is not dependent on a 
simultaneous decrease of the level of circulating histamine, since the latter is 
back to normal long before the end of the secretory response (cf. p. 207), 
the characteristic shape of the descending parts of the curves possibly corres­
ponds to the rate of diffusion of histamine out of the secretory biophase. Ho­
wever, other explanations can be given. 
Also the duration of the preceding secretory period does not seem to have 
any influence on the character of the descending leg of the curves. This is illus­
trated in fig. 47A, which shows the descending part of a secretory response to a 
histamine infusion of more than 5 h duration; also longer infusion periods 
make no difference in this respect. The same, typical descent of the secretory 
curve was seen when the secretion was maintained at a constant level with a 
cholinergic stimulus and the cholinergic receptors then were abruptly blocked 
by the administration of a massive dose of the competitive cholinolytic drug 
atropine (fig. 47B). This last finding can be reconciled quite well with the sup­
position that a cholinergic stimulus acts via histamine, released directly in the 
gastric mucosa. 
A FURTHER SEARCH FOR COMPETITIVE ANTAGONISTS OF HISTAMINE 
WITH RESPECT TO GASTRIC ACID SECRETION 
A. Introduction; the effect of atropine on histamine-induced gastric acid secretion 
As mentioned, one of the attractive aspects of the experiments on anaes­
thetized animals was that, if necessary, the test substances could be administered 
in very high doses. However, in view of the pA2-values of the test compounds 
determined with respect to the cholinergic system in the rat intestine (table I) 
it was to be expected that, in the higher dosage ranges, many of the compounds 
would exert a distinct anticholinergic action. It seemed desirable, therefore, 
to see to it that the secretory response against which the possible antisecretory 
action of the test compounds would be examined would be purely histaminergic 
and that no cholinergic component would play a part in it. If this was neglected, 
it would be impossible to interpret a smaller decrease of the secretion following 
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administration of a test compound, it might be caused either by an anticho-
linergic action or by a 'ß-histammergic-blocking action' (cf ρ 2) of the com­
pound in question 
In order to exclude the possibility that a spontaneous cholinergic component, 
present in the histamine-induced acid secretion, would thus complicate the 
situation, it seemed indicated to atropinize the experimental animal before 
the effect of a test substance on gastric secretion was examined In this connec­
tion it had to be considered which kind of effect a large dose of atropine (i mg/ 
kg) would have on the histamine-induced secretion Theoretically three different 
effects are possible If a cholinergic component was present in the secretory 
stimulus, the level of the acid secretion will be lowered On the other hand, the 
yuE<j acid /mm 
18 
FIG 48 Registrograms of the rate of gastnc acid secretion in 3 different cats with perfused 
stomachs Secretion was maintained by continuous intravenous infusion of histamine, in 
figs 48A and в of 1 μg/kg/mln, in fig 48c of 2 3 μg/kg/mln In all three cases a dose of atro­
pine was administered (1 mg/kg in a 15 mm intravenous infusion) when the secretory level 
had been constant for at least 40 mm 
Note, that the atropine administration causes an increase or a decrease of the histamine-
mduced gastric acid secretion or that it does not influence the latter For a discussion of these 
results, see text 
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secretory level may also be raised temporarily, since atropine has a histamine-
liberating action (845). Finally no change in the secretion will occur if both 
influences are absent or if they cancel out. 
In the course of 8 experiments in which atropine was administered during 
a continuous histamine infusion all three types of effect were observed in 
reality (fig. 48). However, in 7 animals the secretory level was unaltered or 
slightly and temporarily elevated whereas the secretion diminished slightly 
in one case only. This finding together with the fact that, in the course of the 
whole series of experiments, a spontaneous secretion of gastric juice was very 
seldom observed suggests that in the experimental set-up used the chance of 
spontaneous cholinergic activity is rather small. Nevertheless, in order to be on 
the safe side, and in view of the fact that atropine did not interfere with the 
histaminergic secretory mechanism, the following experiments were performed 
routinely on atropinized animals (atropine 1 mg/kg, intravenously infused 
before the start of the histamine infusion). 
B. The N-substituted derivatives of 2-(§-aminoethyl)-pyridine 
The reasons for testing a series of amino-substituted derivatives of 2-(ß-
aminoethyl)-pyridine have been discussed in chapter VII (p. 170). Three com-
pounds from this series were tested on the gastric fistula dogs; the methyl-
derivative (compound 2) had a secretory action, the propyl- and the N-methyl-
N-phenylpropyl-derivatives (compounds 5 and 13) in the doses given did not 
antagonize histamine with respect to the gastric acid secretion. Four more 
members of the series now were tested on anaesthetized cats with perfused 
stomach. Each compound was tested in 2 or 3 différents cats, the doses were 
administered as io min intravenous infusions. 
Compound 1 (2-(ß-aminoethyl)-pyridine) was tested in doses of 2.5, 10 and 
25 μ π ι ο ί ^ . Since the drug is a gastric secretagogue itself (cf. p. 170), it was 
administered alone (without simultaneous infusion of histamine). The first 
dose caused a small effect (duration ± 40 min, peak secretion ± 4 μΕς/ιηίη), 
the second dose caused a stronger stimulation (duration ± 60 min, peak secre­
tion ± 7 μΕς/ιηιη), the highest dose caused a still larger response (duration 
± 90 min, peak secretion ± 14 μΕς/πιίη). The slope of the descending leg of 
the curve is much less steep than after histamine (fig. 49). A similar difference 
with the histamine-induced secretory response was seen after administration 
of N-methyl- and N-ethyl-histamine to gastric fistula dogs (p. 179). 
Compound 3 (the N-ethyl-derivative of 2-(ß-aminoethyl)-pyridine) was tested 
in doses of 25 and 250 μ ι η ο ΐ ^ . The compound likewise induces gastric acid 
secretion ; the lower dose is ± inactive, but the higher dose causes a strong sti-
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mulation of the gastric acid secretion (peak secretion rate : ± 13 μΕς/ιηίη, the 
descending leg of the curve is still less steep than in the case of compound i). 
Compound 4 (the N-isopropyl-derivative of 2-(ß-aminoethyl)-pyridine), tested 
in doses of 250 and 750 μιηοΐ/ΐ^, and compound 6 (the N-butyl-derivative), 
tested in doses of 75 μηιοΐ/ΐ^ and 250 цтоі/к^ have no secretory potency 
themselves and did not cause a decrease of the histamine-induced gastric acid 
secretion. 
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FIG. 49. Registrogram of the rate of gastric acid secretion in a cat 
with perfused stomach. The secretion was caused by intravenous in­
fusion of compound 1, z-iß-aminoethyO-pyridine, in a dose of 
25 μπιοΐ/ΐ^. 
Note, that both the ascending and the descending leg of the secre­
tory curve have a slope which is less steep than that of a curve of 
comparable height caused by a histamine infusion. 
C. Other compounds tested as possible antagonists of histamine-induced gastric 
acid secretion 
In addition a number of other compounds were tested as possible antagonists 
of the histamine-induced gastric acid secretion in the experimental set-up 
described above (anaesthetized and atropinized cats with a continuous gastric 
acid secretion at a submaximal level, maintained by continuous intravenous 
infusion of histamine). Each compound was tested in 2 or 3 different cats. 
Compound 24, a representative member of the series of compounds which 
contain a piperazine-ring (table I compounds 15-27) had been tested already in 
the gastric fistula dogs in a dosage of 20 цтоі/к^ (10.9 mg/kg). In this dosage 
it did not antagonize histamine with respect to gastric acid secretion (cf. p. 175). 
Tested in a dosage of 80 ц т о і у ^ in the cat with perfused stomach it did not 
214 
influence the histamine-induced gastric acid production; a dosis of 200 μ η ι ο ί ^ 
was lethal. 
Compound 34 is a representative member of the series of new anti-histamines 
which contain a 'mimetic moiety' in their molecular structure (compounds 
28-44 a n d 58-60). Of this series compound 58 had been tested in the gastric 
fistula dogs and found to be inactive against histamine-induced gastric acid 
secretion (cf. p. 177). Compound 34 was selected for a further trial since it 
has the highest рАг- аІие with respect to the histaminergic system in the 
guinea-pig ileum of the series of compounds in question (a factor 200-300 higher 
than that of compound 58). 
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ne. 50. Registrogram of the rate of gastric acid 
secretion in a cat with perfused stomach. The se­
cretion was stimulated by continuous intravenous 
infusion of histamine (4 Ц8/^/тіп). 
Note, that administration of a very high dose of the 
highly active antihistamine compound 70 (dex-
chlorphenhydramine) has no influence on the his­
tamine-induced gastric acid secretion. 
Compound 34 was tested in doses of i, 2, 4 and 8 ц т о і ^ i.v. (1.6, 3.2, 6.4 
and 12.8 mg/kg). In none of the experiments any antagonism against the his­
tamine-induced gastric acid secretion was observed. On the contrary; the ad­
ministration of the drug regularly resulted in a small and transient elevation 
of the secretory level. 
Compound 68 (p-methyl-diphenhydramine) was selected for testing as an 
example of the commercially available antihistamines with very high pAz-values 
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with respect to the histaminergic system in the guinea-pig ileum. The same holds 
true with respect to the compounds 70, 71 and 72. 
Compound 68 was tested in doses of 2.5, 10 and 20 mg/kg i.v. In these very 
high doses the drug did not have any influence on the histamine-induced gastric 
acid secretion. 
Compound 70 (dexchlorphenhydramine) is a commercially available anti­
histamine which has the highest рАг with respect to the histaminergic system 
in the guinea-pig ileum of the whole series of compounds listed in table I. In 
the anaesthetized cat with perfused stomach it was tested in doses of 3, 6 and 
24 mg/kg i.v. ; even in the very high last dosis it did not cause any change in a 
histamine-induced, constant submaximal level of gastric acid secretion (fig. 50). 
In another experiment the same dose of compound 70 caused a short-lasting 
elevation of the secretory level. 
Compound 7J (cyproheptadine) was tested in the doses of 3 and 10 mg/kg 
i.v. The highest dose had no effect in one experiment and caused an increase of 
the histamine-induced acid secretion in another (the increase of the acid pro­
duction rate amounted to 6 μΕς/πυη and lasted about 45 min). 
Compound 72 (dimethindene) was tested in the doses of 12, 18 and 24 mg/kg 
i.v. Also this drug either caused no change in the secretory level or a transient 
increase of the secretion. In one cat the dose of 24 mg/kg proved to be lethal. 
Finally two drugs were tested which are not primarily anti-histamines but 
competitive antagonists of acetylcholine, viz. compound 74 (glycopyrronium) 
and scopolamine butyl bromide. The reason for testing these drugs in atropinized 
cats with a constant, submaximal level of acid secretion maintained by a 
continuous intravenous infusion of histamine was, that the drugs in question, 
which are clinically used in peptic ulcer patients, have been supposed to diminish 
acid production not only by their anticholinergic action, but also by a direct 
antihistaminergic effect. 
Both drugs were tested in doses of 1 mg/kg i.v. In no case the acid secretion 
rate was adversily influenced; on the contrary, analogous to what was found 
with atropine, generally a small and transient raise of the acid production was 
observed. 
Summarising it can be stated that in all experiments without a single excep­
tion the gastric acid secretion was either not influenced by the compounds 
administered, or was transiently and slightly raised. The last phenomenon 
probably is the result of histamine liberation; many antihistamines are known 
to cause a release of histamine (58, 696). The conclusion which already could 
be reached with some reservation on the basis of the experiments on gastric 
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fístula dogs now can be affirmed with a high degree of certainty : none of the 
compounds tested - neither the newly synthetized substances containing a 
'mimetic moiety' in their molecular structure nor some of the commercially 
available antihistamines with very high pAz-values with respect to the hista-
minergic system in the guinea-pig ileum have a measurable ß-histaminergic 
blocking action. 
This thesis is not concluded with a summary, since the topics discussed in 
it are too numerous and too diverse to allow the presentation of general con-
clusions in a short review. Instead the structure of the work is elucidated in 
chapter I (p. 3-4) and a very detailed table of content is presented on p. VIl-X. 
For the conclusions reached with respect to specific topics the reader may be 
referred to the various chapters. 
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STELLINGEN 
I 
Het is ongewenst de proportionaliteitsconstante β', die voorkomt in eer­
der gepubliceerde formules voor de metactoïde interactie, te introduceren als 
de intrinsieke activiteit van de metactoïd werkende stof, daar dit het nood-
zakelijk maakt de intrinsieke activiteit van een metactoïde substantie wezen-
lijk anders te definieren dan die van een agonist, terwijl beide categorieën 
stoffen zich formeel slechts van elkaar onderscheiden in de wijze waarop de 
gevormde stimulus tot uitdrukking komt. 
E. J. Ariëns, J. M. van Rossum en A. M. Simonis, Arzneimittel-Forschung 6: 
611, 1956. 
J. M. van Rossum, Proefschrift, Nijmegen, 1958 
Dit proefschrift, p. 49-53. 
II 
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van de interactie van farmaca met biologische membranen de introductie 
van een „intrinsieke activiteit" van een farmacon niet langer noodzakelijk 
maakt, wijst erop dat genoemde auteurs een verkeerde voorstelling hebben 
van de inhoud van het begrip intrinsieke activiteit. 
J.-P. Changeux, J. Thiéry, Y. Tung en С Kittel, Proc. Nat. Acad. Sci. 57: 
335, 1967. 
Dit proefschrift, p. 31. 
III 
De argumenten waarop Wohl et al. hun veronderstelling baseren dat diaz-
oxide met barium competeert om specifieke receptors in de spierwand van de 
rattenaorta zijn verre van overtuigend. 
A. J. Wohl, L. M. Hausier en F. E. Roth, J. Pharmacol. Exp. Therap. 158: 
531, 1967 
IV 
Aangezien alle thans beschikbare gegevens erop wijzen dat pentagastrine 
een veilig en physiologisch stimulans is van de maagzuursecretie en de test 
van de secretore capaciteit van de maag met behulp van pentagastrine repro-
duceerbare resultaten oplevert, verdient het aanbeveling voor deze test in het 
algemeen geen gebruik meer te maken van histamine of betazole. 
Dit proefschrift, p. 150. 
De veronderstelling dat er een oorzakelijk verband zou bestaan tussen 
corticoïdtherapie als zodanig en een verhoogde frequentie van het ulcus pep-
ticum wordt door de huidige gegevens niet gerechtvaardigd. 
R. Bowen, Jr., J. G. Mayne, J. C. Cain en L. G. Bartholomew, Mayo Clin. 
Proc. 35: 537, 1960. 
W. H. Kammerer, R. H. Freiberger en A. Rivelis, Arthr. Rheum. 1: 122, 1958. 
W. E. de Lange, Corticosteroïden, kaliumtekort en H-ion-secretie. Proef-
schrift, Groningen, 1965. 
О. J. ten Thije, in: Integration in Internal Medicine, Ed. by A. J. Dunning, 
Excerpta Medica Foundation, Amsterdam, 1967, p. 181. 
VI 
Ter staving van zijn bewering dat het enzym ^-glucuronidase een functie 
heeft bij de vorming van glucuroniden beroept Dohrman zich ten onrechte 
op de experimentele resultaten van Sie and Fishman. 
R. E. Dohrman, Arzneim.-Forsch. 18: 854, 1968. 
H.-G. Sie en W. H. Fishman, J. Biol. Chem. 225: 453, 1957. 
VII 
Het nadeel dat de everterende darmnaad heeft in vergelijking met de in-
verterende is niet, zoals vrij algemeen werd aangenomen, gelegen in een 
grotere kans op naadlekkage, maar in een grotere tendentie tot vorming van 
adhaesies in de peritoneale holte. 
J. H. Hertzier en W. M. Tuttle, Arch. Surg. 65: 398, 1952. 
W. Galluzzi en В. Possenti, Minerva Chir., Тог., 1954: 1008. 
L. С. Getzen, Surg. Gyn. Obst. 123: 1027, 1966. 
L. С. Getzen, R. D. Roe en С. I. Holloway, Surg. Gyn. Obst. 123: 129, 1966. 
M. M. Ravitch, F. Canalis, A. Weinsheibaum en J. McCormick, Ann. Surg. 
166: 670, 1967. 
F. Canalis en M. Ravitch, Surg. Gyn. Obst. 126: 109, 1968. 
Vili 
De wijze waarop in vele medisch-biologische publicaties bepaalde statis-
tische technieken worden toegepast op basismateriaal dat zich daartoe niet 
leent, of waarvan althans niet is nagegaan of het er zich toe leent suggereert 
dat deze technieken voor de betrokken auteurs magische, doch in wezen 
onbegrepen rituelen vormen. 
IX 
Tegen de aan artikel 1.1 van het voorontwerp van wet op de dierproeven 
toegevoegde beperking, die stelt dat van een dierproef in de zin van dit artikel 
slechts sprake is „voor zover redelijkerwijs moet worden aangenomen, dat 
daardoor de gezondheid van het dier kan worden benadeeld dan wel noe-
menswaardige pijn, letsel of ernstig ander ongemak aan het dier kan worden 
berokkend" zijn ernstige bezwaren aan te voeren. 
Advies inzake het Voorontwerp van een Wet op de dierproeven, Staatsuit-
geverij, 's-Gravenhage, 1968. 
M. J. Dobbelaar, W. J. I. van der Gulden en J. M. van Gaaien, Landbouw-
kundig Tijdschrift 80: 197, 1968. 
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